<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003229.pub3" GROUP_ID="PVD" ID="329400091813512223" MERGED_FROM="" MODIFIED="2016-04-01 10:02:40 +0100" MODIFIED_BY="Marlene Stewart" REVIEW_NO="561" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2016-04-01 10:02:40 +0100" MODIFIED_BY="Marlene Stewart">
<TITLE>Phlebotonics for venous insufficiency</TITLE>
<CONTACT MODIFIED="2016-04-01 10:02:40 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="15772" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria José</FIRST_NAME><LAST_NAME>Martinez-Zapata</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>mmartinezz@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 08</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-04-01 10:02:40 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="15772" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria José</FIRST_NAME><LAST_NAME>Martinez-Zapata</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>mmartinezz@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 08</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON><PERSON ID="z1402250931410462437091445028514" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Robin</FIRST_NAME><MIDDLE_INITIALS>WM</MIDDLE_INITIALS><LAST_NAME>Vernooij</LAST_NAME><POSITION>Research associate</POSITION><EMAIL_1>rwmvernooij@cochrane.es</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</ORGANISATION><ADDRESS_1>&#8203;C/ Sant Antoni Maria Claret 167</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Barcelona</REGION><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="49646634089875690582120502154458" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sonia Maria</FIRST_NAME><LAST_NAME>Uriona Tuma</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>soniauriona@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Preventive Medicine and Public Health</DEPARTMENT><ORGANISATION>Vall Hebron University Hospital</ORGANISATION><ADDRESS_1>Passeig Vall Hebron 119-129</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08035</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 931 854 646</PHONE_1></ADDRESS></PERSON><PERSON ID="17067" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Airton</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Stein</LAST_NAME><POSITION>Professor of of Public Health</POSITION><EMAIL_1>airton.stein@gmail.com</EMAIL_1><EMAIL_2>astein@ghc.com.br</EMAIL_2><URL>wwww.ufcspa.edu.br</URL><MOBILE_PHONE>555191136377</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health</DEPARTMENT><ORGANISATION>Universidade Federal de Ciências da Saúde</ORGANISATION><ADDRESS_1>Ulbra and Grupo Hospitalar Conceição</ADDRESS_1><CITY>Porto Alegre</CITY><ZIP>9</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+555133572376</PHONE_1><FAX_1>+555133572461</FAX_1></ADDRESS></PERSON><PERSON ID="995C846082E26AA2009B3E5E94AF462C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rosa</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Moreno</LAST_NAME><POSITION>Chief</POSITION><EMAIL_1>rmorca@gmail.com</EMAIL_1><MOBILE_PHONE>34656447001</MOBILE_PHONE><ADDRESS><DEPARTMENT>Angiology, Vascular and Endovascular Surgery</DEPARTMENT><ORGANISATION>Universitary Hospital La Princesa</ORGANISATION><ADDRESS_1>C/ Diego de León, 62</ADDRESS_1><CITY>Madrid</CITY><ZIP>28040</ZIP><REGION>Madrid</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>34656447001</PHONE_1><PHONE_2>34915202268</PHONE_2></ADDRESS></PERSON><PERSON ID="995C82F982E26AA2009B3E5E2ED4175E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Emilio</FIRST_NAME><LAST_NAME>Vargas</LAST_NAME><POSITION>Medical Director</POSITION><EMAIL_1>evargas@ucm.es</EMAIL_1><EMAIL_2>emilio.vargas@salud.madrid.org</EMAIL_2><ADDRESS><ORGANISATION>Hospital Clínico San Carlos. Universidad Complutense de Madrid</ORGANISATION><ADDRESS_1>Prof. Martin Lagos s.n.</ADDRESS_1><CITY>Madrid</CITY><ZIP>28040</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 91 330 34 13</PHONE_1><FAX_1>+34 91 330 32 99</FAX_1></ADDRESS></PERSON><PERSON ID="995C819182E26AA2009B3E5E3FEE6484" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dolors</FIRST_NAME><LAST_NAME>Capellà</LAST_NAME><EMAIL_1>dolors.capella@udg.edu</EMAIL_1><ADDRESS><DEPARTMENT>Unit of Clinical Pharmacology, TransLab Research Group, Department of Medical Sciences</DEPARTMENT><ORGANISATION>Faculty of Medicine, Universitat de Girona</ORGANISATION><CITY>Girona</CITY><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="D3B1F77E82E26AA200831C1940F4DA2E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xavier</FIRST_NAME><LAST_NAME>Bonfill Cosp</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>xbonfill@santpau.cat</EMAIL_1><EMAIL_2>director@cochrane.es, XBonfill@hsp.santpau.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret, 167</ADDRESS_1><ADDRESS_2>Pavilion 18 (D-13)</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 10</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-09-24 08:55:42 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="8" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="8" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="8" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-03-30 15:47:55 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-30 15:47:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Searches rerun, 6 new studies included, 2 publications added to already included studies and 1 study reclassified as an included study, 115 new studies excluded and 3 new ongoing studies identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-03-30 15:47:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Searches rerun, 6 new studies included, 1 study reclassified as an included study, 115 new studies excluded and 3 new ongoing studies identified. New authors have joined the review team. Risk of bias assessed for all included studies and 'Summary of findings' table added. Review updated according to current Cochrane reporting guidelines</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-25 10:24:15 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-25 10:24:15 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-14 11:44:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Edited update. CDSR citations updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-01-13 16:15:03 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-01-13 16:15:03 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-08-17 11:07:32 +0100" MODIFIED_BY="[Empty name]">
<NAME>The Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The Cochrane Vascular editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-01-13 16:15:03 +0000" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Dr. Mª José Martinez Zapata is funded by a Miguel Servet research contract from the Instituto de Salud Carlos III (CP15/00116).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-01 09:23:29 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-03-31 14:31:53 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Drugs to improve blood flow for people who have poor blood circulation in the veins of their legs</TITLE>
<SUMMARY_BODY MODIFIED="2016-03-31 14:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>Background</U>
</P>
<P>Insufficient blood circulation in the veins of the legs might be caused by genetic factors, may occur after trauma, or may result from a blood clot. Poor movement of blood up the legs may cause swelling and puffiness, feelings of heaviness, tingling, cramps, pain, varicose veins and changes in skin pigmentation. If severe insufficient blood circulation occurs, ulcers and skin wasting can develop. Drugs such as natural flavonoids extracted from plants and similar synthetic products may improve blood circulation. These drugs are known collectively as venoactive drugs or phlebotonics. This review examined evidence from randomised controlled clinical trials comparing these drugs versus inactive treatment (placebo), generally given over one to three months.</P>
<P>
<U>Key results</U>
</P>
<P>In total, 66 studies (53 with quantifiable data, including 6013 participants; mean age 50 years) met the eligibility criteria for this review (current until August 2015). Moderate-quality evidence from 13 studies (involving 1245 people) suggests that phlebotonics reduce puffiness (oedema) compared with placebo. Low quality evidence suggests there is no difference in the proportion of healed ulcers with phlebotonics compared with placebo. For quality of life, it was not possible to combine all studies because of differences between the studies. However, individual phlebotonic treatments shows high quality evidence there is no difference in quality of life for the phlebotonic calcium dobesilate. Low-quality evidence revealed improvement of quality of life for aminaftone when compared to placebo. Furthermore evidence suggests phlebotonics have beneficial effects on trophic disorders, cramps, restless legs, swelling and tingling. However, the relevance of these findings to the overall clinical state remains unclear. Moderate-quality evidence from 33 studies (involving 3975 people) shows that phlebotonics produce more side effects, especially gastrointestinal disorders.</P>
<P>
<U>Quality of the evidence</U>
</P>
<P>The quality of evidence was downgraded because of selective reporting for the outcome ulcer healing, for incomplete outcome data for the outcomes ulcer healing, oedema and adverse events and for unclear randomisation and imprecision of the overall results for the outcome quality of life.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-04-01 09:20:49 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-03-30 15:47:55 +0100" MODIFIED_BY="[Empty name]">
<P>Chronic venous insufficiency (CVI) is a common condition caused by valvular dysfunction with or without associated obstruction, usually in the lower limbs. It might result in considerable discomfort with symptoms such as pain, itchiness and tiredness in the legs. Patients with CVI may also experience swelling and ulcers. Phlebotonics are a class of drugs often used to treat CVI. This is an update of a review first published in 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-02-24 16:47:57 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of phlebotonics administered both orally and topically for treatment of signs and symptoms of lower extremity CVI.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-04-01 09:20:49 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (August 2015), as well as the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7). The reference lists of the articles retrieved by electronic searches were searched for additional citations. We also contacted pharmaceutical companies and searched the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal for ongoing studies (last searched in August 2015).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-03-30 15:48:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trials (RCTs) assessing the efficacy of rutosides, hidrosmine, diosmine, calcium dobesilate, chromocarbe, Centella asiatica, disodium flavodate, french maritime pine bark extract, grape seed extract and aminaftone in patients with CVI at any stage of the disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed the quality of included RCTs. We estimated the effects of treatment by using risk ratios (RRs), mean differences (MDs) and standardised mean differences (SMDs), according to the outcome assessed. We calculated 95% confidence interval (CIs) and percentage of heterogeneity (I<SUP>2</SUP>). Additionally, we performed sensitivity analyses.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-03-31 14:30:52 +0100" MODIFIED_BY="[Empty name]">
<P>We included 66 RCTs of oral phlebotonics, but only 53 trials provided quantifiable data (involving 6013 participants; mean age 50 years) for the efficacy analysis: 28 for rutosides, 10 hidrosmine and diosmine, nine calcium dobesilate, two Centella asiatica, two aminaftone, two french maritime pine bark extract and one grape seed extract. No studies evaluating topical phlebotonics, chromocarbe, naftazone or disodium flavodate fulfilled the inclusion criteria.</P>
<P>Moderate-quality evidence suggests that phlebotonics reduced oedema in the lower legs compared with placebo. Phlebotonics showed beneficial effects among participants including reduced oedema (RR 0.70, 95% CI 0.63 to 0.78; I<SUP>2 </SUP>= 20%; 1245 participants) and ankle circumference (MD -4.27 mm, 95% CI -5.61 to -2.93 mm; I<SUP>2 </SUP>= 47%; 2010 participants). Low-quality evidence reveals no difference in the proportion of ulcers cured with phlebotonics compared with placebo (RR 0.94, 95% CI 0.79 to 1.13; I<SUP>2 </SUP>= 5%; 461 participants). In addition, phlebotonics showed greater efficacy for trophic disorders, cramps, restless legs, swelling and paraesthesia, when compared with placebo. We identified heterogeneity for the variables of pain, itching, heaviness, quality of life and global assessment by participants. For quality of life, it was not possible to pool the studies because heterogeneity was high. However, high-quality evidence suggests no differences in quality of life for calcium dobesilate compared with placebo (MD -0.60, 95% CI -2.15 to 0.95; I<SUP>2</SUP> = 40%; 617 participants), and low-quality evidence indicates that in the aminaftone group, quality of life was improved over that reported in the placebo group (MD -10.00, 95% CI -17.01 to - 2.99; 79 participants). Moderate-quality evidence shows that the phlebotonics group had greater risk of non-severe adverse events than the placebo group (RR 1.21, 95% CI 1.05 to 1.41; I<SUP>2</SUP> = 0; 3975 participants). Gastrointestinal disorders were the most frequently reported adverse events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-03-31 14:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>Moderate-quality evidence shows that phlebotonics may have beneficial effects on oedema and on some signs and symptoms related to CVI such as trophic disorders, cramps, restless legs, swelling and paraesthesia when compared with placebo but can produce more adverse effects. Phlebotonics showed no differences compared with placebo in ulcer healing. Additional high-quality RCTs focused on clinically important outcomes are needed to improve the evidence base.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-01 09:23:29 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Chronic venous insufficiency (CVI) is a condition in which veins are unable to transport blood unidirectionally toward the heart with flow adapted to tissue drainage needs, temperature regulation and haemodynamic reserve, regardless of their position and activity. CVI first manifests as an increase in venous tension (venous hypertension, or high blood pressure in the veins) with or without reflux (<LINK REF="REF-Kurz-1999" TYPE="REFERENCE">Kurz 1999</LINK>). Depending on its cause, CVI can be congenital, primary (with undetermined cause) or secondary (post-thrombotic, post-traumatic or other). Depending on its pathophysiology, CVI can be related to occlusion (blocked veins), reflux or both. Finally, it might depend on superficial or deep venous systems or on perforator anomalies (<LINK REF="REF-Porter-1995" TYPE="REFERENCE">Porter 1995</LINK>).</P>
<P>CVI is an important cause of discomfort and inability to work, and many people find it difficult to live with this condition. Its prevalence has not been clearly determined because available studies regarding this subject are few, and those that are available present limitations. Some studies do not cover the whole pathological spectrum and focus only on varicose veins or ulcers; others do not use standardised definitions of the illness and apply a variety of diagnostic criteria (<LINK REF="REF-Nicolaides-2000" TYPE="REFERENCE">Nicolaides 2000</LINK>). As a result, prevalence has been estimated at between 1% and 50% (<LINK REF="REF-Evans-1999" TYPE="REFERENCE">Evans 1999</LINK>; <LINK REF="REF-Stanhope-1975" TYPE="REFERENCE">Stanhope 1975</LINK>; <LINK REF="REF-Van-den-Oever-1998" TYPE="REFERENCE">Van den Oever 1998</LINK>). The Framingham Study showed an annual incidence of 2.6% among women and 1.9% among men (<LINK REF="REF-Brand-1988" TYPE="REFERENCE">Brand 1988</LINK>). In a recent publication of the Edinburgh Vein Study, incidence of CVI was reported as 1% among the general population of the UK (<LINK REF="REF-Robertson-2014" TYPE="REFERENCE">Robertson 2014</LINK>).</P>
<P>Causes of CVI are unknown, although it has been associated with venous dilation, deformity and valvular venous incompetence. Trophic skin disorders and venous ulcers result from severe varicose illness (<LINK REF="REF-Carpentier-2000" TYPE="REFERENCE">Carpentier 2000</LINK>). Varicose veins have a multi-factorial origin related to advanced age and certain lifestyles (sedentary life), pregnancy, hereditary factors and obesity. Risk of ulcers may be increased by trauma and previous episodes of deep venous thrombosis (clinical or subclinical) (<LINK REF="REF-Scott-1995" TYPE="REFERENCE">Scott 1995</LINK>).</P>
<P>Clinical manifestations of CVI differ according to stage of the illness and can include feelings of heaviness in the extremities, paraesthesia (tingling), cramps, pain, oedema (swellings), varicose veins, skin pigmentation, varicose sores and signs of skin atrophy (wasting). Symptoms are frequently related to extent of disease. Underlying venous disease (superficial, deep or both, with or without obstruction) has a major impact on both manifestations of the disease and response to treatment. Since 1994, International Consensus has been used to define and classify CVI in a standardised fashion (<LINK REF="REF-Porter-1995" TYPE="REFERENCE">Porter 1995</LINK>). According to this Consensus, clinical signs (C), aetiology (E), anatomical distribution (A) and physiological conditions (P) (CEAP) are used to classify CVI. A later revision of the CEAP classification established a means of differentiating between chronic venous disorder (referring to all morphology and functional abnormalities of the venous system) and CVI (reserved for more advanced stages of the disease with oedema, skin changes or venous ulcers) (<LINK REF="REF-Ekl_x00f6_f-2004" TYPE="REFERENCE">Eklöf 2004</LINK>). In parallel, a venous clinical severity score (ranging from none (0) to severe (3)) was established to assess pain, varicose veins, venous oedema, skin pigmentation, inflammation, induration, active ulcer (number, duration and size) and use of compression therapy (<LINK REF="REF-Vasquez-2010" TYPE="REFERENCE">Vasquez 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery, sclerotherapy and mechanical compression are generally preferred treatments for CVI. However, pharmacological treatments or phlebotonics are often used because they are easy to administer, and because compliance with compressive treatments (such as elastic stockings) is often poor.</P>
<P>Phlebotonics represent a heterogeneous group of medications used to treat CVI. Most of these drugs are natural flavonoids extracted from plants. Synthetic products with flavonoid-like properties are also used to treat venous disorders. In the Anatomical Therapeutic Chemical (ATC) system, phlebotonics are classified as vasoprotective agents (<LINK REF="REF-ATC-2015" TYPE="REFERENCE">ATC 2015</LINK>). Within this classification system, active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties<I>.</I> Phlebotonics are known as venoactive drugs whose mechanism of action is not scientifically well established despite the availability of numerous studies examining their pharmacological and clinical properties. These medications are associated with effects on macrocirculation (e.g. they may improve venous tone) (<LINK REF="REF-Tsouderos-1991" TYPE="REFERENCE">Tsouderos 1991</LINK>) and on microcirculatory parameters (e.g. they may decrease capillary hyperpermeability) (<LINK REF="REF-Behar-1988" TYPE="REFERENCE">Behar 1988</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Although phlebotonics are commercialised in many countries, in others they are not widely available. In some countries, such as Spain, for certain phlebotonics (calcium dobesilate, chromocarbe and naftazone) the CVI indication has been withdrawn, and for several other phlebotonics, such as aminaftone, diosmine, hidrosmine, escin and some rutosides, conditions of use during exacerbations of CVI have been limited to two or three months by the Spanish Ministry of Health (<LINK REF="REF-Spanish-Min.-Health" TYPE="REFERENCE">Spanish Min. Health</LINK>).</P>
<P>Controversy surrounds the clinical relevance of the efficacy and benefit-risk balance of phlebotonics. Case-control studies have found that risk of agranulocytosis is associated with some phlebotonics (<LINK REF="REF-Iba_x00f1_ez-2000" TYPE="REFERENCE">Ibañez 2000</LINK>; <LINK REF="REF-Ib_x00e1__x00f1_ez-2005" TYPE="REFERENCE">Ibáñez 2005</LINK>; <LINK REF="REF-Kaufman-1991" TYPE="REFERENCE">Kaufman 1991</LINK>). As efficacy is not well defined and serious harmful effects have been associated with phlebotonics, evaluation of available evidence is needed.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-02-24 16:48:30 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of phlebotonics administered both orally and topically for treatment of signs and symptoms of lower extremity CVI.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-03-31 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised, double-blind, controlled trials assessing the efficacy and/or safety of phlebotonics compared with placebo in patients with CVI at any stage of the disease. We excluded from this systematic review (SR) studies that did not meet the above criteria. We did not choose specific diagnostic classifications of CVI a priori because most of the studies were carried out before 1994 - the year of the international diagnostic consensus of CVI. Therefore, we included RCTs with different diagnostic criteria. We included studies in which use of compression measures (support tights) was similar across groups.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Participants included males and females over 18 years of age suffering from any type of CVI. CVI could be diagnosed according to explicit clinical criteria and/or by objective instruments. Patient background, ethnicity and medical co-morbidities at the beginning of the study did not influence the decision to include or exclude the study. We excluded studies that included patients with active thrombophlebitis and those including pregnant women.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We considered the following interventions to treat CVI acceptable for inclusion: treatments including venoactive drugs or phlebotonics, administered orally or topically, at any dosage and independently of the duration of treatment, compared with placebo. We did not include in this review studies that compared phlebotonics among themselves or with any other therapeutic method (i.e. support tights or surgery).</P>
<UL>
<LI>Natural products.</LI>
<UL>
<LI>Flavonoids: rutoside, french maritime pine bark extract, grape seed extract, diosmine and hidrosmine, disodium flavodate.</LI>
<LI>Saponosides: Centella asiatica.</LI>
</UL>
<LI>Synthetic products: calcium dobesilate, naftazone, aminaftone, chromocarbe.</LI>
</UL>
<P>We excluded escin (horse chestnut seed extract), as it is covered in another Cochrane review (<LINK REF="REF-Pittler-2012" TYPE="REFERENCE">Pittler 2012</LINK>).</P>
<P>Pentoxifylline is classified as a peripheral vasodilator, not as a vasoprotective agent (<LINK REF="REF-ATC-2015" TYPE="REFERENCE">ATC 2015</LINK>); therefore, we excluded it from this review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We included studies that assessed any of the following outcome measures.<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Oedema in the lower limb measured by the dichotomous variable 'oedema' and the continuous variables 'ankle perimeter circumference' and 'volume of the leg'.</LI>
<LI>Specific quality of life (QoL) scales (e.g. Chronic Venous Insufficiency International Questionnaire (CIVIQ)).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>
<I>Assessment of CVI: objective signs </I>
</LI>
<UL>
<LI>Skin manifestations such as venous ulcers and trophic alterations (e.g. lipodermatosclerosis (hardening of the skin that may cause red/brown pigmentation and is accompanied by wasting of subcutaneous fat), telangiectasia (small red points on the skin caused by permanently opened tiny blood vessels), reticular veins (dilated veins that show as a net-like pattern on the skin), varicose veins (permanently dilated veins)).</LI>
</UL>
<LI>
<I>Assessment of CVI: subjective symptoms </I>
</LI>
<UL>
<LI>Pain in the lower legs.</LI>
<LI>Cramps in the lower legs.</LI>
<LI>Restless legs.</LI>
<LI>Itching in the lower legs.</LI>
<LI>Feeling of heaviness in the lower legs.</LI>
<LI>Swelling in the lower legs.</LI>
<LI>Paraesthesias (abnormal sensations, such as prickling, burning, tingling) in the lower legs.</LI>
<LI>Satisfaction of participants.</LI>
</UL>
<LI>
<I>Adverse events </I>
</LI>
<UL>
<LI>Adverse reactions experienced by participants during the trial, as reported by questionnaire or related by participants and specified within the publication.</LI>
</UL>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-03-31 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-03-31 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (August 2015), along with the Cochrane Central Register of Controlled Trials (<A HREF="http://www.metaxis.com/CRSWeb/Index.asp">http://www.metaxis.com/CRSWeb/Index.asp</A>) (CENTRAL; 2015, Issue 7). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search the CRS. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Vascular module in <I>The Cochrane Library</I> (<A HREF="http://www.cochranelibrary.com/">www.cochranelibrary.com</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we searched the reference lists of articles retrieved by electronic searches for additional citations. We also contacted authors of unpublished studies.</P>
<P>We searched for ongoing studies in the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal (<A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>) (last searched August 2015, using the terms "chronic venous" AND "placebo" and the recruitment status "recruiting patients").</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-03-30 15:50:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>In the first version of this SR, two review authors (MMZ and RV, DC or EV) assessed independently the eligibility of studies identified by the searches. Some disagreements arose about the eligibility assessment; consequently, a third review author (XB) evaluated these studies independently and discussed them with the rest of the team, and a consensus opinion was reached. In the present update, two review authors (RV and SU) assessed independently the eligibility of new studies identified by the searches. A third review author (MMZ) helped to resolve disagreements.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>In the update of this SR, two review authors (RV and SU) independently extracted data from new studies and entered them on a previously tested standardised form. A third review author (MMZ) checked the extracted data. Collected information includes characteristics of study participants, characteristics of intervention and control groups and outcome characteristics of every group of participants. For cross-over studies, we extracted and analysed only data related to the first period of treatment.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (RV and SU) assessed independently the risk of bias of included studies. A third review author (MMZ) helped to resolve disagreements. We specifically assessed the randomisation method (sequence generation and allocation concealment); blinding of participants, caregivers/study researchers and outcome assessors to the intervention; whether outcome data were incomplete; and selection bias.</P>
<P>Once this information was gathered, review authors classified each study into one of three levels of risk of bias: low, unclear or high, based on the criteria specified in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We also evaluated the quality of the evidence by using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) system and developed a 'Summary of findings' table (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). We rated the quality (certainty) of the evidence as high, moderate, low or very low while considering several components (risk of bias, consistency, directness, precision and publication bias).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We estimated effects of treatment with phlebotonics by using risk ratios (RRs) for dichotomous variables and mean differences (MDs) or standardised mean differences (SMDs) for continuous variables, along with their corresponding 95% confidence intervals (CIs). We calculated SMDs when studies used different instruments to measure the same variable.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-09-09 16:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed dichotomous variables by applying the intention-to-treat (ITT) principle to analyse every individual in the randomly assigned treatment group regardless of whether individuals completed treatment or withdrew prematurely from the study. We included in the ITT analysis only studies that provided data from all randomised participants, or that stated the number of participants lost during follow-up. We numerically imputed missing values due to withdrawal of participants or loss to follow-up as therapeutic failures in both comparative groups. For continuous variables, we analysed data as provided by study authors, either per protocol or as ITT values.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Before obtaining global effect estimators, we carried out an analysis to detect the presence of heterogeneity by using the I<SUP>2</SUP> statistic. The I<SUP>2</SUP> statistic describes the percentage of total variation across studies that is due to heterogeneity rather than to sampling error (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). When statistical heterogeneity was high (I<SUP>2</SUP> &gt; 75%), we did not pool studies. For levels of I<SUP>2</SUP> less than 50%, we applied a fixed-effect model; for levels of I<SUP>2</SUP> greater than 50% but less than 75%, we applied a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We constructed a funnel plot to assess whether oedema (dichotomous variable) was subject to publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We obtained data from the included studies for variables evaluated at the end of treatment. In addition, we obtained data from measures of change when no significant baseline differences were evident between compared groups. We then pooled these together with other similar continuous outcomes.</P>
<P>We split outcomes of variables measured by ordinal categorical scales in the included studies into two groups of response. We considered one group as showing success (no signs or symptoms or mild manifestations) and the other as showing failure (moderate, severe or very severe persistence of signs and symptoms).</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings</HEADING>
<P>We used the principles of the GRADE system to assess the quality of the body of evidence associated with main outcomes and constructed a &#8217;Summary of findings&#8217; (SoF) table using GRADE profiler software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the quality of a body of evidence considers within-study risk of bias, directness of the evidence, heterogeneity in the data, precision of effect estimates and additional considerations (including risk of publication bias) (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>).</P>
<P>Two review authors (MMZ and RV) independently assessed the quality of the body of evidence on the following outcomes.</P>
<UL>
<LI>Oedema in the lower legs (dichotomous variable).</LI>
<LI>Oedema in the lower legs (circumference mm).</LI>
<LI>Quality of life.</LI>
<LI>Participants with ulcer cured.</LI>
<LI>Participants with adverse events.</LI>
</UL>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Apart from the overall analysis of phlebotonics, we carried out subgroup analyses of the active principles. These included looking at the influence on results of the following phlebotonics: rutosides, hidrosmine, diosmine, calcium dobesilate, disodium flavodate, grape seed extract, french maritime pine bark extract, chromocarbe and aminaftone.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-03-30 15:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analyses to assess the influence on data of assumptions and decisions of review authors during the review process. We re-analysed data by:</P>
<UL>
<LI>excluding studies that used compression measures;</LI>
<LI>excluding unpublished studies; and</LI>
<LI>excluding studies with high or unclear risk of bias.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-01 09:23:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Details of all included studies are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<P>We applied no language restrictions.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2015-10-20 12:26:09 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we identified six new included studies (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>). We reclassified one study that was previously excluded as an included study (<LINK REF="STD-Cesarone-2002" TYPE="STUDY">Cesarone 2002</LINK>). We obtained information from researchers about the unpublished and interrupted clinical trial <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>. In total, we included 66 studies. Of the 66 included double-blind, placebo-controlled clinical trials, we did not include 13 studies in the efficacy analysis; 10 studies corresponded to the rutoside group (<LINK REF="STD-Bergqvist-1981" TYPE="STUDY">Bergqvist 1981</LINK>; <LINK REF="STD-Cloarec-1994" TYPE="STUDY">Cloarec 1994</LINK>; <LINK REF="STD-Jongste-1986" TYPE="STUDY">Jongste 1986</LINK>; <LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>; <LINK REF="STD-Nocker-1990" TYPE="STUDY">Nocker 1990</LINK>; <LINK REF="STD-Prerovsky-1972" TYPE="STUDY">Prerovsky 1972</LINK>; <LINK REF="STD-Renton-1994" TYPE="STUDY">Renton 1994</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>; <LINK REF="STD-Rudofsky-1989" TYPE="STUDY">Rudofsky 1989</LINK>; <LINK REF="STD-Sentou-1984" TYPE="STUDY">Sentou 1984</LINK>), two corresponded to calcium dobesilate (<LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Pecchi-1990" TYPE="STUDY">Pecchi 1990</LINK>) and another corresponded to french bark pine extract (<LINK REF="STD-Petrassi-2000" TYPE="STUDY">Petrassi 2000</LINK>). Most studies were published in English, but five were published in German (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Kiesewetter-1997" TYPE="STUDY">Kiesewetter 1997</LINK>; <LINK REF="STD-Koscielnny-1996" TYPE="STUDY">Koscielnny 1996</LINK>; <LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>), eight in French (<LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Chassignolle-1994" TYPE="STUDY">Chassignolle 1994</LINK>; <LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>; <LINK REF="STD-Zucarelli-1987" TYPE="STUDY">Zucarelli 1987</LINK>), four in Spanish (<LINK REF="STD-Flota_x002d_Cervera-2008" TYPE="STUDY">Flota-Cervera 2008</LINK>; <LINK REF="STD-Kl_x00fc_ken-1971" TYPE="STUDY">Klüken 1971</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Serralde-1990" TYPE="STUDY">Serralde 1990</LINK>) and three in Italian (<LINK REF="STD-Allegra-1981" TYPE="STUDY">Allegra 1981</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-Pecchi-1990" TYPE="STUDY">Pecchi 1990</LINK>).</P>
<P>We excluded these studies from the efficacy analysis for these reasons.</P>
<UL>
<LI>Only mean data were provided without standard deviations (SDs) or standard errors (SEs) (<LINK REF="STD-Sentou-1984" TYPE="STUDY">Sentou 1984</LINK>).</LI>
<LI>Medians were provided instead of means (<LINK REF="STD-Renton-1994" TYPE="STUDY">Renton 1994</LINK>).</LI>
<LI>Outcomes were reported by graph only (<LINK REF="STD-Nocker-1990" TYPE="STUDY">Nocker 1990</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>; <LINK REF="STD-Rudofsky-1989" TYPE="STUDY">Rudofsky 1989</LINK>).</LI>
<LI>First period data were not provided in studies of cross-over design (<LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Prerovsky-1972" TYPE="STUDY">Prerovsky 1972</LINK>).</LI>
<LI>No data were provided for any variable (<LINK REF="STD-Bergqvist-1981" TYPE="STUDY">Bergqvist 1981</LINK>; <LINK REF="STD-Cloarec-1994" TYPE="STUDY">Cloarec 1994</LINK>; <LINK REF="STD-Jongste-1986" TYPE="STUDY">Jongste 1986</LINK>).</LI>
<LI>Measured changes were reported when significant differences in baseline were noted between compared groups (<LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>; <LINK REF="STD-Petrassi-2000" TYPE="STUDY">Petrassi 2000</LINK>).</LI>
<LI>A quasi-randomisation method was used in which treatments were alternatively allocated depending on participants' order of arrival (<LINK REF="STD-Pecchi-1990" TYPE="STUDY">Pecchi 1990</LINK>).</LI>
<LI>At baseline, a significant imbalance in the ulcer area was evident between groups (1130 mm<SUP>2</SUP> in the rutoside group vs 430 mm<SUP>2</SUP> in the placebo group; P value = 0.039) (<LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>).</LI>
</UL>
<P>Of the 53 studies with oral phlebotonics included in the efficacy analysis, studied phlebotonics corresponded to 28 studies of rutosides, 10 of hidrosmine and diosmine, nine of calcium dobesilate, two of Centella asiatica, two of aminaftone, one of french maritime pine bark extract and one of grape seed extract. No studies with topical phlebotonics or chromocarbe or naftazone or disodium flavodate fulfilled the inclusion criteria. Length of treatment and participant follow-up ranged from 28 days to four months, except for two studies, in which follow-up lasted six months.</P>
<P>Overall, we included 6013 participants in the meta-analysis; 81% were female and 19% were male; mean age was 50 years (range 32 to 62 years). The mean number of participants included per clinical trial was 113 (range 20 to 660). All participants met the respective CVI criteria of every study, although we noted variation between studies in degree of progression to CVI, as well as in diagnostic classification criteria applied. Only 28% of studies reported the diagnostic classification used. Among studies that did report on the diagnostic classification of CVI, the CEAP classification (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>) was used most often, followed by Widmer's classification (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Koscielnny-1996" TYPE="STUDY">Koscielnny 1996</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>). Wert's was the only other classification used (<LINK REF="STD-Kiesewetter-1997" TYPE="STUDY">Kiesewetter 1997</LINK>).</P>
<P>Differences in severity of disease were observed: Some studies (<LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>; <LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>) were performed with participants at early and symptomatic CVI stages, and others (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Schultz_x002d_Ehrenburg-1993" TYPE="STUDY">Schultz-Ehrenburg 1993</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) included participants at advanced stages because of long progression of the disease or the presence of venous ulcers. However, most studies included participants at moderate CVI stages with oedema, skin pigmentation, varicose veins and post-thrombotic syndromes.</P>
<P>Ten studies specified that investigators used compression therapy (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Schultz_x002d_Ehrenburg-1993" TYPE="STUDY">Schultz-Ehrenburg 1993</LINK>; <LINK REF="STD-Zucarelli-1987" TYPE="STUDY">Zucarelli 1987</LINK>).</P>
<P>Ten studies used a visual analogue scale (VAS) to measure subjective variables (<LINK REF="STD-Alterkamper-1987" TYPE="STUDY">Alterkamper 1987</LINK>; <LINK REF="STD-Cesarone-2002" TYPE="STUDY">Cesarone 2002</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>; <LINK REF="STD-Zucarelli-1987" TYPE="STUDY">Zucarelli 1987</LINK>). Other studies used ordinal categorical scales with a scoring system from -3 to +1 (<LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>), -1 to + 1 (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>), 0 to 1 (<LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>), 0 to 2 (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>; <LINK REF="STD-Kiesewetter-1997" TYPE="STUDY">Kiesewetter 1997</LINK>), 0 to 3 (<LINK REF="STD-Allegra-1981" TYPE="STUDY">Allegra 1981</LINK>; <LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>; <LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Pointel-1986" TYPE="STUDY">Pointel 1986</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Serralde-1990" TYPE="STUDY">Serralde 1990</LINK>; <LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>; <LINK REF="STD-Tsouderos-1989" TYPE="STUDY">Tsouderos 1989</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), 0 to 4 (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Chassignolle-1994" TYPE="STUDY">Chassignolle 1994</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Flota_x002d_Cervera-2008" TYPE="STUDY">Flota-Cervera 2008</LINK>), 0 to 5 (<LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>), 0 to 7 (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>) or 0 to 9 (<LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>). Likewise, some of these scales were used to evaluate signs or objective variables such as oedema or trophic disorders. Methods used to measure oedema included metric tape to measure ankle or calf circumference and plethysmographic values (used in most studies) to determine leg volume.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we excluded an additional 115 studies (<LINK REF="STD-Akbulut-2010" TYPE="STUDY">Akbulut 2010</LINK>; <LINK REF="STD-Allaert-1992" TYPE="STUDY">Allaert 1992</LINK>; <LINK REF="STD-Amato-1994" TYPE="STUDY">Amato 1994</LINK>; <LINK REF="STD-Androulakis-1989" TYPE="STUDY">Androulakis 1989</LINK>; <LINK REF="STD-Avram-1996" TYPE="STUDY">Avram 1996</LINK>; <LINK REF="STD-Bacci-2003" TYPE="STUDY">Bacci 2003</LINK>; <LINK REF="STD-Bastide-1976" TYPE="STUDY">Bastide 1976</LINK>; <LINK REF="STD-Batchvarova-1989" TYPE="STUDY">Batchvarova 1989</LINK>; <LINK REF="STD-Batchvarova-1989a" TYPE="STUDY">Batchvarova 1989a</LINK>; <LINK REF="STD-Behar-1993" TYPE="STUDY">Behar 1993</LINK>; <LINK REF="STD-Belcaro-1986" TYPE="STUDY">Belcaro 1986</LINK>; <LINK REF="STD-Belcaro-1995" TYPE="STUDY">Belcaro 1995</LINK>; <LINK REF="STD-Belcaro-2002" TYPE="STUDY">Belcaro 2002</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Belcaro-2008b" TYPE="STUDY">Belcaro 2008b</LINK>; <LINK REF="STD-Bello-1990" TYPE="STUDY">Bello 1990</LINK>; <LINK REF="STD-Beltramino-1999" TYPE="STUDY">Beltramino 1999</LINK>; <LINK REF="STD-Bento-2006" TYPE="STUDY">Bento 2006</LINK>; <LINK REF="STD-Berson-1978" TYPE="STUDY">Berson 1978</LINK>; <LINK REF="STD-Berson-1980" TYPE="STUDY">Berson 1980</LINK>; <LINK REF="STD-Bohm-1989" TYPE="STUDY">Bohm 1989</LINK>; <LINK REF="STD-Bolliger-1972" TYPE="STUDY">Bolliger 1972</LINK>; <LINK REF="STD-Bosse-1985" TYPE="STUDY">Bosse 1985</LINK>; <LINK REF="STD-Brami-1983" TYPE="STUDY">Brami 1983</LINK>; <LINK REF="STD-Brock-1991" TYPE="STUDY">Brock 1991</LINK>; <LINK REF="STD-Brock-2001" TYPE="STUDY">Brock 2001</LINK>; <LINK REF="STD-Carstens-1985" TYPE="STUDY">Carstens 1985</LINK>; <LINK REF="STD-Cesarone-1992" TYPE="STUDY">Cesarone 1992</LINK>; <LINK REF="STD-Cesarone-1994" TYPE="STUDY">Cesarone 1994</LINK>; <LINK REF="STD-Cesarone-2001b" TYPE="STUDY">Cesarone 2001b</LINK>; <LINK REF="STD-Cesarone-2001d" TYPE="STUDY">Cesarone 2001d</LINK>; <LINK REF="STD-Cesarone-2001e" TYPE="STUDY">Cesarone 2001e</LINK>; <LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Cesarone-2005" TYPE="STUDY">Cesarone 2005</LINK>; <LINK REF="STD-Cesarone-2006" TYPE="STUDY">Cesarone 2006</LINK>; <LINK REF="STD-Cesarone-2006a" TYPE="STUDY">Cesarone 2006a</LINK>; <LINK REF="STD-Cesarone-2006b" TYPE="STUDY">Cesarone 2006b</LINK>; <LINK REF="STD-Cesarone-2006c" TYPE="STUDY">Cesarone 2006c</LINK>; <LINK REF="STD-Cesarone-2006d" TYPE="STUDY">Cesarone 2006d</LINK>; <LINK REF="STD-Cesarone-2010" TYPE="STUDY">Cesarone 2010</LINK>; <LINK REF="STD-Chiummariello-2009" TYPE="STUDY">Chiummariello 2009</LINK>; <LINK REF="STD-Cospite-1989" TYPE="STUDY">Cospite 1989</LINK>; <LINK REF="STD-Cospite-1996" TYPE="STUDY">Cospite 1996</LINK>; <LINK REF="STD-Cospite-1998" TYPE="STUDY">Cospite 1998</LINK>; <LINK REF="STD-Delacroix-1981" TYPE="STUDY">Delacroix 1981</LINK>; <LINK REF="STD-Delecluse-1991" TYPE="STUDY">Delecluse 1991</LINK>; <LINK REF="STD-de-Parades-1990" TYPE="STUDY">de Parades 1990</LINK>; <LINK REF="STD-Dustmann-1984" TYPE="STUDY">Dustmann 1984</LINK>; <LINK REF="STD-Erdlen-1989" TYPE="STUDY">Erdlen 1989</LINK>; <LINK REF="STD-Erler-1991" TYPE="STUDY">Erler 1991</LINK>; <LINK REF="STD-Fitzgerald-1967" TYPE="STUDY">Fitzgerald 1967</LINK>; <LINK REF="STD-Glinski-1999" TYPE="STUDY">Glinski 1999</LINK>; <LINK REF="STD-Gonzalez_x002d_Fajardo-1990" TYPE="STUDY">Gonzalez-Fajardo 1990</LINK>; <LINK REF="STD-Henriet-1995" TYPE="STUDY">Henriet 1995</LINK>; <LINK REF="STD-Honorato-1990" TYPE="STUDY">Honorato 1990</LINK>; <LINK REF="STD-Horvath-1985" TYPE="STUDY">Horvath 1985</LINK>; <LINK REF="STD-Incandela-2001a" TYPE="STUDY">Incandela 2001a</LINK>; <LINK REF="STD-Incandela-2001b" TYPE="STUDY">Incandela 2001b</LINK>; <LINK REF="STD-Incandela-2002b" TYPE="STUDY">Incandela 2002b</LINK>; <LINK REF="STD-ISRCTN5340167" TYPE="STUDY">ISRCTN5340167</LINK>; <LINK REF="STD-Janssens-1999" TYPE="STUDY">Janssens 1999</LINK>; <LINK REF="STD-Janssens-1999a" TYPE="STUDY">Janssens 1999a</LINK>; <LINK REF="STD-Jantet-2000" TYPE="STUDY">Jantet 2000</LINK>; <LINK REF="STD-Kalus-2004" TYPE="STUDY">Kalus 2004</LINK>; <LINK REF="STD-Koch-2002" TYPE="STUDY">Koch 2002</LINK>; <LINK REF="STD-Koltringer-1993" TYPE="STUDY">Koltringer 1993</LINK>; <LINK REF="STD-Kostering-1985" TYPE="STUDY">Kostering 1985</LINK>; <LINK REF="STD-Kr_x00e4_henb_x00fc_hl-1975" TYPE="STUDY">Krähenbühl 1975</LINK>; <LINK REF="STD-Krc_x00ed_lek-1973" TYPE="STUDY">Krcílek 1973</LINK>; <LINK REF="STD-Le-D_x00e9_v_x00e9_hat-1989" TYPE="STUDY">Le Dévéhat 1989</LINK>; <LINK REF="STD-Lefebvre-1991" TYPE="STUDY">Lefebvre 1991</LINK>; <LINK REF="STD-Marastoni-1982" TYPE="STUDY">Marastoni 1982</LINK>; <LINK REF="STD-Marastoni-1982a" TYPE="STUDY">Marastoni 1982a</LINK>; <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK>; <LINK REF="STD-Monreal-1997" TYPE="STUDY">Monreal 1997</LINK>; <LINK REF="STD-Monteil_x002d_Seurin-1993" TYPE="STUDY">Monteil-Seurin 1993</LINK>; <LINK REF="STD-Monteverde-1987" TYPE="STUDY">Monteverde 1987</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Muschietti-1978" TYPE="STUDY">Muschietti 1978</LINK>; <LINK REF="STD-Naser_x002d_Hijazi-2004" TYPE="STUDY">Naser-Hijazi 2004</LINK>; <LINK REF="STD-NCT01654016" TYPE="STUDY">NCT01654016</LINK>; <LINK REF="STD-NCT02191163" TYPE="STUDY">NCT02191163</LINK>; <LINK REF="STD-NCT02191254" TYPE="STUDY">NCT02191254</LINK>; <LINK REF="STD-NCT02191280" TYPE="STUDY">NCT02191280</LINK>; <LINK REF="STD-Neumann-1995" TYPE="STUDY">Neumann 1995</LINK>; <LINK REF="STD-Neumann_x002d_Mangoldt-1979" TYPE="STUDY">Neumann-Mangoldt 1979</LINK>; <LINK REF="STD-Nill-1970" TYPE="STUDY">Nill 1970</LINK>; <LINK REF="STD-Ottillinger-2001" TYPE="STUDY">Ottillinger 2001</LINK>; <LINK REF="STD-Paciaroni-1982" TYPE="STUDY">Paciaroni 1982</LINK>; <LINK REF="STD-Partsch-1981" TYPE="STUDY">Partsch 1981</LINK>; <LINK REF="STD-Paul-1983" TYPE="STUDY">Paul 1983</LINK>; <LINK REF="STD-Pauschinger-1987" TYPE="STUDY">Pauschinger 1987</LINK>; <LINK REF="STD-Pecking-1998" TYPE="STUDY">Pecking 1998</LINK>; <LINK REF="STD-Pointel-1987b" TYPE="STUDY">Pointel 1987b</LINK>; <LINK REF="STD-Pokrovskii-2005" TYPE="STUDY">Pokrovskii 2005</LINK>; <LINK REF="STD-Questel-1983" TYPE="STUDY">Questel 1983</LINK>; <LINK REF="STD-Rabe-2011b" TYPE="STUDY">Rabe 2011b</LINK>; <LINK REF="STD-Rehn-1993" TYPE="STUDY">Rehn 1993</LINK>; <LINK REF="STD-Rehn-1993b" TYPE="STUDY">Rehn 1993b</LINK>; <LINK REF="STD-Riccioni-2004" TYPE="STUDY">Riccioni 2004</LINK>; <LINK REF="STD-Roztocil-1977" TYPE="STUDY">Roztocil 1977</LINK>; <LINK REF="STD-Roztocil-2003" TYPE="STUDY">Roztocil 2003</LINK>; <LINK REF="STD-Sadoun-1993" TYPE="STUDY">Sadoun 1993</LINK>; <LINK REF="STD-Sanctis-2001" TYPE="STUDY">Sanctis 2001</LINK>; <LINK REF="STD-Schmeck_x002d_Lindenau-2003" TYPE="STUDY">Schmeck-Lindenau 2003</LINK>; <LINK REF="STD-Stefanini-1996" TYPE="STUDY">Stefanini 1996</LINK>; <LINK REF="STD-Steiner-1990" TYPE="STUDY">Steiner 1990</LINK>; <LINK REF="STD-Steiner-1992" TYPE="STUDY">Steiner 1992</LINK>; <LINK REF="STD-Strefezza-2010" TYPE="STUDY">Strefezza 2010</LINK>; <LINK REF="STD-Topalov-1990" TYPE="STUDY">Topalov 1990</LINK>; <LINK REF="STD-Tsukanov-2010" TYPE="STUDY">Tsukanov 2010</LINK>; <LINK REF="STD-Turio-2000" TYPE="STUDY">Turio 2000</LINK>; <LINK REF="STD-Weindorf-1987" TYPE="STUDY">Weindorf 1987</LINK>; <LINK REF="STD-Zuccarelli-1996" TYPE="STUDY">Zuccarelli 1996</LINK>), making a total of 163 studies excluded for a variety of reasons (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details). In total, we excluded 31 studies because they did not use placebo as a control (<LINK REF="STD-Amato-1994" TYPE="STUDY">Amato 1994</LINK>; <LINK REF="STD-Avram-1996" TYPE="STUDY">Avram 1996</LINK>; <LINK REF="STD-Belcaro-1986" TYPE="STUDY">Belcaro 1986</LINK>; <LINK REF="STD-Belcaro-2002" TYPE="STUDY">Belcaro 2002</LINK>; <LINK REF="STD-Beltramino-1999" TYPE="STUDY">Beltramino 1999</LINK>; <LINK REF="STD-Berson-1976" TYPE="STUDY">Berson 1976</LINK>; <LINK REF="STD-Berson-1980" TYPE="STUDY">Berson 1980</LINK>; <LINK REF="STD-Brock-1991" TYPE="STUDY">Brock 1991</LINK>; <LINK REF="STD-Brock-2001" TYPE="STUDY">Brock 2001</LINK>; <LINK REF="STD-Cesarone-2005" TYPE="STUDY">Cesarone 2005</LINK>; <LINK REF="STD-Cesarone-2006" TYPE="STUDY">Cesarone 2006</LINK>; <LINK REF="STD-Cesarone-2006a" TYPE="STUDY">Cesarone 2006a</LINK>; <LINK REF="STD-Cesarone-2006b" TYPE="STUDY">Cesarone 2006b</LINK>; <LINK REF="STD-Cospite-1989" TYPE="STUDY">Cospite 1989</LINK>; <LINK REF="STD-Cospite-1998" TYPE="STUDY">Cospite 1998</LINK>; <LINK REF="STD-Honorato-1990" TYPE="STUDY">Honorato 1990</LINK>; <LINK REF="STD-ISRCTN5340167" TYPE="STUDY">ISRCTN5340167</LINK>; <LINK REF="STD-Koch-2002" TYPE="STUDY">Koch 2002</LINK>; <LINK REF="STD-Marastoni-1982a" TYPE="STUDY">Marastoni 1982a</LINK>; <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK>; <LINK REF="STD-Monteverde-1987" TYPE="STUDY">Monteverde 1987</LINK>; <LINK REF="STD-Muschietti-1978" TYPE="STUDY">Muschietti 1978</LINK>; <LINK REF="STD-Neumann-1995" TYPE="STUDY">Neumann 1995</LINK>; <LINK REF="STD-Rehn-1993" TYPE="STUDY">Rehn 1993</LINK>; <LINK REF="STD-Rehn-1996" TYPE="STUDY">Rehn 1996</LINK>; <LINK REF="STD-Sadoun-1993" TYPE="STUDY">Sadoun 1993</LINK>; <LINK REF="STD-Stefanini-1996" TYPE="STUDY">Stefanini 1996</LINK>; <LINK REF="STD-Stegmann-1987" TYPE="STUDY">Stegmann 1987</LINK>; <LINK REF="STD-Strefezza-2010" TYPE="STUDY">Strefezza 2010</LINK>; <LINK REF="STD-Tsukanov-2010" TYPE="STUDY">Tsukanov 2010</LINK>; <LINK REF="STD-Zicot-1993" TYPE="STUDY">Zicot 1993</LINK>), 56 because the intervention used by researchers was not included in this SR (<LINK REF="STD-Akbulut-2010" TYPE="STUDY">Akbulut 2010</LINK>; <LINK REF="STD-Bacci-2003" TYPE="STUDY">Bacci 2003</LINK>; <LINK REF="STD-Bastide-1976" TYPE="STUDY">Bastide 1976</LINK>; <LINK REF="STD-Batchvarova-1989a" TYPE="STUDY">Batchvarova 1989a</LINK>; <LINK REF="STD-Behar-1993" TYPE="STUDY">Behar 1993</LINK>; <LINK REF="STD-Bello-1990" TYPE="STUDY">Bello 1990</LINK>; <LINK REF="STD-Bento-2006" TYPE="STUDY">Bento 2006</LINK>; <LINK REF="STD-Berson-1978" TYPE="STUDY">Berson 1978</LINK>; <LINK REF="STD-Bohm-1989" TYPE="STUDY">Bohm 1989</LINK>; <LINK REF="STD-Bolliger-1972" TYPE="STUDY">Bolliger 1972</LINK>; <LINK REF="STD-Bosse-1985" TYPE="STUDY">Bosse 1985</LINK>; <LINK REF="STD-Brami-1983" TYPE="STUDY">Brami 1983</LINK>; <LINK REF="STD-Carstens-1985" TYPE="STUDY">Carstens 1985</LINK>; <LINK REF="STD-Cataldi-2001" TYPE="STUDY">Cataldi 2001</LINK>; <LINK REF="STD-Cesarone-2001b" TYPE="STUDY">Cesarone 2001b</LINK>; <LINK REF="STD-Chiummariello-2009" TYPE="STUDY">Chiummariello 2009</LINK>; <LINK REF="STD-Cospite-1996" TYPE="STUDY">Cospite 1996</LINK>; <LINK REF="STD-de-Parades-1990" TYPE="STUDY">de Parades 1990</LINK>; <LINK REF="STD-Delacroix-1981" TYPE="STUDY">Delacroix 1981</LINK>; <LINK REF="STD-Delecluse-1991" TYPE="STUDY">Delecluse 1991</LINK>; <LINK REF="STD-Dustmann-1984" TYPE="STUDY">Dustmann 1984</LINK>; <LINK REF="STD-Erdlen-1989" TYPE="STUDY">Erdlen 1989</LINK>; <LINK REF="STD-Erler-1991" TYPE="STUDY">Erler 1991</LINK>; <LINK REF="STD-Henriet-1995" TYPE="STUDY">Henriet 1995</LINK>; <LINK REF="STD-Horvath-1985" TYPE="STUDY">Horvath 1985</LINK>; <LINK REF="STD-Janssens-1999a" TYPE="STUDY">Janssens 1999a</LINK>; <LINK REF="STD-Kiesewetter-2000" TYPE="STUDY">Kiesewetter 2000</LINK>; <LINK REF="STD-Koltringer-1993" TYPE="STUDY">Koltringer 1993</LINK>; <LINK REF="STD-Kr_x00e4_henb_x00fc_hl-1975" TYPE="STUDY">Krähenbühl 1975</LINK>; <LINK REF="STD-Krc_x00ed_lek-1973" TYPE="STUDY">Krcílek 1973</LINK>; <LINK REF="STD-Languillat-1988b" TYPE="STUDY">Languillat 1988b</LINK>; <LINK REF="STD-Marastoni-1982" TYPE="STUDY">Marastoni 1982</LINK>; <LINK REF="STD-Monteil_x002d_Seurin-1993" TYPE="STUDY">Monteil-Seurin 1993</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-NCT02191163" TYPE="STUDY">NCT02191163</LINK>; <LINK REF="STD-NCT02191254" TYPE="STUDY">NCT02191254</LINK>; <LINK REF="STD-NCT02191280" TYPE="STUDY">NCT02191280</LINK>; <LINK REF="STD-Neumann_x002d_Mangoldt-1979" TYPE="STUDY">Neumann-Mangoldt 1979</LINK>; <LINK REF="STD-Nill-1970" TYPE="STUDY">Nill 1970</LINK>; <LINK REF="STD-Ottillinger-2001" TYPE="STUDY">Ottillinger 2001</LINK>; <LINK REF="STD-Paciaroni-1982" TYPE="STUDY">Paciaroni 1982</LINK>; <LINK REF="STD-Partsch-1981" TYPE="STUDY">Partsch 1981</LINK>; <LINK REF="STD-Paul-1983" TYPE="STUDY">Paul 1983</LINK>; <LINK REF="STD-Pauschinger-1987" TYPE="STUDY">Pauschinger 1987</LINK>; <LINK REF="STD-Pointel-1987b" TYPE="STUDY">Pointel 1987b</LINK>; <LINK REF="STD-Pokrovskii-2005" TYPE="STUDY">Pokrovskii 2005</LINK>; <LINK REF="STD-Rabe-2011b" TYPE="STUDY">Rabe 2011b</LINK>; <LINK REF="STD-Riccioni-2004" TYPE="STUDY">Riccioni 2004</LINK>; <LINK REF="STD-Sanctis-2001" TYPE="STUDY">Sanctis 2001</LINK>; <LINK REF="STD-Steiner-1990" TYPE="STUDY">Steiner 1990</LINK>; <LINK REF="STD-Steiner-1992" TYPE="STUDY">Steiner 1992</LINK>; <LINK REF="STD-Topalov-1990" TYPE="STUDY">Topalov 1990</LINK>; <LINK REF="STD-Turio-2000" TYPE="STUDY">Turio 2000</LINK>; <LINK REF="STD-Weindorf-1987" TYPE="STUDY">Weindorf 1987</LINK>; <LINK REF="STD-Widmer-1972" TYPE="STUDY">Widmer 1972</LINK>; <LINK REF="STD-Zuccarelli-1996" TYPE="STUDY">Zuccarelli 1996</LINK>), 29 because no clinical endpoints were assessed or only outcomes not included in this SR were reported (<LINK REF="STD-Androulakis-1989" TYPE="STUDY">Androulakis 1989</LINK>; <LINK REF="STD-Auteri-1990" TYPE="STUDY">Auteri 1990</LINK>; <LINK REF="STD-Belcaro-1995" TYPE="STUDY">Belcaro 1995</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Boisseau-1995" TYPE="STUDY">Boisseau 1995</LINK>; <LINK REF="STD-Bort-1995" TYPE="STUDY">Bort 1995</LINK>; <LINK REF="STD-Cesarone-1992" TYPE="STUDY">Cesarone 1992</LINK>; <LINK REF="STD-Cesarone-1994" TYPE="STUDY">Cesarone 1994</LINK>; <LINK REF="STD-Cesarone-2001" TYPE="STUDY">Cesarone 2001</LINK>; <LINK REF="STD-Cesarone-2001c" TYPE="STUDY">Cesarone 2001c</LINK>; <LINK REF="STD-Chant-1973" TYPE="STUDY">Chant 1973</LINK>; <LINK REF="STD-Clemens-1986" TYPE="STUDY">Clemens 1986</LINK>; <LINK REF="STD-Duchene-1988" TYPE="STUDY">Duchene 1988</LINK>; <LINK REF="STD-Forconi-1977" TYPE="STUDY">Forconi 1977</LINK>; <LINK REF="STD-Gonzalez_x002d_Fajardo-1990" TYPE="STUDY">Gonzalez-Fajardo 1990</LINK>; <LINK REF="STD-Incandela-1995" TYPE="STUDY">Incandela 1995</LINK>; <LINK REF="STD-Incandela-1996" TYPE="STUDY">Incandela 1996</LINK>; <LINK REF="STD-Janssens-1999" TYPE="STUDY">Janssens 1999</LINK>; <LINK REF="STD-Kalus-2004" TYPE="STUDY">Kalus 2004</LINK>; <LINK REF="STD-Kostering-1985" TYPE="STUDY">Kostering 1985</LINK>; <LINK REF="STD-Languillat-1989" TYPE="STUDY">Languillat 1989</LINK>; <LINK REF="STD-Le-D_x00e9_v_x00e9_hat-1989" TYPE="STUDY">Le Dévéhat 1989</LINK>; <LINK REF="STD-Le-D_x00e9_v_x00e9_hat-1997" TYPE="STUDY">Le Dévéhat 1997</LINK>; <LINK REF="STD-Naser_x002d_Hijazi-2004" TYPE="STUDY">Naser-Hijazi 2004</LINK>; <LINK REF="STD-Neumann-1988" TYPE="STUDY">Neumann 1988</LINK>; <LINK REF="STD-Neumann-1990" TYPE="STUDY">Neumann 1990</LINK>; <LINK REF="STD-Questel-1983" TYPE="STUDY">Questel 1983</LINK>; <LINK REF="STD-Roztocil-1977" TYPE="STUDY">Roztocil 1977</LINK>; <LINK REF="STD-Seydewitz-1992" TYPE="STUDY">Seydewitz 1992</LINK>), 16 because they were not double-blinded (<LINK REF="STD-Belcaro-1989" TYPE="STUDY">Belcaro 1989</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Cesarone-2001a" TYPE="STUDY">Cesarone 2001a</LINK>; <LINK REF="STD-Cesarone-2010" TYPE="STUDY">Cesarone 2010</LINK>; <LINK REF="STD-De-Anna-1989" TYPE="STUDY">De Anna 1989</LINK>; <LINK REF="STD-De-Sanctis-2001" TYPE="STUDY">De Sanctis 2001</LINK>; <LINK REF="STD-Frausini-1985" TYPE="STUDY">Frausini 1985</LINK>; <LINK REF="STD-Glinski-1999" TYPE="STUDY">Glinski 1999</LINK>; <LINK REF="STD-Granger-1995" TYPE="STUDY">Granger 1995</LINK>; <LINK REF="STD-Incandela-2001" TYPE="STUDY">Incandela 2001</LINK>; <LINK REF="STD-Incandela-2002" TYPE="STUDY">Incandela 2002</LINK>; <LINK REF="STD-Menyhei-1994" TYPE="STUDY">Menyhei 1994</LINK>; <LINK REF="STD-NCT01654016" TYPE="STUDY">NCT01654016</LINK>; <LINK REF="STD-Petruzzellis-2002" TYPE="STUDY">Petruzzellis 2002</LINK>; <LINK REF="STD-Roztocil-2003" TYPE="STUDY">Roztocil 2003</LINK>; <LINK REF="STD-Steru-1988" TYPE="STUDY">Steru 1988</LINK>) and seven because they were not considered RCTs (<LINK REF="STD-Batchvarova-1989" TYPE="STUDY">Batchvarova 1989</LINK>; <LINK REF="STD-Belcaro-2008b" TYPE="STUDY">Belcaro 2008b</LINK>; <LINK REF="STD-Berson-1978" TYPE="STUDY">Berson 1978</LINK>; <LINK REF="STD-Cesarone-2006c" TYPE="STUDY">Cesarone 2006c</LINK>; <LINK REF="STD-Fitzgerald-1967" TYPE="STUDY">Fitzgerald 1967</LINK>; <LINK REF="STD-Jantet-2000" TYPE="STUDY">Jantet 2000</LINK>; <LINK REF="STD-Pollastri-1982" TYPE="STUDY">Pollastri 1982</LINK>). Furthermore, we excluded 24 studies because the study population did not include patients with venous insufficiency (<LINK REF="STD-Allaert-1992" TYPE="STUDY">Allaert 1992</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Boccalon-1989" TYPE="STUDY">Boccalon 1989</LINK>; <LINK REF="STD-Cesarone-2001d" TYPE="STUDY">Cesarone 2001d</LINK>; <LINK REF="STD-Cesarone-2001e" TYPE="STUDY">Cesarone 2001e</LINK>; <LINK REF="STD-Cesarone-2002a" TYPE="STUDY">Cesarone 2002a</LINK>; <LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Cesarone-2006d" TYPE="STUDY">Cesarone 2006d</LINK>; <LINK REF="STD-Friederich-1978" TYPE="STUDY">Friederich 1978</LINK>; <LINK REF="STD-Gouny-1999" TYPE="STUDY">Gouny 1999</LINK>; <LINK REF="STD-Incandela-2001a" TYPE="STUDY">Incandela 2001a</LINK>; <LINK REF="STD-Incandela-2001b" TYPE="STUDY">Incandela 2001b</LINK>; <LINK REF="STD-Incandela-2002b" TYPE="STUDY">Incandela 2002b</LINK>; <LINK REF="STD-Kranendonk-1993" TYPE="STUDY">Kranendonk 1993</LINK>; <LINK REF="STD-Lambelet-1973" TYPE="STUDY">Lambelet 1973</LINK>; <LINK REF="STD-Lefebvre-1991" TYPE="STUDY">Lefebvre 1991</LINK>; <LINK REF="STD-Monreal-1997" TYPE="STUDY">Monreal 1997</LINK>; <LINK REF="STD-Pecking-1998" TYPE="STUDY">Pecking 1998</LINK>; <LINK REF="STD-Petruzzellis-1990" TYPE="STUDY">Petruzzellis 1990</LINK>; <LINK REF="STD-Rehn-1993b" TYPE="STUDY">Rehn 1993b</LINK>; <LINK REF="STD-Rish-1972" TYPE="STUDY">Rish 1972</LINK>; <LINK REF="STD-Schmeck_x002d_Lindenau-2003" TYPE="STUDY">Schmeck-Lindenau 2003</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Strauss-1992" TYPE="STUDY">Strauss 1992</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-01 09:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Only four studies (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) presented low risk of bias (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).<BR/>
</P>
<ALLOCATION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 66 studies included, 19 (29%) submitted details on the randomisation process (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>Only 12 (18%) studies provided an accurate explanation of the allocation concealment process. Two used the sealed envelope method (<LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>), four used indistinguishable number packaging (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>), one used randomised numbered bottles provided by an external investigator (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>), two used allocation concealment by direct phone calls (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) and the remaining three studies (<LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) used computerised random assignment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 66 studies included, 39 (59%) reported that the placebo used was identical to the active treatment; thus participants, study researchers and outcome assessors were blinded to the intervention. The other studies did not mention whether placebo had identical characteristics to those of the active drug (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-04-01 09:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 66 studies included, 51 (77%) reported participant withdrawals. The percentage of withdrawn participants ranged from 0% to 42.5% (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Only seven (16%) studies included in the efficacy analysis stated that investigators carried out an ITT analysis (<LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>). Six studies had high risk of bias in this domain (<LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>; <LINK REF="STD-Sentou-1984" TYPE="STUDY">Sentou 1984</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>): four described an important percentage of losses (42.5% <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; 18% <LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>; 39% <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>; 34% <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>), one interrupted recruitment because financial support was interrupted (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>) and one did not specify the number of participants included (<LINK REF="STD-Sentou-1984" TYPE="STUDY">Sentou 1984</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 66 studies included, 56 (85%) reported all outcomes specified in the methods section. We evaluated six studies as having high risk of selective reporting bias because we noted differences between outcomes reported in the methods and results sections (<LINK REF="STD-Cloarec-1994" TYPE="STUDY">Cloarec 1994</LINK>; <LINK REF="STD-Jongste-1986" TYPE="STUDY">Jongste 1986</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>), and because data before the cross-over were not reported (<LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>). One study was interrupted, and results of this study were not published (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>). <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK> provided no information about adverse events.</P>
<P>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> shows that all studies, except one (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>), are located symmetrically around the effect measure at the top of the pyramid, indicating highly precise results. Apart from one imprecise study favouring phlebotonics (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>), no small or heterogeneous studies provided results favouring placebo or phlebotonics.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-03-31 10:25:14 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> for the main comparison. Results of all analysed outcomes are specified in an additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Results of outcomes analysed by active agent (aminaftone, calcium dobesilate, Centella asiatica, diosmine and hidrosmine, french maritime pine bark extract, grape seed extract and rutosides) are specified in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; and <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>, respectively.</P>
<P>Of the 66 included studies, we excluded 13 studies (<LINK REF="STD-Bergqvist-1981" TYPE="STUDY">Bergqvist 1981</LINK>; <LINK REF="STD-Cloarec-1994" TYPE="STUDY">Cloarec 1994</LINK>; <LINK REF="STD-Jongste-1986" TYPE="STUDY">Jongste 1986</LINK>; <LINK REF="STD-Mann-1981" TYPE="STUDY">Mann 1981</LINK>; <LINK REF="STD-Nocker-1990" TYPE="STUDY">Nocker 1990</LINK>; <LINK REF="STD-Padros-1972" TYPE="STUDY">Padros 1972</LINK>; <LINK REF="STD-Pecchi-1990" TYPE="STUDY">Pecchi 1990</LINK>; <LINK REF="STD-Petrassi-2000" TYPE="STUDY">Petrassi 2000</LINK>; <LINK REF="STD-Prerovsky-1972" TYPE="STUDY">Prerovsky 1972</LINK>; <LINK REF="STD-Renton-1994" TYPE="STUDY">Renton 1994</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>; <LINK REF="STD-Rudofsky-1989" TYPE="STUDY">Rudofsky 1989</LINK>; <LINK REF="STD-Sentou-1984" TYPE="STUDY">Sentou 1984</LINK>) from the efficacy analysis for the reasons explained under <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>. <LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK> compared three different interventions with placebo. For the analysis, we included only the comparison of aminaftone with placebo because the other two interventions were combinations of different drugs (micronised diosmine and hesperidin; coumarin and troxerutin).</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of CVI: objective signs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oedema in the lower limb</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 13 trials in the analysis: seven corresponding to rutosides (<LINK REF="STD-Cauwenberge-1972" TYPE="STUDY">Cauwenberge 1972</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>; <LINK REF="STD-Kriner-1985" TYPE="STUDY">Kriner 1985</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), two to calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>), two to hidrosmine and diosmine (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>), one to grape seed extract (<LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>) and one to aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>), with a total of 626 participants in the active treatment group and 619 in the placebo group. The overall quality of the evidence was moderate because incomplete outcome data for one study led to high risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Pooled results were statistically significant and favoured phlebotonics (risk ratio (RR) 0.70, 95% confidence interval (CI) 0.63 to 0.78; I<SUP>2 </SUP>= 20%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variables</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Ankle perimeter circumference</HEADING>
<P>We included 15 studies in the analysis: seven corresponding to rutosides (<LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), five to calcium dobesilate (<LINK REF="STD-Flota_x002d_Cervera-2008" TYPE="STUDY">Flota-Cervera 2008</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and three to diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Tsouderos-1989" TYPE="STUDY">Tsouderos 1989</LINK>), with a total of 1001 participants given active treatment and 1009 given placebo. The overall quality of the evidence was moderate because 12 studies had unclear risk of bias. Pooled results significantly favoured phlebotonics (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (mean difference (MD) -4.27 mm, 95% CI -5.61 to -2.93; I<SUP>2 </SUP>= 47%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Volume of the leg</HEADING>
<P>We included nine studies in the analysis: five corresponding to rutosides (<LINK REF="STD-Burnand-1989" TYPE="STUDY">Burnand 1989</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>; <LINK REF="STD-Kiesewetter-1997" TYPE="STUDY">Kiesewetter 1997</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>), three to calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and one to aminaftone (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>), with a total of 512 participants treated with phlebotonics and 529 with placebo. Pooled results significantly favoured phlebotonics (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (standardised mean difference (SMD) -0.38 mL, 95% CI -0.50 to -0.25; I<SUP>2 </SUP>= 11%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Skin manifestations</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Ulcer cured</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Dichotomous variable</HEADING>
<P>We included six trials in the analysis: one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>), one on calcium dobesilate (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>), two on diosmine (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>) and two on rutoside (<LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Schultz_x002d_Ehrenburg-1993" TYPE="STUDY">Schultz-Ehrenburg 1993</LINK>), with a total of 230 participants in the active treatment group and 231 in the placebo group. Pooled results of these six studies showed no statistically significant differences between phlebotonics and placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (RR 0.94; 95% CI 0.79 to 1.13; I<SUP>2 </SUP>= 5%). The quality of the evidence was low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trophic disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Dichotomous variable</HEADING>
<P>We included six studies in the analysis: four on hidrosmine and diosmine (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>), one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>) and one on rutosides (<LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>), with a total of 355 participants in the phlebotonics group and 350 in the placebo group. Pooled results significantly favoured phlebotonics (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (RR 0.87, 95% CI 0.81 to 0.95; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Telangiectasia, reticular veins and varicose veins</HEADING>
<P>Included studies did not report data on improvement in skin signs such as telangiectasia, reticular veins and varicose veins. Only <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK> reported results regarding varicose veins. Before treatment, 3/16 (18.8%) participants presented varicose veins in the hidrosmine group and 2/12 participants in the placebo group (16.7%). After treatment, one participant from the hidrosmine group was cured of varicose veins, and no participants from the placebo group were cured.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of CVI: subjective symptoms</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pain in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 20 trials in the analysis: 10 on rutosides (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Cauwenberge-1972" TYPE="STUDY">Cauwenberge 1972</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Kl_x00fc_ken-1971" TYPE="STUDY">Klüken 1971</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), four on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Flota_x002d_Cervera-2008" TYPE="STUDY">Flota-Cervera 2008</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>), four on diosmine and hidrosmine (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>), one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>), with a total of 1294 participants treated with phlebotonics and 953 with placebo (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 78%); therefore, we did not pool the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included nine studies in the analysis: four on calcium dobesilate (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>), three on rutosides (<LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>), one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>), with a total of 588 participants assigned to phlebotonics and 597 to placebo (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 80%); therefore, we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cramps in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 14 studies in the analysis: eight on rutosides (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), three on diosmine and hidrosmine (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>), two on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>), with a total of 1072 participants treated with phlebotonics and 721 with placebo (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Pooled results significantly favoured phlebotonics (RR 0.72, 95% CI 0.58 to 0.89; I<SUP>2 </SUP>= 73%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included four studies in the analysis: two on rutosides (<LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>), one on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) and one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>), with 363 participants treated with phlebotonics and 366 with placebo (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 86%); therefore, we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Restless legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included seven studies in the analysis: four on rutosides (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>), two on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and one on diosmine (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>). A total of 329 participants were treated with phlebotonics and 323 with placebo (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Pooled results significantly favoured phlebotonics (RR 0.81, 95% CI 0.72 to 0.91; I<SUP>2 </SUP>= 18%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Itching in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included four studies in the analysis: two on rutoside (<LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>), one on hidrosmine (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>) and one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>). A total of 206 participants were included in the active treatment group and 199 in the placebo group (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 92%); therefore, we did not pool the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included two studies in the analysis: one on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) and one on rutosides (<LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>). A total of 234 participants were treated with phlebotonics and 242 with placebo (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 82%), and we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Feeling of heaviness in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 19 studies in the analysis: nine on rutosides (<LINK REF="STD-Cauwenberge-1972" TYPE="STUDY">Cauwenberge 1972</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), four on diosmine and hidrosmine (<LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>; <LINK REF="STD-Tsouderos-1989" TYPE="STUDY">Tsouderos 1989</LINK>), three on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>), one on aminaftone (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>), one on Centella asiatica (<LINK REF="STD-Pointel-1986" TYPE="STUDY">Pointel 1986</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>). A total of 1257 participants were included in the active treatment group and 909 in the placebo group (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 80%), and we did not pool the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included 10 studies in the analysis: six on rutosides (<LINK REF="STD-Alterkamper-1987" TYPE="STUDY">Alterkamper 1987</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>), two on calcium dobesilate (<LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>), one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>). A total of 557 participants were included in the active treatment group and 557 in the placebo group (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 91%); therefore, we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Swelling in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 14 studies in the analysis: nine on rutosides (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Kriner-1985" TYPE="STUDY">Kriner 1985</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), two on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>), two on diosmine and hidrosmine (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>), with 544 participants included in the active treatment group and 528 in the placebo group (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). Pooled results significantly favoured phlebotonics (RR 0.63, 95% CI 0.50 to 0.80; I<SUP>2 </SUP>= 69%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included six studies in the analysis: three on rutosides (<LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>), one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>), one on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) and one on french maritime pine bark extract (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>), with 436 participants assigned to active treatment and 435 to placebo (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 95%), and we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Paraesthesia in the lower legs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included nine studies in the analysis: four on rutosides (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Cauwenberge-1978" TYPE="STUDY">Cauwenberge 1978</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), three on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and two on diosmine and hidrosmine (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>), with 896 participants assigned to active treatment and 560 to placebo (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). Pooled results significantly favoured phlebotonics (RR 0.67, 95% CI 0.50 to 0.88; I<SUP>2 </SUP>= 72%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included two studies in the analysis: one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>) and one on rutoside (<LINK REF="STD-Cornu_x002d_Thenard-1985" TYPE="STUDY">Cornu-Thenard 1985</LINK>), with 97 participants assigned to active treatment and 91 to placebo (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). Outcomes of the analysis were not statistically significantly different between phlebotonics and placebo (SMD -0.15, 95% CI -0.44 to 0.13; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Global assessment measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Five studies (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>) evaluated quality of life (QoL). <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK> and <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK> assessed QoL by using a questionnaire (EuroQol Measure of Health-Related QoL and Freiburg Life Quality Assessment, respectively) and therefore did not provide quantifiable results. <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK> and <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK> evaluated QoLvia the Chronic Venous Insufficiency International Questionnaire (CIVIQ).<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK> used a specific questionnaire for chronic venous disease adapted from <LINK REF="STD-Cesarone-2006b" TYPE="STUDY">Cesarone 2006b</LINK>. It was not possible to pool results of these three studies because heterogeneity was assessed at 76% (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
<P>The subgroup analysis of aminaftone showed favourable results compared with placebo, but the confidence interval was wide because few participants were included (MD -10.00, 95% CI -17.01 to - 2.99). However, pooled results of the two studies of dobesilate were not statistically significantly different between phlebotonics and placebo (MD -0.60, 95% CI -2.15 to 0.95; I<SUP>2 </SUP>= 40%). The quality of the evidence was low for aminaftone and high for dobesilate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Global assessment by the participant</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous variable</HEADING>
<P>We included 16 studies in the analysis: eight on rutosides (<LINK REF="STD-Burnand-1989" TYPE="STUDY">Burnand 1989</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Pedersen-1992" TYPE="STUDY">Pedersen 1992</LINK>; <LINK REF="STD-Pulvertaft-1983" TYPE="STUDY">Pulvertaft 1983</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>), three on calcium dobesilate (<LINK REF="STD-Casley_x002d_Smith-1988" TYPE="STUDY">Casley-Smith 1988</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>), four on diosmine (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Chassignolle-1994" TYPE="STUDY">Chassignolle 1994</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>) and one on Centella asiatica (<LINK REF="STD-Allegra-1981" TYPE="STUDY">Allegra 1981</LINK>), with a total of 1265 participants treated with phlebotonics and 939 with placebo (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 86%), and we did not pool the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous variable</HEADING>
<P>We included seven studies in the analysis: four on rutosides (<LINK REF="STD-Cesarone-2002" TYPE="STUDY">Cesarone 2002</LINK>; <LINK REF="STD-Cloarec-1996" TYPE="STUDY">Cloarec 1996</LINK>; <LINK REF="STD-Ihme-1996" TYPE="STUDY">Ihme 1996</LINK>; <LINK REF="STD-Kiesewetter-1997" TYPE="STUDY">Kiesewetter 1997</LINK>), two on calcium dobesilate (<LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>) and one on diosmine (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>), with 440 participants treated with phlebotonics and 441 with placebo (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>). The analysis showed heterogeneity (I<SUP>2</SUP> = 85%), and we did not pool the data.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Trials considering rutosides (16 trials), hidrosmine-diosmine (eight trials), calcium dobesilate (seven trials), aminaftone (one trial), grape seed extract (one trial) and Centella asiatica (one trial) reported information on adverse events.</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>We included in the analysis a total of 2080 participants treated with phlebotonics and 1974 with placebo. Pooled results statistically significantly favoured the placebo group (RR 1.21, 95% CI 1.05 to 1.40; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The quality of the evidence was moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events analysed by active agent</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Aminaftone</HEADING>
<P>Only one trial reported adverse events (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>). One participant presented with headache in the group given aminaftone, and two in the placebo group dropped out as the result of subjective worsening of leg pain (RR 0.60, 95% CI 0.06 to 6.32).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium dobesilate</HEADING>
<P>In total, seven trials evaluated adverse events (<LINK REF="STD-Flota_x002d_Cervera-2008" TYPE="STUDY">Flota-Cervera 2008</LINK>; <LINK REF="STD-Hachen-1982" TYPE="STUDY">Hachen 1982</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Widmer-1990" TYPE="STUDY">Widmer 1990</LINK>). Twenty per cent of participants in the calcium dobesilate group (153/758) experienced an adverse event and 15.4% (110/715) in the placebo group. Pooled results showed no statistically significant differences between phlebotonics and placebo (RR 1.23, 95% CI 0.99 to 1.53; I<SUP>2 </SUP>= 43%; P value = 0.06). The most common adverse event was a gastrointestinal event (epigastric discomfort, vomiting). No agranulocytosis or white blood cell disorders were identified. Nineteen participants were withdrawn from the calcium dobesilate group and 10 from the placebo group as the result of adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Centella asiatica</HEADING>
<P>One study reported information on adverse events (<LINK REF="STD-Pointel-1986" TYPE="STUDY">Pointel 1986</LINK>). Thirty-one per cent of participants in the Centella asiatica group (19/61) suffered from adverse events and 27.3% (9/33) in the placebo group. Comparison between groups showed no statistically significant differences between phlebotonics and placebo (RR 1.14, 95% CI 0.58 to 2.23). Two participants who took Centella asiatica 120 mg withdrew - one because of gastralgia (gastric colic) and the other because of neurological absence (absence of nerve activity). One participant taking placebo discontinued the study because of cyanosis of the extremities (bluish discolouration caused by lack of oxygen in the blood).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diosmine and hidrosmine</HEADING>
<P>Eight studies reported the number of participants who experienced adverse events (<LINK REF="STD-Biland-1982" TYPE="STUDY">Biland 1982</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-Dominguez-1992" TYPE="STUDY">Dominguez 1992</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>). Fifty adverse events were identified in the hidrosmine and diosmine group (50/424) and 49 (49/413) in the placebo group. Pooled results showed no statistically significant differences between phlebotonics and placebo (RR 1.01, 95% CI 0.70 to 1.44; I<SUP>2 </SUP>= 0%). Gastrointestinal disorders were the most significant adverse events (heartburn and nausea): 12 cases were reported in the hidrosmine and diosmine group and 11 in the placebo group.</P>
<P>Nine participants withdrew from the hidrosmine group and 11 from the placebo group as the result of adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Grape seed extract</HEADING>
<P>One study reported information regarding adverse events (<LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>). Eleven per cent of participants (4/35) receiving active treatment reported adverse effects (three withdrew): Two participants had gastralgia, one participant had a headache and one had an allergic reaction. Twenty per cent of participants in the placebo group (8/40) experienced adverse effects (one withdrew); these included constipation, gastralgia, tiredness, dry mouth and discomfort. Pooled results showed no statistically significant differences between phlebotonics and placebo (RR 0.57, 95% CI 0.19 to 1.74).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Rutoside</HEADING>
<P>Sixteen trials reported information regarding the number of participants who experienced adverse events (<LINK REF="STD-Alterkamper-1987" TYPE="STUDY">Alterkamper 1987</LINK>; <LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Jongste-1989" TYPE="STUDY">Jongste 1989</LINK>; <LINK REF="STD-Koscielnny-1996" TYPE="STUDY">Koscielnny 1996</LINK>; <LINK REF="STD-Kriner-1985" TYPE="STUDY">Kriner 1985</LINK>; <LINK REF="STD-Languillat-1988" TYPE="STUDY">Languillat 1988</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Parrado-1999" TYPE="STUDY">Parrado 1999</LINK>; <LINK REF="STD-Serralde-1990" TYPE="STUDY">Serralde 1990</LINK>; <LINK REF="STD-Unkauf-1996" TYPE="STUDY">Unkauf 1996</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>; <LINK REF="STD-Vin-1994" TYPE="STUDY">Vin 1994</LINK>; <LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>; <LINK REF="STD-Zucarelli-1987" TYPE="STUDY">Zucarelli 1987</LINK>). Thirteen per cent of participants (102/766) in the rutoside group suffered from adverse events and 9.7% (71/730) in the placebo group. Comparison between groups statistically significantly favoured the placebo group (RR 1.41, 95% CI 1.08 to 1.83; I<SUP>2 </SUP>= 0%). The most common adverse events were gastrointestinal in nature (constipation, dry mouth, epigastric discomfort, vomiting): 90 in the rutoside group and 62 in the placebo group, followed by headache (23 in the rutoside group, 21 in the placebo group) and tiredness (17 in the rutoside group, nine in the placebo group).</P>
<P>Six participants withdrew from the rutoside group and 13 from the placebo group as the result of adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion of studies using compression measures (elastic stockings)</HEADING>
<P>When we re-analysed the data excluding studies that allowed the use of elastic stockings (<LINK REF="STD-Balmer-1980" TYPE="STUDY">Balmer 1980</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Schultz_x002d_Ehrenburg-1993" TYPE="STUDY">Schultz-Ehrenburg 1993</LINK>; <LINK REF="STD-Zucarelli-1987" TYPE="STUDY">Zucarelli 1987</LINK>), we found that general results did not change, except for the following variables.</P>
<UL>
<LI>Global analysis of the dichotomous variable pain significantly favoured phlebotonics (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) (RR 0.69, 95% CI 0.57 to 0.82; 1467 participants; 17 studies; I<SUP>2</SUP> = 67%).</LI>
<LI>Global analysis of the continuous variable cramps significantly favoured phlebotonics (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>) (SMD -0.70, 95% CI -1.15 to -0.24; 314 participants; three studies; I<SUP>2</SUP> = 73%).</LI>
<LI>Global analysis of the dichotomous variable global assessment by the participant significantly favoured phlebotonics (<LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>) (RR 0.69, 95% CI 0.53 to 0.90; 1193 participants; 12 studies; I<SUP>2</SUP> = 73%).</LI>
<LI>Global analysis of the continuous variable quality of life showed favourable results compared with placebo, but the confidence interval was wide because few participants were included (<LINK REF="CMP-002.19" TYPE="ANALYSIS">Analysis 2.19</LINK>) (MD -10.00, 95% CI -17.01 to - 2.99).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion of unpublished data</HEADING>
<P>Only one study, which focused on rutosides, was not published (<LINK REF="STD-Welch-1985" TYPE="STUDY">Welch 1985</LINK>). When we re-analysed the data while excluding this study, we found results very similar to those of the main analysis for all outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis based on studies at low risk of bias</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Exclusion of studies at high or unclear risk of bias</HEADING>
<P>In judging quality levels based on the aforementioned criteria, we identified only four studies (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) with low risk of bias. Consequently, limited sensitivity analyses for the included variables were possible.</P>
<P>Results changed only for the following variables.</P>
<UL>
<LI>Analysis of the dichotomous variable oedema in one study on calcium dobesilate (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>) was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) (RR 0.99, 95% CI 0.63 to 1.55; 260 participants).</LI>
<LI>Global analysis of the continuous variable oedema (measure of ankle circumference in mm) in three studies on calcium dobesilate (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>) was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) (MD -2.34 mm, 95% CI -8.79 to 4.11; 867 participants; I<SUP>2</SUP> = 65%).</LI>
<LI>Analysis of the continuous variable oedema (measure of leg volume in mL) in two studies (<LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) favoured phlebotonics (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) (MD -59.08 mL, 95% CI -84.40 to -33.76; 418 participants; I<SUP>2</SUP> = 0%).</LI>
<LI>Analysis of the dichotomous variable itching in one study on rutoside (<LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) favoured phlebotonics (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>) (RR 0.44, 95%CI 0.32 to 0.62; 231 participants).</LI>
<LI>Analysis of the continuous variable itching in one study on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) was not significantly different (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>) (MD 4.60 cm, 95% CI -5.66 to 14.86; 416 participants).</LI>
<LI>Analysis of the dichotomous variable heaviness in one study on rutoside (<LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) favoured phlebotonics (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) (RR 0.62, 95% CI 0.47 to 0.82; 231 participants).</LI>
<LI>Analysis of the continuous variable heaviness in one study on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>) (MD -2.40 cm, 95% CI -7.89 to 3.09; 417 participants).</LI>
<LI>Analysis of the continuous variable swelling in one study on calcium dobesilate (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>) (MD -1.30 cm, 95% CI -6.72 to 4.12; 417 participants).</LI>
<LI>Analysis of the dichotomous variable global assessment by the participant in two studies on calcium dobesilate (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>) was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.14" TYPE="ANALYSIS">Analysis 4.14</LINK>) (RR 1.04, 95% CI 0.81 to 1.32; 476 participants; I<SUP>2</SUP> = 0%).</LI>
<LI>Analysis of the continuous variable global assessment by the participant in one study on calcium dobesilate (<LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>) favoured phlebotonics (<LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>) (MD -5.64, 95% CI -8.85 to -2.43; 223 participants).</LI>
<LI>Analysis of the dichotomous variable adverse events in the four included studies was not significantly different between phlebotonics and placebo (<LINK REF="CMP-004.16" TYPE="ANALYSIS">Analysis 4.16</LINK>) (RR 1.59, 95% CI 0.97 to 2.63; 1257 participants; I<SUP>2</SUP> = 63%).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated the efficacy and safety of phlebotonics in the treatment of chronic venous insufficiency (CVI). Only analyses of studies with oral phlebotonics were possible because no identified study of topical phlebotonics met the inclusion criteria of this systematic review (SR). This SR included 66 randomised controlled trials (RCTs) and analysed data from 53 trials involving 6013 participants. Studies included in the review generally provided objective measurement of ankle and calf oedema reduction, as well as subjective assessment of other signs and symptoms of CVI. According to the intention-to-treat (ITT) analysis, studies showed a moderate beneficial effect for the dichotomous variable oedema. Analyses in general point to possible beneficial efficacy of phlebotonics for oedema. In addition, phlebotonics showed possible beneficial effects for trophic disorders, cramps, swelling, paraesthesia and restless legs.</P>
<P>However, regarding results of the dichotomous variable ulcer cured and the continuous variable paraesthesias, we found no differences between phlebotonics and placebo. For quality of life (QoL) the results were heterogeneous; evidence of low quality favoured aminaftone, and high-quality evidence showed no significant differences between calcium dobesilate and placebo. Furthermore, the incidence of adverse events was higher in the phlebotonics group than in the placebo group. Gastrointestinal disorders were the most frequently reported adverse events among studies that provided this information (rutosides, calcium dobesilate, diosmine-hidrosmine). Our SR did not report agranulocytosis associated with calcium dobesilate, although this adverse effect was described in a previous case-control study that detected potential risk of agranulocytosis, with an incidence rate of 1.21 cases per 10,000 patient-years of treatment (<LINK REF="REF-Iba_x00f1_ez-2000" TYPE="REFERENCE">Ibañez 2000</LINK>; <LINK REF="REF-Ib_x00e1__x00f1_ez-2005" TYPE="REFERENCE">Ibáñez 2005</LINK>). This could be explained by the small number of participants in the included RCTs and the short period of participant follow-up provided.</P>
<P>One study on aminaftone presented favourable results for the dichotomous variables oedema, pain, cramps, itching and heaviness, although this is an old study that was not replicated later (<LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>). Another more recent study of aminaftone presented favourable results for the continuous variables oedema (volume) and QoL, and non-significant results for adverse events (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>). Calcium dobesilate showed favourable results for continuous volume of the leg and global assessment by the participant. Meanwhile, results were not significant for the following continuous variables: ankle perimeter circumference, pain, restless legs, itching, heaviness and QoL. Calcium dobesilate showed favourable results for the following dichotomous variables: cramps, restless legs and swelling. However, it did not present significant differences in the dichotomous variables ulcer cured and paraesthesia. The incidence of adverse events was similar between phlebotonics and placebo groups. Centella asiatica was assessed in two studies. One study showed non-significant results compared with placebo in the dichotomous variable heaviness (<LINK REF="STD-Pointel-1986" TYPE="STUDY">Pointel 1986</LINK>); the other study showed favourable results for Centella asiatica in the dichotomous variable global assessment by the participant (<LINK REF="STD-Allegra-1981" TYPE="STUDY">Allegra 1981</LINK>). The number of participants with adverse events was not significantly different between Centella asiatica and placebo. Diosmine and hidrosmine showed favourable results for the dichotomous variables oedema and trophic disorders. Results of analyses of the dichotomous and continuous variables cramps and swelling favoured the diosmine and hidrosmine group, as did results of analyses of the continuous variables pain, restless, heaviness and global assessment by the participant. Results of analyses of the dichotomous variables ulcer cured, ulcer, pain, restlessness, itching, heaviness and paraesthesia were non-significant. The incidence of adverse events was not significant when we compared diosmine and hidrosmine with placebo. French maritime pine bark extract was assessed in only one study and was favoured in both dichotomous and continuous variables of pain (<LINK REF="STD-Arcangeli-2000" TYPE="STUDY">Arcangeli 2000</LINK>). Results favoured phlebotonics in the continuous variables heaviness and swelling but were non-significant in the dichotomous variables heaviness and swelling. Grape seed extract was assessed in one study, with non-significant results reported in the dichotomous variable oedema (<LINK REF="STD-Thebaut-1985" TYPE="STUDY">Thebaut 1985</LINK>). Rutosides were included in the greatest number of clinical trials, showing favourable results for the dichotomous variables oedema, swelling and paraesthesia, although results were not significant for the corresponding continuous variable. Results of the variables ulcer cured, trophic disorder and restless legs were non-significant when compared with placebo. The incidence of adverse events significantly favoured the placebo group.</P>
<P>No evidence was found regarding the efficacy of disodium flavodate, naftazone, chromocarbe or topical phlebotonics.<BR/>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Several limitations were identified in the included studies. Only 28% of studies specified standard diagnostic criteria for CVI, and different studies applied different criteria. Only nine studies (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>; <LINK REF="STD-Danielsson-2002" TYPE="STUDY">Danielsson 2002</LINK>; <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Marinello-2002" TYPE="STUDY">Marinello 2002</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>) used the currently accepted Clinical-Aetiology-Anatomy-Pathophysiology (CEAP) classification (<LINK REF="REF-Porter-1995" TYPE="REFERENCE">Porter 1995</LINK>). Therefore, homogeneity in diagnostic criteria is limited, and potential misclassification bias cannot be ruled out. Furthermore, we were unable to perform a subgroup analysis by CVI stage because severity of CVI was variable.</P>
<P>In most RCTs, the way in which participants were included is heterogeneous, and this may have led to differences in response to treatment. In addition, too few participants were included in the studies, and investigators failed to find statistically significant differences when an effect could have occurred (beta error, or type II error). Different instruments were used to measure signs and symptoms, and sometimes results were inconclusive; some were positive, and others were not significant. Only five RCTs assessed the variable QoL using a standardised questionnaire (<LINK REF="STD-Belczak-2014" TYPE="STUDY">Belczak 2014</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>), but two studies (<LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>; <LINK REF="STD-Vanscheidt-2002b" TYPE="STUDY">Vanscheidt 2002b</LINK>) did not provide quantifiable information. Although some studies favoured phlebotonics, the clinical relevance of these findings remains questionable.</P>
<P>Although infrequent, important signs such as venous ulcers have been poorly evaluated. Only six studies included participants with venous ulcers (<LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>; <LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Guilhou-1997" TYPE="STUDY">Guilhou 1997</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Schultz_x002d_Ehrenburg-1993" TYPE="STUDY">Schultz-Ehrenburg 1993</LINK>) and, when pooled, showed none that yielded a difference in ulcer healing.</P>
<P>All studies addressing trophic disorders (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Laurent-1988" TYPE="STUDY">Laurent 1988</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>) except for two (<LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>) did not define this term. However, in two studies, trophic disorders were assessed subjectively as present or absent (<LINK REF="STD-Fermoso-1992" TYPE="STUDY">Fermoso 1992</LINK>; <LINK REF="STD-MacLennan-1994" TYPE="STUDY">MacLennan 1994</LINK>), or as reported on semiquantitative four-item scales (<LINK REF="STD-Gilly-1994" TYPE="STUDY">Gilly 1994</LINK>; <LINK REF="STD-Lazzarini-1982" TYPE="STUDY">Lazzarini 1982</LINK>; <LINK REF="STD-Planchon-1990" TYPE="STUDY">Planchon 1990</LINK>). Therefore, although data from the examination of trophic alterations were analysed, these results should be interpreted with caution.</P>
<P>Most studies provided short-term results (one to three months). Given the chronic nature of the disease, more long-term data on the efficacy and safety of phlebotonics are needed (at least one-year follow-up). To achieve homogeneous data collection and to specify evidence on the efficacy of phlebotonics, measurement of signs and symptoms should be standardised. Although we have done a subgroup analysis by drugs, we noted that different doses were involved, and we are unable to comment on which is the optimal dose.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of bias of the included studies is somewhat uncertain regarding randomisation and blinding because only a limited number of studies specifically reported details regarding these issues. It is difficult to determine whether this is a result of poor design or publication restrictions. As a result, among the 66 RCTs included in this SR, 38 explained the double-blinding procedure in detail, 18 provided data on randomisation and 10 explained blinding of the randomisation. Furthermore, 13 studies had attrition bias. These issues were not addressed in the remaining included studies, and this adds uncertainty to the quality of evidence. Only four studies (<LINK REF="STD-Labs-2004" TYPE="STUDY">Labs 2004</LINK>; <LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>; <LINK REF="STD-Rabe-2011" TYPE="STUDY">Rabe 2011</LINK>; <LINK REF="STD-Vanscheidt-2002a" TYPE="STUDY">Vanscheidt 2002a</LINK>) were graded as having low risk of bias.</P>
<P>In the clinical area of CVI, results lack reliability if the RCT did not include a placebo group because of seasonal exacerbations (spring and summer) that might be self limiting and highly subjective symptoms. Consequently, an adequate control group is needed, and both randomisation and treatment should be appropriately blinded (preferably double-blinded). For this reason, studies that did not include a control group and single-blinded studies were excluded from the SR. Among studies identified as double-blinded, those with inappropriate blinding of treatments or randomisation were excluded from the meta-analyses.</P>
<P>We adopted a conservative approach in our SR, which prioritised the ITT analysis in terms of both treatment losses and failures. On the other hand, we used change measures only if conditions of the compared groups at baseline were the same, to avoid bias in the assessment of results related to participants' baseline differences.</P>
<P>We evaluated the quality of the body of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) approach (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>), which is based on five considerations including study limitations, directness of the evidence, heterogeneity in the data, precision of effect estimates and additional considerations (including risk of publication bias) to assess the quality of the body of evidence for a priori selected outcomes (in our SR, these included the dichotomous variable of oedema in the lower legs and the continuous variables of oedema in the lower legs, quality of life, participants with ulcer cured and participants with adverse events) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>In this SR, the overall quality of evidence is ranked from low (ulcer cured and QoL for aminaftone) to moderate (dichotomous and continuous outcomes of oedema and adverse events) to high (QoL for calcium dobesilate).</P>
<P>Reasons for rating down the quality of evidence for the outcome ulcer cured include the presence of selective reporting and incomplete outcome data; for the outcome QoL for aminaftone unclear generation of randomisation and imprecision (wide confidence intervals); for the dichotomous variables oedema and adverse events incomplete outcome data and for the continuous variable oedema unclear risk of bias of one trial.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses did not significantly alter the results of this review. Whether elastic stockings were used did not influence pooled results, supporting the view that an appropriate randomisation method results in a homogeneous distribution of the groups under comparison.</P>
<P>Any SR is influenced by the quality of included studies and reports. In this respect, we classified only four RCTs as having low risk of bias, and we considered most included studies to have moderate risk of potential bias. We excluded RCTs with high risk of bias. Therefore, conclusions about the results of these studies should be interpreted with caution.</P>
<P>The heterogeneity of several analysis variables may be due to the following.</P>
<UL>
<LI>Different diagnosis classification criteria have been applied; therefore, characteristics of the included population in terms of degree of progression of CVI might vary among studies.</LI>
<LI>No standardisation is involved in measuring variables, given the different scales that have been used, some of which are not validated. Although the same criteria were applied to the data dichotomisation (participants without symptoms/signs or with mild symptoms/sign vs participants with moderate to severe symptoms/signs), these may not be equally relevant, as they result from the application of different scales.</LI>
<LI>On the other hand, the same subjectivity of collected variables may represent differences among individuals and may influence the variability of results.</LI>
<LI>In addition, efficacy of evaluated treatments may not be the same because different active principles were used. This explains observed differences among treatments in the subgroup analysis.</LI>
</UL>
<P>All these considerations limit the validity of included clinical trials and the conclusions of this review. The existence of such heterogeneity restricts the importance of its detection in the process of generating hypotheses (i.e. phlebotonics could be effective for treatment of the pain, cramps, heaviness and swelling of CVI).</P>
<P>Only 51% of included studies reported information on adverse events. However, to adequately assess adverse events related to phlebotonics, it is necessary to include observational study designs that were excluded from our review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Several reviews have tried to evaluate the clinical benefit of phlebotonics. Some of these used poor methods, which did not include information on search strategies and data collection sources, extraction and statistical treatment (diosmine, escin and rutosides (<LINK REF="REF-Diehm-1996b" TYPE="REFERENCE">Diehm 1996b</LINK>); flavonoids, tribenosides, escin and calcium dobesilate (<LINK REF="REF-Markwardt--1996" TYPE="REFERENCE">Markwardt 1996</LINK>); rutosides (<LINK REF="REF-Wadworth-1992" TYPE="REFERENCE">Wadworth 1992</LINK>); flavonoids (<LINK REF="REF-Rabe-2013" TYPE="REFERENCE">Rabe 2013</LINK>)). Other reviews are more elaborate and were developed systematically (global phlebotonics (<LINK REF="REF-Boada-1999" TYPE="REFERENCE">Boada 1999</LINK>); calcium dobesilate (<LINK REF="REF-Ciapponi-2004" TYPE="REFERENCE">Ciapponi 2004</LINK>); escin (<LINK REF="REF-Pittler-1998" TYPE="REFERENCE">Pittler 1998</LINK>); rutosides (<LINK REF="REF-Aziz-2015" TYPE="REFERENCE">Aziz 2015</LINK>; <LINK REF="REF-Poynard-1994" TYPE="REFERENCE">Poynard 1994</LINK>)). Four reviews pursued data meta-analysis (<LINK REF="REF-Aziz-2015" TYPE="REFERENCE">Aziz 2015</LINK>; <LINK REF="REF-Boada-1999" TYPE="REFERENCE">Boada 1999</LINK>; <LINK REF="REF-Ciapponi-2004" TYPE="REFERENCE">Ciapponi 2004</LINK>; <LINK REF="REF-Poynard-1994" TYPE="REFERENCE">Poynard 1994</LINK>).</P>
<P>One review specifically evaluated hydroxyethylrutosides: Review authors included 15 randomised studies and applied a per-protocol (PP) analysis. They stated that rutosides were better than control for controlling symptoms of pain, cramps and heaviness (<LINK REF="REF-Aziz-2015" TYPE="REFERENCE">Aziz 2015</LINK>).</P>
<P>Another review analysed rutosides: Review authors included 12 randomised, double-blind, placebo-controlled studies and applied an ITT analysis. They stated that rutosides were better than placebo for controlling symptoms of pain, cramps, heaviness, swelling and tiredness of affected legs. They mentioned no CVI signs (<LINK REF="REF-Poynard-1994" TYPE="REFERENCE">Poynard 1994</LINK>).</P>
<P>Another review covered all drugs that have been evaluated for CVI through randomised, double-blind, placebo-controlled trials without concomitant compression procedures. These included traditional agents such as hidrosmine, diosmine, escin, rutosides and calcium dobesilate, along with other, less usual ones such as extract of Centella asiatica, benzarone, tribenoside, flunarizine, dihydroergotamine mesylate and mucopolysaccharide sulphate. The conclusion of the <LINK REF="REF-Boada-1999" TYPE="REFERENCE">Boada 1999</LINK> review was that phlebotonics might improve leg heaviness in patients with CVI. Review authors presented no conclusive data regarding other signs or symptoms. However, review authors performed PP rather than ITT analysis and provided no information on individual phlebotonics (<LINK REF="REF-Boada-1999" TYPE="REFERENCE">Boada 1999</LINK>).</P>
<P>The review led by Ciapponi analysed calcium dobesilate: Review authors included 10 double-blind, randomised, placebo-controlled studies and applied a PP analysis. They stated that calcium dobesilate was better than placebo for controlling cramps and discomfort. Subgroup analysis showed greater efficacy in more severe cases of the disease in terms of improving symptoms (pain, heaviness and swelling) and signs (leg volume). Sensitivity analysis based on the ITT analysis did not influence these results (<LINK REF="REF-Ciapponi-2004" TYPE="REFERENCE">Ciapponi 2004</LINK>).</P>
<P>Except for <LINK REF="REF-Aziz-2015" TYPE="REFERENCE">Aziz 2015</LINK>, the above-cited reviews were published a relatively long time ago and have not been updated. Our SR updates evidence on phlebotonics in general and by drug group.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Phlebotonics present limited efficacy for oedema and for some signs and symptoms related to chronic venous insufficiency (CVI). Investigators reported no differences compared with placebo for ulcer healing. Additional high-quality randomised controlled trials (RCTs) are needed to improve the evidence base, with greater attention paid to methodological quality and clinically important outcomes.</P>
<P>Moderate-quality evidence supports the efficacy of phlebotonics in oedema. Low-quality evidence indicates that these drugs do not influence ulcer healing.</P>
<P>Some specific groups of phlebotonics were effective for certain symptoms and signs; however, given the limited number of studies and the discordance in their results, these findings are uncertain.</P>
<P>On the other hand, moderate-quality evidence shows that phlebotonics are associated with higher risk of adverse events than placebo, especially in the rutoside group. Studies included in this systematic review (SR) provided only short-term safety data; therefore, the middle- and long-term safety of phlebotonics could not be estimated.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>As a result of the importance of phlebotonics and the limitations of current evidence, high-quality RCTs are needed to evaluate the efficacy and adverse effects of this group of drugs in an independent and rigorous manner. However, the new studies included in this SR have improved methodological aspects and have already considered in a standardised manner the diagnostic classification of participants, measurement of signs and symptoms, larger sample sizes and longer follow-up, and future trials should continue these recommendations. Additional research regarding quality of life (QoL) and both ulcers and trophic disorders is needed, particularly with an accurate definition of the term and the use of objective measurements. More and better assessments of venous ulcers should be made, and QoL surveys specifically validated for CVI should be introduced. Furthermore, currently available data on safety refer to a short administration period; therefore, long-term observational follow-up studies are needed to better define the safety profile of each of the phlebotonics and to outline more clearly the risk/benefit ratio.</P>
<P>When the efficacy of phlebotonics is investigated, restriction criteria are recommended to avoid situations that are more likely to result in adverse effects, including long-term administration, important co-morbidity, leucopenia, ageing and multiple medications. In addition, researchers involved in these trials should make an explicit statement regarding their conflicts of interest.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Marta Roqué for statistical advice provided on the first version of this review. We also want to express our acknowledgement to the Spanish Drug Agency for providing us with several papers used in an in-house assessment process, and to Dr. A. Cachá, a member of the Safety Committee Task Force of the Agencia Española del Medicamento, who initially participated in the process of selection of clinical trials.</P>
<P>We also acknowledge the Cochrane Vascular TSC for assistance in searching for trials.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Dr D Capellà, Dr X Bonfill Cosp, Dr RM Moreno and Dr E Vargas were part of an advisory group of the Safety Committee of the Spanish Drug Agency, whose objective was to assess the efficacy and safety of phlebotonics during 2002. Dr MJ Martínez assisted with technical work for this group.</P>
<P>Dr RM Moreno, Dr X Bonfill Cosp and Dr MJ Martínez-Zapata were authors of a published double-blind, placebo-controlled clinical trial (<LINK REF="STD-Martinez_x002d_Zapata-2008" TYPE="STUDY">Martinez-Zapata 2008</LINK>) that is included in this review. This study was sponsored by Laboratorios Dr Esteve, which markets calcium dobesilate (Doxium). Laboratorios Dr Esteve signed a written commitment to fully respect the researchers' independence and to allow dissemination of results, whatever they could be. Furthermore, Dr RM Moreno, Dr X Bonfill Cosp and Dr MJ Martínez-Zapata were researchers in the included clinical trial <LINK REF="STD-DOBESILATO500_x002f_2" TYPE="STUDY">DOBESILATO500/2</LINK>, which was prematurely interrupted because of lack of funding.</P>
<P>Dr MJ Martínez-Zapata: none known.<BR/>Dr RWM Vernooij: none known.<BR/>Dr SM Uriona Tuma: none known.<BR/>Dr AT Stein: none known.<BR/>Dr RM Moreno: none known.<BR/>Dr E Vargas: none known.<BR/>Dr D Capellà: chair of the Independent Drug Monitoring Committee of the clinical trial "Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy", carried out by the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) with support from the European Commission, FP7-HEALTH-2011-GA No. 278040 and sponsored by BCN Peptides.<BR/>Dr X Bonfill Cosp: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>All reviewers contributed to development of the protocol, selected and assessed clinical trials and evaluated their quality. In the first version of this SR:</P>
<UL>
<LI>MJ Martinez, RM Moreno and D Capellà extracted data for the first version of this SR. SM Uriona and RWM Vernooij extracted data from new studies and assessed risk of bias of all included studies;</LI>
<LI>RM Moreno provided clinical experience and insight on the protocol and review reports;</LI>
<LI>MJ Martinez was responsible for statistical and methodological aspects and for overall compiling of this SR; and</LI>
<LI>MJ Martinez, RWM Vernooij, SM Uriona, AT Stein, RM Moreno, E Vargas, D Capellà and X Bonfill Cosp were responsible for manuscript development and revision of this SR.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>We have noted some differences between the protocol and this systematic review (SR), specifically in the following items.</P>
<UL>
<LI>In the previous version of this SR, we made different assumptions to examine adverse events. In this current SR, we have simplified the analyses. We calculated the risk of adverse events by considering the number of participants with adverse events reported in the papers as the numerator and the number of participants randomised by group as the denominator.</LI>
<LI>In the previous version of this SR, we considered the Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and the Cochrane criteria (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>) to assess the risk of bias of included RCTs. In this current SR, we used only the current Cochrane criteria to assess risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>In the previous version of this SR, we considered statistical heterogeneity of P value &lt; 0.1 as a reason for not pooling results of the studies. In this current SR, we used the I<SUP>2 </SUP>statistic and considered I<SUP>2 </SUP>&gt; 75% a reason for not pooling the results of RCTs.</LI>
<LI>In the previous version of this SR, we specified to use a random-effects statistical model in all analyses. In this current SR, however, we used this model only when I<SUP>2 </SUP>was between 50% and 75%.</LI>
<LI>In the previous version of this SR, we performed a sensitivity analysis by level of quality of studies according to the Cochrane criteria (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>). In this current SR, we performed a sensitivity analysis that included only studies with low risk of bias according to the Cochrane risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>In the previous version of this SR, assessment of publication bias was not specified. In this current SR, we constructed a funnel plot to explore publication bias.</LI>
<LI>In the previous version of this SR, the quality of evidence was assessed by the Cochrane criteria. In this current SR, we applied GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>) criteria and presented a 'Summary of findings' table (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-01 09:56:14 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-04-01 09:55:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allegra-1981" NAME="Allegra 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allegra C. Pollari G, Criscuolo A, Bonifacio M, Tabassi D</AU>
<TI>Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo</TI>
<SO>Clinica Terapeutica</SO>
<YR>1981</YR>
<VL>99</VL>
<NO>5</NO>
<PG>507-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alterkamper-1987" NAME="Alterkamper 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alterkamper H</AU>
<TI>Efficacy of antivaricotic drugs can be measured objectively</TI>
<SO>Phlebologie in der Praxis</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>9-10</NO>
<PG>19-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arcangeli-2000" NAME="Arcangeli 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arcangeli P</AU>
<TI>Pycnogenol in chronic venous insufficiency</TI>
<SO>Fitoterapia</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>3</NO>
<PG>236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balmer-1980" MODIFIED="2013-12-26 14:37:29 +0000" MODIFIED_BY="[Empty name]" NAME="Balmer 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-12-26 14:37:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Some patients wear elastic stokings&lt;/p&gt;" NOTES_MODIFIED="2013-12-26 14:37:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Balmer A, Limoni C</AU>
<TI>Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients</TI>
<SO>Vasa</SO>
<YR>1980</YR>
<VL>9</VL>
<NO>1</NO>
<PG>76-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blume J</AU>
<TI>Therapy of venous oedemas</TI>
<TO>Tratamento do edema de origem venosa</TO>
<SO>Revista Brasileira de Medicina</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>3</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belczak-2014" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belczak 2014" YEAR="2013">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R</AU>
<TI>Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial</TI>
<SO>Phlebology</SO>
<YR>2014</YR>
<VL>29</VL>
<NO>7</NO>
<PG>454-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1981" NAME="Bergqvist 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berqvist D, Hallböök T, Lindblad B, Lindhagen A</AU>
<TI>A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency</TI>
<SO>Vasa</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>3</NO>
<PG>253-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biland-1982" NAME="Biland 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biland L, Blättler P, Scheibler P, Studer S, Widmer K</AU>
<TI>Zur therapie sogenannt venosër beinsbeschwerden</TI>
<SO>Vasa</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burnand-1989" NAME="Burnand 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burnand KG, Powell S, Bishop C, Stacey M, Pulvertaft T</AU>
<TI>Effect of Paroven on skin oxygenation in patients with varicose veins</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casley_x002d_Smith-1988" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Casley-Smith 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casley-Smith JR</AU>
<TI>A double-blind trial of calcium dobesilate in chronic venous insufficiency</TI>
<SO>Angiology</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>10</NO>
<PG>853-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Casley-Smith JR</AU>
<TI>A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency</TI>
<SO>Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September</SO>
<YR>1989</YR>
<ED>Davy A and Stemmer R</ED>
<PB>John Libbey Eurotext Ltd</PB>
<CY>London and Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-17 06:21:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casley-Smith JR</AU>
<TI>A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>709-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cauwenberge-1972" MODIFIED="2014-10-16 14:30:35 +0100" MODIFIED_BY="[Empty name]" NAME="Cauwenberge 1972" YEAR="1972">
<REFERENCE MODIFIED="2014-10-16 14:30:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Description of two clinical trial (CT): one is a parallel CT and other is a crossover CT.&lt;/p&gt;" NOTES_MODIFIED="2014-10-16 14:30:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cauwenberge H</AU>
<TI>Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease</TI>
<SO>Archives of Internal Pharmacodynamics and Therapeutics</SO>
<YR>1972</YR>
<VL>196</VL>
<NO>Suppl 196</NO>
<PG>122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cauwenberge-1978" MODIFIED="2015-09-18 15:12:01 +0100" MODIFIED_BY="[Empty name]" NAME="Cauwenberge 1978" YEAR="1978">
<REFERENCE MODIFIED="2015-09-18 15:12:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cauwenberge H</AU>
<TI>Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosidesin th treatment of venous disorders</TI>
<TO>Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses</TO>
<SO>Mèdicine et Hygiène</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>4175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2002" MODIFIED="2015-09-27 21:32:44 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-27 21:32:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Griffin M, Ippolito E, et al</AU>
<TI>Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>S21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chassignolle-1994" NAME="Chassignolle 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;THERE IS NO VOLUME NUMBER FOR THIS JOURNAL - ONLY A SUPPLEMENT NUMBER. THIS HAS BEEN CHECKED AND IS CORRECT.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chassignolle JF, Amiel M, Lanfranchi G, Barbe R</AU>
<TI>Activite therapeutique de daflon 500 mg dans l'insuffisance veineuse fonctionnelle</TI>
<SO>Journal International de Medicine</SO>
<YR>1994</YR>
<VL>Suppl 99</VL>
<PG>32-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cloarec-1994" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cloarec 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cloarec M, Clement R, Griton P, Guillou GB, Golden G</AU>
<TI>A double blind three centre trial on efficacy of o-(beta-hydroxyethyl) rutosides in patients with venous insufficiency</TI>
<SO>International Angiology</SO>
<YR>1994</YR>
<VL>13 Suppl 1(2)</VL>
<PG>74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cloarec-1996" NAME="Cloarec 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cloarec M, Clément R, Griton P</AU>
<TI>A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency</TI>
<SO>Phlebology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>76-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornu_x002d_Thenard-1985" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cornu-Thenard 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Some patients wear elastic stockings&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Cornu-Thenard A, Dahan B, De Parades B</AU>
<TI>Study of the action in venous insufficiency of the legs</TI>
<SO>Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danielsson-2002" MODIFIED="2014-10-16 14:30:16 +0100" MODIFIED_BY="[Empty name]" NAME="Danielsson 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-10-16 14:30:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danielsson G, Jungbeck C, Peterson K, Norgren L</AU>
<TI>A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>1</NO>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diebschlag-1994" NAME="Diebschlag 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diebschlag W, Nocker W, Lehmacher W, Rehn D</AU>
<TI>A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency</TI>
<SO>Journal of Pharmaceutical Medicine</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-DOBESILATO500_x002f_2" MODIFIED="2016-02-24 17:52:41 +0000" MODIFIED_BY="[Empty name]" NAME="DOBESILATO500/2" YEAR="2007">
<REFERENCE MODIFIED="2016-02-24 17:52:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Fundación Iberoamericana Itaca</AU>
<TI>Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2016-02-24 17:52:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:17:00 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:17:00 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT00979836"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominguez-1992" MODIFIED="2015-08-17 12:05:12 +0100" MODIFIED_BY="[Empty name]" NAME="Dominguez 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-08-17 12:05:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez C, Brautigham I, González E, González JA, Nazco J, Valiente R, et al</AU>
<TI>Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>10</NO>
<PG>623-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fermoso-1992" MODIFIED="2015-08-17 12:05:28 +0100" MODIFIED_BY="[Empty name]" NAME="Fermoso 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-08-17 12:05:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fermoso J, Legido AG, Del Pino J, Valiente R</AU>
<TI>Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1992</YR>
<VL>52</VL>
<NO>1</NO>
<PG>124-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Flota_x002d_Cervera-2008" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Flota-Cervera 2008" YEAR="1999">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Flota LF</AU>
<TI>Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease</TI>
<TO>Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa</TO>
<SO>Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A</AU>
<TI>Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease</TI>
<SO>Angiology</SO>
<YR>2008</YR>
<VL>59(3)</VL>
<PG>352-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilly-1994" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Gilly 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frileux C, Gilly R</AU>
<TI>Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs</TI>
<SO>Journal Internationale de Medicine</SO>
<YR>1994</YR>
<VL>Suppl 99</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gilly R, Pillion G, Frileux C</AU>
<TI>Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study</TI>
<SO>Phlebology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>2</NO>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Abstract&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiollet M, Frileux C, Gilly R</AU>
<TI>Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>2</NO>
<PG>447</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guilhou-1997" MODIFIED="2015-08-17 11:57:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guilhou 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-08-17 11:57:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al</AU>
<TI>Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients</TI>
<SO>Angiology</SO>
<YR>1997</YR>
<VL>48</VL>
<NO>1</NO>
<PG>77-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hachen-1982" NAME="Hachen 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hachen HJ, Lorenz P</AU>
<TI>Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders</TI>
<SO>Angiology</SO>
<YR>1982</YR>
<VL>33</VL>
<NO>7</NO>
<PG>480-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ihme-1996" MODIFIED="2015-08-17 11:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ihme 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-17 11:58:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ihme N, Kiesewetter H, Jung F, Hoffmann KH, Birk A, Müller A, et al</AU>
<TI>Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>50</VL>
<NO>6</NO>
<PG>443-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jongste-1986" MODIFIED="2015-09-27 21:33:39 +0100" MODIFIED_BY="[Empty name]" NAME="Jongste 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-09-27 21:33:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jongste AB, Ten Cate JW, Huisman MV</AU>
<TI>The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS)</TI>
<SO>Phlebology</SO>
<YR>1986</YR>
<VL>85 Suppl 285</VL>
<PG>837-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jongste-1989" MODIFIED="2015-08-17 12:05:37 +0100" MODIFIED_BY="[Empty name]" NAME="Jongste 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jongste AB, Jonker JJC, Huisman MV, Cate JW, Azar AJ</AU>
<TI>A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome</TI>
<SO>Phlebology</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>21-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-17 12:05:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jongste AB, Jonker JJC, Huisman MV, den Cate JW, Azar AJ</AU>
<TI>A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1989</YR>
<VL>62</VL>
<NO>3</NO>
<PG>826-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiesewetter-1997" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kiesewetter 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiesewetter H, Koscielny J, Grützner K, Müller A, Hoffmann KH, Birk A</AU>
<TI>Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency</TI>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>341-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kl_x00fc_ken-1971" NAME="Klüken 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klüken N</AU>
<TI>Double-blind clinical trial to assess the therapy with drugs for venous disorders</TI>
<TO>Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos</TO>
<SO>Therapiewoche</SO>
<YR>1971</YR>
<VL>21</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koscielnny-1996" MODIFIED="2015-08-17 11:58:11 +0100" MODIFIED_BY="[Empty name]" NAME="Koscielnny 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-17 11:58:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;German article. Randomized, double-blind placebo controlled. Buckwheat herb tea&lt;br&gt;67 p with CVI stage I-II Widmer&lt;br&gt;Outcome-oedema by reduction of leg volume, symptoms and side effects &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-08-17 11:58:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koscielnny J, Radtke H, Hoffmann, Jung F, Müller A, Grützner KI, et al</AU>
<TI>Fagorutin buckwheat herb tea in chronic venous insufficiency</TI>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>3</NO>
<PG>147-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kriner-1985" NAME="Kriner 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kriner E, Braun R, Hirche H, Van Laak HH</AU>
<TI>Treatment of venous insufficiency. A double-blind trial with Phlebodril</TI>
<SO>Zeitschrift für Allgemeinmedizin</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>9</NO>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Labs-2004" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Labs 2004" YEAR="2001">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaeger K</AU>
<TI>Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study</TI>
<SO>International Angiology</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2 Suppl 1</NO>
<PG>239</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Jaeger K</AU>
<TI>Efficacy and safety of doxium in chronic venous insufficiency</TI>
<SO>OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Labs KH, Degischer S, Gamba G, Jaeger KA, on behalf of the CVI Study Group</AU>
<TI>Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial</TI>
<SO>Phebology</SO>
<YR>2004</YR>
<VL>19(3)</VL>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Languillat-1988" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Languillat 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Languillat N</AU>
<TI>Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity</TI>
<SO>Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurent-1988" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Laurent 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurent R, Gilly R, Frileux C</AU>
<TI>Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg</TI>
<SO>International Angiology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>2 Suppl</NO>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazzarini-1982" NAME="Lazzarini 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;SOURCE MISSING!&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazzarini A, Danieli L</AU>
<TI>Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers</TI>
<TO>Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche</TO>
<SO>Rassegna Internazionale di Clinica e Terapia</SO>
<YR>1982</YR>
<VL>62</VL>
<NO>12</NO>
<PG>825-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacLennan-1994" NAME="MacLennan 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;The study was part of The clinical trial of the MacLennan WJ.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dikland WJ</AU>
<TI>A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography</TI>
<SO>Scripta Phlebologica</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>4-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacLennan WJ, Wilson J, Rattenhuber V, Dikland WJ, Vanerdonckt J, Moriau M</AU>
<TI>Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability</TI>
<SO>Gerontology</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>1</NO>
<PG>45-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mann-1981" MODIFIED="2014-12-03 14:12:42 +0000" MODIFIED_BY="[Empty name]" NAME="Mann 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann RJ</AU>
<TI>A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1981</YR>
<VL>35</VL>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marinello-2002" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Marinello 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marinello J, Videla S</AU>
<TI>Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>10</NO>
<PG>775-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Marinello J, et al</AU>
<TI>Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency</TI>
<TO>Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99</TO>
<SO>Laboratorios Dr. Esteve</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez_x002d_Zapata-2008" MODIFIED="2015-08-17 12:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-08-17 12:04:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Zapata MJ, Moreno RM, Gich I, Urrútia G, Bonfill X, Chronic Venous Insufficiency Study Group</AU>
<TI>A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>3</NO>
<PG>358-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nocker-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Nocker 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nocker W, Diebschlag W, Lehmacher W</AU>
<TI>Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency</TI>
<SO>Phlebology</SO>
<YR>1990</YR>
<VL>5 Suppl 1</VL>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nocker W, Diebschlag W, Lehmacher W</AU>
<TI>Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution</TI>
<SO>Vasa</SO>
<YR>1989</YR>
<VL>18</VL>
<NO>3</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nocker W, Diebschlag W</AU>
<TI>An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides</TI>
<SO>Vasa</SO>
<YR>1987</YR>
<VL>16</VL>
<PG>365-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padros-1972" MODIFIED="2016-02-24 17:53:18 +0000" MODIFIED_BY="[Empty name]" NAME="Padros 1972" YEAR="1972">
<REFERENCE MODIFIED="2016-02-24 17:53:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Padrós W</AU>
<TI>Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency</TI>
<SO>Medicina Clínica</SO>
<YR>1972</YR>
<VL>58</VL>
<NO>6</NO>
<PG>515-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-27 17:21:55 +0000" MODIFIED_BY="[Empty name]" NOTES="0978090606" NOTES_MODIFIED="2015-12-27 17:21:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padros W</AU>
<TI>Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch)</TI>
<SO>Ars Medici Internationaal Tijdschrift voor Praktische Therapie</SO>
<YR>1977</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1977</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-27 17:21:55 +0000" MODIFIED_BY="[Empty name]" NOTES="1978092961" NOTES_MODIFIED="2015-12-27 17:21:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padros W</AU>
<TI>Double blind study of the action of calcium dobesilate on venous insufficiency syndromes</TI>
<SO>Ars Medici Revue Internationale de Therapie Pratique</SO>
<YR>1977</YR>
<VL>32</VL>
<NO>8</NO>
<PG>783-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parrado-1999" NAME="Parrado 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parrado F, Buzzi A</AU>
<TI>A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>4</NO>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pecchi-1990" NAME="Pecchi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pecchi S, De Franco V, Damiani P, Guerrini M, Di Perri T</AU>
<TI>Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study</TI>
<TO>Il dobesilato di calcio nel trattamento del l´insufficienza venosa primitiva degli arti inferiori</TO>
<SO>Clinica Terapeutica</SO>
<YR>1990</YR>
<VL>132</VL>
<NO>6</NO>
<PG>409-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1992" NAME="Pedersen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen FM, Hamberg O, Sorensen MD, Neland K</AU>
<TI>The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1992</YR>
<VL>154</VL>
<NO>38</NO>
<PG>2561-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrassi-2000" NAME="Petrassi 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrassi C, Mastromarino A, Spartera C</AU>
<TI>Pycnogenol in chronic venous insufficiency</TI>
<SO>Phytomedicine</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>5</NO>
<PG>383-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planchon-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Planchon 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Planchon B</AU>
<TI>Venous insufficiency and Daflon 500 mg</TI>
<TO>Insuffisance veineuse et Daflon 500 mg</TO>
<SO>Artères et Veines</SO>
<YR>1990</YR>
<VL>IX</VL>
<NO>4</NO>
<PG>376-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pointel-1986" MODIFIED="2013-12-29 17:03:50 +0000" MODIFIED_BY="[Empty name]" NAME="Pointel 1986" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pointel JP, Boccalon H, Cloarec M, Le Devehat C, Joubert M</AU>
<TI>Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs</TI>
<SO>Angiology</SO>
<YR>1987</YR>
<VL>38</VL>
<NO>1 Pt 1</NO>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pointel JP</AU>
<TI>Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs</TI>
<SO>Angiology</SO>
<YR>1986</YR>
<VL>37</VL>
<NO>5</NO>
<PG>420-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prerovsky-1972" NAME="Prerovsky 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prerovsky I, Roztocil K, Hlavova A, Koleilat Z, Razgova L, Oliva I</AU>
<TI>The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double blind study</TI>
<SO>Angiologica</SO>
<YR>1972</YR>
<VL>9</VL>
<NO>3-6</NO>
<PG>408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulvertaft-1983" NAME="Pulvertaft 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Some patients wear elastic support&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pulvertaft TB</AU>
<TI>General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK</TI>
<SO>Vasa</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>4</NO>
<PG>373-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;TITLE MISSING&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulvertaft TB</AU>
<TI>Paroven in the treatment of chronic venous insufficiency</TI>
<SO>Practitioner</SO>
<YR>1979</YR>
<VL>223</VL>
<NO>1338</NO>
<PG>838-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-2011" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Rabe 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe E, Jaeger KA, Bulitta M, Pannier F</AU>
<TI>Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial</TI>
<SO>Phlebology</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>162&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renton-1994" NAME="Renton 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renton S, Leon M, Belcaro G, Nicolaides AN</AU>
<TI>The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study</TI>
<SO>International Angiology</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>3</NO>
<PG>259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1970" MODIFIED="2015-12-27 17:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Rose 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-12-27 17:22:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose SS</AU>
<TI>A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1970</YR>
<VL>24</VL>
<NO>4</NO>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudofsky-1989" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Rudofsky 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Rudofsky G, Diehm C, Grub J, Hartmann M, Schultz-Ehrenburg HU, Bisler H</AU>
<TI>Ruscus saponines and the flavonoid hesperidinmethylchalcone in the treatment of chronic venous insufficiency</TI>
<SO>Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September</SO>
<YR>1989</YR>
<PG>728-30</PG>
<ED>Davy A, Stemmer R</ED>
<PB>John Libbey Eurotext Ltd</PB>
<CY>London and Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudofsky G, Diehm C, Gruss JD, Hartman M, Schultz-Ehrenburg HK, Bisler H</AU>
<TI>Chronic venous insufficiency: treatment with Ruscus extract and trimethyl hesperidine chalcone</TI>
<SO>Münchener Medizinische Wochenschrift</SO>
<YR>1990</YR>
<VL>132</VL>
<NO>13</NO>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schultz_x002d_Ehrenburg-1993" MODIFIED="2015-09-27 21:35:39 +0100" MODIFIED_BY="[Empty name]" NAME="Schultz-Ehrenburg 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-09-27 21:35:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Treatment of leg ulcers. All patients received pressure bandaging&lt;/p&gt;" NOTES_MODIFIED="2015-09-27 21:35:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schultz-Ehrenburg U, Müller B</AU>
<TI>Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers</TI>
<SO>Phlebology</SO>
<YR>1993</YR>
<VL>8 Suppl 1</VL>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sentou-1984" NAME="Sentou 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sentou Y</AU>
<TI>Double blind study of the activity of Cyclo 3 in man</TI>
<SO>International Angiology</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>106-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serralde-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Serralde 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serralde CF, Aceves AQ</AU>
<TI>Clinical trial of the O-(&#946;-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency</TI>
<TO>Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica</TO>
<SO>Revista Médica del Hospital General de México</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>2</NO>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thebaut-1985" NAME="Thebaut 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thebaut JF, Thebaut P, Vin F</AU>
<TI>Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases)</TI>
<SO>Gazette Medicale</SO>
<YR>1985</YR>
<VL>92</VL>
<NO>12</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsouderos-1989" MODIFIED="2015-09-27 21:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Tsouderos 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-09-24 12:36:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tsouderos Y</AU>
<TI>Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency. Our experience with Daflon 500 mg</TI>
<SO>International Angiology</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>4</NO>
<PG>53-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-27 21:35:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsouderos Y</AU>
<TI>Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1991</YR>
<VL>80 Suppl 7</VL>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unkauf-1996" NAME="Unkauf 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unkauf M, Rehn D, Klinger J, Motte S, Grobmann K</AU>
<TI>Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>5</NO>
<PG>478-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanscheidt-2002a" MODIFIED="2015-08-17 11:58:22 +0100" MODIFIED_BY="[Empty name]" NAME="Vanscheidt 2002a" YEAR="2002">
<REFERENCE MODIFIED="2015-08-17 11:58:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanscheidt W, Rabe E, Naser-Hijazi B, Ramelet AA, Partsch H, Diehm C, et al</AU>
<TI>The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study</TI>
<SO>Vasa</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>3</NO>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanscheidt-2002b" MODIFIED="2015-08-17 11:58:29 +0100" MODIFIED_BY="[Empty name]" NAME="Vanscheidt 2002b" YEAR="2002">
<REFERENCE MODIFIED="2015-08-17 11:58:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanscheidt W, Jost V, Wolna P, Lücker A, Muller A, Theurer C, et al</AU>
<TI>Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>4</NO>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vin-1994" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Vin 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-08-17 11:58:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vin E, Chabanel A, Taccoen A, Ducros J, Grufaz J, Hutinel B, et al</AU>
<TI>Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI</TI>
<SO>International Angiology</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>Suppl 1</NO>
<PG>99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vin F, Chabanel A, Taccoen A, Ducros J, Gruffaz J, Hutinel B, et al</AU>
<TI>Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo</TI>
<SO>Artères et Veines</SO>
<YR>1992</YR>
<VL>XI</VL>
<PG>333-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-17 11:58:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vin F, Chabanel A, Taccoen A, Ducros J, Gruffaz J, Hutinel B, et al</AU>
<TI>Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency</TI>
<SO>Phlebology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>2</NO>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Welch-1985" MODIFIED="2015-10-20 08:12:36 +0100" MODIFIED_BY="[Empty name]" NAME="Welch 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-10-20 08:12:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Welch W, Moriau M, van Gysel JP</AU>
<TI>A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency</TI>
<SO>Novartis</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Widmer-1990" NAME="Widmer 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Widmer L, Biland L, Barras JP</AU>
<TI>Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study</TI>
<SO>International Angiology</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zucarelli-1987" NAME="Zucarelli 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zucarelli F</AU>
<TI>Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial.</TI>
<TO>Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo</TO>
<SO>Gazette Médicale</SO>
<YR>1987</YR>
<VL>94</VL>
<NO>32</NO>
<PG>80-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-04-01 09:55:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akbulut-2010" MODIFIED="2013-12-23 16:51:04 +0000" MODIFIED_BY="[Empty name]" NAME="Akbulut 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-23 16:51:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akbulut B</AU>
<TI>Calcium dobesilate and oxerutin: effectiveness of combination therapy</TI>
<SO>Phlebology</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allaert-1992" MODIFIED="2014-10-16 14:29:46 +0100" MODIFIED_BY="[Empty name]" NAME="Allaert 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-10-16 14:29:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allaert FA, Vin F, Levardon M</AU>
<TI>[Comparative study of the effectiveness of continuous or intermittent courses of a phlebotonic drug on venous disorders disclosed or aggravated by oral, estrogen-progesterone contraceptives]</TI>
<SO>Phlébologie</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1994" MODIFIED="2013-12-23 16:51:44 +0000" MODIFIED_BY="[Empty name]" NAME="Amato 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-23 16:51:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato C</AU>
<TI>Advantage of micronized flavonoidic fraction (daflon 500 mg) in comparison with a nonmicronized diosmin</TI>
<SO>Angiology</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>6, part 2</NO>
<PG>531-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Androulakis-1989" MODIFIED="2013-12-23 16:51:59 +0000" MODIFIED_BY="[Empty name]" NAME="Androulakis 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-12-23 16:51:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Androulakis G, Panoysis PA</AU>
<TI>Plethysmographic confirmation of the beneficial effect of calcium dobesilate in primary varicose veins</TI>
<SO>Angiology</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auteri-1990" NAME="Auteri 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auteri A, Blardi P, Frigerio C, de Lillo L, di Perri T</AU>
<TI>Pharmacodynamics of troxerutine in patients with chronic venous insufficiency: correlations with plasma drug levels</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>4</NO>
<PG>235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avram-1996" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Avram 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Avram J, Avram R, Colban O, Murariu M, Toma D, Preda D</AU>
<TI>The treatment of venous insufficiency with daflon 500 mg</TI>
<SO>International Angiology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>2 Suppl</NO>
<PG>1-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bacci-2003" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Bacci 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Internet&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bacci PA, Allegra C, Botta G, Mancini S</AU>
<TI>The role of a multifunctional plant complex in phlebolymphology: randomized, placebo-controlled double-blind clinical study</TI>
<SO>Amercian College of Phlebology. Abstracts from the 17th Annual Congress, August 27 - 31, 2003 &#8212; San Diego, California</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bastide-1976" MODIFIED="2013-12-23 16:55:05 +0000" MODIFIED_BY="[Empty name]" NAME="Bastide 1976" YEAR="1976">
<REFERENCE MODIFIED="2013-12-23 16:55:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1978006624&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 16:55:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bastide G, Becade P, Goulley Y</AU>
<TI>Double blind study of Dihydroergotamine Sandoz in venous pathology of lower limbs</TI>
<SO>Angeiologie</SO>
<YR>1976</YR>
<VL>28</VL>
<NO>5</NO>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batchvarova-1989" MODIFIED="2014-10-16 11:59:22 +0100" MODIFIED_BY="[Empty name]" NAME="Batchvarova 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-10-16 11:59:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batchvarova V</AU>
<TI>Clinical effect of Troxevit on chronic venous insufficiency</TI>
<TO>Effet clinique du Troxevit sur l'insuffisance veineuse chronique</TO>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>42</VL>
<PG>703-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batchvarova-1989a" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Batchvarova 1989a" YEAR="1989">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Source: From Wounds Group. Language: French with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Batchvarova V</AU>
<SO>Effet Clinique du Troxevit sur l'Insuffisance Veineuse Chronique</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>703-5</PG>
<PB>John Libby Eurotext Ltd</PB>
<CY>London &amp; Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behar-1993" MODIFIED="2014-10-29 09:29:40 +0000" MODIFIED_BY="[Empty name]" NAME="Behar 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-29 09:29:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behar A, Nathan P, Lavieuville M, Allaert FA</AU>
<TI>Effect of veinotonyl 75 on the capillary permeability test using technetium albumin in cyclic orthostatic edemas</TI>
<SO>Phlébologie</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>4</NO>
<PG>721-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-1986" MODIFIED="2016-04-01 09:53:16 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-04-01 09:53:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;In conference proceedings for Phlebology 85&lt;/p&gt;" NOTES_MODIFIED="2016-04-01 09:53:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Belcaro GV</AU>
<TI>Treatment of chronic venous hypertension of the lower limbs by O-(beta-hydroxyethyl)-rutoside and elastic compression</TI>
<SO>Phlebology 85</SO>
<YR>1986</YR>
<PG>834-6</PG>
<ED>Negus D, Jantet G</ED>
<PB>John Libbey</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-1989" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Rulo A, Candiani C</AU>
<TI>Evaluation of the microcirculatory effects of Venorutin in patients with chronic venous hypertension by laser Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements</TI>
<SO>Vasa</SO>
<YR>1989</YR>
<VL>18</VL>
<PG>146-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Open randomized placebo controlled study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Rulo A, Candiani C</AU>
<TI>Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laser-Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements</TI>
<SO>Phlebology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-1995" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, De Sanctis MT, Incandela L, Laurora G, Fevrier B, et al</AU>
<TI>Laser doppler and transcutaneous oxymetry: modern investigations to assess drug efficacy in chronic venous insufficiency</TI>
<SO>International Journal of Microcirculation: Clinical and Experimental</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2002" MODIFIED="2013-12-23 17:00:59 +0000" MODIFIED_BY="[Empty name]" NAME="Belcaro 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-23 17:00:59 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12232562&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:00:59 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Bavera P, Ricci A, Renton S, Leon M, et al</AU>
<TI>HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>3</NO>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2003" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2003107597&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Nicolaides AN, Geroulakos G, Acerbi G, Candiani C, et al</AU>
<TI>The LONFLIT4-VENORUTON study: a randomized trial prophylaxis of flight-edema in normal subjects</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-27 23:07:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12678187&lt;/p&gt;" NOTES_MODIFIED="2015-09-27 23:07:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Brandolini R, Di Renzo A, Bavera P, Dugall M, et al</AU>
<TI>The LONFLIT4-Venoruton Study: a randomized trial--prophylaxis of flight-edema in venous patients</TI>
<SO>Angiology</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>2</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2008" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G. Rosaria Cesarone M, Ledda A, Cacchio M, Ruffini I, Ricci A, et al</AU>
<TI>O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study</TI>
<SO>Angiology</SO>
<YR>2008</YR>
<VL>59(Suppl 1)</VL>
<PG>7S-13S</PG>
<IDENTIFIERS MODIFIED="2014-10-16 14:29:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2008b" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Belcaro 2008b" YEAR="2008">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, et al</AU>
<TI>5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(&#946;-hydroxyethyl)-rutosides: a prospective comparative clinical registry</TI>
<SO>Angiology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>1</NO>
<PG>14S-20S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bello-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Bello 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bello AA, Meyer K, Garcia AT, Reinaga VV</AU>
<TI>Calcium dobesilate combined with a heparinoid in the topical treatment of chronic venous insufficiency: a double-blind study</TI>
<SO>Acta Therapeutica</SO>
<YR>1990</YR>
<VL>16</VL>
<NO>1</NO>
<PG>79-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beltramino-1999" MODIFIED="2013-12-26 15:04:16 +0000" MODIFIED_BY="[Empty name]" NAME="Beltramino 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-23 17:01:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;20269662. Found by Mary Sanderson 18/7/00.&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:01:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beltramino R, Penenory A, Buceta AM</AU>
<TI>An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency</TI>
<SO>International Angiology</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>4</NO>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-26 15:04:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;20372246&lt;/p&gt;" NOTES_MODIFIED="2013-12-26 15:04:16 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beltramino R, Penenory A, Buceta AM</AU>
<TI>An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency</TI>
<SO>Angiology</SO>
<YR>2000</YR>
<VL>51</VL>
<NO>7</NO>
<PG>535-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bento-2006" MODIFIED="2013-12-23 17:03:24 +0000" MODIFIED_BY="[Empty name]" NAME="Bento 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-23 17:03:24 +0000" MODIFIED_BY="[Empty name]" NOTES="2006483110" NOTES_MODIFIED="2013-12-23 17:03:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bento C, Branda~o DDC, Smith P</AU>
<TI>A multicentric, IV phase, multidisciplinary, prospective, randomized, double blinded, comparative study to evaluate the castanha-da-india, rutina, smilax japicanga and polygonum punctatum combination efficacy and tolerability in the treatment of patients suffering from symptomatic venous insufficiency comparing to placebo treatment</TI>
<SO>Revista Brasileira de Medicina</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>8</NO>
<PG>422-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berson-1976" NAME="Berson 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berson I</AU>
<TI>A double blind clinical trial in cases of CVI with doxivenil gel and another gel containing only a heparinoid</TI>
<TO>Expérimentation clinique dans l'IVC (double aveugle) du gel Doxivenil et d' un gel contenant un héparinoïde seul</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1976</YR>
<VL>65</VL>
<NO>32</NO>
<PG>991-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berson-1978" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Berson 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berson I</AU>
<TI>About a new medicamentous treatment of the varicose syndrome</TI>
<SO>Schweiz Rundschau Med (PRAXIS)</SO>
<YR>1978</YR>
<VL>67</VL>
<PG>981-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berson-1980" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Berson 1980" YEAR="1980">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Xreference with ID 4535. Language: French with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berson I, Geiser J-D</AU>
<TI>An open comparative study of two phlebotoniques</TI>
<SO>Etude Comparative Ouverte Entre Deux phl &#8218;Botropes Chez Deux Groupes r&#8218; Partis au Hasard</SO>
<YR>1980</YR>
<VL>69</VL>
<NO>35</NO>
<PG>1244-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blume-1996" NAME="Blume 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blume J, Wüstenberg P</AU>
<TI>Chronic vein insufficiency. Treatment results with benzopyrones during and after compression therapy</TI>
<TO>Cronisch-venöse Insuffizienz (CVI). Behandlungsergebnisse mit benzopyronen und nach Kompressiontherapie</TO>
<SO>Therapiewoche</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>10</NO>
<PG>540-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blume J</AU>
<TI>Therapy of venous oedema</TI>
<TO>Tratamento do edema de origem venosa. Eficácia de um tratamento medicamentoso em combinaçao com o tratamento compresivo</TO>
<SO>Revista Brasileira de Medicina</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>3</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boccalon-1989" NAME="Boccalon 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boccalon H</AU>
<TI>Cyclo 3 fort and antagonism of plethysmographic disturbances observed upon exposure to heat: preliminary results</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohm-1989" MODIFIED="2013-12-23 17:03:59 +0000" MODIFIED_BY="[Empty name]" NAME="Bohm 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-12-23 17:03:59 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1989182142&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:03:59 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohm C</AU>
<TI>Venodiuretics: a new combination of diuretic and edema protective drugs</TI>
<SO>Medizinische Welt</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>30-31</NO>
<PG>887-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boisseau-1995" NAME="Boisseau 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boisseau MR, Taccoen A, Garreau C, Vergnes C, Roudaut MF, Garreau-Gomez B</AU>
<TI>Fibrinolysis and hemorheology in chronic venous insufficiency: a double-blind study of troxerutin efficiency</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>4</NO>
<PG>369-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolliger-1972" MODIFIED="2013-12-27 09:25:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bolliger 1972" YEAR="1972">
<REFERENCE MODIFIED="2013-12-27 09:25:29 +0000" MODIFIED_BY="[Empty name]" NOTES="1974000627" NOTES_MODIFIED="2013-12-27 09:25:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger AA</AU>
<TI>Results of a double blind trial of percutaneously administered rutoside</TI>
<SO>Angiologica</SO>
<YR>1972</YR>
<VL>9</VL>
<PG>397-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bort-1995" MODIFIED="2014-10-29 09:30:10 +0000" MODIFIED_BY="[Empty name]" NAME="Bort 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-10-29 09:30:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bort H, Hahn M, Klyscz T, Junger M</AU>
<TI>The influence of rutosides on increased capillary permeability in chronic venous insufficiency as measured by video capillaroscopy</TI>
<SO>Proceedings of the Union Internationale de Phlebologie - 12th World Congress, London, 3-8 September</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosse-1985" MODIFIED="2013-12-25 11:15:04 +0000" MODIFIED_BY="[Empty name]" NAME="Bosse 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-12-25 11:15:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosse K, Drieschner P, Klose L</AU>
<TI>Comparative studies concerning the effectiveness of therapeutic agents in chronic venous insufficiency</TI>
<SO>Phlebologie und Proktologie</SO>
<YR>1985</YR>
<VL>14</VL>
<PG>111-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brami-1983" MODIFIED="2013-12-23 17:04:57 +0000" MODIFIED_BY="[Empty name]" NAME="Brami 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-12-23 17:04:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brami C, Morere MCNK, Megret G, Elbaz C</AU>
<TI>Double-blind controlled trial against placebo of dihydroergocryptine mesilate plus caffeine in chronic venous insufficiency</TI>
<SO>Angeiologie</SO>
<YR>1983</YR>
<VL>35</VL>
<NO>8</NO>
<PG>281-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brock-1991" MODIFIED="2009-01-06 22:52:44 +0000" MODIFIED_BY="[Empty name]" NAME="Brock 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-01-06 22:52:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brock FE</AU>
<TI>Arnica montana and vein disease</TI>
<SO>Zeitschrift fur Phytotherapie</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>5</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brock-2001" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Brock 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brock FE</AU>
<TI>Synergystic effect of vein - typical hydrotherapy according to Kneipp and topical arnica - treatment in patients with chronic venous insufficiency</TI>
<SO>Erfahrungsheilkunde</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>357-63</PG>
<IDENTIFIERS MODIFIED="2014-10-29 09:30:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carstens-1985" MODIFIED="2013-12-24 18:59:27 +0000" MODIFIED_BY="[Empty name]" NAME="Carstens 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-12-24 18:59:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carstens C, Hampel H</AU>
<TI>Treatment of oedemata in chronic venous insufficiency by means of an additional therapy with DIU Venostatin</TI>
<SO>Die Medizinische Welt</SO>
<YR>1985</YR>
<VL>36</VL>
<PG>867-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cataldi-2001" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cataldi 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cataldi A, Gasbarro V, Viaggi R, Soverini R, Gresta E, Mascoli F</AU>
<TI>Effectiveness of the association of alphatocopherol, rutin, melilotus and centella asiatica in the treatment of patients affected by chronic venous insufficiency</TI>
<TO>Efficacia clinica di un'associazine di alfatocoferoli, rutina, meliloto e centella asiatica nel trattamento di pazienti con insufficienza venosa cronica</TO>
<SO>Minerva Cardioangiologica</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>2</NO>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-1992" MODIFIED="2013-12-23 17:09:48 +0000" MODIFIED_BY="[Empty name]" NAME="Cesarone 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-12-23 17:09:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Laurora G, Ricci A, Belcaro G, Pomante P, Candiani C, et al</AU>
<TI>Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study)</TI>
<SO>Vasa</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>1</NO>
<PG>76-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-1994" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C, et al</AU>
<TI>Microcirculatory activity of centella asiatica in venous insufficiency</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>6</NO>
<PG>299-304</PG>
<IDENTIFIERS MODIFIED="2014-10-16 14:28:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001" MODIFIED="2015-09-27 18:42:46 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-09-27 18:42:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M, Bavera P, et al</AU>
<TI>Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel--a placebo-controlled, randomized study</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 3</VL>
<PG>S11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001a" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001a" YEAR="2001">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, De Sanctis MT, Incandela L, Cacchio M, Bavera P, et al</AU>
<TI>Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S15&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001b" MODIFIED="2015-09-27 18:40:16 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001b" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 11:10:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Incandela L, Belcaro G, Sanctis MT, Ricci A, Griffin M</AU>
<TI>Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy--a placebo-controlled, randomized study</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 3</VL>
<PG>S43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001c" MODIFIED="2015-09-27 18:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001c" YEAR="2001">
<REFERENCE MODIFIED="2015-09-27 18:43:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Rulo A, Griffin M, Ricci A, Ippolito E, et al</AU>
<TI>Microcirculatory effects of total triterpenic fraction of Centella asiatica in chronic venous hypertension: measurement by laser Doppler, TcPO2-CO2, and leg volumetry 93</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001d" MODIFIED="2015-09-27 18:40:00 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001d" YEAR="2001">
<REFERENCE MODIFIED="2013-12-23 17:10:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11666121&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:10:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, et al</AU>
<TI>Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2001e" MODIFIED="2015-09-27 18:39:52 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2001e" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 11:10:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Incandela L, Sanctis MT, Belcaro G, Bavera P, Bucci M, et al</AU>
<TI>Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiatica: a clinical prospective randomized trial with a microcirculatory model</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2002a" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2002a" YEAR="2002">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Incandela L, Geroulakos G, Griffin M, Lennox A, et al</AU>
<TI>Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>S17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2002b" MODIFIED="2015-09-28 13:30:41 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2002b" YEAR="2002">
<REFERENCE MODIFIED="2015-09-27 18:43:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Dugall M, Acerbi G</AU>
<TI>Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>S25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2003" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Geroulakos G, Griffin M, Ricci A, Brandolini R, et al</AU>
<TI>Flight microangiopathy on long-haul flights: prevention of edema and microcirculation alterations with Venoruton</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>2</NO>
<PG>109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2005" MODIFIED="2015-08-17 11:56:51 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-08-17 11:56:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Di Renzo A, Vinciguerra G, et al</AU>
<TI>HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study</TI>
<SO>Angiology</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2014-10-29 09:30:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2006" MODIFIED="2013-12-24 19:07:25 +0000" MODIFIED_BY="[Empty name]" NAME="Cesarone 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-24 19:07:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al</AU>
<TI>Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study</TI>
<SO>Angiology</SO>
<YR>2006</YR>
<VL>57</VL>
<PG>569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2006a" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2006a" YEAR="2006">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16518519 References checked&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al</AU>
<TI>Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency</TI>
<SO>Angiology</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>2</NO>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2006b" MODIFIED="2013-12-23 17:17:24 +0000" MODIFIED_BY="[Empty name]" NAME="Cesarone 2006b" YEAR="2006">
<REFERENCE MODIFIED="2013-12-23 17:17:24 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16708123&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:17:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al</AU>
<TI>Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>205-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2006c" MODIFIED="2014-10-29 09:31:51 +0000" MODIFIED_BY="[Empty name]" NAME="Cesarone 2006c" YEAR="2006">
<REFERENCE MODIFIED="2014-10-29 09:31:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al</AU>
<TI>Circulating endothelial cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: improvement with Venoruton</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>1</NO>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2006d" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarone 2006d" YEAR="2006">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al</AU>
<TI>Improvement of diabetic microangiopathy with pycnogenol: a prospective, controlled study</TI>
<SO>Angiology</SO>
<YR>2006</YR>
<VL>57</VL>
<PG>431-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2010" MODIFIED="2014-10-29 09:33:22 +0000" MODIFIED_BY="[Empty name]" NAME="Cesarone 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-29 09:33:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al</AU>
<TI>Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study</TI>
<SO>Phytomedicine</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>11</NO>
<PG>835-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chant-1973" NAME="Chant 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chant AD</AU>
<TI>The effect of paroven (HR) of the clearance of sodium-24 from the subcutaneous tissues of the foot in patients with varicose veins</TI>
<SO>Vasa</SO>
<YR>1973</YR>
<VL>2</VL>
<NO>3</NO>
<PG>288-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiummariello-2009" MODIFIED="2013-12-24 19:15:13 +0000" MODIFIED_BY="[Empty name]" NAME="Chiummariello 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-24 19:15:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiummariello S, De Gado F, Monarca C, Ruggiero M, Carlesimo B, Scuderi N, et al</AU>
<TI>[Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs]</TI>
<SO>Il Giornale di chirurgia</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>11-12</NO>
<PG>497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clemens-1986" NAME="Clemens 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Only hemodynamic parameters&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clemens S, Bisler H, Braun R</AU>
<TI>Phlebodril: Influences on the venous regurgitation</TI>
<SO>Phlebologie und Proktologie</SO>
<YR>1986</YR>
<VL>15</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1989" MODIFIED="2013-12-23 17:18:34 +0000" MODIFIED_BY="[Empty name]" NAME="Cospite 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-12-23 17:18:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cospite M, Dominici A</AU>
<TI>Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form</TI>
<SO>International Angiology</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>4</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1996" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cospite 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cospite M, Milio G</AU>
<TI>Heparan sulfate vs diosmin: effects on microcirculation in chronic venous insufficiency of the lower extremities</TI>
<SO>Advances in Therapy</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>3</NO>
<PG>178-190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1998" MODIFIED="2013-12-23 17:19:39 +0000" MODIFIED_BY="[Empty name]" NAME="Cospite 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-12-23 17:19:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cospite M, Dominici A</AU>
<TI>Advantage of micronisation of Daflon 500 mg compared with a simple diosmine in the treatment of venous insufficiency. Double blind study</TI>
<SO>Phlebologie</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Anna-1989" MODIFIED="2016-03-17 06:58:47 +0000" MODIFIED_BY="[Empty name]" NAME="De Anna 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-08-17 11:59:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Compresive therapie in both treatment groups&lt;/p&gt;" NOTES_MODIFIED="2015-08-17 11:59:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Anna D, Mari F, Intini S, Gasbarro V, Sortini A, Pozza E, et al</AU>
<TI>Effects of therapy with aminaftone on chronic venous and lymphatic stasis</TI>
<TO>Effetti della terapia con aminaftone sulla stasi venosa e linfatica cronica</TO>
<SO>Minerva Cardioangiologica</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>5</NO>
<PG>251-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-17 06:58:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Anna D, Risaliti A, Intini S, Terrosu G, Petri R, Taddeo U, et al</AU>
<TI>Aminaphtone therapy in venous lymphatic stasis of lower limbs</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>753-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-17 12:00:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Anna D, Risaliti A, Intini S, Uzzau A, Terrosu G, Petri R, et al</AU>
<TI>Aminaphtone therapy in venous and lymphatic stasis of lower limbs</TI>
<SO>Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29-September 1989</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>251</NO>
<PG>753-5</PG>
<ED>Davy A and Stemmer R</ED>
<PB>John Libbey Eurotext Ltd</PB>
<CY>London and Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delacroix-1981" MODIFIED="2013-12-23 17:24:35 +0000" MODIFIED_BY="[Empty name]" NAME="Delacroix 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-12-23 17:24:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delacroix P</AU>
<TI>Double-blind trial of endotelon (TM) in chronic venous insufficiency</TI>
<SO>La Revue de Medecine</SO>
<YR>1981</YR>
<VL>22</VL>
<NO>27-28</NO>
<PG>1793-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delecluse-1991" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Delecluse 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language - french.&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delecluse M, Ducros JJ, Egal G, Hamel H, Junk R, Leroux A, et al</AU>
<TI>[Clinical study of Diovenor 300 mg versus a mixture of flavonoides in 90 % of diosmine in the treatment of symptoms of chronic venous insufficiency in young active females]</TI>
<SO>Essai Clinique Pragmatique de Diovenor 300 mg Versus Melange de Flavonoides a 90 % de Diosmine Dans le Traitement des Manifestations d'Insuffisance Veineuse Chronique Chez la Femme Active Jeune</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>7</NO>
<PG>498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Parades-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="de Parades 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Parades B, Demarez JP, Cauquil J</AU>
<TI>Comparative analysis of the therapeutic effects of Cyclo 3 Fort and Diosmin 450 mg in combination with hesperidin 50 mg in venous insufficiency of the legs</TI>
<SO>Vie Medicale</SO>
<YR>1990</YR>
<VL>6</VL>
<PG>226-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Sanctis-2001" MODIFIED="2015-08-17 12:00:08 +0100" MODIFIED_BY="[Empty name]" NAME="De Sanctis 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-08-17 12:00:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Sanctis MT, Belcaro G, Incandela L, Cesarone MR, Griffin M, Ippolito E, et al</AU>
<TI>Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52</VL>
<NO>Suppl 2</NO>
<PG>S55-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duchene-1988" MODIFIED="2015-09-27 18:47:51 +0100" MODIFIED_BY="[Empty name]" NAME="Duchene 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-09-27 18:47:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duchene Marullaz P, Amiel M, Barbe R</AU>
<TI>Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg</TI>
<SO>International Angiology</SO>
<YR>1988</YR>
<VL>7 Suppl 2</VL>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dustmann-1984" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Dustmann 1984" YEAR="1984">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1984205792 MHP states RCT&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dustmann HO, Godolias G, Seibel K</AU>
<TI>Foot volume with chronic venous insufficiency while standing: effect of a new treatment</TI>
<SO>Therapiewoche</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>36</NO>
<PG>5077-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erdlen-1989" MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NAME="Erdlen 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: German with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-02-24 17:10:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erdlen F</AU>
<TI>Clinical efficacy of venostasin. A double blind trial</TI>
<SO>Medizinische Welt</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>36</NO>
<PG>994-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erler-1991" MODIFIED="2013-12-23 17:30:32 +0000" MODIFIED_BY="[Empty name]" NAME="Erler 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-23 17:30:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1991223034&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:30:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erler M</AU>
<TI>Horse chestnut seed extract in the therapy of the peripheral venous edema - Clinical therapies in comparison</TI>
<SO>Medizinische Welt</SO>
<YR>1991</YR>
<VL>42</VL>
<NO>7</NO>
<PG>593-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-1967" MODIFIED="2014-02-01 17:50:56 +0000" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 1967" YEAR="1967">
<REFERENCE MODIFIED="2014-02-01 17:50:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald DE</AU>
<TI>A clinical trial of troxerutin in venous insufficiency of the lower limb</TI>
<SO>The Practitioner</SO>
<YR>1967</YR>
<VL>198</VL>
<NO>185</NO>
<PG>406-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forconi-1977" NAME="Forconi 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forconi S, Guerrini M, Di Perri T</AU>
<TI>Study of the activity of a flavonoid, O-(beta-hydroxyethyl)-rutoside, at high dose levels of venous tone measured by "strain gauge" plethysmography</TI>
<SO>Vasa</SO>
<YR>1977</YR>
<VL>6</VL>
<NO>3</NO>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frausini-1985" MODIFIED="2015-08-17 12:00:55 +0100" MODIFIED_BY="[Empty name]" NAME="Frausini 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-08-17 12:00:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AUTHOR LIST NEES COMPLETING&lt;/p&gt;" NOTES_MODIFIED="2015-08-17 12:00:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frausini G, Rotatori P, Oliva S</AU>
<TI>Controlled trial on clinical-dynamic effects of three treatments in chronic venous insufficiency</TI>
<SO>Giornale Italiano di Angiologica</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friederich-1978" NAME="Friederich 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friederich HC, Vogelsberg H, Neiss A</AU>
<TI>Evaluation of internally effective venous drugs</TI>
<SO>Zeitschrift fur Hautkrankheiten</SO>
<YR>1978</YR>
<VL>53</VL>
<NO>11</NO>
<PG>369-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glinski-1999" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Glinski 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lecewicz Torun B, Kaszuba A, et al</AU>
<TI>The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study</TI>
<SO>Phlebology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>4</NO>
<PG>151-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-26 16:31:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11292954&lt;/p&gt;" NOTES_MODIFIED="2013-12-26 16:31:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lecewicz-Torun B, Kaszuba A, et al</AU>
<TI>Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>2</NO>
<PG>107-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez_x002d_Fajardo-1990" MODIFIED="2013-12-23 17:35:34 +0000" MODIFIED_BY="[Empty name]" NAME="Gonzalez-Fajardo 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-12-23 17:35:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Fajardo JA, Rodriguez-Camarero SJ, de Marino P, Castro Villamor MA, March Garcia JR, Carpintero Mediavilla L, et al</AU>
<TI>[Photoplethysmographic evaluation of the effect of a vascular tonic drug]</TI>
<SO>Angiologia</SO>
<YR>1990</YR>
<VL>42</VL>
<NO>5</NO>
<PG>167-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gouny-1999" NAME="Gouny 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gouny AM, Horovitz D, Gouny P, Sauvage E, Nussaume O</AU>
<TI>Effectiveness and safety of hydroxyethyl-rutosides in the local treatment of symptoms of venous insufficiency during air travel</TI>
<TO>Etude d'efficacite et de tolerance des hydroxyethyl-rutosides dans le traitement local des symptomes d'insuffisance veineuse survenant au cours des transports aeriens</TO>
<SO>Journal des Maladies Vasculaires</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>3</NO>
<PG>214-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granger-1995" MODIFIED="2015-09-27 18:44:17 +0100" MODIFIED_BY="[Empty name]" NAME="Granger 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-09-27 18:44:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granger C, Laveille C, Vilain C, Jochemsen R</AU>
<TI>Correlation between haemodynamic parameters of venous tone and clinical symptoms improvement in patients with chronic venous insufficiency. A controlled randomised study of Daflon 200 mg 2 tablets per day versus placebo during two months of treatment</TI>
<SO>International Angiology</SO>
<YR>1995</YR>
<VL>14 Suppl 1</VL>
<PG>343</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriet-1995" MODIFIED="2015-09-27 18:44:25 +0100" MODIFIED_BY="[Empty name]" NAME="Henriet 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-09-27 18:44:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriet J-P</AU>
<TI>[Functional venous insufficiency: clinical study comparing once a day DIOVENOR 600 mg (600 mg of diosmine d'hemisyntheses) versus two doses per day of a mixture of 500 mg of flavonoides (900 mg of diosmine)]</TI>
<SO>Phlebologie</SO>
<YR>1995</YR>
<VL>48</VL>
<NO>2</NO>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honorato-1990" MODIFIED="2013-12-23 17:37:39 +0000" MODIFIED_BY="[Empty name]" NAME="Honorato 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-12-23 17:37:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language - spanish with english summary.&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:37:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Honorato Perez J, Arcas Meca R</AU>
<TI>Double blind comparative study of hidrosmin-diosmin in peripheral vein disease</TI>
<SO>Revista de Medicina de la Universidad de Navarra</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>2</NO>
<PG>77-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horvath-1985" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Horvath 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: Geran with English Summary. Translator: Mark McConville&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath W, Tomschi F</AU>
<TI>[The postthrombotic state and the effect of dihydroergotamine]</TI>
<SO>Das Postthrombotische Zustandsbild und Seine Beeinflussung Durch Dihyrdroergotamin</SO>
<YR>1985</YR>
<VL>14</VL>
<NO>1</NO>
<PG>84-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-1995" MODIFIED="2015-09-27 18:47:26 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-09-27 18:47:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Cesarone MR, De Sanctis MT, Laurora G, Ricci A, Gerentes I</AU>
<TI>Evaluation of the microcirculatory effects of veinamitol 3500 mg in chronic venous insufficiency</TI>
<SO>International Angiology</SO>
<YR>1995</YR>
<VL>14 Suppl 1</VL>
<PG>98-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-1996" MODIFIED="2015-08-17 12:01:10 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-17 12:01:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, De Sanctis MT, Cesarone MR, Laurora G, Belcaro G, Taccoen A, et al</AU>
<TI>Efficacy of troxerutin in patients with chronic venous insufficiency: a double-blind, placebo-controlled study</TI>
<SO>Advances in Therapy</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>3</NO>
<PG>161-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2001" MODIFIED="2015-08-17 12:01:19 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-08-17 12:01:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Belcaro G, De Sanctis MT, Cesarone MR, Griffin M, Ippolito E, et al</AU>
<TI>Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S61-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2001a" MODIFIED="2014-08-29 11:16:31 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 11:16:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Belcaro G, Cesarone MR, Sanctis MT, Griffin M</AU>
<TI>Microvascular alterations in diabetic microangiopathy: topical treatment with Essaven gel--a placebo-controlled, randomized study</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 3</VL>
<PG>S35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2001b" MODIFIED="2014-08-29 11:16:36 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 2001b" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 11:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Belcaro G, Cesarone MR, Sanctis MT, Nargi E, Patricelli P, et al</AU>
<TI>Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled randomized study</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 2</VL>
<PG>S27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2002" MODIFIED="2015-09-27 18:44:43 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-27 18:44:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Belcaro G, Renton S, DeSanctis T, Cesarone MR, Bavera P, et al</AU>
<TI>HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2002b" MODIFIED="2014-08-29 11:18:01 +0100" MODIFIED_BY="[Empty name]" NAME="Incandela 2002b" YEAR="2002">
<REFERENCE MODIFIED="2014-08-29 11:18:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Cesarone MR, DeSanctis MT, Belcaro G, Dugall M, Acerbi G</AU>
<TI>Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>S11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN5340167" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN5340167" YEAR="2013">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN53430167</AU>
<TI>Clinical acceptability study in patients suffering from chronic venous disease (CVD) comparing micronized purified flavonoid fraction (MPFF) 1000 mg, one tablet daily, to MPFF 500 mg tablet twice a day</TI>
<SO>http://www.isrctn.com/search?q=ISRCTN53430167 (accessed 28 September 2015)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssens-1999" MODIFIED="2009-01-05 18:36:58 +0000" MODIFIED_BY="[Empty name]" NAME="Janssens 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-05 18:36:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssens D, Michiels C, Guillaume G, Cuisinier B, Louagie Y, Remacle J</AU>
<TI>Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssens-1999a" MODIFIED="2013-12-23 17:38:56 +0000" MODIFIED_BY="[Empty name]" NAME="Janssens 1999a" YEAR="1999">
<REFERENCE MODIFIED="2013-12-23 17:38:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9890390&lt;br&gt;Clinical Trial. Journal Article. Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:38:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssens D, Michiels C, Guillaume G, Cuisinier B, Louagie Y, Remacle J</AU>
<TI>Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jantet-2000" MODIFIED="2013-12-23 17:39:20 +0000" MODIFIED_BY="[Empty name]" NAME="Jantet 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-23 17:39:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;20129103&lt;/p&gt;" NOTES_MODIFIED="2013-12-23 17:39:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jantet G</AU>
<TI>RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids</TI>
<SO>Angiology</SO>
<YR>2000</YR>
<VL>51</VL>
<NO>1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalus-2004" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kalus 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-26 17:14:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2004081316&lt;/p&gt;" NOTES_MODIFIED="2013-12-26 17:14:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalus U, Koscielny J, Grigorov A, Schaefer E, Peil H, Kiesewetter H</AU>
<TI>Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by oral therapy with red wine leaf extract AS 195</TI>
<SO>Vasomed</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2004205214&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalus U, Koscielny J, Grigorov A, Schaefer E, Peil H, Kiesewetter H</AU>
<TI>Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study</TI>
<SO>Drugs in R &amp; D</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiesewetter-2000" MODIFIED="2015-08-17 12:01:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kiesewetter 2000" YEAR="">
<REFERENCE MODIFIED="2015-08-17 12:01:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiesewetter H, Koscielny J, Kalus U, Vix JM, Peil H, Petrini O, et al</AU>
<TI>Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>2</NO>
<PG>109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koch-2002" MODIFIED="2013-12-24 15:03:42 +0000" MODIFIED_BY="[Empty name]" NAME="Koch 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-24 15:03:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11933130&lt;/p&gt;" NOTES_MODIFIED="2013-12-24 15:03:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch R</AU>
<TI>Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency</TI>
<SO>Phytotherapy Research</SO>
<YR>2002</YR>
<VL>16 Suppl 1</VL>
<PG>S1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koltringer-1993" MODIFIED="2014-10-28 13:26:55 +0000" MODIFIED_BY="[Empty name]" NAME="Koltringer 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-28 13:26:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Details sent to CENTRAL - 8/1/98 WAS IN NOT RELEVANT&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 13:26:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O</AU>
<TI>Hemorheologic effects of ginkgo biloba extract EGb 761. Dose- dependent effect of EGb 761 on microcirculation and viscoelasticity of blood. [German]</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1993</YR>
<VL>111</VL>
<NO>10</NO>
<PG>170-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kostering-1985" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kostering 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: German/English summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostering H, Bandura B, Merten HA, Wieding JU</AU>
<TI>The behaviour of blood clotting and its inhibitors under long-term with 5,6-benzo-alpha-pyrone (coumarin). Double-blind study</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kr_x00e4_henb_x00fc_hl-1975" MODIFIED="2014-10-29 09:23:38 +0000" MODIFIED_BY="[Empty name]" NAME="Krähenbühl 1975" YEAR="1975">
<REFERENCE MODIFIED="2014-10-29 09:23:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krähenbühl B</AU>
<TI>Chronic arterial insufficiency of lower limbs: treatment by bencyclan (fludilat)</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1975</YR>
<VL>64</VL>
<NO>20</NO>
<PG>632-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranendonk-1993" NAME="Kranendonk 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranendonk SE, Koster AM</AU>
<TI>A double-blind clinical trial of the efficacy and tolerability of O-(beta-hydroxyethyl)-rutosides and compression stockings in the treatment of leg oedema and symptoms following surgery for varicose veins</TI>
<SO>Phlebology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>2</NO>
<PG>77-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krc_x00ed_lek-1973" MODIFIED="2014-10-29 09:24:37 +0000" MODIFIED_BY="[Empty name]" NAME="Krcílek 1973" YEAR="1973">
<REFERENCE MODIFIED="2014-10-29 09:24:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krcílek A, Smejkal V</AU>
<TI>Therapeutic effects of venotonics in clinical pharmacotherapeutical evaluations by double-blind tests</TI>
<SO>Casopis Lekaru Ceskych</SO>
<YR>1973</YR>
<VL>112</VL>
<PG>930-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambelet-1973" NAME="Lambelet 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambelet F</AU>
<TI>Le traitement des troubles circulatoires veineux: une étude en double-insu avec le Sandovène</TI>
<SO>Praxis</SO>
<YR>1973</YR>
<VL>62</VL>
<PG>925-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Languillat-1988b" NAME="Languillat 1988b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Languillat N, Zucarrelli F</AU>
<TI>Etude en double aveugle contre placebo de l'activite veinotonique due veliten: evolution de la permeabilite capillare et de lat vitesse de circulation veineuse</TI>
<SO>Acta Medica Internationale Angiologie</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>83</NO>
<PG>3-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Languillat-1989" NAME="Languillat 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Languillat N, Zuccarelli F, Hariton C</AU>
<TI>Radioisotopic comparative double-blind study of venous capillary permeability and circulation rate after treatment by Veliten (R) in venous insufficiency of inferior limbs</TI>
<SO>Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September</SO>
<YR>1989</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-D_x00e9_v_x00e9_hat-1989" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Le Dévéhat 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-10-28 13:25:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Le Dévéhat C, Vimeux M, Bandoux G</AU>
<TI>Hemoreological effects of oral troxerutin treatment versus placebo in venous insufficiency of the lower limbs</TI>
<SO>Clinical Hemorrheology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>4</NO>
<PG>543-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-17 07:07:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Dévéhat C, Vimeux M, Bondoux G, Khodabandehlou T</AU>
<TI>Hemorheological effects of oral troxerutin treatment in venous insufficiency of the lower limbs</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>766-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Le Devehat C, Lemoine A</AU>
<TI>Effet hemorheological de la troxerutine dans l'insuffisance veineuse</TI>
<TO>Effet hemorheological de la troxerutine dans l'insuffisance veineuse</TO>
<SO>Phlebology 1985</SO>
<YR>1986</YR>
<PG>850-2</PG>
<ED>Negus D, Jantet G</ED>
<PB>John Libbey and Co Ltd</PB>
<CY>Herts, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-D_x00e9_v_x00e9_hat-1997" MODIFIED="2013-12-26 17:22:43 +0000" MODIFIED_BY="[Empty name]" NAME="Le Dévéhat 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-12-24 15:17:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C</AU>
<TI>Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg</TI>
<SO>International Journal of Microcirculation: Clinical and Experimental</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefebvre-1991" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Other speciality preg.Code word not added until may 2012&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefebvre G, Lacombe C</AU>
<TI>Venous insufficiency during pregnancy. Rheological improvement by troxerutine</TI>
<SO>Revue Française de Gynecologie et d'Obstetrique</SO>
<YR>1991</YR>
<VL>86</VL>
<PG>206-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marastoni-1982" MODIFIED="2013-12-24 15:18:09 +0000" MODIFIED_BY="[Empty name]" NAME="Marastoni 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-12-24 15:18:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marastoni F, Crespi B, Montorsi M, De Stefano A</AU>
<TI>A clinical and instrumental assessment of the effect of dihydroergotamine in lower extremity venous insufficiency</TI>
<SO>Archivio per le Scienze Mediche</SO>
<YR>1982</YR>
<VL>139</VL>
<NO>2</NO>
<PG>165-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marastoni-1982a" MODIFIED="2013-12-24 15:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Marastoni 1982a" YEAR="1982">
<REFERENCE MODIFIED="2013-12-24 15:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marastoni F, Baldo A, Redaelli G, Ghiringhelli L</AU>
<TI>Centella asiatica extract in venous pathology of the lower limbs and its evaluation as compared with tribenoside</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>4</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menyhei-1994" MODIFIED="2015-09-27 18:45:14 +0100" MODIFIED_BY="[Empty name]" NAME="Menyhei 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-09-27 18:45:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menyhei G, Acsady G, Hetenyi A, Dubeaux D, Rado G</AU>
<TI>Chronobiology and clinical activity of daflon 500 mg in chronic venous insufficiency</TI>
<SO>Phlebology</SO>
<YR>1994</YR>
<VL>9 Suppl 1</VL>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1994" MODIFIED="2013-12-24 15:18:50 +0000" MODIFIED_BY="[Empty name]" NAME="Monreal 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-24 15:18:50 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;copy available&lt;/p&gt;" NOTES_MODIFIED="2013-12-24 15:18:50 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Callejas JM, Martorell A, Lisbona C, Lerma R</AU>
<TI>A prospective study of the long-term efficacy of two different venoactive drugs in patients with post-thrombotic syndrome</TI>
<SO>Phlebology</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1997" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Monreal 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Randomised by randmisation schedule&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Callejas JM, Martorell A, Sahuquillo JC, Contel E</AU>
<TI>Prevention of post-thrombotic syndrome with hidrosmina: a prospective pilot study</TI>
<SO>Phlebology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteil_x002d_Seurin-1993" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Monteil-Seurin 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: French with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monteil-Seurin J</AU>
<TI>Lymphatic venous insufficiency: comparative study of Cyclo 3 Fort(TM) versus diosmin</TI>
<SO>Comptes Rendus de Therapeutique et de Pharmacologie Clinique</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>109</NO>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteverde-1987" MODIFIED="2013-12-24 15:19:39 +0000" MODIFIED_BY="[Empty name]" NAME="Monteverde 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-12-24 15:19:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monteverde A, Occhipinti P, Rossi F, Vellata D</AU>
<TI>Comparison between Extract of Centella Asiatica and O-(beta- hydroxyethyl) rutoside in the treatment of venous insufficiency of the lower limbs</TI>
<SO>Acta Therapeutica</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>6</NO>
<PG>629-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1993" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Morales 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales CA, Barros RM</AU>
<TI>Efficacy and safety on use of dried horse chestnut extract in the treatment of chronic venous insufficiency of the limbs</TI>
<TO>Eficácia e segurança do extracto seco da semente de castanha-da-India no tratamento da insuficiencia venosa crônica de membros inferiores</TO>
<SO>Revista Brasileira de Medicina</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>11</NO>
<PG>1563-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muschietti-1978" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Muschietti 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language - french with english summary.&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muschietti B</AU>
<TI>[Clinical double blind trial with natural diosmin, synthetic diosmin and tribenoside]</TI>
<SO>Comparaison Clinique en Double Insu Entre la Diosmine Naturelle et Synthetique et le Tribenoside</SO>
<YR>1978</YR>
<VL>67</VL>
<PG>1449-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naser_x002d_Hijazi-2004" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Naser-Hijazi 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naser-Hijazi B, Gallenkemper G, Rieckemann B, Vanscheidt W</AU>
<TI>In contrast to its derivatives, coumarin does not influence prothrombin time: results from a randomised placebo-controlled study</TI>
<SO>Phlebologie</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmeck-Lindenau HJ, Naser-Hijazi B, Becker EW, Henneicke von HH, Schnitker J</AU>
<TI>Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>5</NO>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01654016" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01654016" YEAR="4016">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01654016</AU>
<TI>Study of antiinflammatory effects of Detralex (Daflon)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT01654016 (accessed 9 September 2015)</SO>
<IDENTIFIERS MODIFIED="2015-09-28 20:43:06 +0100" MODIFIED_BY="Karen Welch"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:26:29 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:26:29 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT01654016"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02191163" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02191163" YEAR="1183">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02191163</AU>
<TI>Efficacy of Antlstax In improving microcirculation of the skin in the leg in patients suffering from chronic venous insufficiency</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02191163 (accessed 9 Sepember 2015)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:27:54 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:27:54 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT02191163"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02191254" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02191254" YEAR="1254">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02191254</AU>
<TI>Efficacy and tolerablllty of Antlstax in male and female patients sufferlng from chronlc venous insufllclency</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02191254 (accessed 9 September 2015)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:43:41 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:43:41 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT02191254"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02191280" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02191280" YEAR="1280">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02191280</AU>
<TI>Antistax In patlents wlth chronlc venous insutflclency</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02191280 (accessed 9 September 2015)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:45:00 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:45:00 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT02191280"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-1988" NAME="Neumann 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann HAM, Van Den Broek MTJB</AU>
<TI>Double blind study of the influence of O-(beta-hydroxyethyl)-rutosides on the TcpO2 and LRR curve in patients with chronic venous insufficiency</TI>
<SO>International Angiology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>4</NO>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-1990" MODIFIED="2015-09-27 18:46:04 +0100" MODIFIED_BY="[Empty name]" NAME="Neumann 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-09-27 18:46:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuman HAM, Van der Broek MJTB</AU>
<TI>Evaluation of O-(beta-hydroxyethyl)-rutosides in chronic venous insufficiency by means of non-invasive techniques</TI>
<SO>Phlebology</SO>
<YR>1990</YR>
<VL>5 Suppl 1</VL>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-1995" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Neumann 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: French with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann HAM, Van Den Broek MJTB</AU>
<TI>A comparative clinical trial of graduated compression stockings and O-(beta-hydroxy-ethyl)-rutosides (HR) in the treatment of patients with chronic venous insufficiency</TI>
<SO>Phlébologie</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>3</NO>
<PG>78-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-01 17:51:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann HAM, Van Den Broek MJTB</AU>
<TI>A comparative clinical trial of graduated compression stockings and O-(beta-hydroxyethyl)-rutosides (HR) in the treatment of patients with chronic venous insufficiency</TI>
<SO>Zeitschrift fur Lymphologie</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>1</NO>
<PG>8-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann_x002d_Mangoldt-1979" MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NAME="Neumann-Mangoldt 1979" YEAR="1979">
<REFERENCE MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language German with English summary Duplicate of 3462&lt;/p&gt;" NOTES_MODIFIED="2016-02-24 17:10:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann-Mangoldt VP</AU>
<TI>Treatment of venous disorders of the lower extremities with Essaven-capsules, results of a double blind trial</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1979</YR>
<VL>97</VL>
<NO>45</NO>
<PG>2117-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nill-1970" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Nill 1970" YEAR="1970">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;4938002&lt;br&gt;Clinical Trial. Comparative Study. Controlled Clinical Trial. Journal Article&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nill HJ, Fischer H, Nill HJ, Fischer H</AU>
<TI>Comparative investigations concerning the effect of extract of horse chestnut upon the pressure-volume-diagram of patients with venous disorders. [German]</TI>
<SO>Arztliche Forschung</SO>
<YR>1970</YR>
<VL>24</VL>
<NO>5</NO>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ottillinger-2001" MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NAME="Ottillinger 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11747472. 2 studies. Open with regard to compression group.&lt;/p&gt;" NOTES_MODIFIED="2016-02-24 17:10:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ottillinger B, Greeske K</AU>
<TI>Rational therapy of chronic venous insufficiency--chances and limits of the therapeutic use of horse-chestnut seeds extract</TI>
<SO>BMC Cardiovascular Disorders</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>1</NO>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paciaroni-1982" MODIFIED="2014-10-28 13:23:44 +0000" MODIFIED_BY="[Empty name]" NAME="Paciaroni 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-10-28 13:23:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paciaroni E, Marini M</AU>
<TI>Topical therapy for phlebopathies. Results of a controlled clinical study</TI>
<SO>Policlinico - Sezione Medica</SO>
<YR>1982</YR>
<VL>89</VL>
<PG>255-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ID: 8761"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Partsch-1981" MODIFIED="2016-03-24 14:58:44 +0000" MODIFIED_BY="[Empty name]" NAME="Partsch 1981" YEAR="1981">
<REFERENCE MODIFIED="2016-03-24 14:58:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language: German.&lt;/p&gt;" NOTES_MODIFIED="2016-03-24 14:58:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Partsch H</AU>
<TI>Improvement of venous insufficiency with oral dehydroergotamine</TI>
<TO>Besserung der venosen insuffizienz durch orales dihydroergotamin</TO>
<SO>Die Medizinische Welt</SO>
<YR>1981</YR>
<VL>32</VL>
<PG>1668-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paul-1983" MODIFIED="2013-12-24 15:43:12 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-12-24 15:43:12 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Randomisation: Odd and even year of birth&lt;/p&gt;" NOTES_MODIFIED="2013-12-24 15:43:12 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paul V, Lange A</AU>
<TI>Benzarone in edema of the legs due to chronic venous insufficiency</TI>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1983</YR>
<VL>125</VL>
<NO>16</NO>
<PG>343-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauschinger-1987" MODIFIED="2016-03-30 13:39:37 +0100" MODIFIED_BY="[Empty name]" NAME="Pauschinger 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-03-30 13:39:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Xref with ID 3963. Language: German with English Summary&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 13:39:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauschinger P</AU>
<TI>Clinical and experimental examination of the effect of horse-chestnut extract on the transcapillary filtratrion and the intravasel volume in patients with chronic venous insufficiency</TI>
<TO>Klinisch experimentelle Untersuchungen zur Wirkung von Rosskastanien-samenextrakt auf die transkapilläre Filtration und das intravasale Volumen an Parienten mit chronisch venöser Insuffizienz</TO>
<SO>Phlebol Proktol</SO>
<YR>1987</YR>
<VL>16</VL>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pecking-1998" MODIFIED="2014-10-28 13:23:14 +0000" MODIFIED_BY="[Empty name]" NAME="Pecking 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-10-28 13:23:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pecking AP, Fevrier B, Wargon C, Pillion G</AU>
<TI>Efficacy of daflon 500 mg in the treatment of lymphedema (secondary to conventonal therapy of breast cancer)</TI>
<TO>Efficacite de daflon 500 mg dans le traitment du lymphoedeme (secondaire au traitement conventionnel du cancer du sein)</TO>
<SO>Phlébologie</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>4</NO>
<PG>519-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petruzzellis-1990" NAME="Petruzzellis 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;source required&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petruzzellis V, Quaranta D, Sacchetta AC, Candiani C</AU>
<TI>Therapeutic activity of O-(beta-hydroxyethyl)-rutosides in acute superficial phlebitis in patients suffering from chronic venous insufficiency</TI>
<SO>Giornale Italiano di Angiologia</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>81-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petruzzellis-2002" MODIFIED="2015-08-17 12:01:40 +0100" MODIFIED_BY="[Empty name]" NAME="Petruzzellis 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-08-17 12:01:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The treatment concealment is not correct or it is not correctly explain&lt;/p&gt;" NOTES_MODIFIED="2015-08-17 12:01:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, et al</AU>
<TI>Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study</TI>
<SO>Angiology</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3</NO>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pointel-1987b" MODIFIED="2016-03-30 13:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Pointel 1987b" YEAR="1987">
<REFERENCE MODIFIED="2016-03-30 13:42:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Language - french. Write to author regarding randomisation methods - 5/96.&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 13:42:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pointel JP, Got I, Ziegler OI, Fontaine M, Benedetti F, Drouin P, et al</AU>
<TI>Double-blind controlled study of a combination of vitamin C, Ruscus aculeatus and Ribes nigrum anthocyanosides on capillary filtration in venous insufficiency</TI>
<TO>Essai controle en double insu d'une association vitamine C, ruscus aculeatus et anthocyanosides de ribes nigrum sur la filtration capillaire dans l'insuffisance veineuse</TO>
<SO>Arteres et veines</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>5</NO>
<PG>395-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pokrovskii-2005" MODIFIED="2014-10-28 13:17:04 +0000" MODIFIED_BY="[Empty name]" NAME="Pokrovskii 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-10-28 13:17:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16439948&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 13:17:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pokrovskii AV, Sapelkin SV, Galaktionova LA, Fedorov EE</AU>
<TI>The assessment of medical therapy effectiveness of patients with lower limb chronic venous insufficiency: the results of prospective study with Ginkor Fort. [Russian]</TI>
<SO>Angiologiia i Sosudistaia Khirurgiia/Angiology and Vascular Surgery</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollastri-1982" MODIFIED="2015-08-17 12:01:48 +0100" MODIFIED_BY="[Empty name]" NAME="Pollastri 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-08-17 12:01:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollastri M, Cipriani C, Barletta S, Borgioli A, Boscarino A, Tesi CU, et al</AU>
<TI>A clinical contribution to the pharmacology of chronic venous insufficiency: the effects of disodium flavodate</TI>
<SO>Gazzetta Medica Italiana</SO>
<YR>1982</YR>
<VL>141</VL>
<NO>4</NO>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Questel-1983" MODIFIED="2009-01-05 18:26:44 +0000" MODIFIED_BY="[Empty name]" NAME="Questel 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-01-05 18:26:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Questel R, Walrant P</AU>
<TI>Randomized, placebo-controlled trial of extracts of Ruscus aculeatus and Ribes nigrum plus ascorbic acid in venous insufficiency: Observation of microcirculation by conjunctival capillarography</TI>
<SO>Gazette Medicale de France</SO>
<YR>1983</YR>
<VL>90</VL>
<NO>6</NO>
<PG>508-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-2011b" MODIFIED="2014-10-28 13:16:49 +0000" MODIFIED_BY="[Empty name]" NAME="Rabe 2011b" YEAR="2011">
<REFERENCE MODIFIED="2014-10-28 13:16:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe E, Stucker M, Esperester A, Schafer E, Ottillinger B</AU>
<TI>Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency - results of a double-blind placebo-controlled study</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2011</YR>
<VL>41</VL>
<NO>4</NO>
<PG>540-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rehn-1993" MODIFIED="2013-12-24 18:32:25 +0000" MODIFIED_BY="[Empty name]" NAME="Rehn 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-12-24 18:32:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rehn D, Golden G, Nocker W, Diebschlag W, Lehmacher W</AU>
<TI>Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>10</NO>
<PG>1060-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rehn-1993b" MODIFIED="2013-12-26 18:15:22 +0000" MODIFIED_BY="[Empty name]" NAME="Rehn 1993b" YEAR="1993">
<REFERENCE MODIFIED="2013-12-24 18:32:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rehn D, Nocker W, Diebschlag W, Golden G</AU>
<TI>Time course of the anti-oedematous effect of different dose regimens of O-(beta-hydroxyethyl) rutosides in healthy volunteers</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>3</NO>
<PG>335-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rehn-1996" NAME="Rehn 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;single-blind study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rehn D, Brunnauer H, Diebschlag W, Lehmacher W</AU>
<TI>Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>5</NO>
<PG>488-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riccioni-2004" MODIFIED="2014-10-28 13:16:10 +0000" MODIFIED_BY="[Empty name]" NAME="Riccioni 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-10-28 13:16:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riccioni C, Sarcinella R, Izzo A, Palermo G, Liguori M</AU>
<TI>Effectiveness of Troxerutin in association with Pycnogenol in the pharmacological treatment of venous insufficiency</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>2004</YR>
<VL>52</VL>
<NO>1</NO>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rish-1972" NAME="Rish 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rish L, Rodriguez JC</AU>
<TI>Effect of O-(beta-hydroxyethyl)-rutosides on oedema in chronic venous insufficiency of the lower limb. A double blind trial</TI>
<SO>Angiologica</SO>
<YR>1972</YR>
<VL>9</VL>
<NO>1</NO>
<PG>62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roztocil-1977" MODIFIED="2014-10-28 13:15:36 +0000" MODIFIED_BY="[Empty name]" NAME="Roztocil 1977" YEAR="1977">
<REFERENCE MODIFIED="2014-10-28 13:15:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roztocil K, Prerovsky I, Oliva I</AU>
<TI>The effect of hydroxyethylrutosides on capillary filtration rate in the lower limb of man</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1977</YR>
<VL>11</VL>
<PG>435-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roztocil-2003" MODIFIED="2016-03-30 14:44:17 +0100" MODIFIED_BY="[Empty name]" NAME="Roztocil 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-25 17:20:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roztocil K, Stvrtinova V, Strejcek J</AU>
<TI>Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency</TI>
<SO>International Angiology</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>1</NO>
<PG>24-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadoun-1993" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Sadoun 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadoun S, Allaert FA, Danel P, Mercier M</AU>
<TI>Venous and trophic disease, efficacy of chromocarbe diethylamine on functional and organic symptoms</TI>
<TO>Maladie veineuse et troubles trophiques, efficacite du chromocarbe diethylamine sur la symptomatologie fonctionnelle et organique</TO>
<SO>Artères et Veines</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>4</NO>
<PG>225-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="  ISSN  0293-5090 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanctis-2001" MODIFIED="2014-08-29 11:20:22 +0100" MODIFIED_BY="[Empty name]" NAME="Sanctis 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 11:20:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Ricci A, Griffin M</AU>
<TI>Four-week treatment with Essaven gel in diabetic microangiopathy--a placebo-controlled, randomized study</TI>
<SO>Angiology</SO>
<YR>2001</YR>
<VL>52 Suppl 3</VL>
<PG>S49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmeck_x002d_Lindenau-2003" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Schmeck-Lindenau 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12776809&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmeck-Lindenau HJ, Naser-Hijazi B, Becker EW, Henneicke von HH, Schnitker J</AU>
<TI>Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>5</NO>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seydewitz-1992" NAME="Seydewitz 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seydewitz V, Berg D, Staubesand J, Welbers P</AU>
<TI>Impact of drug treatment on the activity of lysosomal enzymes in the wall of varicose veins</TI>
<TO>Einflub einer medikamentösen therapie auf die aktivität lysosomaler enzyme in der varikös veränderten Venenwand</TO>
<SO>Phlebologie</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>6</NO>
<PG>288-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefanini-1996" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Stefanini 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefanini L, Gigli P, Galassi A, Pierallini F, Tillieci A, Scalabrino F, et al</AU>
<TI>Pharmacologic treatment and/or balneotherapy of chronic venous insufficiency</TI>
<SO>Gazzetta Medica Italiana</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>4</NO>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmann-1987" NAME="Stegmann 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmann W, Hubner K, Deichmann B, Muller B</AU>
<TI>Efficacy of O-(beta-hydroxyethyl)-rutosides in the treatment of venous leg ulcers</TI>
<TO>L'efficacite des O-(beta-hydroxyethyl)-rutosides dans le traitement de l'ulcere de jambe veineux</TO>
<SO>Phlebologie</SO>
<YR>1987</YR>
<VL>40</VL>
<NO>1</NO>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1986" NAME="Steiner 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner M, Hillemans HG</AU>
<TI>Tests for antiedema action of a vein drug</TI>
<SO>Münchener Medizinische Wochenschrift</SO>
<YR>1986</YR>
<VL>128</VL>
<NO>31</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1990" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Steiner 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner M</AU>
<TI>Investigation on the edema-reducing and edema-protective effect of horse chestnut seed extract</TI>
<SO>Phlebol Proktol</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>5</NO>
<PG>239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1992" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Steiner 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Handsearched by Hazel Dunn&lt;/p&gt;" NOTES_MODIFIED="2016-03-30 15:48:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Steiner M</AU>
<SO>The Extent of the Edema Protective Effect of Horse Chestnut Seed Extract</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>715</PG>
<PB>John Libbey Eurotext</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steru-1988" MODIFIED="2014-10-28 13:15:05 +0000" MODIFIED_BY="[Empty name]" NAME="Steru 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-10-28 13:15:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steru D, Steru L</AU>
<TI>Evaluation clinique d'un phlebotrope: application a l'etude du veinamitol</TI>
<TO>Evaluation clinique d'un phlebotrope: application a l'etude du veinamitol</TO>
<SO>Arteres et Veines</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>4</NO>
<PG>362-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strauss-1992" NAME="Strauss 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strauss AL, Rieder H</AU>
<TI>Antiedematous effect of a drug combination in the orthostatic test</TI>
<SO>Phlebologie</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strefezza-2010" MODIFIED="2014-10-29 09:32:40 +0000" MODIFIED_BY="[Empty name]" NAME="Strefezza 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-29 09:32:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2010230240 201020&lt;/p&gt;" NOTES_MODIFIED="2014-10-29 09:32:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strefezza EF</AU>
<TI>Comparative study of the formulations of diosmin/hesperidin and sachet in the treatment of the pain and edema of inferior members in the chronic venous disease [Portuguese]</TI>
<SO>Revista Brasileira de Medicina</SO>
<YR>2010</YR>
<VL>67</VL>
<NO>1-2</NO>
<PG>21-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Topalov-1990" MODIFIED="2016-04-01 09:55:37 +0100" MODIFIED_BY="[Empty name]" NAME="Topalov 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-04-01 09:55:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topalov Y, Marinov H, Stanchev S</AU>
<TI>Troxesamol. Clinical application of the preparation in patients with vascular insufficiency of the lower extremities</TI>
<SO>Medico Biologie Information</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>4</NO>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsukanov-2010" MODIFIED="2014-10-28 13:13:14 +0000" MODIFIED_BY="[Empty name]" NAME="Tsukanov 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-28 13:13:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;21280296&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 13:13:14 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsukanov IuT, Tsukanov AI, Vasilevich VV</AU>
<TI>Assessment of dose-dependent effect during phlebotropic therapy of chronic diseases of lower-limb veins. [Russian]</TI>
<SO>Angiologiia i Sosudistaia Khirurgiia/Angiology &amp; Vascular Surgery</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>3</NO>
<PG>71-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turio-2000" MODIFIED="2013-12-24 18:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Turio 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-24 18:36:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turio E, Romanelli M, Barachini P</AU>
<TI>Clinical arid instrumental evaluation of the efficacy of a vasoactive drug containing vitamin PP, vitamin C and phyto-therapeutic extracts titrated in escin, bromelain and anthocyanosides for the treatment of varicose leg ulcers</TI>
<SO>Giornale Italiano di Dermatologia e Venereologia</SO>
<YR>2000</YR>
<VL>135</VL>
<NO>1</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weindorf-1987" MODIFIED="2014-10-28 13:12:46 +0000" MODIFIED_BY="[Empty name]" NAME="Weindorf 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-10-28 13:12:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weindorf N, Schultz Ehrenburg U</AU>
<TI>Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone</TI>
<SO>Zeitschrift fur Hautkrankheiten</SO>
<YR>1987</YR>
<VL>62</VL>
<PG>28-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Widmer-1972" NAME="Widmer 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Widmer LK, Glaus L, Raps E</AU>
<TI>Local treatment of leg disorders and chronic venous insufficiency. Double blind study of 55 patients</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1972</YR>
<VL>61</VL>
<NO>42</NO>
<PG>1300-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zicot-1993" NAME="Zicot 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zicot M</AU>
<TI>Multicenter study of the efficacy and tolerance of naftazone (Mediaven 10 mg). Comparison of 2 dosage schemes</TI>
<SO>Revue Medicale de Liege</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>4</NO>
<PG>224-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuccarelli-1996" MODIFIED="2014-10-28 13:11:27 +0000" MODIFIED_BY="[Empty name]" NAME="Zuccarelli 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-10-28 13:11:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuccarelli F</AU>
<TI>Evaluation of the effectiveness of Ginkor Fort on the symptoms of chronic venous insufficiency</TI>
<SO>Phlébologie</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>1</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-02-01 17:51:11 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-10-20 08:22:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN18841175" MODIFIED="2015-10-01 22:30:01 +0100" MODIFIED_BY="Karen Welch" NAME="ISRCTN18841175" YEAR="2012">
<REFERENCE MODIFIED="2015-10-01 22:30:01 +0100" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN18841175</AU>
<TI>Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease</TI>
<SO>http://www.isrctn.com/ISRCTN18841175 (date accessed 28 October 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-10-01 22:29:32 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-10-01 22:29:32 +0100" MODIFIED_BY="Karen Welch" TYPE="ISRCTN" VALUE="18841175"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01532882" MODIFIED="2015-10-20 08:22:22 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01532882" YEAR="2012">
<REFERENCE MODIFIED="2015-10-20 08:22:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01532882</AU>
<TI>Efficacy and safety of Diosmin 600mg versus placebo on painful symptomatology in patients with chronic venous disease of lower limbs (EDEN)</TI>
<SO>http://clinicaltrials.gov/show/NCT01532882 (date accessed 28 October 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:47:28 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:47:28 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT01532882"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01848210" MODIFIED="2015-10-20 08:22:42 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01848210" YEAR="2013">
<REFERENCE MODIFIED="2015-10-20 08:22:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01848210</AU>
<TI>Efficacy and safety of Coumarin and Troxerutin in the symptomatic treatment of chronic venous insufficiency</TI>
<SO>http://clinicaltrials.gov/ct2/results?term=NCT01848210 (date accessed 28 October 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 20:47:40 +0100" MODIFIED_BY="Karen Welch">
<IDENTIFIER MODIFIED="2015-09-28 20:47:40 +0100" MODIFIED_BY="Karen Welch" TYPE="CTG" VALUE="NCT01848210"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-01 09:56:14 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-01 09:56:14 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ATC-2015" MODIFIED="2016-02-24 17:54:48 +0000" MODIFIED_BY="[Empty name]" NAME="ATC 2015" TYPE="OTHER">
<TI>Anatomical Therapeutic Chemical (ATC) system classification</TI>
<SO>http://www.whocc.no/atc_ddd_index/?code=C05</SO>
<YR>(accessed December 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aziz-2015" MODIFIED="2015-10-20 08:14:21 +0100" MODIFIED_BY="[Empty name]" NAME="Aziz 2015" TYPE="JOURNAL_ARTICLE">
<AU>Aziz Z, Tang WL, Chong NJ, Tho LY</AU>
<TI>A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2015</YR>
<VL>40</VL>
<NO>2</NO>
<PG>177-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Behar-1988" NAME="Behar 1988" TYPE="JOURNAL_ARTICLE">
<AU>Behar A, Lagrue G, Cohen-Boulakia F, Baillet J</AU>
<TI>Capillary filtration in idiopathic cyclic edema - effects of Daflon 500 mg</TI>
<SO>Nuklearmedizin</SO>
<YR>1988</YR>
<VL>27</VL>
<NO>3</NO>
<PG>105-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boada-1999" NAME="Boada 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boada JN, Nazco GJ</AU>
<TI>Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>413-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brand-1988" NAME="Brand 1988" TYPE="JOURNAL_ARTICLE">
<AU>Brand FN, Dannenberg AL, Abbott RD, Kannel WB</AU>
<TI>The epidemiology of varicose veins: the Framingham Study</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>2</NO>
<PG>96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpentier-2000" MODIFIED="2008-07-17 15:10:51 +0100" MODIFIED_BY="[Empty name]" NAME="Carpentier 2000" TYPE="JOURNAL_ARTICLE">
<AU>Carpentier PH</AU>
<TI>Epidemiology and physiopathology of chronic venous leg diseases</TI>
<SO>Revue du Praticien</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>11</NO>
<PG>1176-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciapponi-2004" NAME="Ciapponi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ciapponi A, Laffaire E, Roque M</AU>
<TI>Calcium dobesilate for chronic venous insuffciency: a systematic review</TI>
<SO>Angiology</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>2</NO>
<PG>147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2003" MODIFIED="2016-04-01 09:56:14 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2003" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers&#8217; Handbook [updated March 2003]</TI>
<SO>Oxford, UK: The Cochrane Library. The Cochrane Collaboration. Update Software; Issue 2, 2003</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diehm-1996b" NAME="Diehm 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Diehm C</AU>
<TI>The role of oedema protective drugs in the treatment of chronic venous insufficiency: a review of evidence based on placebo-controlled clinical trials with regard to efficacy and tolerance</TI>
<SO>Phlebology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekl_x00f6_f-2004" MODIFIED="2014-10-28 13:05:20 +0000" MODIFIED_BY="[Empty name]" NAME="Eklöf 2004" TYPE="JOURNAL_ARTICLE">
<AU>Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification</AU>
<TI>Revision of the CEAP classification for chronic venous disorders: consensus statement</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>6</NO>
<PG>1248-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1999" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 1999" TYPE="JOURNAL_ARTICLE">
<AU>Evans CJ, Fowkes FG, Ruckley CV, Lee AJ</AU>
<TI>Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro Version 3.2 for Windows</TI>
<TO>GRADEpro. www.gradepro.org].</TO>
<YR>2008</YR>
<PB>McMaster University</PB>
<CY>Ontario, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iba_x00f1_ez-2000" NAME="Ibañez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ibañez L, Ballarín E, Vidal X, Laporte JR</AU>
<TI>Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>9-10</NO>
<PG>763-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ib_x00e1__x00f1_ez-2005" MODIFIED="2014-10-28 13:00:17 +0000" MODIFIED_BY="[Empty name]" NAME="Ibáñez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ibáñez L, Vidal X, Ballarín E, Laporte JR</AU>
<TI>Population-based drug-induced agranulocytosis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>8</NO>
<PG>869-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2016-03-30 13:38:24 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-1991" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kaufman 1991" TYPE="BOOK">
<AU>Kaufman DW, Kelly JP, Levy Shapiro S</AU>
<SO>The Drug Ethiology of Agranulocytosis and Aplastic Anemia</SO>
<YR>1991</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurz-1999" MODIFIED="2015-08-17 12:01:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kurz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kurz X, Kahn SR, Abenhaim L, Clement D, Norgren L, Baccaglini U, et al</AU>
<TI>Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies</TI>
<SO>International Angiology</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>2</NO>
<PG>83-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Markwardt--1996" MODIFIED="2014-03-24 15:30:03 +0000" MODIFIED_BY="[Empty name]" NAME="Markwardt  1996" TYPE="JOURNAL_ARTICLE">
<AU>Markwardt F</AU>
<TI>Pharmacology of oedema protective drugs</TI>
<SO>Phlebology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>10-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicolaides-2000" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Nicolaides 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nicolaides AN. Cardiovascular Disease Educational and Research Trust. European Society of Vascular Surgery. The International Angiology Scientific Activity Congress Organization. International Union of Angiology. Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay</AU>
<TI>Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997)</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>20</NO>
<PG>E126-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-1998" NAME="Pittler 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pittler MH, Ernst E</AU>
<TI>Horse-Chestnut seed extract for chronic venous insufficiency: a criteria-based systematic review</TI>
<SO>Archives of Dermatology</SO>
<YR>1998</YR>
<VL>134</VL>
<NO>11</NO>
<PG>1356-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2012" MODIFIED="2014-10-28 12:57:22 +0000" MODIFIED_BY="[Empty name]" NAME="Pittler 2012" TYPE="COCHRANE_REVIEW">
<AU>Pittler MH, Ernst E</AU>
<TI>Horse chestnut seed extract for chronic venous insufficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2014-10-28 12:57:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-28 12:57:04 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003230.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Porter-1995" NAME="Porter 1995" TYPE="JOURNAL_ARTICLE">
<AU>Porter JM, Moneta GL</AU>
<TI>Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>4</NO>
<PG>635-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1994" NAME="Poynard 1994" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Valterio C</AU>
<TI>Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency</TI>
<SO>Vasa</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>3</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabe-2013" MODIFIED="2014-08-29 11:19:24 +0100" MODIFIED_BY="[Empty name]" NAME="Rabe 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rabe E, Guex JJ, Morrison N, Ramelet AA, Schuller-Petrovic S, Scuderi A, et al</AU>
<TI>Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. [Review]</TI>
<SO>Phlebology</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>6</NO>
<PG>308-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-2014" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Robertson 2014" TYPE="JOURNAL_ARTICLE">
<AU>Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV, Fowkes FG</AU>
<TI>Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2014</YR>
<VL>48</VL>
<NO>2</NO>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8220;Summary of findings&#8221; tables</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration. www.cochrane-handbook.org</PB>
<CY>London, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1995" MODIFIED="2008-07-17 15:12:56 +0100" MODIFIED_BY="[Empty name]" NAME="Scott 1995" TYPE="JOURNAL_ARTICLE">
<AU>Scott TE, LaMorte WW, Gorin DR, Menzoain JO</AU>
<TI>Risk factors for chronic venous insufficiency: a dual case-control study</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>5</NO>
<PG>622-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spanish-Min.-Health" MODIFIED="2016-03-30 13:47:41 +0100" MODIFIED_BY="[Empty name]" NAME="Spanish Min. Health" TYPE="OTHER">
<TI>Re-evaluation of the risk-benefit relationship of oral phlebotonic agents</TI>
<TO>Re-evaluación de la relación benefico-riesgo de los agentes flebotónicos para administración por vía oral</TO>
<SO>http://www.hsanmillan.es/farma/flebotonicos.htm (accessed May 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanhope-1975" NAME="Stanhope 1975" TYPE="JOURNAL_ARTICLE">
<AU>Stanhope JM</AU>
<TI>Varicose veins in a population of New Guinea</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1975</YR>
<VL>4</VL>
<NO>3</NO>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsouderos-1991" MODIFIED="2015-09-27 21:36:47 +0100" MODIFIED_BY="[Empty name]" NAME="Tsouderos 1991" TYPE="JOURNAL_ARTICLE">
<AU>Tsouredos Y</AU>
<TI>Venous tone: are the phlebotonics properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1991</YR>
<VL>80 Suppl 7</VL>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Oever-1998" MODIFIED="2008-07-17 15:13:01 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Oever 1998" TYPE="JOURNAL_ARTICLE">
<AU>Van den Oever R, Hepp B, Debbaut B, Simon I</AU>
<TI>Socio-economic impact of chronic venous insufficiency. An underestimated public health problem</TI>
<SO>International Angiology</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vasquez-2010" MODIFIED="2014-10-16 14:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Vasquez 2010" TYPE="JOURNAL_ARTICLE">
<AU>Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, et al</AU>
<TI>Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>5</NO>
<PG>1387-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wadworth-1992" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Wadworth 1992" TYPE="JOURNAL_ARTICLE">
<AU>Wadworth AN, Faulds D</AU>
<TI>Hydroxyethylrutosides. A review of its pharmacology and therapeutic efficacy in venous insufficiency and related disorders</TI>
<SO>Drugs</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1013-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-09-09 16:55:29 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Martinez-2001" MODIFIED="2015-09-09 16:55:29 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez 2001" TYPE="COCHRANE_PROTOCOL">
<AU>Martinez MJ, Bonfill X, Moreno RM, Cachà A, Vargas E, Capellà D</AU>
<TI>Phlebotonics for venous insufficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-07-27 15:06:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-27 15:06:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Zapata-2005" MODIFIED="2014-10-28 12:48:59 +0000" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2005" TYPE="COCHRANE_REVIEW">
<AU>Martinez-Zapata MJ, Bonfill Cosp X, Moreno RM, Vargas E, Capellà D</AU>
<TI>Phlebotonics for venous insufficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-10-28 12:48:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-28 12:48:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003229.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-10-01 22:30:42 +0100" MODIFIED_BY="Karen Welch"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-03-31 10:53:59 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-03-31 10:53:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allegra-1981">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: table of random numbers</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: hospital</P>
<P>Number: 80 patients</P>
<P>Age: not stated</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: patients with postphlebitic syndrome, oedema of the lower limb, phlebolymphoedema, constitutional venous stasis, varices</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 2 × 10 mg Centella tablets 3× per day</P>
<P>Control: placebo</P>
<P>Duration: 30 days</P>
<P>Follow-up: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heavy legs, pain, cramps, global assessment by participant and by physician measured by an ordinal scale (0 to 3)</LI>
<LI>Signs - leg oedema, venous dilatation and skin trophism measured by an ordinal scale (0 to 3). Venous pressure measured by echo Doppler</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Tolerance</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alterkamper-1987">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 3/50 (6%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: not stated</P>
<P>Number: 50 patients</P>
<P>Age: mean 53 ± 9 years</P>
<P>Gender: 13 M:37 F</P>
<P>Inclusion criteria: symptomatic stage I to II of CVI</P>
<P>Exclusion criteria: oedemas requiring compression, post-thrombotic syndrome, lymphoedema; cardiac, renal or hepatic failure; diuretics; pregnancy; severe disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 1.86 mg ruscus and 75 mg hesperidin. 2 capsules 3× per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tired, heavy legs; pain and swelling measured by a visual analogue scale (VAS)</LI>
<LI>Signs - venous refilling time by light reflection rheography (LRR)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:46:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arcangeli-2000">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: clinical centre</P>
<P>Number: 40 patients</P>
<P>Age: mean 57.95 ± 12.78 years pycnogenol group; mean 61.40 ± 10.62 years placebo group</P>
<P>Gender: 13 M:27 F</P>
<P>Inclusion criteria: symptomatic CVI as a consequence of deep venous thrombosis or idiopathic venous lymphatic deficiency</P>
<P>Exclusion criteria: cardiovascular, diuretics, analgesic or anti-inflammatory drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: french maritime pine bark extract, 100 mg 3× per day</P>
<P>Control: placebo</P>
<P>Duration: 69 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:46:23 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heavy legs, pain and swelling measured by means of a semiquantitative scale (0 to 3)</LI>
<UL>
<LI>Percentage of participants showing disappearance of each symptom</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Venous blood flow measured by Doppler ultrasound</LI>
<LI>Tolerability</LI>
<LI>Global assessment by physicians at the end of the trial</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:46:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balmer-1980">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Switzerland</P>
<P>Setting: not stated</P>
<P>Number: 40 patients</P>
<P>Age: mean 46.2 ± 14.1 years active group; mean 52.3 ± 14.1 years placebo group</P>
<P>Gender: 4 M:36 F</P>
<P>Inclusion criteria: CVI without venous ulcers</P>
<P>Exclusion criteria: varicose ulcers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 900 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
<P>Compression therapy was allowed if participants were unwilling to abandon this support</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema as measured by circumference of ankle and calf (mm)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - pain, cramps, tiredness, pins and needles, swelling, restless legs measured by an ordinal scale (0 to 4)</LI>
<LI>Clinician's assessment</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belczak-2014">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 9/136 (6.6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Brazil</P>
<P>Setting: Department of Vascular Surgery of Sao Camilo Medical School</P>
<P>Number: 136 patients</P>
<P>Age: mean 52.8 ± 16.4 years active group; mean 50.6 ± 13.1 years placebo group</P>
<P>Gender: 33 M:103 F</P>
<P>Inclusion criteria: treatment-naïve (no history of pharmacological or compression therapy), CVD (CEAP grades 2 to 5)</P>
<P>Exclusion criteria: other conditions that might produce lower extremity-related symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatments: micronised diosmine (450 mg) + hesperidin (50 mg), aminaftone (75 mg), coumarin (15 mg), troxerutin (90 mg)</P>
<P>Control: placebo</P>
<P>Duration: 112 days</P>
<P>Follow-up: 112 days</P>
<P>Compression therapy: not used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Quality of life</LI>
<LI>Mean limb volumes</LI>
<LI>Mean joint range of motion</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: all medications and placebos purchased by the investigators</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergqvist-1981">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, cross-over, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 6/149 (4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden.</P>
<P>Setting: outpatient clinic and local population</P>
<P>Number: 149 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 33 M:116 F</P>
<P>Inclusion criteria: symptoms related to varicose veins and CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 1000 mg intravenous injection followed by 1 tablet of 500 mg per 8 hours</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, tired legs, pruritus, swelling, side effects</LI>
<LI>Signs - plethysmographic values, calf circumference</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:46:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biland-1982">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 14/70 (20%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: hospital</P>
<P>Number: 70 patients</P>
<P>Age: mean 43 ± 13 years diosmine group; mean 39 ± 12.5 years placebo group</P>
<P>Gender: 7 M:49 F</P>
<P>Inclusion criteria: symptoms related to CVI and oedema</P>
<P>Exclusion criteria: phlebitis, venous thromboses, post-thrombotic syndrome, ulcus cruris, heart insufficiency, recent sclerotherapy or venous stripping, trauma, neuropathy, arthrosis, pregnancy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 450 mg plus hesperidin 50 mg, 2 capsules twice a day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, swelling, restless legs measured by an ordinal scale (0 to 2)</LI>
<UL>
<LI>Oedema - circumference of ankle and calf</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Clinical assessment by participants and doctors</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burnand-1989">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital</P>
<P>Number: 49 patients</P>
<P>Age: mean 53 years </P>
<P>Gender: 18 M:31 F</P>
<P>Inclusion criteria: venous reflux by volumetry, with varicose veins and lipodermatosclerosis</P>
<P>Exclusion criteria: patients with ankle-to-arm arterial Doppler pressure ratio &lt; 1.0 (significant arterial disease)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxerutin (Paroven) 500 mg per 12 hours</P>
<P>Control: placebo</P>
<P>Duration: 30 days</P>
<P>Follow-up: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Signs - oedema (foot volumes) measured by water displacement, transcutaneous oximetry (TCPO2)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casley_x002d_Smith-1988">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Australia</P>
<P>Setting: university</P>
<P>Number: 60 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 28 M:32 F</P>
<P>Inclusion criteria: 30 normal volunteer participants and 30 patients with CVI grade I to III Widmer (dilated subcutaneous veins, alteration of pigmentation, open or healed crural ulcer)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 42 days</P>
<P>Follow-up: 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tenderness, swelling, tiredness, pain, cramps, restless legs, paraesthesias and general well-being measured by an ordinal scale scored from -1 (deterioration) to +1 (total relief)</LI>
<LI>Signs - oedema measured by a semiquantitative scale scored from -1 (deterioration) to +1 (total relief). Foot volume and lower limb (measured by standardised water displacement plethysmographic tank)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:46:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cauwenberge-1972">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 7/44 (16%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium</P>
<P>Setting: Liège</P>
<P>Number: 44 patients</P>
<P>Age: 'adults'</P>
<P>Exclusion criteria: not stated</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: varicose veins and postphlebitic syndrome</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-hydroxyethyl)-rutoside 900 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema</LI>
<LI>Pain</LI>
<LI>Heaviness</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Description of 2 clinical trials (CTs): One is a parallel CT, and the other is a cross-over CT. Only the parallel CT is included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cauwenberge-1978">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 51/120 (42.5%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium</P>
<P>Setting: Liège</P>
<P>Number: 120 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: varicose veins, postphlebitic syndrome</P>
<P>Exclusion criteria: symptoms not attributed to CVI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-hydroxyethyl)-rutoside 1200 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema</LI>
<LI>Pain</LI>
<LI>Cramps</LI>
<LI>Tiredness</LI>
<LI>Swelling</LI>
<LI>Restless legs</LI>
<LI>Paraesthesia</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2002">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: hospital</P>
<P>Number: 46 patients and 10 healthy individuals</P>
<P>Age: 44 to 45 years</P>
<P>Gender: percentages/numbers of men and women not specified</P>
<P>Inclusion criteria: severe superficial venous incompetence with a normal deep venous system</P>
<P>Exclusion criteria: diabetes, peripheral arterial disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment A: hidroxirutoxide 500 mg tid</P>
<P>Treatment B: hidroxirutoxide 1000 mg tid</P>
<P>Control (group C): placebo tid</P>
<P>Treatment D: hidroxirutoxide 1000 mg/d</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:07 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Plethysmographic parameters</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>CVI symptoms - swelling sensation, restlessness of lower limbs, pain, tiredness, cramps measured by a visual analogue scale (0 to 10). Global evaluation of symptoms (average score of symptoms)</LI>
<LI>Tolerance</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-27 22:03:14 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chassignolle-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 4/40 (10%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 40 patients</P>
<P>Age: 32.0 (1.3) years active group; 35.6 (1.1) years placebo group</P>
<P>Gender: female</P>
<P>Inclusion criteria: women with functional CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Plethysmographic parameters</LI>
<LI>CVI symptoms - heaviness, pain, tiredness, itching, paraesthesias and cramps measured by an ordinal scale (0 to 4). Global evaluation of symptoms (score functional)</LI>
<LI>CVI signs - oedema, cyanosis, redness, leg heat and induration measured by an ordinal scale (0 to 4). Global evaluation of signs (score objective)</LI>
<LI>Tolerance</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cloarec-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: 16/120 (13%)</P>
<P>Losses to follow-up: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: not stated</P>
<P>Number: 120 patients</P>
<P>Age: mean 50 years</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: history of CVI for several years</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-hydroxyethyl)-rutoside 2000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:19 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Reduction in calf and ankle circumference</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Pain</LI>
<LI>Cramps</LI>
<LI>Tiredness</LI>
<LI>Swelling</LI>
<LI>Restless legs</LI>
<LI>Pitting oedema measured by a scale (0 to 3)</LI>
<LI>Plethysmographic parameters</LI>
<LI>Transcutaneous oxygen tension</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This clinical trial is published in abstract format; not possible to extract data showing results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cloarec-1996">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: 5/109 (5%)</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: outpatient university clinic in a military hospital</P>
<P>Number: 109 patients</P>
<P>Age: 48 ± 14 years active group; 53.6 ± 13.6 years placebo group</P>
<P>Gender: 16 M:88 F</P>
<P>Inclusion criteria: CVI (Widmer grade II) and oedema and symptoms</P>
<P>Exclusion criteria: elastic stockings, arterial insufficiency, venous ulcers or superficial thrombophlebitis, venous surgery or sclerotherapy in the preceding 6 months, other possible causes of leg oedema, pregnancy, irregular menstrual cycles; therapy with diuretics, steroids, anti-inflammatories or venous drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-hydroxyethyl)-rutoside 1000 mg per 12 hours</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heavy legs, swelling, restless legs measured by a semiquantitative scale (0 to 3)</LI>
<UL>
<LI>Oedema - pitting present or absent, circumference of ankle and calf; plethysmographic parameters</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Global opinion of investigators and participants</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: random distribution of numbered batches</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: not stated</P>
<P>Number: 83 patients</P>
<P>Age: 20 to 65 years; mean 43.73 ± 11.92 years active group; mean 43.55 ± 11.42 years placebo group</P>
<P>Gender: 6 M:77 F</P>
<P>Inclusion criteria: symptoms related to CVI</P>
<P>Exclusion criteria: severe damage to venous musculature requiring urgent treatment - surgery or sclerosis; surgical operation on venous or deep or superficial vein thrombosis in the past year; sclerosis or heavy support bandages (light support bandages not excluded), major trophic lesions, Raynaud's syndrome, arteritis, lymphoedema, renal or cardiac insufficiency; anti-migraine treatment, analgesic or anti-inflammatory treatment, diuretic treatment, low-sodium diet, treatment for cardiovascular system (except nifedipine)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: extract Ruscus aculeatus 75 mg plus hesperidin 75 mg plus ascorbic acid 50 mg per day (Cyclo 3)</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
<P>Light compression therapy allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heavy legs, paraesthesia, pins and needles, burning and restless legs measured by a semiquantitative scale (0 to 3)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Doctor's global assessment</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danielsson-2002">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: sealed envelope principle</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 4/101 (4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden</P>
<P>Setting: hospital</P>
<P>Number: 101 patients</P>
<P>Age: 18 to 65 years</P>
<P>Gender: 28 M:73 F</P>
<P>Inclusion criteria: symptomatic CVI with reflux venous, CEAP II classification</P>
<P>Exclusion criteria: diabetes; inflammatory, heart, renal, hepatic or peripheral arterial disease. Treatment with diuretics or anti-inflammatory drugs (steroids, NSAIDs). Allergic reactions to venoactive drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: micronised purified flavonoid fraction (MPFF) 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness, tiredness, ankle swelling, pain and cramps measured by an ordinal scale (0 to 3)</LI>
<UL>
<LI>Oedema - foot volumetry by plethysmography</LI>
</UL>
<UL>
<LI>Reflux by Duplex ultrasonography</LI>
</UL>
<UL>
<LI>Improvement in global score of symptoms</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No description of double-blind<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diebschlag-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: not stated</P>
<P>Number: 60 postmenopausal females</P>
<P>Age: 'adults'</P>
<P>Gender: 60 F</P>
<P>Inclusion criteria: stage II CVI (oedema and symptoms)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxerutin 500 mg per day or 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 84 days</P>
<P>Follow-up period: 112 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:50 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heavy legs, swelling, restless legs measured by a semiquantitative scale (0 to 3)</LI>
<UL>
<LI>Oedema - pitting present or absent, circumference of ankle and calf; plethysmographic parameters</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Global opinion of investigators and participants</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:47:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DOBESILATO500_x002f_2">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: random list generated by computer</P>
<P>Exclusions post randomisation: study interrupted</P>
<P>Losses to follow-up: study interrupted</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: hospital</P>
<P>Number: 69 patients</P>
<P>Age: 60.9 (13.9) years placebo; 63.0 (20.5) years calcium dobesilate</P>
<P>Gender: 36 M:33 F</P>
<P>Inclusion criteria: adult patients with venous ulcer (CEAP 6) that affected epidermis, dermis and/or subcutaneous tissue, with an area superior to 3 cm<SUP>2</SUP>, an ankle-arm index 0.9 or superior and written informed consent of patients</P>
<P>Exclusion criteria: diabetes mellitus I or II. Renal failure and dialysis. Vascular surgery needed<BR/>Impossibility to use compressive measures on the leg. Use of topical antibiotics, silver dressing, growth factors; plasma-rich platelets, skin graft, pentoxifylline, ultrasound, laser, hyperbaric oxygen, electrical stimulation or vacuum. Pregnancy. Breast feeding. No anti-contraceptive measures. Allergy or intolerance to phlebotonics. Background of neutropenia or leucopenia. Basal leucocytes &lt; 3.500/mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 500 mg 3× per day (capsules)</P>
<P>Control: placebo</P>
<P>Duration: 180 days</P>
<P>Follow-up period: 365 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:47:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Healed venous ulcers at 6 months of treatment</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Percentage of re-epithelialisation area (cm<SUP>2</SUP>)</LI>
<LI>Length of time to ulcer healing</LI>
<LI>Ulcer recurrence</LI>
<LI>Ulcer pain</LI>
<LI>Safety</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Financial support for Laboratories Dr Esteve was withdrawn and the study was interrupted. Register at clinicatrial.gov: NCT00979836</P>
<P>We obtained information from researchers who conducted this unpublished and interrupted clinical trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dominguez-1992">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: computer-generated random number table</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 7/57 (12%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: hospital</P>
<P>Number: 57 patients</P>
<P>Age: 20 to 65 years</P>
<P>Gender: 5 M:52 F</P>
<P>Inclusion criteria: symptomatic CVI and varicose veins and oedema</P>
<P>Exclusion criteria: elastic bandages, anti-inflammatory drugs and diuretics not permitted. Surgical operation, thrombophlebitis, pregnancy, diabetes, cardiopathy, hepatopathy, nephropathy, varicose veins secondary to extrinsic compression and varicose ulcers excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: hidrosmine 600 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 45 days</P>
<P>Follow-up: 45 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness, pain and cramps measured by an ordinal scale (0 to 9); pruritus and cramps measured by a semiquantitative scale (0 to 3); ankle swelling, measure of narrowest section by photogram</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:48:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fermoso-1992">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 6/34 (18%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: hospital</P>
<P>Number: 34 patients</P>
<P>Age: mean 53 ± 18 (range 21 to 86) years</P>
<P>Gender: 20 M:14 F</P>
<P>Inclusion criteria: CVI (varicose veins and/or disturbances of venous circulation by Doppler)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: hidrosmine 600 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - local tension, pain, paraesthesia, heaviness, pruritus, cramps measured by a semiquantitative scale (0 to 4)</LI>
<LI>Signs - oedema, varicose ulcers, trophic disorders and abnormal skin colour as measured by presence or absence</LI>
<UL>
<LI>Venous circulation using Doppler</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:48:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Mexico</P>
<P>Setting: hospital</P>
<P>Number: 49 patients (25 in the calcium dobesilate group; 24 in the placebo group)</P>
<P>Age: mean 52.20 ± 8.45 years</P>
<P>Gender: 5 M:44 F</P>
<P>Inclusion criteria: venous oedema</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1500 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 49 days</P>
<P>Follow-up: 49 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:48:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Signs - oedema; thigh, calf and ankle circumference</LI>
<UL>
<LI>Overall efficacy assessed by physician; safety</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - pain measured by an ordinal scale of 4 items (from no pain to severe pain)</LI>
<UL>
<LI>Plethysmographic parameters</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:48:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilly-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 10/160 (6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 160 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 26 M:134 F</P>
<P>Inclusion criteria: symptomatic disturbances of the veno-lymphatic system</P>
<P>Exclusion criteria: other or associated vascular diseases; oedema of cardiac, renal or hepatic origin; symptoms or signs of arterial, metabolic, neurological or orthopaedic origin; pregnancy; recent venous surgery; deep or superficial thrombosis in the past 6 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: micronised purified flavonoid fraction (MPFF) 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 42 days</P>
<P>Follow-up: 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - discomfort, pain, swelling, paraesthesia, redness and/or cyanosis, burning, heaviness, tiredness and cramps measured by a semiquantitative scale (0 to 3)</LI>
<UL>
<LI>Oedema - circumference of calf and ankle</LI>
</UL>
<UL>
<LI>Trophic disorders measured by investigator on a verbal scale (disappearance, improvement, stabilisation or aggravation)</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:48:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guilhou-1997">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 6/107 (6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 107 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 30 M:77 F</P>
<P>Inclusion criteria: venous ulcers</P>
<P>Exclusion criteria: not stated</P>
<P>Randomisation of treatment stratified according to ulcer size: &lt; 10 cm or &#8805; 10 cm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 450 mg plus hesperidin 50 mg per 12 hours plus compression stockings</P>
<P>Control: placebo and standard compression stockings</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Primary endpoint</P>
<UL>
<LI>Percentage of participants with complete healing at 2 months</LI>
</UL>
<P>Secondary endpoint</P>
<UL>
<LI>Percentage of surface area healed</LI>
<LI>Aspect of ulcer and peri-ulcerous skin of the reference ulcer</LI>
<LI>Total number of healed ulcers in cases of multiple ulcers</LI>
<LI>Evolution of symptoms of CVI</LI>
<LI>Socioeconomic incidence</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:48:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hachen-1982">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 2/50 (4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Switzerland</P>
<P>Setting: hospital</P>
<P>Number: 50 females</P>
<P>Age: 10 to 45 years </P>
<P>Gender: 50 F</P>
<P>Inclusion criteria: recent onset of CVI; no venous surgery, presence of symptoms (heaviness, fatigue, etc.) or aggravation during prolonged sitting or standing or during premenstrual periods</P>
<P>Exclusion criteria: pregnancy, diabetes, polyneuropathy, osteo-articular lesions in the legs, arterial peripheral insufficiency, oral contraceptives, poor co-operation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:48:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Plethysmographic parameters</LI>
<LI>Symptoms - pain, heaviness, swelling and paraesthesia measured by an ordinal scale scored from -3 (total relief) to +1 (deterioration)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Global score of symptoms</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:45:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ihme-1996">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: Rancode computer software</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 11/77 (14%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: hospital</P>
<P>Number: 77 patients</P>
<P>Age: mean 57.3 ± 9.6 years active group; mean 59.8 ± 7.3 years placebo group</P>
<P>Gender: 24 M:53 F</P>
<P>Inclusion criteria: CVI stages I and II (oedema, symptoms, stem varicosis, post-thrombotic syndrome, valvular insufficiency of the deep veins)</P>
<P>Exclusion criteria: varicosis with surgical indication; active or healed ulcus cruris; acute thrombosis or venous inflammation; oedema due to cardiac or renal insufficiency; treatment with a diuretic, dihydroergotamine or any other drugs for venous therapy; other severe disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Buckwheat herb tea (rutoside) 270 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 112 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:45:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Signs - oedema, lower leg volume of more seriously affected leg by a Gutmann volumeter and ultrasound</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - tenseness, heaviness, swelling by an ordinal scale (0, 1, 2). Pain, paraesthesia, cramps, burning feet, restless legs by an ordinal scale (0, 0.5, 1)</LI>
<UL>
<LI>Side effects</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:49:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jongste-1986">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands</P>
<P>Setting: outpatient</P>
<P>Number: 80 patients</P>
<P>Age: 20 to 75 years</P>
<P>Gender: male and female; breakdown not given</P>
<P>Inclusion criteria: unilateral post-thrombotic syndrome</P>
<P>Exclusion criteria: elastic stockings; diuretics; venoactive drugs; open venous ulcers; paralysis of the leg with post-thrombotic syndrome; arterial disease; oedema of other origin; regular users of anti-inflammatories, corticosteroids or analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-Hydroxyethyl)-rutosides 1200 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:49:00 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms (tiredness, pain, heaviness, cramps, swelling feeling, restless legs) measured by an ordinal scale (0 to 3)</LI>
<LI>Signs - pitting oedema, circumference of ankle and calf, pitting oedema, venous pressure</LI>
</UL>
<UL>
<UL>
<LI>Overall efficacy assessed by physician and participant</LI>
</UL>
<UL>
<LI>Side effects</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:49:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jongste-1989">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: computerised random assignment method used</P>
<P>Exclusions post randomisation: 17/101 (17%)</P>
<P>Losses to follow-up: 3 (0.3%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands</P>
<P>Setting: hospital</P>
<P>Number: 101 patients</P>
<P>Age: 53 ± 12 years active group; 54 ± 13 years placebo group</P>
<P>Gender: 48 M:35 F</P>
<P>Inclusion criteria: unilateral post-thrombotic syndrome &gt; 6 months' duration and history of venography with deep vein thrombosis</P>
<P>Exclusion criteria: elastic stockings; veno-active drugs within 2 weeks of entry into the trial; active venous ulcer; pregnancy; age &gt; 75 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutosides 1200 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tiredness, pain, heaviness, swelling feeling, restless legs, cramps, pitting oedema measured by an ordinal scale (0 to 3)</LI>
<LI>Signs - circumference of calf and ankle</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Physicians' and participants' opinions on efficacy of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Concealment of placebo not explicit<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiesewetter-1997">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: university</P>
<P>Number: 81 patients</P>
<P>Age: mean 59 ± 7 years</P>
<P>Gender: 26 M:55 F</P>
<P>Inclusion criteria: stage I to II of Wert CVI</P>
<P>Exclusion criteria: acute thromboses; ulcus cruris; heart insufficiency; recent venous surgery; venoactive drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 500 mg Buckwheat herb and 30 mg troxerutin. 2 tablets 3× per day</P>
<P>Control: placebo</P>
<P>Duration: 84 days</P>
<P>Follow-up: 112 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Lower leg volume determined by ultrasound of the more affected leg</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - pain, paraesthesia, cramps, swelling, restless legs, burning feet measured by an ordinal scale (0 to 2)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:49:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kl_x00fc_ken-1971">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: hospital</P>
<P>Number: 60 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: CVI (varicoses or post-thrombotic syndrome)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: troxerutin 75 mg and coumarin 15 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 21 days</P>
<P>Follow-up: 21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, tension measured by a qualitative scale</LI>
<UL>
<LI>Oedema - circumference of calf and ankle</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:49:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koscielnny-1996">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 6/77 (8%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: university</P>
<P>Number: 94 patients selected; 67 randomised</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: CVI stage I to II Widmer</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Buckwheat herb tea 3× 1.8 g per day</P>
<P>Control: placebo tea</P>
<P>Duration: 84 days</P>
<P>Follow-up: 112 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:49:47 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema, by reduction of leg volume</LI>
<LI>Symptoms - tenseness, heaviness, swelling, pain, paraesthesia, cramps, burning feet, restless legs, itching</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kriner-1985">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: hospital</P>
<P>Number: 50 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: disturbances of venous blood flow, oedema</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: ruscus extract 75 mg and hesperidin 75 mg 2 × 2 capsules per day. rutoside cream once per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema - circumference of foot, heel and calf</LI>
<LI>Symptoms - fatigue, tension, heaviness, cramps, burning, itching</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Labs-2004">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: computerised random assignment method</P>
<P>Exclusions post randomisation: 7/260 (0.3%), protocol violation</P>
<P>Losses to follow-up: 21/260 (8%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Switzerland</P>
<P>Setting: university</P>
<P>Number: 260 patients</P>
<P>Age: 20 to 70 years</P>
<P>Gender: 16 M:201 F</P>
<P>Inclusion criteria: CVI class 1 to 4 (CEAP classification), oedema and symptoms</P>
<P>Exclusion criteria: CVI class 5 to 6 (CEAP classification); other causes of oedema (cardiac, renal, etc.); hypertension with change in treatment within 6 weeks of study start; obesity; peripheral arterial occlusive disease; venous surgery in the past 12 months or sclerotherapy during the past 6 months; irregular menstrual cycle; elevated transaminases; neutropenia; significant renal insufficiency; gastrointestinal disease; allergy to study medication; pregnant or lactating women; unreliable patient (psychiatric disorders, alcoholism, etc.); compression stockings or bandages; diuretics; venotropic medication; antiphlogistic drugs; corticosteroids; analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1500 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Signs - oedema, reduction in leg volume (&#8805; 25 mL/litre tissue), circumference of ankle and calf</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - pain and discomfort measured by a visual analogue scale</LI>
<UL>
<LI>Discomfort measured as the sum of frequencies of symptoms: heaviness, tingling and itching</LI>
</UL>
<UL>
<LI>Pain measured as the sum of frequencies of symptoms: pain and cramps</LI>
</UL>
<UL>
<LI>Total symptoms score (discomfort and pain)</LI>
</UL>
<UL>
<LI>Overall efficacy assessed by physician and participant on a 7-point scale</LI>
</UL>
<UL>
<LI>Side effects</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Reasons for withdrawal unknown<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Languillat-1988">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 20 patients</P>
<P>Age: 20 and 65 years</P>
<P>Gender: 1 M:19 F</P>
<P>Inclusion criteria: symptomatic CVI and oedema</P>
<P>Exclusion criteria: previous venous sclerosis; surgery or elastic support; trophic disturbances; ulcers or permanent oedema; cardiac, renal, hepatic insufficiency or arterial disease; Raynaud's phenomenon; lymphoedema; pregnancy; venoactive drugs; any significant change in patient lifestyle or work</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: extract Ruscus aculeatus 450 mg plus hesperidin 450 mg plus ascorbic acid 300 mg per 12 hours</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Venous circulatory velocity measured by Xenon 133</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - heavy legs, pain, paraesthesias, cramp, restlessness, swelling measured by a semiquantitative scale (0 to 3)</LI>
<LI>Overall assessment by investigator</LI>
<LI>Safety</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-22 14:42:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laurent-1988">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: 2 randomised, double-blind, placebo-controlled studies analysed together</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 5/200 (2.5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 200 patients</P>
<P>Age: mean 49 (range 22 to 82) years</P>
<P>Gender: 26 M:174 F</P>
<P>Inclusion criteria: One study included patients with functional venous insufficiency (presence of symptoms but not signs); n = 83. The other study included patients with chronic organic venous insufficiency (varicose disease, post-thrombotic syndrome); n = 117<BR/>Elastic stockings permitted</P>
<P>Exclusion criteria: not exclusively venous symptoms (arterial, neurological or metabolic origin, disorders of static equilibrium); venotropic drugs in the past 3 months; pregnancy; prolonged immobilisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 450 mg plus hesperidin 50 mg per 12 hours</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - functional discomfort, evening oedema, redness or cyanosis, heart or burning pain, paraesthesia, heaviness, cramps measured by an ordinal scale (0 to 3). Clinicians' overall assessment by a qualitative scale (results very good, useful or nil)</LI>
<LI>Signs - oedema measured by circumference of ankle; changes in trophic disorders</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Safety</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazzarini-1982">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: hospital</P>
<P>Number: 100 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 23 M:74 F</P>
<P>Inclusion criteria: stratification for participant groups: varicose legs, ulcer, thrombophlebitis, slight CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: aminaftone 150 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:29 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - itching, heaviness, cramps and pain measured by an ordinal scale (0 to 3)</LI>
<LI>Signs - oedema, dystrophy and ulcer measured by an ordinal scale (0 to 3)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacLennan-1994">
<CHAR_METHODS MODIFIED="2016-03-31 10:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: 2 independent, randomised, double-blind, cross-over, placebo-controlled trials</P>
<UL>
<LI>In the first trial, outcomes are haemodynamic, so this trial was not included</LI>
<LI>The second trial is included</LI>
</UL>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 16/104 (15%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital</P>
<P>Number: 104 patients</P>
<P>Age: &#8805; 65 years </P>
<P>Gender: 24 M:62 F</P>
<P>Inclusion criteria: unilateral or bilateral symptoms and signs of CVI. Compression stockings allowed</P>
<P>Exclusion criteria: bed-bound or with cardiac or renal or hepatic disease or clinically important obesity; arterial insufficiency of the legs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-31 10:50:39 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment</P>
<UL>
<LI>Oxirutoside 900 mg per day for 180 days</LI>
<LI>Oxirutoside 1000 mg per day for 180 days</LI>
<LI>Oxirutoside 1200 mg per day for 180 days</LI>
<LI>Placebo for 180 days</LI>
</UL>
<P>Follow-up: 180 days</P>
<P>Participants who wore elastic support stockings had to continue to wear them throughout the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema, by reduction of leg volume</LI>
<LI>Symptoms - tenseness, heaviness, swelling, pain, paraesthesia, cramps, burning feet, restless legs and itching</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mann-1981">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 5/28 (18%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: outpatient</P>
<P>Number: 28 patients</P>
<P>Age: mean 69 years active treatment; mean 63 years placebo</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: &#8805; 1 venous ulcer</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: hidroxirutoside 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 90 days</P>
<P>Concomitant therapy: topical therapy and an "elastoweb" bandage<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tiredness, pain, heaviness, swelling feeling, restless legs, cramps, pitting oedema measured by an ordinal scale (0 to 3)</LI>
<LI>Signs - circumference of calf and ankle</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Physicians' and participants' opinions on the efficacy of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:50:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marinello-2002">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 21/123 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: hospital</P>
<P>Number: 143 patients</P>
<P>Age: mean 52.87 (range 19 to 72) years </P>
<P>Gender: 25 M:77 F</P>
<P>Inclusion criteria: CVI stage CEAP III, IV and V</P>
<P>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1000 mg per day or calcium dobesilate 2000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 84 days</P>
<P>Follow-up: 84 days</P>
<P>Elastic stockings permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:50:55 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness and pain in the legs</LI>
<LI>Signs - transcutaneous PO2 and CO2</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: computer-generated random number table</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 131/509 (25.7%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: hospital</P>
<P>Number: 509 patients</P>
<P>Age: mean 53.3 ± 13.3 years treatment group; mean 54.7 ± 14.9 years placebo group</P>
<P>Gender: 66 M:443 F</P>
<P>Inclusion criteria: adults of either gender with CVD, CEAP clinical grades 1 to 6 and able to complete a QoL questionnaire</P>
<P>Exclusion criteria: chronic or acute disease that limited compliance with the protocol, scheduled surgery or sclerotherapy in the coming calendar year, pregnant or lactating women, patients with allergies or known intolerance to the study medication, history of neutropoenia or leucopoenia, baseline serum leucocyte count &lt; 3500/mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 500 mg capsules of oral calcium dobesilate twice a day for 3 months</P>
<P>Control: placebo: Inactive capsules of identical appearance and weight</P>
<P>Duration: 90 days</P>
<P>Follow-up: 365 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - change in QoL</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Signs - oedema</LI>
<LI>Symptoms - pain or cramps</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-22 14:58:56 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nocker-1990">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: university</P>
<P>Number: 30</P>
<P>Age: 55 to 59 years </P>
<P>Gender: menopausal females</P>
<P>Inclusion criteria: stage II CVI with symptoms</P>
<P>Exclusion criteria: venoactive drugs, anti-inflammatories, corticosteroids or diuretics in the last 8 days before the start of the study; use of compression bandages or elastic stockings</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 600 mg or 900 mg or 1200 mg or 1500 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 112 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tired and heavy legs, tenseness, tingling measured by means of a visual analogue scale (VAS)</LI>
<LI>Signs - oedema by volume of leg</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Padros-1972">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, cross-over, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Setting: university</P>
<P>Number: 30 females</P>
<P>Age: 48 to 51 years</P>
<P>Gender: female</P>
<P>Inclusion criteria: CVI with signs (oedema, venous ectasia) and symptoms (heaviness, paraesthesias)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 250 mg tablet 3× per day</P>
<P>Control: placebo tablet 3× per day</P>
<P>Duration: 21 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness and paraesthesias</LI>
<LI>Signs - oedema and venous ectasia</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Tolerance</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parrado-1999">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: table of random numbers</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Argentina</P>
<P>Setting: hospital</P>
<P>Number: 60 patients</P>
<P>Age: 30 to 70 years </P>
<P>Gender: 16 M:44 F</P>
<P>Inclusion criteria: CVI, stages I to II of the Widmer classification (pigmentation, oedema, varicoses and symptoms)</P>
<P>Exclusion criteria: elastic stockings; urgent surgical treatment or venous surgical treatment or sclerotherapy in previous 6 months; cardiac, renal or hepatic insufficiency; anti-migraine drugs; analgesics; NSAIDs; diuretics or cardiovascular drugs; pregnant women or women who had given birth during previous 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Ruscus aculeatus with hesperidin and vitamin C 300 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness, pain, cramps, tiredness, pruritus, tingling sensation, swelling, measured by means of an ordinal scale from 0 to 3 (from no symptoms to severe symptoms)</LI>
<UL>
<LI>Participants' global assessment by a qualitative scale</LI>
</UL>
<LI>Signs - venous inflammation, pigmentation, trophic ulceration and oedema (circumference of ankle measured by a medical ribbon and by the ordinal scale)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pecchi-1990">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: use of alternation by order of arrival of each participant</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: university</P>
<P>Number: 40 patients</P>
<P>Age: mean 48.2 ± 15.7 years </P>
<P>Gender: 4 M:36 F</P>
<P>Inclusion criteria: primary CVI and post-thrombotic syndrome</P>
<P>Exclusion criteria: postphlebitic syndrome; severe trophic lesions; no venous oedema; patients taking diuretics, corticosteroids or vasoactive drugs; elastic stockings or bandages</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 30 days</P>
<P>Follow-up: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heaviness, pruritus, swelling and paraesthesia measured by a semiquantitative scale (0 to 4)</LI>
<LI>Signs - oedema measured by plethysmographic parameters and circumference of ankle; varicoses in the legs measured by a semiquantitative scale (0 to 4)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-22 17:11:19 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedersen-1992">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Denmark</P>
<P>Setting: not stated</P>
<P>Number: 43 patients</P>
<P>Age: 'adults'</P>
<P>Gender: 8 M:41 F</P>
<P>Inclusion criteria: symptoms of CVI and oedema</P>
<P>Exclusion criteria: diuretic drugs; venotonic drugs; pregnant women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 900 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema, circumference of legs</LI>
<LI>Symptoms - swelling, pain, heaviness, restlessness, itching, cramps measured by a qualitative scale (from 'get worse' to 'improvement')</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrassi-2000">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: computer-elaborated simple randomisation table</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Setting: ambulatory</P>
<P>Number: 20 patients</P>
<P>Age: 47.7 (3.65) years active group; 36.7 (3.66) placebo group</P>
<P>Gender: 3 M:19 F</P>
<P>Inclusion criteria: CVI symptoms (heaviness and subcutaneous swelling) and venous pressure &gt; 40 mmHg</P>
<P>Exclusion criteria: cardiovascular drugs, diuretic drugs and analgesic or anti-inflammatory compounds</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: french bark pine extract capsules 100 mg 3× per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - evening oedema, swelling, pain, heaviness, cramps and paraesthesias measured by an ordinal scale (from 0 to 3)</LI>
<LI>Signs - ambulatory venous leg pressure</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Global assessment by the physician</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Planchon-1990">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 6/110 (5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 110 participants</P>
<P>Age: mean 50 (range 22 to 79) years</P>
<P>Gender: 18 M:92 F</P>
<P>Inclusion criteria: symptoms of functional and organic (post-thrombotic syndrome and varices) CVI</P>
<P>Exclusion criteria: venous thrombosis; long-term immobilisation; hepatic, renal and cardiac oedema; neurological, arterial and metabolic symptoms<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 450 mg plus hesperidin 50 mg × 2 capsules per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:47 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms of CVI and oedema</LI>
<UL>
<LI>Symptoms - pain, cramps, heaviness, paraesthesias measured by an ordinal scale (0 to 3)</LI>
</UL>
<UL>
<LI>Oedema - circumference of ankle</LI>
</UL>
<UL>
<LI>Cyanosis and redness measured by an ordinal scale (0 to 3)</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pointel-1986">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 4 (4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 94 patients</P>
<P>Age: mean 49 ± 12 years</P>
<P>Gender: 8 M:86 F</P>
<P>Inclusion criteria: CVI</P>
<P>Exclusion criteria: severe varicose veins requiring an elastic strip, postphlebitic patients, those with unilateral venous insufficiency, those treated with a venoactive drug before the start of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Centella asiatica (TECA) 120 mg: two 30-mg capsules twice a day vs Centella asiatica (TECA) 60 mg: one 30-mg capsule twice a day</P>
<P>Control: placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms of CVI (pain, heaviness) and oedema measured by an ordinal scale (0 to 3)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Venous distensibility measured by plethysmography</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:51:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prerovsky-1972">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: 2 independent, randomised, double-blind, cross-over, placebo-controlled trials</P>
<UL>
<LI>In the first trial, outcomes are haemodynamic, so this trial was not included</LI>
<LI>The second trial is included</LI>
</UL>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Czechoslovakia</P>
<P>Setting: research centre</P>
<P>Number: 50 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: signs (oedema, pigmentation, post-thrombotic syndrome) and symptoms of CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 1200 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 126 days</P>
<P>Follow-up: 126 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema, leg volume, pitting oedema, cellulitis</LI>
<LI>Symptoms - heavy legs, fatigue, pain, cramps, swelling scored by a qualitative scale (improvement, without changes, deterioration)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pulvertaft-1983">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 64/660 (10%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: general practice</P>
<P>Number: 660 patients</P>
<P>Age: 54 years</P>
<P>Gender: 220 M:440 F</P>
<P>Inclusion criteria: symptomatic CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutoside 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
<P>Participants who wore elastic support had to continue to wear it throughout the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heavy or swelling, pain, restless legs, paraesthesia, cramps assessed on a 3-point scale (none, moderate or severe)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Doctor's global assessment (better, unchanged or worse)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabe-2011">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, multi-centre, double-blind, placebo-controlled</P>
<P>Method of randomisation: table of random numbers</P>
<P>Exclusions post randomisation: 22 (8%)</P>
<P>Losses to follow-up: 32/256 (12.5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Countries: Germany and Switzerland</P>
<P>Setting: not stated</P>
<P>Number: 256 patients</P>
<P>Age: mean 53.2 ± 11.5 years treatment group; mean 53.5 ± 12.1 years placebo group</P>
<P>Gender: 38 M:218 F</P>
<P>Inclusion criteria: pitting oedema due to CVI (C3-C5 according to CEAP classification) and &#8805; 1 of the symptoms such as discomfort and pain</P>
<P>Exclusion criteria: disease that imitates symptoms of CVI, cardiac insufficiency, ulceration of the lower leg, diabetes mellitus, hypertension, lymphoedema, sclerotherapy during the past 6 months, lipoedema, obesity (BMI &gt; 30 kg/m<SUP>2</SUP>), disease of the gastrointestinal tract; female patients who were pregnant, lactating or of childbearing potential and not protected from pregnancy by a sufficiently reliable method; malignant disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1500 mg per day</P>
<P>Control: matching placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up post treatment: 70 days</P>
<P>Elastic stockings permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Signs - relative leg volume change in the most pathological leg assessed by a volumetric measurement with a calibrated tape and calculated by assimilating the lower leg volume to a truncated cone</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Signs - change in leg perimeters</LI>
<LI>Symptoms - subjective symptoms (pain, discomfort, feeling of tired or heavy legs, tingling, itching and cramps) on a five-point categorical scale. Pain and discomfort were assessed by 100-mm visual analogue scales, and quality of life was assessed by chronic lower limb venous insufficiency (CIVIQ)</LI>
<LI>Assessment of overall efficacy by participant and investigator</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-22 17:32:23 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Renton-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 9/40 (22.5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: ambulatory</P>
<P>Number: 40 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: ankle oedema due to mild to moderate venous hypertension</P>
<P>Exclusion criteria: peripheral arterial disease, diabetes or normal Doppler ultrasound</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: hidroxirutoside 500 mg × 2 capsules twice a day</P>
<P>Control: placebo</P>
<P>Duration: 30 days</P>
<P>Follow-up: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Microcirculatory parameters (resting flux, standing flux, venoarteriolar response measured with a laser Doppler flow meter and transcutaneous PO2 and PCO2)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Oedema and subjective symptoms (pain, cramps, paraesthesias, restless legs) measured by VAS</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rose-1970">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, cross-over, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 39% (13/33)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Setting: hospital</P>
<P>Number: 33 patients</P>
<P>Age: not stated</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: CVI associate with varicose disorders or postphlebitic syndrome</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: hidroxirutoside 1200 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 180 days</P>
<P>Follow-up: 270 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Complete relief of CVI symptoms (not specified)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-27 21:22:33 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rudofsky-1989">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: randomisation stratified by centre</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 10/151 (7%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: hospital</P>
<P>Number: 151 patients</P>
<P>Age: mean 49.7 (range 21 to 73) years </P>
<P>Gender: not stated</P>
<P>Inclusion criteria: stage I and II CVI, primary varicosis and post-thrombotic symptoms</P>
<P>Exclusion criteria: morning oedema (stage I to II CVI); acute thrombosis; leg ulcer; other peripheral arterial occlusive disorders; heart failure; severe cardiac arrhythmia; severe hypertension; diuretics; dihydroergotamine products; pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: ruscus extract plus hesperidinmethylchalcone × 2 capsules 3 times per day for 4 weeks, then 2 capsules twice per day for 8 weeks</P>
<P>Control: placebo</P>
<P>Duration: 56 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Reduction in oedema volume of the foot and ankle region measured by a water volumeter</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Oedema - volume</LI>
<LI>Plethysmographic parameters</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: 2 prospective, multi-centre, randomised, double-blind, placebo-controlled trials</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 7/55 (13%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: outpatient</P>
<P>Number: 55 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: unilateral venous leg ulcers and chronic venous insufficiency (deep or superficial)</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-31 10:52:27 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment</P>
<UL>
<LI>Trial A - O-(beta-hydroxyethyl)-rutoside 1000 mg per day</LI>
<LI>Trial B - O-(beta-hydroxyethyl)-rutoside 2000 mg per day</LI>
</UL>
<P>Control: placebo</P>
<P>Duration: 84 days</P>
<P>Follow-up: 84 days</P>
<P>All participants received pressure bandaging</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Ulcer healed or not</LI>
<LI>Ulcer surface area recorded in square millimetres by planimetry with transparent foil</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Ulcer healing phase: cleansing, granulating or epithelialising</LI>
<LI>Oedema: circumference of ankle and calf</LI>
<LI>Symptoms: ulcer pain and orthostatic complaints</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction possible only in trial A<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sentou-1984">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 1 participant</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: ambulatory</P>
<P>Number: not stated</P>
<P>Age: 34.6 ± 9.18 years active product; 38.2 ± 12.44 years placebo</P>
<P>Gender: female</P>
<P>Inclusion criteria: slight or moderate varicose disease<BR/>Exclusion criteria: surgical indication or trophic disorders, other vasoactive drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: extract Ruscus aculeatus 450 mg plus hesperidin 450 mg plus ascorbic acid 300 mg per day (Cyclo 3: 3 capsules twice per day)</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 20 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness, cramps and paraesthesia by an ordinal scale (0 to +++)</LI>
<LI>Signs - oedema measured by an ordinal scale (0 to +++) and by circumference of calf and ankle</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Number of included participants not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serralde-1990">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not losses</P>
<P>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-31 10:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Mexico</P>
<P>Setting: hospital</P>
<P>Number: 52 patients</P>
<P>Age: 42.4 ± 11.6 years active treatment; 42.3 ± 8.4 years placebo</P>
<P>Gender: 11 M:41 F</P>
<P>Inclusion criteria: CVI and oedema</P>
<P>Exclusion criteria: venoactive drugs, diuretics, anti-inflammatories and steroid drugs; elastic stockings or bandages; other causes of oedema; superficial thrombophlebitis; venous ulcer; venous surgery; pregnant women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxirutosides 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 56 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:46 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - tiredness, pain, heaviness, swelling feeling, restless legs, cramps by an ordinal scale (0 to 3)</LI>
<LI>Signs - circumference of calf and ankle</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Participants' opinion on efficacy of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thebaut-1985">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: throwing dice</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 14/92 (15%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-31 10:52:50 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: ambulatory</P>
<P>Number: 92 patients</P>
<P>Age: 38.9 ± 10.1 years active treatment; 40.7 ± 11.4 years placebo</P>
<P>Gender: 8 M:63 F</P>
<P>Inclusion criteria: CVI with leg heaviness or paraesthesias (16 to 65 years old)</P>
<P>Exclusion criteria: venoactive drugs, elastic stockings or bandages; deep venous insufficiency by echo Doppler, venous complications, postphlebitic syndrome<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: grape seed extract tablets 300 mg every 8 hours</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - cramps, pain heaviness and subjective oedema. Each item measured by an ordinal scale (0 to 3) and added together. Change in total punctuation (0 to 12) between baseline and final study results analysed</LI>
<LI>Signs - plethysmographic parameters</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:52:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsouderos-1989">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 4 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 40 patients</P>
<P>Age: 'adults'</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: functional CVI</P>
<P>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: diosmine 450 mg plus hesperidin 50 mg per 12 hours</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Plethysmographic parameters (venous tone)</LI>
<LI>Signs - oedema measured by circumference of ankle</LI>
<LI>Symptoms - functional discomfort, evening oedema, redness or cyanosis, heart or burning, pain, paraesthesia, heaviness, cramps measured by an ordinal scale (0 to 3). Clinicians' overall assessment by a qualitative scale (results very good, useful or nil)</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Overall assessment by the clinician</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This publication describes 3 clinical trials. Only 1 is included here. The others are phase 2 clinical trials</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Unkauf-1996">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, parallel, placebo-controlled trial</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 23/133 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: outpatients</P>
<P>Number: 133 patients</P>
<P>Age: mean 58.9 ± 8.6 years active group; mean 60.6 ± 10.0 years placebo group</P>
<P>Gender: 133 F</P>
<P>Inclusion criteria: CVI grade II (according to Widmer)</P>
<P>Exclusion criteria: premenstrual syndrome oedema; acute phlebitis or thrombosis; cardiac insufficiency or peripheral arterial disease; other venotonic drugs, laxatives, theophylline, diuretics, cardiac glycosides, angiotensin-converting enzyme or calcium antagonist within preceding 8 days; changes in postmenopausal hormone therapy within preceding 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: oxerutins 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 90 days</P>
<P>All participants received standard compression stockings</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema - leg volume</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Symptoms - tension, tired, heavy legs, tingling measured by a visual analogue scale (cm)</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanscheidt-2002a">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 52/231 (22.5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: university</P>
<P>Number: 231 patients</P>
<P>Age: mean 55.1 (range 23 to 78) years</P>
<P>Gender: 48 M:183 F</P>
<P>Inclusion criteria: stages 3 to 5 of CEAP</P>
<P>Exclusion criteria: surgical treatment of CVI; heart insufficiency; arterial occlusive disease; diabetes mellitus; neuropathy; acute thrombosis; lymphoedema; renal insufficiency or impaired liver function; malignant disease; pregnancy or breast feeding; major surgery; drugs with influence on the veins</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: SB-LOT (15 mg coumarin and 90 mg troxerutin) 2 tablets 3× per day for 16 weeks<BR/>
</P>
<P>Control: placebo</P>
<P>Duration: 112 days</P>
<P>Follow-up: 112 days</P>
<P>All participants received standard compression stockings during first 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Differences in lower leg volume after completion of treatment period as compared with baseline, measured by water displacement plethysmometry</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Tired legs, heavy legs, feeling of tension, feeling of swelling, aching, itching, burning, quality of life (EUROQOL), Clinical Global Impression</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanscheidt-2002b">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation: computer-generated random number table</P>
<P>Exclusions post randomisation: not stated</P>
<P>Losses to follow-up: 56/167 (34%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Setting: university</P>
<P>Number: 167 patients</P>
<P>Age: mean 53.2 ± 13.3 years active group; mean 53 ± 10.9 years placebo group</P>
<P>Gender: 166 F</P>
<P>Inclusion criteria: stages I and II of Widmer or CEAP 3 to 4</P>
<P>Exclusion criteria: other diseases with oedema, compression therapy for the past 6 months before the study; support stockings; patients more than 30% overweight; any concomitant medication that may interfere with study treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Ruscus aculeatus 72 to 75 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Oedema - leg volume change measured by water plethysmography</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Oedema - circumference of lower leg and ankle</LI>
<LI>Symptoms - tiredness, heaviness, tension, tingling measured by VAS</LI>
<LI>Quality questionnaire: Freiburg Life Quality Assessment (FLQA)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vin-1994">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: multi-centre, randomised, double-blind, placebo-controlled with a placebo run-in period</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 4/73 (4%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: hospital</P>
<P>Number: 73 patients</P>
<P>Age: mean 55.7 ± 15.8 years active treatment; mean 53.6 ± 16.7 years placebo</P>
<P>Gender: 10 M:59 F</P>
<P>Inclusion criteria: presence of truncal varicose veins with ostial reflux and subjective symptoms of venous origin</P>
<P>Exclusion criteria: occlusive arterial disease; osteoarticular disease; diabetes; acute or chronic inflammatory syndromes; haematological diseases; venoactive drugs; pregnancy; smoking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: troxerutin 3500 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 60 days</P>
<P>Follow-up: 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:32 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - heaviness, aching scored from 0 to 9 by multiplying intensity score (0 to 3) by time of onset (0 to 3)</LI>
<UL>
<LI>Oedema, swelling scored from 0 to 6 by multiplying intensity score (0 to 3) by time of onset (0 to 2)</LI>
</UL>
<UL>
<LI>Atypical pain (cramps, paraesthesia) scored from 0 to 2</LI>
</UL>
<UL>
<LI>Venous claudication scored as present (1) or absent (2)</LI>
</UL>
<LI>Signs - ankle circumference, photoplethysmography, haemorrheological parameters</LI>
</UL>
<P>Secondary</P>
<UL>
<LI>Not stated</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Welch-1985">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: not stated</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 7/147 (5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium</P>
<P>Setting: hospital</P>
<P>Number: 147 patients</P>
<P>Age: mean 44.5 ± 14 years active group; mean 43.6 ± 14 years placebo group</P>
<P>Gender: 26 M:119 F</P>
<P>Inclusion criteria: CVI with oedema and &#8805; 1 related symptom</P>
<P>Exclusion criteria: elastic stockings or compressive bandages; leg oedema from another origin; arterial insufficiency; superficial thrombophlebitis; varicose eczema or ulcer; diuretics, analgesics, steroids, NSAIDs or other venous drugs; pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: O-(beta-hydroxyethyl)-rutoside 1000 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heavy legs, swelling, restlessness, itching and paraesthesia measured by a semiquantitative scale (0 to 3)</LI>
<UL>
<LI>Oedema - pitting measured by a semiquantitative scale (0 to 3), circumference of ankle and calf</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
<LI>Global opinion of investigators and participants</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Widmer-1990">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: randomisation list prepared by statistician</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 17/225 (7%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Switzerland</P>
<P>Setting: hospital</P>
<P>Number: 225 patients</P>
<P>Age: 20 to 70 years </P>
<P>Gender: 27 M:181 F</P>
<P>Inclusion criteria: CVI grade I to II (alterations in pigmentation, with or without subcutaneous veins, oedema and symptoms of the disease)</P>
<P>Exclusion criteria: CVI grade III with open or healed varicose ulcer; venous surgery during past 12 months or sclerotherapy during past 6 months; symptomatic peripheral arterial occlusion; renal or cardiac insufficiency; lymphoedema; diabetes; hypertension; overweight; pregnancy; compression therapy or drugs that might interfere with clinical results (diuretics); intolerance to the active drug of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: calcium dobesilate 1500 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 28 days</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heaviness, paraesthesia and restlessness measured by a visual analogue scale</LI>
<LI>Signs - oedema measured by circumference of ankle</LI>
<UL>
<LI>Discomfort measured as the sum of frequencies of symptoms: pain, heaviness, paraesthesia and restlessness</LI>
</UL>
<UL>
<LI>Total score of all observed symptoms</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Overall efficacy assessed by physician and participant</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-31 10:53:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zucarelli-1987">
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled</P>
<P>Method of randomisation: throwing dice</P>
<P>Exclusions post randomisation: none</P>
<P>Losses to follow-up: 25/149 (16%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>Setting: outpatients</P>
<P>Number: 149 patients</P>
<P>Age: mean 33 ± 9.4 years active treatment; mean 32 ± 8 years placebo</P>
<P>Gender: 149 F</P>
<P>Inclusion criteria: CVI stage I (functional symptoms and oedema)<BR/>Participants allowed to wear elastic support</P>
<P>Exclusion criteria: chronic venous with trophic alterations; varices; phlebitis; postphlebitic syndrome; lymphoedema; arteriopathy; pregnancy; other phlebotonics; anti-inflammatories; diuretics; anti-platelet or vasculo-protector treatments</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: coumarin 10.5 mg per day plus troxerutin 1050 mg per day</P>
<P>Control: placebo</P>
<P>Duration: 90 days</P>
<P>Follow-up: 90 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-31 10:53:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary</P>
<UL>
<LI>Symptoms - pain, cramps, heavy legs and paraesthesias measured by a visual analogue scale</LI>
<UL>
<LI>Oedema - measured by circumference of leg</LI>
</UL>
</UL>
<P>Secondary</P>
<UL>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CEAP classification (clinical signs (C), aetiology (E), anatomical distribution (A) and physiological conditions (P) of CVI)<BR/>CIVIQ: Chronic Venous Insufficiency International Questionnaire<BR/>CT: clinical trial<BR/>CVD: cardiovascular disease<BR/>CVI: chronic venous insufficiency<BR/>EuroQoL: Descriptive system of health-related quality of life states<BR/>FLQA: Freiburg Life Quality Assessment<BR/>h: hour<BR/>ITT: intention-to-treat<BR/>LRR: light reflection rheography<BR/>NSAIDs: non-steroidal anti-inflammatories<BR/>QoL: quality of life<BR/>tid: 3 times a day<BR/>VAS: visual analogue scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:15:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akbulut-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:15:23 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed the combination of calcium dobesilate and oxerutin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-24 17:26:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allaert-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-24 17:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed efficacy of drugs for CVI aggravated by oral contraceptives</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amato-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Micronised flavonoid and non-micronised diosmine were compared</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Androulakis-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Principal outcome consists of plethysmographic parameters - a surrogate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-16 06:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Auteri-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-16 06:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Avram-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two flavonoids were compared, and no placebo group was included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:15:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bacci-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:15:44 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed a combination of different active products</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bastide-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed dihydroergotamine, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Batchvarova-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This is not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Batchvarova-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assesses a product with escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Behar-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assesses a product with escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared a rutoside with or without elastic compression and included no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes studied were surrogates (laser Doppler and transcutaneous oximetry)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Venoruton was compared with Daflon</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Prophylaxis with Venoruton was provided for flight oedema in normal participants </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This controlled clinical trial assessed O-(&#946;-Hydroxyethyl)-rutosides, but the study was not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bello-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Calcium dobesilate was combined with a heparinoid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beltramino-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two different drugs (Cyclo 3 Fort vs hydroxyethilrutoside) were compared for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bento-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed a combination of different active products that contain escin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berson-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative group was given a heparinoid rather than placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berson-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two clinical trials are described. One was a non-controlled clinical trial, and in the other, the control group was given naftazone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berson-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two different drugs given for CVI were compared</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blume-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Inadequate blinding: Initial phase of the trial used 'placebo' that was actually a low concentration of the assessed active drug: coumarin 2 mg and rutoside 100 mg</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boccalon-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this study was to check effects of active treatment after microcirculatory disturbances caused by heat</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bohm-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the combination of a diuretic and a drug for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-16 23:56:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boisseau-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-16 23:56:11 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes were not applicable to this review: Biological parameters were measured (erythrocyte aggregation and fibrinolytic activity)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:21:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bolliger-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:21:14 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed the combination of dimethyl sulfoxide and diphenyl butazone with a rutoside</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bort-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosse-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared 2 drugs (Venalot - combination of coumarin and troxerutin - and Benzarone) for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brami-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of a combination of dyhigroergocriptine mesilate and caffeine for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brock-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo was given to the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brock-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo was given to the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:21:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carstens-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:21:44 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed the combination of a diuretic and escin (DIU Venostatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:21:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cataldi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:21:51 +0000" MODIFIED_BY="[Empty name]">
<P>The drug studied was a combination of several active principles, one of which was rutin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:28:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed escin in diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The study was about microvascular parameters: PO2, PCO2 and volume parameters. This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Centella asiatica for flight microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2001e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Centella asiatica for diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-22 14:40:35 +0100" MODIFIED_BY="Karen Welch" STUDY_ID="STD-Cesarone-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-22 14:40:35 +0100" MODIFIED_BY="Karen Welch">
<P>This study assessed hydroxyrutosides for flight microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed variations in plasma free radicals in participants with CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Venoruton for prophylaxis of flight oedema</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared 2 drugs for CVI (beta-hydroxirutoside and diosmine plus hesperidin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study was not double-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared 2 drugs for CVI (Venoruton and Daflon)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared 2 drugs for CVI (Pycnogenol and Daflon)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2006c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This controlled clinical trial was not randomised; it focused on endothelial cells</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2006d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed french maritime pine bark for diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cesarone-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study was not double-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:30:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chant-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:30:44 +0000" MODIFIED_BY="[Empty name]">
<P>Non-clinical criteria were given</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiummariello-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated is a combination of different products for CVI. This study was not double-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clemens-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Only haemodynamic venous parameters were assessed by light reflection rheography</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared 5682 SE (combination of micronised diosmine and hesperidin) vs diosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared heparan sulphate vs diosmine for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared micronised diosmine and hesperidin vs diosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Anna-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Parades-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared Cyclo 3 Fort vs diosmine plus hesperidin for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Sanctis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delacroix-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was escin, which has been excluded from our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delecluse-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared Diovenor versus a combination of flavonoids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duchene-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Only haemodynamic venous parameters were assessed by plethysmography</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dustmann-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was escin, which has been excluded from our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erdlen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Venostasin contains escin, which has been excluded from our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erler-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed escin, which has been excluded from our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzgerald-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>In this cross-over, not-randomised, study, participants received placebo or troxerutin monthly in an alternative way. The paper does not describe numerical results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Forconi-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frausini-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friederich-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Some included patients had thrombophlebitis; these individuals could not be separated out from the patient population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glinski-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was an open RCT conducted to examine venous ulcers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez_x002d_Fajardo-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The outcome assessed was a surrogate (photoplethysmographic evaluation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gouny-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study looked at the efficacy of hydroxyethyl rutosides in the local treatment of symptoms of venous insufficiency during air travel; this topic does not come under the scope of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Granger-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>It is not specified that the trial was double-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henriet-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared the efficacy of Diovenor (diosmine) vs a combination of different flavonoids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Honorato-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared the efficacy of hidrosmine vs diosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horvath-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of dyhidroergotamine, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:48:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:48:30 +0000" MODIFIED_BY="[Empty name]">
<P>This study looked at the effects of troxerutin on microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:48:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed escin for diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Centella asiatica for diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:48:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:48:52 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed a rutoside for diabetic microangiopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN5340167">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared micronised purified flavonoid fraction 1000 mg vs 500 mg</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janssens-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janssens-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study looked at the effects of Ginkor Fort (ginkgo biloba), which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jantet-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalus-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters (cutaneous microcirculation and oxygen supply)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiesewetter-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study evaluated red vine leaf extract, an herbal medicine containing several flavonoids that are not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:49:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koch-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:49:24 +0000" MODIFIED_BY="[Empty name]">
<P>This study compared Venostasin and Pycnogenol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koltringer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Ginkgo biloba, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:49:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kostering-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:49:34 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranendonk-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study focused on patients who had recently undergone venous surgery. Leg oedema and other symptoms could be attributed to the surgery - not to venous insufficiency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krc_x00ed_lek-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kr_x00e4_henb_x00fc_hl-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The bencyclan is a drug with cardiovascular depression effects; it is not included in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambelet-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Some included patients had thrombophlebitis; these could not be separated out from the patient population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Languillat-1988b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug studied (Veliten) was a combination of rutin, ascorbic acid and alpha-tocopherol. No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Languillat-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-D_x00e9_v_x00e9_hat-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes were not applicable to this review: microcirculatory and haemorrheological parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-D_x00e9_v_x00e9_hat-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed troxerutine for CVI: microcirculatory and haemorrheological parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:50:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lefebvre-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:50:20 +0000" MODIFIED_BY="[Empty name]">
<P>This study assessed troxerutine during pregnancy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marastoni-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed dihydroergotamine, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marastoni-1982a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared Centella asiatica vs tribenoside</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menyhei-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group was included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monreal-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two active products for CVI were compared</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monreal-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Investigators examined prevention of post-thrombotic syndrome with hidrosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monteil_x002d_Seurin-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared Cyclo 3 Fort vs diosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monteverde-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared extract of Centella asiatica vs beta-hydroxiethyl-rutoside</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morales-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This RCT assessed escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muschietti-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared natural diosmine, synthetic diosmine and tribenoside</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naser_x002d_Hijazi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This RCT assessed the combination of coumarin and troxerutin (SB-LOT) in CVI. The objective of this study was to assess effects of SB-LOT on blood coagulation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01654016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This is an ongoing single-blinded (outcome assessor) clinical trial about Daflon</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02191163">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the red-vine-leaf extract, which is not included in our review (Antistax)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02191254">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the red-vine-leaf extract, which is not included in our review (Antistax)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02191280">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the red-vine-leaf extract, which is not included in our review (Antistax)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Only haemodynamic venous parameters were assessed by light reflection rheography and transcutaneous oxygen tension measurement (TcPO2)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo group was included. This study assessed the efficacy of 1 tablet or 500 mg HR twice daily or class II compressive stockings</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:55:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann_x002d_Mangoldt-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:55:22 +0000" MODIFIED_BY="[Empty name]">
<P>The drug evaluated contained escin and heparin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nill-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ottillinger-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paciaroni-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Partsch-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed oral dyhidroergotamine, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paul-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was benzarone, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pauschinger-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The drug evaluated was escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pecking-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Daflon for lymphoedema associated with breast cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 17:58:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petruzzellis-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 17:58:42 +0000" MODIFIED_BY="[Empty name]">
<P>This study included patients with superficial phlebitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petruzzellis-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study included 3 comparative groups (2 of different doses of oxirutoside and 1 of placebo), but treatment concealment was incorrect or was not explained correctly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pointel-1987b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed vitamin C combined with Ruscus aculeatus and anthocyanosides from Ribes nigrum (helps to maintain the integrity of capillaries)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pokrovskii-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed Ginkgo biloba, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pollastri-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was a cross-over, double-blind study. The article does not state that this trial was randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Questel-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints were assessed - only microcirculatory parameters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabe-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the red-vine-leaf extract, which is not included in our review (Antistax)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rehn-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared hidroxirutin vs oxerutin for CVI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rehn-1993b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed different dose regimens of O-(beta-hydroxyethyl) rutosides in healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rehn-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This single-blind study looked at the bioequivalence of oxerutins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riccioni-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the combination of troxerutin plus french maritime pine bark</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 18:00:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rish-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 18:00:49 +0000" MODIFIED_BY="[Empty name]">
<P>This study included patients with thrombophlebitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roztocil-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed microcirculatory parameters (capillary filtration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roztocil-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This was an RCT that was not blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadoun-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared the efficacy of 2 different doses of chromocarbe diethylamine (800 and 1200 mg/d/3 mo)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanctis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmeck_x002d_Lindenau-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the hepatic safety of the combination of coumarin-troxerutin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 18:01:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seydewitz-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 18:01:19 +0000" MODIFIED_BY="[Empty name]">
<P>Non-clinical parameters were evaluated in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stefanini-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The control was not placebo - it was balneotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegmann-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This trial did not include a placebo group as control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study included 20 voluntary, ambulant patients with a history of pregnancy-related varicosis, with varicosis with CVI or with both</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the drug escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the drug escin, which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steru-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>It is not specified whether this trial was double-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-28 18:01:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strauss-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-28 18:01:47 +0000" MODIFIED_BY="[Empty name]">
<P>The aim of this study was to check the effects of active treatment following oedema caused by the orthostatic test</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strefezza-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared the effects of different formulations of heperidin and diosmine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Topalov-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of troxesamol (combination of troxerutin, acetylsalicylic acid and dipyridamole)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsukanov-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study looked at doses of a phlebotropic therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turio-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of a combination of vitamin PP (niacin), vitamin C and phyto-therapeutic extracts titrated in escin, bromelain and anthocyanosides</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weindorf-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed the efficacy of the combination of Ruscus aculeatus and trimethylhespiridinchalcone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Widmer-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>The active treatment in this study was phlebolan composed of rutin and several anti-inflammatory agents such as prednisolone and diphenylbutazone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zicot-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This trial did not include a placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zuccarelli-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study assessed GinKor Fort (Ginkgo biloba), which is not included in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CVI: chronic venous insufficiency<BR/>HR: hidroxy rutoside<B>
<BR/>
</B>PO2: pressure of oxygen in blood<BR/>PCO2: pressure of carbon dioxide in blood<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-02-01 17:51:11 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN18841175">
<CHAR_STUDY_NAME MODIFIED="2014-08-27 16:24:45 +0100" MODIFIED_BY="[Empty name]">
<P>Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-08-27 16:26:07 +0100" MODIFIED_BY="[Empty name]">
<P>Single-centre double-blind randomised placebo-controlled parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>240 females 18 to 30 years old suffering from primary chronic venous disease </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Micronised purified flavonoic fraction 500 mg over 4 menstrual cycles vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Effects on microcirculatory and biological parameters over 4 menstrual cycles</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-08-27 16:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>July 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-08-27 16:30:07 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Eliete Bouskela. Instituto de Biologia Roberto Alcantara Gomes Dept Ciências Fisiologicasências Fisiologicas Rua Sao Francisco Xavier 524 - PHLC - Sala 104 - Lab. Presq em Microcirculaçao. Rio de Janeiro. Brazil 20550-013</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-08-27 16:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsor: Institut de Recherches Internationales Servier (France)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01532882">
<CHAR_STUDY_NAME MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy and safety of diosmine 600 mg vs placebo for painful symptoms in patients with chronic venous disease of lower limbs (EDEN)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Multi-centre controlled randomised double-blind placebo-controlled parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>378 patients with painful symptoms of chronic venous disorder (CVD) of the lower limbs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Diosmine 600 mg - DIOVENOR vs placebo (1 tablet per day during 28 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure:</P>
<P>Change in visual analogue scale score for assessment of painful venous symptoms</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-08-27 16:13:56 +0100" MODIFIED_BY="[Empty name]">
<P>January 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-08-27 16:16:41 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Jean-Jérôme GUEX, Nice, France 06000</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-08-27 16:16:58 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsor: Innotech International</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01848210">
<CHAR_STUDY_NAME MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled randomised double-blind placebo-controlled parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>398 patients with chronic venous insufficiency in the reference leg with the clinical classification C3, or C4a or C4b or C5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets (Venalot), orally, 3 times daily for up to 16 weeks vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure:</P>
<P>Mean change from baseline in volume of reference leg at week 16</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-08-27 16:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>May 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-09-18 10:55:11 +0100" MODIFIED_BY="[Empty name]">
<P>Takeda </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-09-18 10:55:08 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsor: Takeda</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-03-31 10:13:25 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-03-31 10:04:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:04:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Quote: "The assignment of patients to one of two treatments, labelled as A or B, was made randomly using a special randomization list"</P>
<P>Comment: a randomisation list is generally accepted as a fair method of ensuring a random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Quote: "In a randomized double-blind study..."</P>
<P>Comment: no information given about method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Quote: "After the 2-week run-in period, the patients were randomly divided into two groups and assigned to a treatment with Pycnogenol, 100 mg × 3/day or a placebo for a period of 2 months"</P>
<P>Comment: no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Quote: "The trial was double-blind, randomised, placebo controlled, between patients..."</P>
<P>Comment: no information given about method of randomisation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into four groups"</P>
<P>Comments: no methods of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Quote: "They were then randomly allocated to treatment with either HR or identical placebo"</P>
<P>Comment: no details of randomisation method provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Quote: "The study was double-blind, randomized, placebo with Daflon"</P>
<P>Comment: no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Quote: "A double-blind controlled trial was undertaken.." and "the two groups of patients were balanced and randomized by trial number so that as far as possible an equal number in each group..."</P>
<P>Comment: no details of randomisation method provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Quote: "A randomized, double-blind, placebo-controlled technique was used. Because of carryover effects, a matched-pair technique was used"</P>
<P>Comment: no methods of randomisation stated<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Quote: "44 patients were treated randomly and under double-blind conditions"</P>
<P>Comment: no specific methods stated for randomisation of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Quote: "The patients are divided into two series according to the degree of symptoms. Within these two series, patients were distributed randomly into two groups, receiving respectively the active ingredient or placebo"</P>
<P>Comment: no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: no randomisation methods stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to two parallel groups of 20"</P>
<P>Comment: no randomisation methods stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Quote: "A multicenter double blind randomized clinical trial was designed"</P>
<P>Comment: no methods described for randomisation of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Quote: "For this reason, we undertook a randomized, double-blind, placebo-controlled trial..."</P>
<P>Comment: no methods for randomisation of participants described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Quote: "A double-blind comparative study against placebo, using two groups treated in parallel, after random distribution of numbered batches of the two treatments to be compared"</P>
<P>Comment: seems like a fair method of randomisation was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Quote: "The allocation to treatment was randomised, centralised and computer stratified in blocks, by ulcer size and centre"</P>
<P>Comment: Random sequence ensured by computer-stratified blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Quote: "One hundred and one patients with symptomatic CVD were randomly allocated to treatment with either MPFF (51 patients) or placebo..."</P>
<P>Comment: no methods described for randomisation of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Quote: "The study design consisted of a double-blind placebo controlled, randomized parallel group comparison with three treatment groups"</P>
<P>Comment: no methods described for randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Quote: "On entry, patients were assigned to one or other of the two treatment groups according to a computer-generated random number table"</P>
<P>Comment: computer-generated random number table considered a fair method to ensure good randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Quote: "The 34 patients chosen were randomly assigned to two treatment groups"</P>
<P>Comment: no methods of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Quote: "A single center, prospective, randomized double-blind, parallel group, placebo-controlled"</P>
<P>Comment: no method of randomisation generation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Quote: "Eighty patients were randomly allocated to the S 5682 group and eighty patients to the placebo group"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Quote: "Randomisation of treatment was stratified according to the size of the ulcers"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Quote: "Fifty female patients with recent onset of venous insufficiency were randomly allocated to two subgroups receiving either calcium dobesilate or a corresponding placebo"</P>
<P>Comment: no method of randomisation of participants described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Quote: "The randomisation was carried out by Rancode computer software (IDV Gauting, Germany)"</P>
<P>Comment: Randomisation seems like a fair method to ensure a random sequence of participants<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Quote: "The trial was double blind, randomised, placebo controlled between patients"</P>
<P>Comment: no methods of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Quote: "Upon entering the study, patients were randomly assigned to receive either HR or placebo with the use of a computerized random assignment method"</P>
<P>Comment: computerised random assignment method generally accepted as a good method to generate a random sequence of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Quote: "For randomization of patients, the program was 'Rancode' of the company IDV data analysis and experimental design, Gauting, used"</P>
<P>Comment: computerised generation of a random sequence generally accepted as a fair method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Quote: "Double-blind, randomized, placebo-controlled. In two parallel groups"</P>
<P>Comment: information about methods of randomisation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Quote: "After a placebo period of two weeks, patients were randomly assigned to active treatment or a placebo group"</P>
<P>Comment: no information about methods of randomisation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Quote: "The two groups were balanced and comparable with respect to age, weight, and type and duration of disturbances"</P>
<P>Comment: no method of randomisation described<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Quote: "The corresponding boxes were randomized in balanced blocks and were labelled by the sponsor with the study number, the dosage, the batch numbers, with the patient number and with the note 'for clinical trials only'. The randomization was done by BIOMETRIX S. A., CH-1911 Gland, Switzerland, using appropriate software"</P>
<P>Comment: computer-generated list of random numbers accepted as a good method for generating a random sequence of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Quote: "This was a double-blind placebo-controlled trial with two groups of patients treated in parallel"</P>
<P>Comment: no method of randomisation described<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Quote: "Randomized trials were conducted versus placebo using appropriate statistical tests determined a priori"</P>
<P>Comment: no methods of sequence generation specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Quote: "The trial was conducted in 100 patients, informed consent and randomized into two groups of 50 and 50 and double-blind treatment, the first with Capillarema and the second with placebo"</P>
<P>Comment: method of randomisation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Quote: "Randomization was made according to a computer-generated randomization list in blocks of 10"</P>
<P>Comment: computer-generated randomisation list generally accepted as an appropriate way to generate a random sequence of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no information provided about the method used for randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Quote: "In total 143 patients 123 were randomized (41 per treatment group)"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Quote: "The allocation to treatment was randomised, centralised and computer stratified in blocks of 10 patients, by clinical CEAP classification and centre"</P>
<P>Comment: Computer-stratified blocks ensure a random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Quote: "Patients were randomized to one of the five groups, receiving oral solutions of HR in small bottles containing 600, 900, 1200, 1500 mg HR or simply distilled water (controls) with six patients in each group"</P>
<P>Comment: no methods described for randomising participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: no methods of random sequence generation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Quote: "The study was double-blind and patients were randomly allocated to be included in one of two parallel groups by using a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Quote: "Patients admitted to the study were randomly divided into two balanced groups treated respectively with calcium or placebo for one month..."</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Quote: "If patients met the inclusion criteria, they were randomised using envelope method, double-blind treatment with Venoruton 300 mg × 3 daily or placebo"</P>
<P>Comment: method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Quote: "They were treated with placebo or Pycnogenol 100mg × 3/day for 2 months according to a computer elaborated simple randomization table"</P>
<P>Comment: computerised randomisation table generally accepted as a proper way to randomise participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Quote: "The award of the therapeutic group membership made by draw lots was ignored until the complete end of the study by both the clinician and the patients"</P>
<P>Comment: drawn seems a method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Quote: "The study conducted in four hospitals according to a controlled, randomized, double-blind (double dummy) study performed on three parallel groups for eight weeks"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Quote: "... after the administration of 3 capsules of HR (900 mg) or 3 capsules of placebo in a double blind cross-over trial in a randomized-order"</P>
<P>Comment: method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Quote: "Four patients would receive active treatment with Paroven and one would be randomly and blindly treated with placebo"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Quote: "Randomization with blocks of four was used. The randomization list was produced by an independent person"</P>
<P>Comment: Randomisation list ensures a random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Quote: "After the final examination, the patients were randomised to receive either...."</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Comment: no methods of random sequence generation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Quote: "Following randomisation, stratified by centre, the patients then received daily 3x2 capsules of identical appearance, containing either active drug or placebo"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Quote: "Two prospective, multicentre, double-blind, randomized, parallel, placebo-controlled trial"</P>
<P>Comment: no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Quote: "The allocation of the subjects to the Cyclo 3 and placebo groups was done at random, in a blind manner, according to the order of admission in the study"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Quote: "The trial was double-blind, randomized, placebo-controlled dose of one tablet of 500 mg twice daily HR or identical placebo"</P>
<P>Comment: method of randomisation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Quote: "The method chosen was that of a controlled trial conducted a double-blind placebo-controlled with throwing dice assigned treatment"</P>
<P>Comment: Throwing dice method seems to be a fair method for generating a random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Quote: "All the studies were conducted double blind, according to the methodology of controlled trials"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Quote: "The study had a double-blind, randomised, multi-centered, paralel-group design with two treatment groups"</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Quote: "The randomisation schedule was generated by the validated PC programme RanCode plus, independently to all study participants. It was based on blocks of 4 patients. All medication was pre-numbered and distributed to the centres"</P>
<P>Comment: computer-generated table of random numbers ensures a random sequence of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Quote: "The study was designed as a multi-center, double-blind, randomized, placebo-controlled trial with women suffering from chronic venous insufficiency..."</P>
<P>Comment: no method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Quote: "The study was controlled, double-blind, randomized, multicentre and with a placebo run-in period"</P>
<P>Comment: no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: method of randomisation not given<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Quote: "The patients were treated for 28 days with either Doxium or placebo at the dosage of 3 capsules daily, according to a randomization list prepared by the statistician"</P>
<P>Comment: randomisation list assumed to be a fair method of assuring a random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Quote: "The methodology used was that of a controlled trial against placebo in double-blind perspective with the drawing of lots to constitute two parallel groups"</P>
<P>Comment: Drawing of lots seems like a fair method of generating an adequate sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-03-31 10:09:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Comment: no information given about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Comment: no method of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Comment: no information given about method of treatment allocation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-09 17:43:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Quote: "All tablets (active and placebo) were randomly divided into numbered bottles by an external investigator..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Quote: "Placebo tablets were given in indistinguishable numbered packaging"</P>
<P>Comment: Indistinguishable number packaging ensures a fair method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Comment: no specific methods stated for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Comment: no method of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: no methods for allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Comment: Treatment allocated by researcher phoning the co-ordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Quote: "After informed consent, patients were randomised in a blinded fashion (sealed envelope principle)"</P>
<P>Comment: sealed envelope principle considered a good method to ensure allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Comment: no methods described for allocation concealment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Quote: "A single center, prospective, randomized double-blind, parallel group, placebo-controlled"</P>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Quote: "A series of coded sealed envelopes for decoding any particular case was supplied to the local hospital pharmacy"</P>
<P>Comment: sealed envelopes generally accepted as a good method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Comment: no information given about methods used for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: no information about methods of allocation concealment provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Comment: no information about methods of allocation concealment provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Quote: "The allocation of the study treatment to each patient was done according to the next available consecutive patient number printed on the prescription card and on the label of the box. This number was recorded on each page of the CRF.¨ and ¨Each investigator was provided with a sealed envelope containing the code for each patients randomisation number"</P>
<P>Comment: seems like a fair method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Comment: no method of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no information provided about the method used for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:08:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Comment: treatment was allocated by researcher phoning the co-ordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no methods for allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:09:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: each bottle of treatment was identical and was numbered in a random way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Quote: "The allocation to individual patients of either type of treatment was performed according to the access sequence number of the patient"</P>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Quote: "If patients met the inclusion criteria, they were randomised using envelope method, double-blind treatment with Venoruton 300 mg × 3 daily or placebo"</P>
<P>Comment: envelope methods generally accepted as a fair method for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Comment: no method described for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Quote: "The study medication was packed in identical boxes marked with a randomization number each newly randomized patient was given the medication with the lowest randomization number available"</P>
<P>Comment: Identical boxes with randomisation provision ensureproper allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Quote: "The active and the placebo material were numbered in randomised order"</P>
<P>Comment: Randomised order prevented knowledge of treatment in advance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: no method of allocation concealment stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Comment: method of allocation concealment unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Comment: no information about allocation concealment provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Quote: "Patients were included in the study by receiving the next consecutive random number. For each patient the study centres were supplied sealed envelopes with the treatment group information"</P>
<P>Comment: sealed envelopes and allocation of participants by giving the next consecutive random number ensure fair allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Comment: no method of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: method of allocation concealment not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: no methods described for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Comment: no methods of allocation concealment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-12-29 10:49:42 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2016-03-31 10:13:03 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding (patients)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Quote: "The Phlebodril and placebo capsules had the same external appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Quote: "The placebo visually matched the test drug"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Quote: "Patients receiving respectively the test drug or identical placebo"<BR/>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Quote: "All tablets (active and placebo) were randomly divided into numbered bottles by an external investigator, and the contents of each bottle were unmasked only at the time of statistical analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Quote: "The placebo regime was identical" and "... or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Quote: "Were given Paroven 500 mg bd or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Quote: "Calcium dobesilate, or an identical placebo, were administered..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Quote: "In addition, a placebo identical in appearance to the active drug..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Quote: "We also used a placebo of identical presentation"</P>
<P>Comment: Identical placebo ensure double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: placebo used with the same frequency as in experimental groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Quote: "The two products to be compared were presented in the form of identical capsules for both Cyclo 3 and placebo"</P>
<P>Comment: Identical placebo ensures a fair method used for double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Quote: "... to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Quote: "All medications appeared to be identical with respect to volume, colour of the bottle and the smell of solution. The difference in taste could be accepted as this type is of solution was not commercially available and, therefore, unknown and unidentifiable to patients"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Quote: "The medications were supplied in identical capsule form"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Quote: "And the other group received placebo capsules indistinguishable from the hidrosmin capsules, according to the double-blind technique"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Comment: placebo capsules identical to calcium dobesilate capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Quote: "Patients fulfilling the inclusion criteria were randomly allocated to receive one S 5682 tablet twice daily or matching placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Quote: "Fifty female patients with recent onset of venous insufficiency were randomly allocated to two subgroups receiving either calcium dobesilate or a corresponding placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Quote: "A blinded taste test with pharmacists demonstrated that the teas were similar in taste and appearance and hard to distinguish"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Quote: "The same number of identical-looking placebo tablets consisting of lactose were given"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Quote: "Placebo is with taste and appearance indistinguishable from the treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Quote: "For the double-blind treatment period, the boxes, labels, and capsules containing Doxium 500 and placebo were identical in appearance for each drug, to ensure patient and investigator blinding"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Quote: "The double-blind nature of the trial was guaranteed by the strictly identical appearance of treatment units (capsules) as well as their packaging (bottles and bags of treatment kits)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Quote: "Patients from each centre in the randomised control group were given placebo capsules identical in appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Quote: "The placebo had the same characteristics which include active treatment. The oral administration was under the same conditions as the active treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Quote: "to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:13:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: each bottle of treatment was identical. Participants did not know the type of treatment administered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Quote: "Bottles, identical in form and presentation contained dobesilate calcium or placebo, according to a randomization code that was opened until the end of experiment"</P>
<P>Comments: Identical presentation of intervention and control groups ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Comment: no methods of blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Quote: "The drugs were prepared in white opaque capsules in order to make the slightly pinkish-coloured Pycnogenol® indistinct from placebo (lactose)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Quote: ".... or a matching placebo ... The study medication was packed in identical boxes..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Quote: "The patients were randomised to receive either 2 tablets of 500mg HR twice daily or a placebo of identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Quote: "The key to the active and placebo capsules was not broken until January of this year, when all the patients had completed treatment for over 6 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Quote: "Following randomisation, stratified by centre, the patients then received daily 3×2 capsules of identical appearance, containing either active drug or placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Quote: "Cyclo 3® and the placebo had an identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Quote: "The trial was double-blind, randomized, placebo-controlled dose of one tablet of 500 mg twice daily HR or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Quote: "Two parallel groups were thus formed, the E group received 300mg per day of Endolelon three times daily, P group receiving placebo - in all respects identical to the active pills - and using the same frequency"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Quote: "Placebo tablets matched the active tablets in taste, smell and appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Quote: "They were then randomly allocated to receive either troxerutin, 3500 mg to be taken in the morning for 2 months, or a placebo with identical appearance and taste"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Quote: "Ampules of placebo, which are in all respects comparable to those of the active..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2016-03-31 10:13:05 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding (study researchers)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Quote: "The Phlebodril and placebo capsules had the same external appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Quote: "The placebo visually matched the test drug"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Quote: "Patients receiving respectively the test drug or identical placebo"<BR/>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Quote: "All tablets (active and placebo) were randomly divided into numbered bottles by an external investigator, and the contents of each bottle were unmasked only at the time of statistical analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Quote: "The placebo regime was identical" and "... or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Quote: "Were given Paroven 500 mg bd or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Quote: "Calcium dobesilate, or an identical placebo, were administered..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Quote: "In addition, a placebo identical in appearance to the active drug..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Quote: "We also used a placebo of identical presentation"</P>
<P>Comment: Identical placebo ensure double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: placebo used with the same frequency as in experimental groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Quote: "The two products to be compared were presented in the form of identical capsules for both Cyclo 3 and placebo"</P>
<P>Comment: Identical placebo ensures a fair method used for double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Quote: "... to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Quote: "All medications appeared to be identical with respect to volume, colour of the bottle and the smell of solution. The difference in taste could be accepted as this type is of solution was not commercially available and, therefore, unknown and unidentifiable to patients"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Quote: "The medications were supplied in identical capsule form"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Quote: "And the other group received placebo capsules indistinguishable from the hidrosmin capsules, according to the double-blind technique"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Comment: placebo capsules identical to calcium dobesilate capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Quote: "Patients fulfilling the inclusion criteria were randomly allocated to receive one S 5682 tablet twice daily or matching placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Quote: "Fifty female patients with recent onset of venous insufficiency were randomly allocated to two subgroups receiving either calcium dobesilate or a corresponding placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Quote: "A blinded taste test with pharmacists demonstrated that the teas were similar in taste and appearance and hard to distinguish"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Quote: "The same number of identical-looking placebo tablets consisting of lactose were given"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Quote: "Placebo is with taste and appearance indistinguishable from the treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Quote: "For the double-blind treatment period, the boxes, labels, and capsules containing Doxium 500 and placebo were identical in appearance for each drug, to ensure patient and investigator blinding"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Quote: "The double-blind nature of the trial was guaranteed by the strictly identical appearance of treatment units (capsules) as well as their packaging (bottles and bags of treatment kits)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Quote: "Patients from each centre in the randomised control group were given placebo capsules identical in appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Quote: "The placebo had the same characteristics which include active treatment. The oral administration was under the same conditions as the active treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Quote: "to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: each bottle of treatment was identical. Researcher did not know the type of treatment administered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Quote: "Bottles, identical in form and presentation contained dobesilate calcium or placebo, according to a randomization code that was opened until the end of experiment"; "Neither the patient nor the medical staff did not know the nature of the substance administered, thereby satisfying the conditions of a double-blind trial"</P>
<P>Comments: Identical presentation of intervention and control groups ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Comment: no methods of blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Quote: "The drugs were prepared in white opaque capsules in order to make the slightly pinkish-coloured Pycnogenol® indistinct from placebo (lactose)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Quote: "The study medication was packed in identical boxes marked with a randomization number each newly randomized patient was given the medication with the lowest randomization number available" ; ".... or a matching placebo ... The study medication was packed in identical boxes..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Quote: "The patients were randomised to receive either 2 tablets of 500mg HR twice daily or a placebo of identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Quote: "The key to the active and placebo capsules was not broken until January of this year, when all the patients had completed treatment for over 6 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Quote: "Following randomisation, stratified by centre, the patients then received daily 3×2 capsules of identical appearance, containing either active drug or placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Quote: "Cyclo 3® and the placebo had an identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Quote: "The trial was double-blind, randomized, placebo-controlled dose of one tablet of 500 mg twice daily HR or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Quote: "Two parallel groups were thus formed, the E group received 300mg per day of Endolelon three times daily, P group receiving placebo - in all respects identical to the active pills - and using the same frequency"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Quote: "Placebo tablets matched the active tablets in taste, smell and appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Quote: "They were then randomly allocated to receive either troxerutin, 3500 mg to be taken in the morning for 2 months, or a placebo with identical appearance and taste"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Quote: "Ampules of placebo, which are in all respects comparable to those of the active..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-03-31 10:13:07 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding (outcome assessment)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Quote: "The Phlebodril and placebo capsules had the same external appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Quote: "The placebo visually matched the test drug"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Quote: "Patients receiving respectively the test drug or identical placebo"<BR/>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Quote: "Assessors were blind to the treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Quote: "The placebo regime was identical" and "... or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Quote: "This code was not broken until the completion of the study"</P>
<P>Comment: outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Quote: "Calcium dobesilate, or an identical placebo, were administered..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Quote: "In addition, a placebo identical in appearance to the active drug..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Quote: "We also used a placebo of identical presentation"</P>
<P>Comment: Identical placebo ensure double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: placebo used with the same frequency as in experimental groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Quote: "The two products to be compared were presented in the form of identical capsules for both Cyclo 3 and placebo"</P>
<P>Comment: Identical placebo ensures a fair method used for double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Quote: "... to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Quote: "All medications appeared to be identical with respect to volume, colour of the bottle and the smell of solution. The difference in taste could be accepted as this type is of solution was not commercially available and, therefore, unknown and unidentifiable to patients"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Quote: "The medications were supplied in identical capsule form"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Quote: "And the other group received placebo capsules indistinguishable from the hidrosmin capsules, according to the double-blind technique"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Comment: placebo capsules identical to calcium dobesilate capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Quote: "Patients fulfilling the inclusion criteria were randomly allocated to receive one S 5682 tablet twice daily or matching placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Quote: "Fifty female patients with recent onset of venous insufficiency were randomly allocated to two subgroups receiving either calcium dobesilate or a corresponding placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Quote: "A blinded taste test with pharmacists demonstrated that the teas were similar in taste and appearance and hard to distinguish"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Quote: "The same number of identical-looking placebo tablets consisting of lactose were given"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Quote: "Placebo is with taste and appearance indistinguishable from the treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Quote: "For the double-blind treatment period, the boxes, labels, and capsules containing Doxium 500 and placebo were identical in appearance for each drug, to ensure patient and investigator blinding"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Quote: "The double-blind nature of the trial was guaranteed by the strictly identical appearance of treatment units (capsules) as well as their packaging (bottles and bags of treatment kits)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Quote: "Patients from each centre in the randomised control group were given placebo capsules identical in appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Quote: "The placebo had the same characteristics which include active treatment. The oral administration was under the same conditions as the active treatment"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Quote: "to placebo (inactive capsules of identical appearance and weight) twice a day"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:13:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: each bottle of treatment was identical. Assessor did not know the type of treatment administered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Quote: "Bottles, identical in form and presentation contained dobesilate calcium or placebo, according to a randomization code that was opened until the end of experiment"; "Neither the patient nor the medical staff did not know the nature of the substance administered, thereby satisfying the conditions of a double-blind trial"</P>
<P>Comments: Identical presentation of intervention and control groups ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Comment: no methods of blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Quote: "The drugs were prepared in white opaque capsules in order to make the slightly pinkish-coloured Pycnogenol® indistinct from placebo (lactose)"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Quote: ".... or a matching placebo ... The study medication was packed in identical boxes..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Quote: "The patients were randomised to receive either 2 tablets of 500mg HR twice daily or a placebo of identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Quote: "The key to the active and placebo capsules was not broken until January of this year, when all the patients had completed treatment for over 6 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Quote: "Following randomisation, stratified by centre, the patients then received daily 3x2 capsules of identical appearance, containing either active drug or placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Quote: "Cyclo 3® and the placebo had an identical appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Quote: "The trial was double-blind, randomized, placebo-controlled dose of one tablet of 500 mg twice daily HR or identical placebo"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Quote: "Two parallel groups were thus formed, the E group received 300mg per day of Endolelon three times daily, P group receiving placebo - in all respects identical to the active pills - and using the same frequency"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Quote: "Placebo tablets matched the active tablets in taste, smell and appearance"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Quote: "They were then randomly allocated to receive either troxerutin, 3500 mg to be taken in the morning for 2 months, or a placebo with identical appearance and taste"</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: no information given about methods used for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Quote: "Ampules of placebo, which are in all respects comparable to those of the active..."</P>
<P>Comment: Identical placebo ensures double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-03-31 10:13:25 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Incomplete outcome data</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Quote: "Three patients dropped out for reasons unconnected with this study"</P>
<P>Comment: number in each group described, and number of participants who dropped out of the study prematurely presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Comment: very few participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Comment: number of participants in each group described. Loss to follow-up described along with exclusions after randomisation, including reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Comment: numbers of participants in each group reported, along with participants excluded after randomisation,reasons for exclusion and information on compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Comment: neither exclusions post randomisation nor losses to follow-up described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Comment: number in each group described, including drop-outs and those excluded after randomisation during follow-up (7/44; 16%); reasons for drop-out not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Comment: number of participants in each group described, but no information given on important characteristics of participants. Number of persons excluded after randomisation was important (51/120; 42.5%). Reasons for exclusion were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: number of participants in each group described, number of participants who dropped out prematurely stated and reasons for dropping out described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: only 13% drop-out rate (16/120) for violation of study protocol reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: only 5% drop-out rate (5/109) for violation of study protocol. Number in each group provided, along with reasons for exclusion after randomisation and information on compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Quote: no information provided about participants who withdrew prematurely from the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Study was interrupted when only 69 of the 230 necessary participants were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Comment: number of participants in each group described. In addition, information given about numbers of participants who withdrew prematurely (4/101; 4%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Comment: number of participants in each group reported, along with information on compliance, drop-outs (7/57; 12%), reasons for drop-out and adverse events. ITT analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Comment: number of participants in each group described. In addition, number of participants who prematurely withdrew from the study (6/34; 18%) described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Comment: no exclusions post randomisation and no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Comment: number of participants in each group described. In addition, adverse events experienced, number of drop-outs and reasons for drop-outs described. Methods used for imputing missed data not described. Six per cent of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: number of participants in each group described. ITT analysis conducted. Information provided about participants who withdrew prematurely from the study, along with reasons for premature withdrawal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Comment: number of participants in each group described. Participants who withdrew prematurely from the trial described, along with reasons for withdrawal. Four per cent of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Comment: number of participants in each group described. Number of drop-outs and reasons for dropping out of the trial described. ITT analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Quote: number of participants in each group described. No losses reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with number of participants who dropped out and number who experienced adverse events </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Comment: number of participants in each group described. No information provided about participants who prematurely dropped out of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: number of participants in each group described. No information provided about the number of participants who dropped out of the study prematurely or the number who experienced adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Comment: number of participants in both placebo and treatment groups described, along with the most important participant characteristics, numbers of participants who dropped out prematurely, reasons for drop-out, influence of drop-outs and information on compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: number in each group described, but important characteristics lacking. In addition, number of participants who dropped out prematurely or were excluded after randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Comment: number of participants in each group described. Adverse events, participant experience, compliance and number of participants who dropped out prematurely reported (29/260 participants)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with the most important baseline characteristics. No losses reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: number of participants in each group provided, along with inclusion and exclusion criteria and characteristics of participants Number of participants who experienced adverse events presented, along with number who dropped out of the study. Losses 2.5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: number of participants in each group described, but important baseline characteristics lacking. In addition, number of participants who withdrew prematurely not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Comment: number of participants described, along with the most important characteristics, number of drop-outs, adverse events and information on compliance </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: number of participants for each group described, but no information provided about participants lost to follow-up or dropped out. Data were missing from the analysis and adverse events were not described. Losses were reported as 18%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with baseline characteristics. In addition, numbers and information provided about adverse events and participants who withdrew prematurely from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:08:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Comment: number in each group was described, and those lost to follow-up (25.7%) and participants who prematurely withdrew were described. Important characteristics were described, and inclusion and exclusion criteria were reported. ITT analysis was conducted, and imputation technique was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no data given about drop-outs. Most important characteristics described with inclusion and exclusion criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: no information on losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Comment: no losses reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Comment: numbers of participants in both groups described. No losses reported. No baseline characteristics of participants provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Comment: number of participants in both groups described, along with the most important characteristics and inclusion and exclusion criteria. Number of participants who withdrew prematurely not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:13:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Comment: number of participants was described in each group, along with the most important characteristics of participants, including inclusion and exclusion criteria. In addition, information was given about drop-outs and adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: number of participants in each group described, as well as the inclusion and exclusion criteria and the most important characteristics. Numbers of participants who withdrew prematurely were described, including reasons for dropping out, information about compliance and adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with inclusion and exclusion criteria and important characteristics for participants. In addition, study author reported the number of adverse events that occurred, the number of participants who withdrew prematurely and reasons for dropping out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: number of participants described in each group, along with the most important characteristics. However, inclusion and exclusion criteria were, apart from clinical features, not well described. Adverse events and drop-outs were well described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: number of participants in each group described, and a table includes the most important characteristics of participants and inclusion and exclusion criteria. In addition, number of participants excluded after randomisation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Comment: number in each group described, as were loss to follow-up and participants who prematurely withdrew. Important characteristics and inclusion and exclusion criteria reported. ITT analysis conducted, but no methods used for imputation of missing values described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with information about the most important characteristics and inclusion and exclusion criteria. In addition, study author described the number of participants who experienced adverse events and the number who withdrew prematurely from the study, including reasons for dropping out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Comment: 39% (13/33) losses; imbalance between groups at the end of follow-up (17 participants received hidroxirutoside; 8 received placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with important characteristics and inclusion and exclusion criteria. Number of patients who withdrew prematurely described, but no information on the reasons why participants dropped out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with number of losses, but not reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Comment: number of included participants not specified. Only 1 participant did not accomplish the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Comment: number of participants in both groups described, along with inclusion and exclusion criteria and the most important characteristics. Adverse events presented. No losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with inclusion and exclusion criteria and the most important characteristics. Information about participants who withdrew prematurely described. In addition, standard deviation lacking in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: 2 participants lost in each group, but reasons not explained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with the most important characteristics and inclusion and exclusion criteria. ITT analysis conducted. Information about adverse events, exclusion after randomisation and loss to follow-up given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with the most important characteristics and inclusion and exclusion criteria. In addition, study author stated the number of participants who withdrew from the study prematurely or were excluded after randomisation (22.5%). ITT analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with important characteristics and inclusion and exclusion criteria. In addition, number of participants who withdrew prematurely described, but percentage was important (34%) and no ITT analysis performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with the most important characteristics and inclusion and exclusion criteria. In addition, information about participants who withdrew prematurely given, including reasons for dropping out. Adverse events given as well</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: number of participants in each group described, and inclusion and exclusion criteria reported as well for the most important characteristics. Number of participants who dropped out prematurely given, along with numbers of and reasons for adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: number of participants in each group described, including most important characteristics and inclusion and exclusion criteria. In addition, reasons for excluding participants after randomisation given, along with number of participants. Number compliant with medication provided, along with adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Comment: number of participants in each group described, along with inclusion and exclusion criteria and the most important characteristics. In addition, tolerance, adverse events and participants who dropped out prematurely described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2016-03-31 10:08:55 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Selective reporting</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:04:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allegra-1981">
<DESCRIPTION>
<P>Comment: the number of participants in both groups was described. However, a table with important characteristics was lacking; this could lower the generalisability. Adverse events, tolerability and signs of intolerance were presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterkamper-1987">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arcangeli-2000">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balmer-1980">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belczak-2014">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1981">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biland-1982">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnand-1989">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casley_x002d_Smith-1988">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1972">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cauwenberge-1978">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2002">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chassignolle-1994">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cloarec-1994">
<DESCRIPTION>
<P>Comment: no protocol identified. In the methods section, subjective symptoms identified that were not reported in the results section (pain, heaviness, swelling, restless leg, cramps, presence of pitting oedema)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cloarec-1996">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cornu_x002d_Thenard-1985">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DOBESILATO500_x002f_2">
<DESCRIPTION>
<P>Study was not published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Danielsson-2002">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diebschlag-1994">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez-1992">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fermoso-1992">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flota_x002d_Cervera-2008">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gilly-1994">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guilhou-1997">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hachen-1982">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ihme-1996">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jongste-1986">
<DESCRIPTION>
<P>Comment: no published protocol identified. In the methods section, outcomes of &#8220;restless legs&#8221; and &#8220;venous pressure&#8221; reported, but in the results/conclusion sections, no data regarding these outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jongste-1989">
<DESCRIPTION>
<P>Comment: no published protocol identified. In the methods section, outcomes of &#8220;restless legs&#8221; and &#8220;venous pressure&#8221; reported, but in the results/conclusion sections, no data regarding these outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiesewetter-1997">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kl_x00fc_ken-1971">
<DESCRIPTION>
<P>Comment: no published protocol identified. No outcomes reported in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koscielnny-1996">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kriner-1985">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labs-2004">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Languillat-1988">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurent-1988">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazzarini-1982">
<DESCRIPTION>
<P>Comment: no information regarding adverse events provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLennan-1994">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mann-1981">
<DESCRIPTION>
<P>Comment: no protocol identified. Differences were noted between methods and results for the following outcomes: tiredness, heaviness, tender legs, distended veins, nights disturbed, daytime cramps</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marinello-2002">
<DESCRIPTION>
<P>Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 10:08:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Zapata-2008">
<DESCRIPTION>
<P>Comment: protocol identified and no differences identified between protocol and article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nocker-1990">
<DESCRIPTION>
<P>Comment: no protocol identified, but no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Padros-1972">
<DESCRIPTION>
<P>Comment: results before cross-over not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parrado-1999">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pecchi-1990">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pedersen-1992">
<DESCRIPTION>
<P>Comment: no protocol identified, but no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrassi-2000">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planchon-1990">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pointel-1986">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prerovsky-1972">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pulvertaft-1983">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabe-2011">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Renton-1994">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rose-1970">
<DESCRIPTION>
<P>Comment: results by symptom before the cross-over not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudofsky-1989">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sentou-1984">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serralde-1990">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thebaut-1985">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsouderos-1989">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Unkauf-1996">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002a">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanscheidt-2002b">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vin-1994">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Welch-1985">
<DESCRIPTION>
<P>Comment: protocol identified and no differences identified between protocol and article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Widmer-1990">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucarelli-1987">
<DESCRIPTION>
<P>Comment: no protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-03-27 17:52:35 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2015-03-27 17:49:38 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Phlebotonics compared with placebo for venous insufficiency</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Phlebotonics compared with placebo for venous insufficiency</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with venous insufficiency<BR/>
<B>Settings: </B>hospital and ambulatory settings<BR/>
<B>Intervention:</B> phlebotonics<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Phlebotonics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Oedema in the lower legs (dichotomous variable)</B>
</P>
<P>Follow-up: 1-6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>575 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>403 per 1000</B>
<BR/>(362 to 449)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.70 </B>
<BR/>(0.63 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1245<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of a positive effect of phlebotonics for patients with CVI regarding oedema in the lower legs with a statistically significant lower risk ratio for the phlebotonics group</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Oedema in the lower legs (circumference, mm)</B>
</P>
<P>Follow-up: 1-12 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Mean oedema in the lower legs (circumference, mm) in the intervention groups was<BR/>
<B>4.27 mm lower</B>
<BR/>(5.61 to 2.93 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2010<BR/>(15 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of a positive effect of phlebotonics for patients with CVI regarding oedema in the lower legs with statistically significant lower mean oedema in the lower legs in the intervention group</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ulcer cured</B>
</P>
<P>Follow-up: 1-12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>381 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>358 per 1000</B>
<BR/>(301 to 430)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.94 </B>
<BR/>(0.79 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>461<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>c,d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No evidence of an effect of phlebotonics for patients with CVI regarding ulcer healing. Differences between phlebotonics and placebo groups were not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life:</B>
</P>
<P>
<B>aminaftone</B>
</P>
<P>Follow-up: mean 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Mean quality of life in the intervention groups was<BR/>
<B>10 lower</B>
<BR/>
</P>
<P>(17.01 to 2.99 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>79<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>e,f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of an effect of phlebotonics for patients with CVI regarding quality of life</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Quality of life:</B>
</P>
<P>
<B>dobesilate</B>
</P>
<P>Follow-up: 2-12 months</P>
<P/>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean quality of life in the intervention groups was<BR/>
<B>0.60 lower</B>
<BR/>(2.15 lower to 0.95 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>617<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>High</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No evidence of an effect of phlebotonics for patients with CVI regarding quality of life. Differences between phlebotonics and placebo groups were not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: 1-12 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>153 per 1000</B>
<BR/>(132 to 177)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(1.05 to 1.40)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4054<BR/>(34 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of a greater incidence of adverse events in the phlebotonics group than in the placebo group</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>One study rated as high risk of bias for incomplete outcome data (number of participants excluded after randomisation was important (51/120; 42.5%), no ITT analysis conducted)<BR/>
<SUP>b</SUP>Some studies presented unclear risk of bias<BR/>
<SUP>c</SUP>One study rated as high risk of bias for incomplete outcome data and selective reporting because this study was not published<BR/>
<SUP>d</SUP>One study rated as high risk of bias for selective reporting<BR/>
<SUP>e</SUP>The generation of randomisation was unclear<BR/>
<SUP>f</SUP>The confidence interval was wide<BR/>
<SUP>g</SUP>One study rated as high risk of bias for incomplete outcome data (number of participants who withdrew prematurely was described, but percentage was high (34%), no ITT analysis conducted)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Results of all outcomes analysed (all phlebotonics)</TITLE>
<TABLE COLS="3" ROWS="17">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>RR 0.70 (0.63 to 0.78)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (mm)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MD -4.27 (-5.61 to -2.93)</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (volume)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.38 (-0.50 to -0.25)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ulcer cured</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Trophic disorders</P>
</TD>
<TD>
<P>RR 0.87 (0.81 to 0.95)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Cramps</P>
</TD>
<TD>
<P>RR 0.72 (0.58 to 0.89)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Restless legs</P>
</TD>
<TD>
<P>RR 0.81 (0.72 to 0.91)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Itching</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Swelling</P>
</TD>
<TD>
<P>RR 0.63 (0.50 to 0.80)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Paraesthesia</P>
</TD>
<TD>
<P>RR 0.67 (0.50 to 0.88)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Quality of life</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment by the participant</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>RR 1.21 (1.05 to 1.40)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: No measures of effect are specified when I<SUP>2</SUP> was &gt; 75% for the subgroup</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant<BR/>RR: risk ratio<BR/>MD: mean difference<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: aminaftone</TITLE>
<TABLE COLS="3" ROWS="11">
<TR>
<TH>
<P>
<B>Variables</B>
</P>
</TH>
<TH>
<P>
<B>Dichotomous</B>
</P>
</TH>
<TD VALIGN="TOP">
<P>
<B>Continous </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>RR 0.53 (0.28 to 0.99)</P>
</TD>
<TD>
<P>SMD -0.17 (-0.61 to 0.28)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ulcer cured</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Trophic disorder</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>RR 0.43 (0.23 to 0.79)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Cramps</P>
</TD>
<TD>
<P>RR 0.56 (0.31 to 0.99)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Itching</P>
</TD>
<TD>
<P>RR 0.53 (0.31 to 0.91)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>RR 0.32 (0.17 to 0.60)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Quality of live</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MD -10.00 (-17.01 to -2.99)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: Only 1 study was analysed</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>MD: mean difference<BR/>NS: non-significant<BR/>RR: risk ratio<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: calcium dobesilate</TITLE>
<TABLE COLS="3" ROWS="16">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (mm)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (volume)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.50 (-0.68 to -0.31)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ulcer cured</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>RR 0.39 (0.16 to 0.93)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Cramps</P>
</TD>
<TD>
<P>RR 0.65 (0.50 to 0.84)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Restless legs</P>
</TD>
<TD>
<P>RR 0.73 (0.59 to 0.91)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Itching</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Swelling</P>
</TD>
<TD>
<P>RR 0.19 (0.08 to 0.41)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Paraesthesia</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Quality of life</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment by the participant</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.52 (-0.71 to -0.33)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: No measures of effect are specified when I<SUP>2</SUP> was &gt; 75% for the subgroup</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant<BR/>RR: risk ratio<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>Results by pharmacological group: Centella asiatica</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment by the participant</P>
</TD>
<TD>
<P>RR 0.28 (0.14 to 0.57)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: Only 1 study was analysed</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant<BR/>RR: risk ratio</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: diosmine, hidrosmine</TITLE>
<TABLE COLS="3" ROWS="15">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>RR 0.63 (0.46 to 0.86)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (mm)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MD -5.98 (-7.78 to -4.18)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ulcer cured</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Trophic disorder</P>
</TD>
<TD>
<P>RR 0.87 (0.81 to 0.94)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>SMD -0.35 (-0.67 to -0.02)</P>
</TD>
</TR>
<TR>
<TD>
<P>Cramps</P>
</TD>
<TD>
<P>RR 0.83 (0.70 to 0.98)</P>
</TD>
<TD>
<P>SMD -0.46 (-0.78 to -0.14)</P>
</TD>
</TR>
<TR>
<TD>
<P>Restless legs</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Itching</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>SMD -0.69 (-1.02 to -0.36)</P>
</TD>
</TR>
<TR>
<TD>
<P>Swelling</P>
</TD>
<TD>
<P>RR 0.70 (0.52 to 0.94)</P>
</TD>
<TD>
<P>SMD -0.92 (-1.26 to -0.58)</P>
</TD>
</TR>
<TR>
<TD>
<P>Paraesthesia</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment by the participant</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.81 (-1.14 to -0.47)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: No measures of effect are specified when I<SUP>2</SUP> was &gt; 75% for the subgroup</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>MD: mean difference<BR/>NS: non-significant<BR/>RR: risk ratio<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: french maritime pine bark extract</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>RR 0.66 (0.48 to 0.91)</P>
</TD>
<TD>
<P>SMD -1.39 (-2.09 to -0.69)</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>SMD -1.50 (-2.21 to -0.79)</P>
</TD>
</TR>
<TR>
<TD>
<P>Swelling</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>SMD -1.65 (-2.38 to -0.92)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: Only 1 study was analysed</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant<BR/>RR: risk ratio<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: grape seed extract</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: Only 1 study was analysed</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]">Results by pharmacological group: rutosides</TITLE>
<TABLE COLS="3" ROWS="16">
<TR>
<TH>
<P>Variables</P>
</TH>
<TH>
<P>Dichotomous</P>
</TH>
<TH>
<P>Continuous</P>
</TH>
</TR>
<TR>
<TD>
<P>Oedema</P>
</TD>
<TD>
<P>RR 0.72 (0.64 to 0.81)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (mm)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Oedema (volume)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.29 (-0.11 to -0.47)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ulcer cured</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Trophic disorder</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.71 (-1.23 to -0.19)</P>
</TD>
</TR>
<TR>
<TD>
<P>Cramps</P>
</TD>
<TD>
<P>RR -0.83 (-1.50 to -0.16)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Restless legs</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Itching</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SMD -0.58 (-1.10 to -0.06)</P>
</TD>
</TR>
<TR>
<TD>
<P>Heaviness</P>
</TD>
<TD>
<P>RR 0.60 (0.48 to 0.74)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Swelling</P>
</TD>
<TD>
<P>RR 0.67 (0.50 to 0.88)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Paraesthesias</P>
</TD>
<TD>
<P>RR 0.55 (0.37 to 0.83)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment by the participant</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>RR 1.41 (1.08 to 1.83)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Note: No measures of effect are specified when I<SUP>2</SUP> was &gt; 75% 
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NS: non-significant<BR/>RR: risk ratio<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-03-31 10:31:32 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-03-31 10:21:44 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Phlebotonics versus placebo</NAME>
<DICH_OUTCOME CHI2="14.974427456271263" CI_END="0.7793532934410896" CI_START="0.6323454798172101" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7020117750352403" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="356" I2="19.86338018570171" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10826562498496604" LOG_CI_START="-0.19904558155331242" LOG_EFFECT_SIZE="-0.1536556032691392" METHOD="MH" MODIFIED="2014-11-25 08:04:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2428380286267775" P_Q="0.7413299671249906" P_Z="3.2465075956476367E-11" Q="1.9697118035929548" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="626" TOTAL_2="619" WEIGHT="99.99999999999999" Z="6.634932639641679">
<NAME>Oedema in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9898150624110164" CI_START="0.2798586531655355" DF="0" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" NO="1" P_CHI2="1.0" P_Z="0.046400600556080585" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="5.308569013917888" Z="1.9917308171456887">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9898150624110164" CI_START="0.2798586531655355" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="1" O_E="0.0" SE="0.3222593538479378" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="41" TOTAL_2="41" VAR="0.10385109114249039" WEIGHT="5.308569013917888"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.899456770961606" CI_END="1.0729272529886107" CI_START="0.47904989932324116" DF="1" EFFECT_SIZE="0.7169279549057601" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" I2="87.34090167217575" ID="CMP-001.01.02" LOG_CI_END="0.030570276768692478" LOG_CI_START="-0.31961924676907805" LOG_EFFECT_SIZE="-0.1445244850001928" NO="2" P_CHI2="0.004944983495852484" P_Z="0.10571250299104047" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="142" WEIGHT="12.201111859114107" Z="1.6177684736135471">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5227592596510281" CI_START="0.03903931472955589" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.28169826577049156" LOG_CI_START="-1.4084978142580222" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="2" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="3.911577168150022"/>
<DICH_DATA CI_END="1.5472751585524283" CI_START="0.6306423336104108" EFFECT_SIZE="0.9878143634949442" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.18956755301077963" LOG_CI_START="-0.20021687939162486" LOG_EFFECT_SIZE="-0.005324663190422592" ORDER="3" O_E="0.0" SE="0.22896130505723078" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.052423279213510296" WEIGHT="8.289534690964086"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.362592785530452" CI_END="0.855954061197527" CI_START="0.4577856440635609" DF="1" EFFECT_SIZE="0.625974025974026" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="43" I2="70.2610436713273" ID="CMP-001.01.03" LOG_CI_END="-0.06754954315437829" LOG_CI_START="-0.33933783071288626" LOG_EFFECT_SIZE="-0.2034436869336323" NO="3" P_CHI2="0.06669306889397486" P_Z="0.0033439515235160924" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="12.655102602838308" Z="2.9342125288318313">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0813372457404962" CI_START="0.6032963966376529" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.03396116215154717" LOG_CI_START="-0.21946926862534452" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="4" O_E="0.0" SE="0.14886628953921083" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.022161172161172152" WEIGHT="4.273151528231117"/>
<DICH_DATA CI_END="0.8601540175978909" CI_START="0.33069013063357905" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.06542377782153407" LOG_CI_START="-0.4805787663059413" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="5" O_E="0.0" SE="0.24386409528607725" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.05946969696969696" WEIGHT="8.38195107460719"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.058592434326117" CI_START="0.5831771688114353" DF="0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" NO="4" P_CHI2="1.0" P_Z="0.11283151328821682" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="8.344697958720047" Z="1.5855936691338377">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.058592434326117" CI_START="0.5831771688114353" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="6" O_E="0.0" SE="0.15209574906326898" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.023133116883116887" WEIGHT="8.344697958720047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1033506685280776" CI_END="0.8096427177170211" CI_START="0.6376353721819942" DF="6" EFFECT_SIZE="0.7185101499950672" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="219" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-0.09170658600408031" LOG_CI_START="-0.19542759889338873" LOG_EFFECT_SIZE="-0.14356709244873453" NO="5" P_CHI2="0.7957680577739613" P_Z="5.768560156314535E-8" STUDIES="7" TAU2="0.0" TOTAL_1="327" TOTAL_2="327" WEIGHT="61.49051856540963" Z="5.4258307497430405">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8442346751174894" CI_START="0.2961261925959252" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.07353681410660659" LOG_CI_START="-0.5285231772213558" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7" O_E="0.0" SE="0.2672612419124244" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.07142857142857142" WEIGHT="5.0291706447643145"/>
<DICH_DATA CI_END="0.9897781719413176" CI_START="0.5595323149391918" EFFECT_SIZE="0.7441860465116279" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="-0.004462128126364944" LOG_CI_START="-0.25217482639299615" LOG_EFFECT_SIZE="-0.12831847725968057" ORDER="8" O_E="0.0" SE="0.14550766515945146" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021172480620155042" WEIGHT="12.01412987360364"/>
<DICH_DATA CI_END="0.8916358832044371" CI_START="0.6245627925209027" EFFECT_SIZE="0.7462456680785522" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" LOG_CI_END="-0.0498124619907061" LOG_CI_START="-0.20442389183840623" LOG_EFFECT_SIZE="-0.12711817691455618" ORDER="9" O_E="0.0" SE="0.09081951923146003" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.008248185073433539" WEIGHT="13.953799320996714"/>
<DICH_DATA CI_END="0.9531541926384666" CI_START="0.5738270411692045" EFFECT_SIZE="0.7395577395577395" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" LOG_CI_END="-0.02083683745690134" LOG_CI_START="-0.24121898980585213" LOG_EFFECT_SIZE="-0.1310279136313767" ORDER="10" O_E="0.0" SE="0.12945356719902176" STUDY_ID="STD-Ihme-1996" TOTAL_1="44" TOTAL_2="43" VAR="0.01675822606055164" WEIGHT="10.456564252460158"/>
<DICH_DATA CI_END="0.9272106717283771" CI_START="0.43674937102598566" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="-0.03282157850469006" LOG_CI_START="-0.3597677117832464" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="11" O_E="0.0" SE="0.19204977709728507" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="0.036883116883116886" WEIGHT="6.146764121378607"/>
<DICH_DATA CI_END="1.089957868614159" CI_START="0.5953622353417175" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.03740971098464494" LOG_CI_START="-0.22521871672130728" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="12" O_E="0.0" SE="0.15426923846616009" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.023798997936928967" WEIGHT="10.058341289528629"/>
<DICH_DATA CI_END="1.4497884349945172" CI_START="0.3093013748065556" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16130463105002965" LOG_CI_START="-0.5096181496069929" LOG_EFFECT_SIZE="-0.1741567592784816" ORDER="13" O_E="0.0" SE="0.39410336247926164" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.1553174603174603" WEIGHT="3.8317490626775728"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="26.631981695902063" CI_END="-2.928112016277743" CI_START="-5.610960427065838" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.269536221671791" ESTIMABLE="YES" I2="47.431625029412594" I2_Q="74.7092557436769" ID="CMP-001.02" MODIFIED="2015-12-19 22:26:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.021486385531907404" P_Q="0.019177578841441445" P_Z="4.424979892897246E-10" Q="7.90803141153099" RANDOM="NO" SCALE="68.57" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1001" TOTAL_2="1009" UNITS="" WEIGHT="100.0" Z="6.238248267413488">
<NAME>Ankle perimeter circumference (mm)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.945952271176779" CI_END="1.4662209350222197" CI_START="-4.84272431360038" DF="4" EFFECT_SIZE="-1.68825168928908" ESTIMABLE="YES" I2="55.287040677740755" ID="CMP-001.02.01" MODIFIED="2013-12-29 06:37:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.062464767195798965" P_Z="0.2941969956959327" STUDIES="5" TAU2="0.0" TOTAL_1="554" TOTAL_2="568" WEIGHT="18.083344328681253" Z="1.048959018488208">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.7960630376235365" CI_START="-41.99606303762347" EFFECT_SIZE="-20.599999999999966" ESTIMABLE="YES" MEAN_1="335.6" MEAN_2="356.2" ORDER="14" SD_1="38.2" SD_2="38.2" SE="10.916559287003698" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.3930651499021087"/>
<CONT_DATA CI_END="6.487842096264158" CI_START="-4.087842096264181" EFFECT_SIZE="1.1999999999999886" ESTIMABLE="YES" MEAN_1="229.5" MEAN_2="228.3" MODIFIED="2013-12-29 06:37:25 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="22.7" SD_2="19.6" SE="2.6979281956066505" STUDY_ID="STD-Labs-2004" TOTAL_1="124" TOTAL_2="123" WEIGHT="6.435396672423271"/>
<CONT_DATA CI_END="-2.301974796401309" CI_START="-21.4980252035987" EFFECT_SIZE="-11.900000000000006" ESTIMABLE="YES" MEAN_1="254.9" MEAN_2="266.8" MODIFIED="2011-01-26 10:20:00 +0000" MODIFIED_BY="[Empty name]" ORDER="934" SD_1="43.2" SD_2="53.9" SE="4.897041618778046" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="193" TOTAL_2="203" WEIGHT="1.9532980000947162"/>
<CONT_DATA CI_END="5.844837594293494" CI_START="-5.4448375942934595" EFFECT_SIZE="0.20000000000001705" ESTIMABLE="YES" MEAN_1="240.9" MEAN_2="240.7" MODIFIED="2013-12-29 06:35:30 +0000" MODIFIED_BY="[Empty name]" ORDER="948" SD_1="21.3" SD_2="21.8" SE="2.8800721027627216" STUDY_ID="STD-Rabe-2011" TOTAL_1="109" TOTAL_2="115" WEIGHT="5.647150660452076"/>
<CONT_DATA CI_END="4.817074484380218" CI_START="-9.217074484380252" EFFECT_SIZE="-2.200000000000017" ESTIMABLE="YES" MEAN_1="230.1" MEAN_2="232.3" ORDER="16" SD_1="21.31" SD_2="29.43" SE="3.5802058301734228" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="3.6544338458090793"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.30722696689729584" CI_END="-4.1792858820031835" CI_START="-7.783338744388352" DF="2" EFFECT_SIZE="-5.981312313195768" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2014-08-27 09:44:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8576034508816595" P_Z="7.74142989994743E-11" STUDIES="3" TAU2="0.0" TOTAL_1="144" TOTAL_2="142" WEIGHT="55.41278322245464" Z="6.5055409350412585">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-4.0519220810061265" CI_START="-7.748077918993872" EFFECT_SIZE="-5.8999999999999995" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.2" MODIFIED="2013-12-29 06:39:00 +0000" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="6.97" SD_2="4.3" SE="0.9429142237159843" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="52.68557464629997"/>
<CONT_DATA CI_END="6.5631280465892505" CI_START="-17.963128046589283" EFFECT_SIZE="-5.700000000000017" ESTIMABLE="YES" MEAN_1="229.1" MEAN_2="234.8" MODIFIED="2014-08-27 09:44:14 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="30.3" SD_2="31.0" SE="6.256812953359988" STUDY_ID="STD-Planchon-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="1.1965469701957654"/>
<CONT_DATA CI_END="1.8424279365966747" CI_START="-19.842427936596675" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="239.1" MEAN_2="248.1" MODIFIED="2014-08-27 09:44:35 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="20.6" SD_2="13.7" SE="5.531952638987431" STUDY_ID="STD-Tsouderos-1989" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.5306616059589089"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.470771046297005" CI_END="0.1537835539687138" CI_START="-5.057461164457367" DF="6" EFFECT_SIZE="-2.4518388052443267" ESTIMABLE="YES" I2="36.647185633888256" ID="CMP-001.02.03" MODIFIED="2013-12-29 06:39:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14878178130708797" P_Z="0.0651413077116476" STUDIES="7" TAU2="0.0" TOTAL_1="303" TOTAL_2="299" WEIGHT="26.5038724488641" Z="1.8442871190389907">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="3.891260641035477" CI_START="-11.891260641035476" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="221.0" MEAN_2="225.0" ORDER="20" SD_1="22.0" SD_2="19.0" SE="4.026227371156171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="2.8896117960050742"/>
<CONT_DATA CI_END="10.395283346346224" CI_START="-5.99528334634619" EFFECT_SIZE="2.200000000000017" ESTIMABLE="YES" MEAN_1="226.8" MEAN_2="224.6" ORDER="21" SD_1="16.4" SD_2="14.0" SE="4.181343846616344" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="33" TOTAL_2="21" WEIGHT="2.6791950382692007"/>
<CONT_DATA CI_END="8.114108504524607" CI_START="-10.114108504524607" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="236.0" MEAN_2="237.0" ORDER="22" SD_1="22.0" SD_2="20.0" SE="4.650140806879887" STUDY_ID="STD-Jongste-1989" TOTAL_1="40" TOTAL_2="42" WEIGHT="2.166226619078414"/>
<CONT_DATA CI_END="26.334813927350318" CI_START="-8.334813927350318" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="258.0" MEAN_2="249.0" ORDER="23" SD_1="40.0" SD_2="42.0" SE="8.844455339019042" STUDY_ID="STD-MacLennan-1994" TOTAL_1="41" TOTAL_2="45" WEIGHT="0.5988167072994071"/>
<CONT_DATA CI_END="-9.197870941782313" CI_START="-58.80212905821769" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="243.0" ORDER="24" SD_1="50.0" SD_2="48.0" SE="12.654380005884656" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.2925191827416165"/>
<CONT_DATA CI_END="0.5214018041077106" CI_START="-6.321401804107712" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-0.8" MODIFIED="2013-12-29 06:39:01 +0000" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="7.2" SD_2="7.3" SE="1.7456452420020427" STUDY_ID="STD-Vin-1994" TOTAL_1="34" TOTAL_2="35" WEIGHT="15.37177848186987"/>
<CONT_DATA CI_END="5.274214804913063" CI_START="-11.67421480491304" EFFECT_SIZE="-3.1999999999999886" ESTIMABLE="YES" MEAN_1="232.5" MEAN_2="235.7" ORDER="26" SD_1="27.4" SD_2="24.9" SE="4.32365843033677" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" WEIGHT="2.50572462360052"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.009638960316225" CI_END="-0.2527761420878134" CI_START="-0.4987560114004943" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.37576607674415385" ESTIMABLE="YES" I2="11.206208869892258" I2_Q="39.74791589752199" ID="CMP-001.03" MODIFIED="2015-12-19 22:27:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34148354490553257" P_Q="0.19019744102660519" P_Z="2.1217976784857754E-9" Q="3.319387254054744" RANDOM="NO" SCALE="2.01" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="512" TOTAL_2="529" UNITS="" WEIGHT="100.0" Z="5.988197156851547">
<NAME>Volume of the leg (mL)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27623133159938895" CI_START="-0.6109215354600945" DF="0" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45965052058283484" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="7.6878023986948705" Z="0.7394224489400971">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="0.27623133159938895" CI_START="-0.6109215354600945" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" MEAN_1="3276.5" MEAN_2="3391.5" MODIFIED="2015-09-09 17:56:21 +0100" MODIFIED_BY="[Empty name]" ORDER="2474" SD_1="584.6" SD_2="751.1" SE="0.2263186655615185" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="7.6878023986948705"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2642349077041737" CI_END="-0.31350404210868443" CI_START="-0.6794514248091101" DF="2" EFFECT_SIZE="-0.4964777334588973" ESTIMABLE="YES" I2="11.669942319372476" ID="CMP-001.03.02" MODIFIED="2015-09-09 17:54:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32235031420408045" P_Z="1.0483726732177644E-7" STUDIES="3" TAU2="0.0" TOTAL_1="238" TOTAL_2="237" WEIGHT="45.181624525163244" Z="5.318133276565082">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-0.29058032887513097" CI_START="-1.8337557124459654" EFFECT_SIZE="-1.0621680206605482" ESTIMABLE="YES" MEAN_1="1097.0" MEAN_2="1205.0" ORDER="27" SD_1="92.95" SD_2="104.57" SE="0.39367442354635207" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.5407887573114554"/>
<CONT_DATA CI_END="-0.23013895092543318" CI_START="-0.7448632504722297" EFFECT_SIZE="-0.4875011006988314" ESTIMABLE="YES" MEAN_1="-64.72" MEAN_2="0.76" MODIFIED="2013-12-29 15:06:52 +0000" MODIFIED_BY="[Empty name]" ORDER="976" SD_1="111.9" SD_2="152.9" SE="0.13130963211744603" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="22.83756467734085"/>
<CONT_DATA CI_END="-0.15787439319036783" CI_START="-0.7106273827218053" EFFECT_SIZE="-0.4342508879560865" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-1.15" ORDER="28" SD_1="6.08" SD_2="6.08" SE="0.14101100680713585" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="19.80327109051094"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.426016798557308" CI_END="-0.11489254978967217" CI_START="-0.47319370317196324" DF="4" EFFECT_SIZE="-0.2940431264808177" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" MODIFIED="2015-09-09 17:54:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4892167164671355" P_Z="0.0012957254426142761" STUDIES="5" TAU2="0.0" TOTAL_1="238" TOTAL_2="249" WEIGHT="47.13057307614188" Z="3.216924826301398">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.06339385236707562" CI_START="-1.21424466831304" EFFECT_SIZE="-0.6388192603400578" ESTIMABLE="YES" MEAN_1="1098.0" MEAN_2="1200.0" ORDER="29" SD_1="157.74" SD_2="156.5" SE="0.2935897866041745" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" WEIGHT="4.568367917654836"/>
<CONT_DATA CI_END="0.1902409432135067" CI_START="-0.5919359804828254" EFFECT_SIZE="-0.20084751863465933" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-4.4" ORDER="30" SD_1="43.4" SD_2="29.2" SE="0.19953859608289842" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="51" TOTAL_2="50" WEIGHT="9.889837026143041"/>
<CONT_DATA CI_END="0.4195584060852926" CI_START="-0.47459950667794526" EFFECT_SIZE="-0.02752055029632632" ESTIMABLE="YES" MEAN_1="2073.0" MEAN_2="2082.0" ORDER="31" SD_1="309.0" SD_2="339.0" SE="0.22810569985373236" STUDY_ID="STD-Ihme-1996" TOTAL_1="40" TOTAL_2="37" WEIGHT="7.567818095698648"/>
<CONT_DATA CI_END="0.18807153574891566" CI_START="-0.6898764827904679" EFFECT_SIZE="-0.2509024735207761" ESTIMABLE="YES" MEAN_1="1992.0" MEAN_2="2111.0" ORDER="32" SD_1="367.0" SD_2="541.0" SE="0.2239704467695645" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="7.849853051465748"/>
<CONT_DATA CI_END="-0.09661376983931858" CI_START="-0.6887830829154231" EFFECT_SIZE="-0.39269842637737085" ESTIMABLE="YES" MEAN_1="-95.7" MEAN_2="-44.6" MODIFIED="2014-08-27 11:52:36 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="127.9" SD_2="131.1" SE="0.15106637615462848" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="86" TOTAL_2="93" WEIGHT="17.254696985179606"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.276556024629766" CI_END="1.1287221257545637" CI_START="0.7898780253740367" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9442207389625584" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="88" I2="5.241222178611679" I2_Q="33.00621787254627" ID="CMP-001.04" LOG_CI_END="0.0525870383776369" LOG_CI_START="-0.1024399681992692" LOG_EFFECT_SIZE="-0.024926464910816157" METHOD="MH" MODIFIED="2015-09-16 09:36:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3830694529048734" P_Q="0.21425886557940688" P_Z="0.5285134127437302" Q="4.47802751946828" RANDOM="YES" SCALE="63.625775799451304" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0037487251435078394" TOTALS="YES" TOTAL_1="230" TOTAL_2="231" WEIGHT="100.00000000000001" Z="0.6302769377523265">
<NAME>Ulcer cured</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1804728481415974" CI_START="0.17686049429055115" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 08:30:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6963273006688617" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="1.5157844738681863" Z="0.3902829903211535">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="3.1804728481415974" CI_START="0.17686049429055115" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 08:30:14 +0100" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="0.7371114795831993" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.5433333333333332" WEIGHT="1.5157844738681863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7371714309336728" CI_START="0.6864574861706699" DF="0" EFFECT_SIZE="1.0920138888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2398426784556285" LOG_CI_START="-0.16338635441151475" LOG_EFFECT_SIZE="0.03822816202205686" MODIFIED="2015-09-15 22:46:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7101690225000545" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="37" WEIGHT="13.855432584899395" Z="0.3716290973675006">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.7371714309336725" CI_START="0.6864574861706699" EFFECT_SIZE="1.0920138888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.23984267845562846" LOG_CI_START="-0.16338635441151475" LOG_EFFECT_SIZE="0.03822816202205686" MODIFIED="2015-01-02 18:33:50 +0000" MODIFIED_BY="[Empty name]" ORDER="943" O_E="0.0" SE="0.23685872992206394" STUDY_ID="STD-DOBESILATO500_x002f_2" TOTAL_1="32" TOTAL_2="37" VAR="0.05610205794029323" WEIGHT="13.855432584899395"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.279678661798027" CI_END="1.00809804912623" CI_START="0.6919135911475826" DF="1" EFFECT_SIZE="0.8351746771782546" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.003502774295623488" LOG_CI_START="-0.1599481385359396" LOG_EFFECT_SIZE="-0.07822268212015808" MODIFIED="2015-09-16 09:36:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5969119722376913" P_Z="0.06066085248988932" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="64" WEIGHT="64.25201725412097" Z="1.875959418931181">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="14.676521957113154" CI_START="0.15330607664232812" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1666231486455823" LOG_CI_START="-0.8144406305342196" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-09-16 08:28:37 +0100" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.1636866703140785" STUDY_ID="STD-Fermoso-1992" TOTAL_1="16" TOTAL_2="12" VAR="1.3541666666666667" WEIGHT="0.6106849478048825"/>
<DICH_DATA CI_END="1.0047067054943812" CI_START="0.6886985965557255" EFFECT_SIZE="0.8318293683347006" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" LOG_CI_END="0.002039300785945326" LOG_CI_START="-0.16197080202807482" LOG_EFFECT_SIZE="-0.07996575062106476" ORDER="34" O_E="0.0" SE="0.0963403462560579" STUDY_ID="STD-Guilhou-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.00928146231673713" WEIGHT="63.64133230631609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11365033071428013" CI_END="1.8645552876370974" CI_START="0.8738153197123735" DF="1" EFFECT_SIZE="1.2764313435465329" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.27057526555182726" LOG_CI_START="-0.05858034551770081" LOG_EFFECT_SIZE="0.10599746001706326" MODIFIED="2015-09-16 08:33:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.73602599872443" P_Z="0.20683074035837334" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="80" WEIGHT="20.376765687111455" Z="1.2623281943219538">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="4.727779042593254" CI_START="0.21151580710326212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6746571711674341" LOG_CI_START="-0.6746571711674341" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-16 08:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.792593923901217" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.6282051282051281" WEIGHT="1.3122136779084692"/>
<DICH_DATA CI_END="1.9160592312884113" CI_START="0.877000074085162" EFFECT_SIZE="1.2962962962962963" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.28240893032922065" LOG_CI_START="-0.05700036994664398" LOG_EFFECT_SIZE="0.11270428019128832" ORDER="35" O_E="0.0" SE="0.19937070308517563" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993" TOTAL_1="27" TOTAL_2="28" VAR="0.039748677248677255" WEIGHT="19.064552009202984"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2504169183636797" CI_END="0.9495827877473972" CI_START="0.8060448886183248" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8748750495834986" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="267" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.0224671660564919" LOG_CI_START="-0.09364077167332872" LOG_EFFECT_SIZE="-0.05805396886491032" METHOD="MH" MODIFIED="2014-12-01 15:02:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.939950086519207" P_Q="0.7978444679912317" P_Z="0.0013869349634246652" Q="0.4516835863982088" RANDOM="NO" SCALE="47.5953890741738" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="350" WEIGHT="100.0" Z="3.1973562993952687">
<NAME>Trophic disorders (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.178481230360658E-31" CI_END="1.4431129148255155" CI_START="0.4061924985931362" DF="0" EFFECT_SIZE="0.7656249999999999" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="100.0" ID="CMP-001.05.01" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537358" NO="1" P_CHI2="0.0" P_Z="0.40892878096210405" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="5.918739729132431" Z="0.8257802261198307">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="1.4431129148255155" CI_START="0.4061924985931362" EFFECT_SIZE="0.765625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537351" ORDER="36" O_E="0.0" SE="0.3234066120763363" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10459183673469387" WEIGHT="5.918739729132431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8533794788973021" CI_END="0.9431456591579286" CI_START="0.80599632187032" DF="3" EFFECT_SIZE="0.8718783930510314" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="216" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.025421229761688955" LOG_CI_START="-0.09366694007464701" LOG_EFFECT_SIZE="-0.05954408491816801" NO="2" P_CHI2="0.8366613631160584" P_Z="6.259350055939437E-4" STUDIES="4" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="80.99914999716665" Z="3.4201200748538434">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="3.045766512884973" CI_START="0.36197784542443584" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.4836966074529867" LOG_CI_START="-0.4413180093131106" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="37" O_E="0.0" SE="0.5433581647846061" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2952380952380952" WEIGHT="1.7589391964639884"/>
<DICH_DATA CI_END="0.9720706154589744" CI_START="0.7758233945767989" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="76" LOG_CI_END="-0.012302184878028533" LOG_CI_START="-0.11023712859981677" LOG_EFFECT_SIZE="-0.06126965673892266" ORDER="38" O_E="0.0" SE="0.05752747072796835" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.003309409888357255" WEIGHT="28.406868022893413"/>
<DICH_DATA CI_END="0.978849596085834" CI_START="0.8198576822426757" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="-0.009284034047752895" LOG_CI_START="-0.08626152954424844" LOG_EFFECT_SIZE="-0.047772781796000675" ORDER="39" O_E="0.0" SE="0.04521696189938959" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.00204457364341085" WEIGHT="35.88235960786536"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="40" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="14.950983169943902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2475566849424438" CI_START="0.71257651260772" DF="0" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.09606028768093586" LOG_CI_START="-0.1471684966257122" LOG_EFFECT_SIZE="-0.025554104472388168" NO="3" P_CHI2="1.0" P_Z="0.6804599978372128" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="13.082110273700913" Z="0.4118355034814503">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.2475566849424438" CI_START="0.71257651260772" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.09606028768093586" LOG_CI_START="-0.1471684966257122" LOG_EFFECT_SIZE="-0.025554104472388168" ORDER="41" O_E="0.0" SE="0.14287379190362523" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.020412920412920407" WEIGHT="13.082110273700913"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="87.72897447821131" CI_END="0.7849752779804552" CI_START="0.57261235664238" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6704375763860464" ESTIMABLE="YES" EVENTS_1="473" EVENTS_2="600" I2="78.34238903052616" I2_Q="33.89853427954664" ID="CMP-001.06" LOG_CI_END="-0.1051440207142862" LOG_CI_START="-0.24213928439039306" LOG_EFFECT_SIZE="-0.17364165255233963" METHOD="MH" MODIFIED="2015-07-27 14:27:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="8.356670910814046E-11" P_Q="0.19534969074290764" P_Z="6.746822220167547E-7" Q="6.051303033001135" RANDOM="YES" SCALE="607.16" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12962991396554888" TOTALS="SUB" TOTAL_1="1294" TOTAL_2="953" WEIGHT="500.0" Z="4.968513160035035">
<NAME>Pain in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Favours phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7915690026239909" CI_START="0.2285590502564194" DF="0" EFFECT_SIZE="0.42534722222222227" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586795" NO="1" P_CHI2="1.0" P_Z="0.006985329843852194" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.00000000000001" Z="2.69754282917697">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.7915690026239909" CI_START="0.2285590502564194" EFFECT_SIZE="0.4253472222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586796" ORDER="42" O_E="0.0" SE="0.31689930588126447" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10042517006802722" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.014391818999428" CI_END="0.9320047135667524" CI_START="0.16373951790175087" DF="3" EFFECT_SIZE="0.39064818248851413" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="121" I2="86.96467834738365" ID="CMP-001.06.02" LOG_CI_END="-0.03058189121806354" LOG_CI_START="-0.7858464926377848" LOG_EFFECT_SIZE="-0.40821419192792424" NO="2" P_CHI2="4.0105347186680795E-5" P_Z="0.03411682294007755" STUDIES="4" TAU2="0.6444098217543911" TOTAL_1="179" TOTAL_2="175" WEIGHT="100.0" Z="2.118688238937399">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5949206861209944" CI_START="0.07718401531191658" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.22554092986137214" LOG_CI_START="-1.1124726320557794" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="43" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.27142857142857146" WEIGHT="21.490900755262874"/>
<DICH_DATA CI_END="0.3646049822641113" CI_START="0.051750510994256024" EFFECT_SIZE="0.13736263736263737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.43817740108140707" LOG_CI_START="-1.2860853575446674" LOG_EFFECT_SIZE="-0.8621313793130372" ORDER="44" O_E="0.0" SE="0.49806533083859533" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="0.24806907378335943" WEIGHT="22.05339769283311"/>
<DICH_DATA CI_END="1.107432316188807" CI_START="0.3250763001380784" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0443171925890425" LOG_CI_START="-0.4880146918217552" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="45" O_E="0.0" SE="0.3126943839882286" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09777777777777774" WEIGHT="26.519160422729993"/>
<DICH_DATA CI_END="1.1105908283879482" CI_START="0.70965574979841" EFFECT_SIZE="0.8877708978328174" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="68" LOG_CI_END="0.04555408260948905" LOG_CI_START="-0.14895227412508424" LOG_EFFECT_SIZE="-0.05169909575779759" ORDER="46" O_E="0.0" SE="0.1142539967678824" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01305397577743528" WEIGHT="29.936541129174035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.90550379500584" CI_END="1.0760407124196056" CI_START="0.6308566465725802" DF="3" EFFECT_SIZE="0.8239098466535053" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="88" I2="49.199931045052644" ID="CMP-001.06.03" LOG_CI_END="0.03182870334216246" LOG_CI_START="-0.200069316945316" LOG_EFFECT_SIZE="-0.08412030680157676" MODIFIED="2014-03-22 11:18:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11629951783100911" P_Z="0.15504307834592618" STUDIES="4" TAU2="0.034293085865943054" TOTAL_1="140" TOTAL_2="131" WEIGHT="99.99999999999999" Z="1.4219420372382767">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.3845753025980523" CI_START="0.7811781691977737" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.14131658060414426" LOG_CI_START="-0.10724990200658352" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="48" O_E="0.0" SE="0.1460091823094744" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.021318681318681334" WEIGHT="33.36588051653022"/>
<DICH_DATA CI_END="1.1243680173221975" CI_START="0.659122633248303" EFFECT_SIZE="0.8608695652173913" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.05090848359314629" LOG_CI_START="-0.1810337751052698" LOG_EFFECT_SIZE="-0.06506264575606176" ORDER="49" O_E="0.0" SE="0.13624403089214698" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.018562435953740304" WEIGHT="35.1058038084542"/>
<DICH_DATA CI_END="1.7255701519985482" CI_START="0.2839641143725649" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.23693261996280243" LOG_CI_START="-0.5467365399342888" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="50" O_E="0.0" SE="0.46033114374845624" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2119047619047619" WEIGHT="7.536766044045263"/>
<DICH_DATA CI_END="0.8834027356612968" CI_START="0.3916908418748" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="34" LOG_CI_END="-0.05384126018203567" LOG_CI_START="-0.40705658257451216" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="51" O_E="0.0" SE="0.20748042881738504" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.043048128342245986" WEIGHT="23.99154963097031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.912082885603881" CI_START="0.47547261450716666" DF="0" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" MODIFIED="2014-03-22 11:18:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.011946501269335262" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.513720672049408">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="0.912082885603881" CI_START="0.47547261450716666" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" ORDER="47" O_E="0.0" SE="0.1661820286338354" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.027616466640856888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="44.53268383993733" CI_END="0.8308846070367559" CI_START="0.47537617679808336" DF="9" EFFECT_SIZE="0.6284765292781512" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="347" I2="79.79012441210939" ID="CMP-001.06.05" LOG_CI_END="-0.0804592866935909" LOG_CI_START="-0.32296258647905934" LOG_EFFECT_SIZE="-0.20171093658632513" NO="5" P_CHI2="1.1256572514106722E-6" P_Z="0.001111992579033493" STUDIES="10" TAU2="0.138901894394023" TOTAL_1="907" TOTAL_2="578" WEIGHT="100.00000000000001" Z="3.2605426099090993">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.5216372682006785" CI_START="0.05325113727704636" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2826313881432527" LOG_CI_START="-1.2736711126240345" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="52" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.3388888888888888" WEIGHT="4.246906906222907"/>
<DICH_DATA CI_END="0.8383828698307714" CI_START="0.2283041041125227" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.07655760394571752" LOG_CI_START="-0.6414862813376184" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="53" O_E="0.0" SE="0.33184190154205606" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.11011904761904762" WEIGHT="8.148443102216458"/>
<DICH_DATA CI_END="1.134445340981303" CI_START="0.5558864888322862" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.05478357586479491" LOG_CI_START="-0.2550138816313306" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="54" O_E="0.0" SE="0.18197656005537105" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.03311546840958607" WEIGHT="11.796093976690573"/>
<DICH_DATA CI_END="1.2464351528371953" CI_START="0.6558182990958795" EFFECT_SIZE="0.904121110176619" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.09566968877837234" LOG_CI_START="-0.18321646951250722" LOG_EFFECT_SIZE="-0.04377339036706745" ORDER="55" O_E="0.0" SE="0.16381910988881074" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02683670076476225" WEIGHT="12.242971984345871"/>
<DICH_DATA CI_END="0.8225193613399201" CI_START="0.3383439819545119" EFFECT_SIZE="0.527536231884058" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.08485387036993415" LOG_CI_START="-0.47064154380646456" LOG_EFFECT_SIZE="-0.27774770708819935" ORDER="56" O_E="0.0" SE="0.2266135890564004" STUDY_ID="STD-Kl_x00fc_ken-1971" TOTAL_1="30" TOTAL_2="28" VAR="0.051353718745023105" WEIGHT="10.665298877520538"/>
<DICH_DATA CI_END="1.2716280494144636" CI_START="0.08737705271779238" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1043600989624348" LOG_CI_START="-1.05860260840176" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="57" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="3.3507898324505185"/>
<DICH_DATA CI_END="1.6076614930719757" CI_START="0.7473919476306546" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.20619460960700486" LOG_CI_START="-0.12645158553162028" LOG_EFFECT_SIZE="0.03987151203769228" ORDER="58" O_E="0.0" SE="0.1953980216496508" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.038180386864597404" WEIGHT="11.458701360924959"/>
<DICH_DATA CI_END="0.5029818868098265" CI_START="0.34516374379253173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="104" LOG_CI_END="-0.29844765430825204" LOG_CI_START="-0.4619748291149599" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="59" O_E="0.0" SE="0.09605667195403049" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009226884226884228" WEIGHT="13.698438589349534"/>
<DICH_DATA CI_END="0.8655808361251482" CI_START="0.502901968655921" EFFECT_SIZE="0.6597744360902256" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="70" LOG_CI_END="-0.062692367368319" LOG_CI_START="-0.2985166642901292" LOG_EFFECT_SIZE="-0.1806045158292241" ORDER="60" O_E="0.0" SE="0.13852435936096785" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.01918899813636656" WEIGHT="12.835230067815532"/>
<DICH_DATA CI_END="1.2931623653008395" CI_START="0.6104395151211877" EFFECT_SIZE="0.8884803921568627" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.11165305692002613" LOG_CI_START="-0.21435736128576102" LOG_EFFECT_SIZE="-0.051352152182867476" ORDER="61" O_E="0.0" SE="0.19150013343167616" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.036672301104349776" WEIGHT="11.557125302463117"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="40.247817862114104" CI_END="-0.15200345417371547" CI_START="-0.49935373749264383" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.32567859583317965" ESTIMABLE="YES" I2="80.12314598667838" I2_Q="78.77219287383235" ID="CMP-001.07" MODIFIED="2015-03-09 13:14:48 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="2.8805319784996897E-6" P_Q="0.002730358470222072" P_Z="2.3751613580949089E-4" Q="14.132406527765568" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.14187084338637532" TOTALS="SUB" TOTAL_1="588" TOTAL_2="597" UNITS="" WEIGHT="400.0" Z="3.6753579831257586">
<NAME>Pain in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Favours phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.303288100640466" CI_END="0.12404236112117598" CI_START="-0.3499888809976044" DF="3" EFFECT_SIZE="-0.1129732599382142" ESTIMABLE="YES" I2="52.40579278463925" ID="CMP-001.07.01" MODIFIED="2015-01-02 18:35:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09775176196335955" P_Z="0.3501930711837262" STUDIES="4" TAU2="0.028684317383899042" TOTAL_1="379" TOTAL_2="397" WEIGHT="100.0" Z="0.9342148829907646">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.4597603348206055" CI_START="-0.6487549174038137" EFFECT_SIZE="-0.09449729129160413" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="11.1" MODIFIED="2015-01-02 18:35:52 +0000" MODIFIED_BY="[Empty name]" ORDER="944" SD_1="12.4" SD_2="19.0" SE="0.2827896994455628" STUDY_ID="STD-DOBESILATO500_x002f_2" TOTAL_1="21" TOTAL_2="31" WEIGHT="13.458935570170295"/>
<CONT_DATA CI_END="0.6062132055429024" CI_START="-0.3615412809659868" EFFECT_SIZE="0.12233596228845776" ESTIMABLE="YES" MEAN_1="33.4" MEAN_2="29.9" MODIFIED="2013-12-29 06:54:31 +0000" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="27.8" SD_2="28.8" SE="0.24688068100802185" STUDY_ID="STD-Marinello-2002" TOTAL_1="35" TOTAL_2="31" WEIGHT="16.314850572703595"/>
<CONT_DATA CI_END="0.1915932515611162" CI_START="-0.1915932515611162" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="37.8" MEAN_2="37.8" MODIFIED="2011-01-26 10:23:57 +0000" MODIFIED_BY="[Empty name]" ORDER="935" SD_1="25.8" SD_2="27.4" SE="0.09775345520243194" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="216" WEIGHT="38.241880985673234"/>
<CONT_DATA CI_END="-0.12002498033634995" CI_START="-0.6316796765336825" EFFECT_SIZE="-0.3758523284350162" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-0.92" MODIFIED="2014-08-27 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="26.2" SD_2="22.9" SE="0.13052655564928728" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="31.984332871452885"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02250226945542" CI_START="-0.6675528983586143" DF="0" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.03601936842423832" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.0967087165869946">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.02250226945542" CI_START="-0.6675528983586143" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.9" ORDER="63" SD_1="0.87" SD_2="0.86" SE="0.16455675563206043" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6923870569134023" CI_START="-2.088246271323353" DF="0" EFFECT_SIZE="-1.3903166641183777" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" MODIFIED="2014-03-22 11:18:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="9.447386050045113E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.9043630770883655">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.6923870569134023" CI_START="-2.088246271323353" EFFECT_SIZE="-1.3903166641183777" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="1.17" ORDER="64" SD_1="0.48" SD_2="0.34" SE="0.35609307758211634" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.824402309833114" CI_END="-0.18863540390384015" CI_START="-1.2303822263893753" DF="2" EFFECT_SIZE="-0.7095088151466078" ESTIMABLE="YES" I2="70.69340421038412" ID="CMP-001.07.04" MODIFIED="2014-03-22 11:18:27 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03296868299606015" P_Z="0.007590342973855331" STUDIES="3" TAU2="0.149417586195416" TOTAL_1="113" TOTAL_2="106" WEIGHT="100.0" Z="2.6697690732247894">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.702291280518464" CI_START="-1.5311239528967693" EFFECT_SIZE="-1.1167076167076166" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.8" ORDER="65" SD_1="0.8" SD_2="0.8" SE="0.2114407914931171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="36.38205168934716"/>
<CONT_DATA CI_END="0.31363504842545054" CI_START="-0.7512746498872284" EFFECT_SIZE="-0.2188198007308889" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.04" ORDER="66" SD_1="1.03" SD_2="1.14" SE="0.27166562924435106" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="30" TOTAL_2="25" WEIGHT="31.639927542402965"/>
<CONT_DATA CI_END="-0.2078591665203685" CI_START="-1.2556038045826323" EFFECT_SIZE="-0.7317314855515005" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.35" ORDER="67" SD_1="0.19" SD_2="0.56" SE="0.267286706880009" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="31.97802076824988"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="48.6993906814664" CI_END="0.8902483505034998" CI_START="0.5788424619631742" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7178534300009304" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="393" I2="73.30562083408688" I2_Q="22.561300834902386" ID="CMP-001.08" LOG_CI_END="-0.050488822335417925" LOG_CI_START="-0.23743961798165314" LOG_EFFECT_SIZE="-0.14396422015853555" METHOD="MH" MODIFIED="2015-03-27 15:33:05 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="4.975312763333406E-6" P_Q="0.27539165777713603" P_Z="0.002539469157282329" Q="3.8740320180276604" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09765125923494605" TOTALS="YES" TOTAL_1="1072" TOTAL_2="721" WEIGHT="100.00000000000003" Z="3.0185984028338866">
<NAME>Cramps in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Favours phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9944179280734241" CI_START="0.3117869045301575" DF="0" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" NO="1" P_CHI2="1.0" P_Z="0.04782921624123524" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="6.5117000632296795" Z="1.9788826843676004">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9944179280734241" CI_START="0.3117869045301575" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" ORDER="68" O_E="0.0" SE="0.29588237897725395" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.08754638218923934" WEIGHT="6.5117000632296795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6229518707645461" CI_END="0.8392082235326647" CI_START="0.4978939577924044" DF="1" EFFECT_SIZE="0.6464028958989984" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="75" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-0.07613026907407978" LOG_CI_START="-0.302863144086741" LOG_EFFECT_SIZE="-0.18949670658041035" NO="2" P_CHI2="0.42995267096033873" P_Z="0.0010522849380123908" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="16.449379391503477" Z="3.2761611660048735">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="69" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="6.369980484566372"/>
<DICH_DATA CI_END="0.8213434036775193" CI_START="0.4592535070488815" EFFECT_SIZE="0.6141700404858299" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="65" LOG_CI_END="-0.08547522638786782" LOG_CI_START="-0.3379475185580027" LOG_EFFECT_SIZE="-0.21171137247293528" ORDER="70" O_E="0.0" SE="0.14830347417873932" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.021993920453484" WEIGHT="10.079398906937104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26013183709740584" CI_END="0.9824327455155154" CI_START="0.7039077444604738" DF="2" EFFECT_SIZE="0.8315900540410143" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="78" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-0.007697170470325016" LOG_CI_START="-0.15248425662095003" LOG_EFFECT_SIZE="-0.08009071354563753" NO="3" P_CHI2="0.8780375560675879" P_Z="0.03013167313367989" STUDIES="3" TAU2="0.0" TOTAL_1="110" TOTAL_2="104" WEIGHT="24.279089467994048" Z="2.168355178890189">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0987179385457573" CI_START="0.6836250549483773" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.04088621521191639" LOG_CI_START="-0.1651820287096053" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="71" O_E="0.0" SE="0.12104550653376048" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.014652014652014652" WEIGHT="10.738346725187286"/>
<DICH_DATA CI_END="2.6910797608830856" CI_START="0.28450475943855263" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4299265700038317" LOG_CI_START="-0.5459104639592052" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="72" O_E="0.0" SE="0.5732115042211109" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3285714285714286" WEIGHT="2.829393009505157"/>
<DICH_DATA CI_END="1.0107411449882746" CI_START="0.6260237223167935" EFFECT_SIZE="0.7954545454545454" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="44" LOG_CI_END="0.004639945207715035" LOG_CI_START="-0.2034092094795386" LOG_EFFECT_SIZE="-0.09938463213591182" ORDER="73" O_E="0.0" SE="0.12220910332321787" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01493506493506494" WEIGHT="10.711349733301605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.92632519040919" CI_END="1.0241627264686997" CI_START="0.4734582316837537" DF="7" EFFECT_SIZE="0.6963463746084145" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="218" I2="81.54316305400936" ID="CMP-001.08.04" LOG_CI_END="0.010368966007721317" LOG_CI_START="-0.32471832827503033" LOG_EFFECT_SIZE="-0.15717468113365454" NO="4" P_CHI2="3.1294851413621316E-6" P_Z="0.06596440907562803" STUDIES="8" TAU2="0.1945578989941707" TOTAL_1="785" TOTAL_2="442" WEIGHT="52.759831077272814" Z="1.8386654436595093">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.9860104274367028" CI_START="0.0035093012367547953" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.00611849220455492" LOG_CI_START="-2.454779350551993" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="74" O_E="0.0" SE="1.43835550926002" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="2.0688665710186513" WEIGHT="0.5566312340160594"/>
<DICH_DATA CI_END="0.8613172651925229" CI_START="0.4316673002365558" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="41" LOG_CI_END="-0.06483684721934725" LOG_CI_START="-0.3648508488760486" LOG_EFFECT_SIZE="-0.2148438480476979" ORDER="75" O_E="0.0" SE="0.17622970966640583" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.031056910569105697" WEIGHT="9.369657693119429"/>
<DICH_DATA CI_END="1.3796221567587041" CI_START="0.7413452390106355" EFFECT_SIZE="1.0113240418118468" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.139760160529198" LOG_CI_START="-0.1299794971759597" LOG_EFFECT_SIZE="0.004890331676619154" ORDER="76" O_E="0.0" SE="0.15844641016884967" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02510526489539535" WEIGHT="9.823929945192898"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="77" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.5477744942342491"/>
<DICH_DATA CI_END="1.940929634757623" CI_START="0.7712361889198123" EFFECT_SIZE="1.2234848484848484" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.28800979103472396" LOG_CI_START="-0.11281260011218036" LOG_EFFECT_SIZE="0.0875985954612718" ORDER="78" O_E="0.0" SE="0.23544505666252696" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.05543437470682053" WEIGHT="7.87762680481564"/>
<DICH_DATA CI_END="0.5160706369098471" CI_START="0.3435291719387765" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="95" LOG_CI_END="-0.28729085046463954" LOG_CI_START="-0.4640363774571312" LOG_EFFECT_SIZE="-0.3756636139608854" ORDER="79" O_E="0.0" SE="0.10382119745985853" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.010778841041998936" WEIGHT="11.12192546434702"/>
<DICH_DATA CI_END="1.0256362635790959" CI_START="0.4745830580100198" EFFECT_SIZE="0.6976744186046512" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.010993367862993894" LOG_CI_START="-0.32368776958284207" LOG_EFFECT_SIZE="-0.15634720085992407" ORDER="80" O_E="0.0" SE="0.19659335683403326" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.03864894795127353" WEIGHT="8.847759796316591"/>
<DICH_DATA CI_END="2.092749239381821" CI_START="0.42850408931161393" EFFECT_SIZE="0.946969696969697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3207171927547774" LOG_CI_START="-0.3680450291503642" LOG_EFFECT_SIZE="-0.023663918197793433" ORDER="81" O_E="0.0" SE="0.4045823385750652" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.1636868686868687" WEIGHT="4.614525645230929"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="21.422747641631275" CI_END="-0.0701757760988462" CI_START="-0.39159322645537453" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23088450127711038" ESTIMABLE="YES" I2="85.99619409150843" I2_Q="70.58211265967168" ID="CMP-001.09" MODIFIED="2014-11-30 15:38:35 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="8.60008215779473E-5" P_Q="0.033397018947131096" P_Z="0.00486543641060323" Q="6.798584741529842" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1761044506088334" TOTALS="SUB" TOTAL_1="363" TOTAL_2="366" UNITS="" WEIGHT="300.0" Z="2.8158104458215965">
<NAME>Cramps in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.09248432803789162" CI_START="-0.2926569625203677" DF="0" EFFECT_SIZE="-0.10008631724123805" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2011-01-26 10:56:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3083605666503222" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="211" WEIGHT="100.0" Z="1.0186681197112695">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.09248432803789162" CI_START="-0.2926569625203677" EFFECT_SIZE="-0.10008631724123805" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="26.9" MODIFIED="2011-01-26 10:26:41 +0000" MODIFIED_BY="[Empty name]" ORDER="936" SD_1="27.1" SD_2="28.7" SE="0.09825213463007604" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="211" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1247995932872627E-31" CI_END="-0.13562938035194616" CI_START="-0.7844441767334328" DF="0" EFFECT_SIZE="-0.4600367785426895" ESTIMABLE="YES" I2="100.0" ID="CMP-001.09.02" MODIFIED="2014-03-22 11:18:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.005446066160000927" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.7793925864087403">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.1356293803519461" CI_START="-0.7844441767334327" EFFECT_SIZE="-0.46003677854268943" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.7" ORDER="82" SD_1="0.87" SD_2="0.86" SE="0.16551702008283187" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.076715053283268" CI_END="-0.1640351444890693" CI_START="-1.4972358265207695" DF="1" EFFECT_SIZE="-0.8306354855049194" ESTIMABLE="YES" I2="75.4704465009241" ID="CMP-001.09.03" MODIFIED="2014-03-22 11:18:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04347820538559566" P_Z="0.014595370668457959" STUDIES="2" TAU2="0.17504944329393862" TOTAL_1="83" TOTAL_2="81" WEIGHT="100.0" Z="2.4422664311716487">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.737539762590484" CI_START="-1.5702757682450441" EFFECT_SIZE="-1.153907765417764" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.6" ORDER="83" SD_1="0.7" SD_2="1.0" SE="0.21243655807532064" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="52.53630320068183"/>
<CONT_DATA CI_END="0.04075842663632262" CI_START="-0.9863864258951338" EFFECT_SIZE="-0.47281399962940557" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.19" ORDER="84" SD_1="0.19" SD_2="0.4" SE="0.2620315629862191" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="47.46369679931818"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.292211963012541" CI_END="0.9133694029655157" CI_START="0.7195952423879156" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8107134369903314" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="215" I2="17.720438867752076" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.03935354095083404" LOG_CI_START="-0.14291171665987373" LOG_EFFECT_SIZE="-0.0911326288053539" METHOD="MH" MODIFIED="2014-11-25 08:00:00 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.29466699879844827" P_Q="0.40771718195594386" P_Z="5.614366751042217E-4" Q="1.7943632554881739" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="329" TOTAL_2="323" WEIGHT="100.00000000000001" Z="3.449590900032811">
<NAME>Restless legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014524314160636997" CI_END="0.9067321847665462" CI_START="0.5885798978528514" DF="1" EFFECT_SIZE="0.7305370193835399" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="83" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.04252096856648605" LOG_CI_START="-0.23019457472139648" LOG_EFFECT_SIZE="-0.13635777164394125" NO="1" P_CHI2="0.9040737254021073" P_Z="0.00439815110243004" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="38.794716325152976" Z="2.848097043690437">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.0471514391769654" CI_START="0.48723046404220255" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.02000949394521839" LOG_CI_START="-0.3122655653016944" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="85" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0380952380952381" WEIGHT="6.471949815921612"/>
<DICH_DATA CI_END="0.9398281433130286" CI_START="0.5729230757694193" EFFECT_SIZE="0.7337909992372235" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="69" LOG_CI_END="-0.026951554096481766" LOG_CI_START="-0.2419036852080609" LOG_EFFECT_SIZE="-0.13442761965227135" ORDER="86" O_E="0.0" SE="0.12626394584515102" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01594258402038723" WEIGHT="32.322766509231364"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1470295339646062" CI_START="0.7007709655708828" DF="0" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.059574600353514244" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" MODIFIED="2014-02-25 15:18:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38500942450946507" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="13.40618176155191" Z="0.8687033375831925">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.1470295339646064" CI_START="0.7007709655708828" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.059574600353514334" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" ORDER="87" O_E="0.0" SE="0.12570377854054737" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.01580143993937098" WEIGHT="13.40618176155191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.29740418942822" CI_END="1.0062969951429677" CI_START="0.720872687890486" DF="3" EFFECT_SIZE="0.8517112302328944" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="103" I2="30.190415707693596" ID="CMP-001.10.03" LOG_CI_END="0.0027261758650494834" LOG_CI_START="-0.1421414285243635" LOG_EFFECT_SIZE="-0.06970762632965699" NO="3" P_CHI2="0.23108919394734628" P_Z="0.05926838167998257" STUDIES="4" TAU2="0.0" TOTAL_1="165" TOTAL_2="162" WEIGHT="47.79910191329513" Z="1.8861972299431267">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.756836446165568" CI_START="0.3810380238094276" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.24473133244919257" LOG_CI_START="-0.4190316838869928" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="88" O_E="0.0" SE="0.38989768147579695" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.15202020202020203" WEIGHT="5.085103426795552"/>
<DICH_DATA CI_END="0.9400697740764922" CI_START="0.5280292072025189" EFFECT_SIZE="0.7045454545454546" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="-0.026839910898372437" LOG_CI_START="-0.277342054405457" LOG_EFFECT_SIZE="-0.15209098265191473" ORDER="89" O_E="0.0" SE="0.1471461991016704" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021652003910068423" WEIGHT="20.340413707182208"/>
<DICH_DATA CI_END="1.1581867758840065" CI_START="0.8019457345949211" EFFECT_SIZE="0.963744232036915" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.06377860187399871" LOG_CI_START="-0.09585501820377643" LOG_EFFECT_SIZE="-0.016038208164888847" ORDER="90" O_E="0.0" SE="0.09376957863284864" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.008792733876981984" WEIGHT="16.697190256382797"/>
<DICH_DATA CI_END="1.767505877093551" CI_START="0.6593575747233957" EFFECT_SIZE="1.0795454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.247360866534032" LOG_CI_START="-0.18087900025667367" LOG_EFFECT_SIZE="0.03324093313867916" ORDER="91" O_E="0.0" SE="0.25155021757438917" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06327751196172252" WEIGHT="5.67639452293457"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.56668125263085" CI_END="1.0235109556345239" CI_START="0.41414655114365456" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6510633858033978" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="117" I2="91.79581001821388" I2_Q="31.958941470202245" ID="CMP-001.11" LOG_CI_END="0.010092495700190102" LOG_CI_START="-0.3828459509307137" LOG_EFFECT_SIZE="-0.18637672761526183" METHOD="MH" MODIFIED="2016-03-31 10:21:07 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="5.6827389349756174E-8" P_Q="0.22999433786651313" P_Z="0.06298718912216998" Q="2.939401654258692" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.44628794453778936" TOTALS="SUB" TOTAL_1="206" TOTAL_2="199" WEIGHT="300.0" Z="1.8592819145817603">
<NAME>Itching in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9101776359707308" CI_START="0.309592344001341" DF="0" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" NO="1" P_CHI2="1.0" P_Z="0.021330988620835198" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.3020741908173297">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9101776359707308" CI_START="0.309592344001341" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" ORDER="92" O_E="0.0" SE="0.2751028540826821" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.07568158032443749" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.248879154931936" CI_START="0.5082566580469068" DF="0" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" NO="2" P_CHI2="1.0" P_Z="0.4100989716659914" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.00000000000001" Z="0.8237194877511418">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="5.248879154931936" CI_START="0.5082566580469068" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" ORDER="93" O_E="0.0" SE="0.5956189257922424" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3547619047619047" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.645066156008205" CI_END="2.211282659580293" CI_START="0.20696351391226026" DF="1" EFFECT_SIZE="0.6765019064865861" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="89" I2="97.34360939663165" ID="CMP-001.11.03" LOG_CI_END="0.3446442602855613" LOG_CI_START="-0.6841062105973242" LOG_EFFECT_SIZE="-0.1697309751558815" NO="3" P_CHI2="8.486296110277181E-10" P_Z="0.5178007897206087" STUDIES="2" TAU2="0.711058010611193" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0" Z="0.6467391418657473">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.2460927890061566" CI_START="0.8423291969842424" EFFECT_SIZE="1.0245098039215685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.09555038281508714" LOG_CI_START="-0.07451814544477672" LOG_EFFECT_SIZE="0.010516118685155208" ORDER="94" O_E="0.0" SE="0.09989909535263612" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.009979829252275085" WEIGHT="50.645077619243956"/>
<DICH_DATA CI_END="0.6163595664241507" CI_START="0.3168008036596062" EFFECT_SIZE="0.4418859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="72" LOG_CI_END="-0.21016585901078652" LOG_CI_START="-0.4992137253638269" LOG_EFFECT_SIZE="-0.35468979218730673" ORDER="95" O_E="0.0" SE="0.1697881475057902" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.02882801503344797" WEIGHT="49.35492238075604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.608100903390151" CI_END="0.18640087983738726" CI_START="-0.17412687749684894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.006137001170269159" ESTIMABLE="YES" I2="82.16865179092105" I2_Q="82.16865179092105" ID="CMP-001.12" MODIFIED="2016-03-31 10:20:46 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0178777505841774" P_Q="0.0178777505841774" P_Z="0.9467997749281273" Q="5.608100903390151" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1826937448578777" TOTALS="SUB" TOTAL_1="234" TOTAL_2="242" UNITS="" WEIGHT="200.0" Z="0.06672607599340309">
<NAME>Itching in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27942681068696745" CI_START="-0.10520880392223587" DF="0" EFFECT_SIZE="0.08710900338236578" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2011-01-26 10:55:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37467420179797384" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="212" WEIGHT="100.0" Z="0.8877519547017505">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.27942681068696745" CI_START="-0.10520880392223587" EFFECT_SIZE="0.08710900338236578" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="31.3" MODIFIED="2011-01-26 10:30:16 +0000" MODIFIED_BY="[Empty name]" ORDER="937" SD_1="68.6" SD_2="30.4" SE="0.09812313329305027" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="212" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06242152989790051" CI_START="-1.0970469534983178" DF="0" EFFECT_SIZE="-0.5797342416981092" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2011-01-26 10:55:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.028058820194008544" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.196463006638366">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.062421529897900396" CI_START="-1.0970469534983178" EFFECT_SIZE="-0.579734241698109" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.42" ORDER="96" SD_1="0.36" SD_2="0.57" SE="0.26393990699865166" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="90.43941532463433" CI_END="0.8212397451304044" CI_START="0.6394358868926531" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7246586539736874" ESTIMABLE="YES" EVENTS_1="505" EVENTS_2="608" I2="80.09717341118517" I2_Q="71.8357387453729" ID="CMP-001.13" LOG_CI_END="-0.08553004045935826" LOG_CI_START="-0.19420299358498488" LOG_EFFECT_SIZE="-0.1398665170221716" METHOD="MH" MODIFIED="2015-03-27 15:37:33 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.2040368702059823E-11" P_Q="0.0032724559012685672" P_Z="4.53267737765416E-7" Q="17.752995382325352" RANDOM="YES" SCALE="397.9" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10146590923539485" TOTALS="SUB" TOTAL_1="1257" TOTAL_2="909" WEIGHT="600.0" Z="5.04510695848331">
<NAME>Heaviness in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5967167771289194" CI_START="0.168201730597713" DF="0" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" NO="1" P_CHI2="1.0" P_Z="3.732965903623685E-4" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.5582762523938705">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.5967167771289194" CI_START="0.168201730597713" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" ORDER="97" O_E="0.0" SE="0.32303617929445816" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10435237313316133" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.418240827894476" CI_END="1.4176733751822248" CI_START="0.07691894388050584" DF="2" EFFECT_SIZE="0.3302210453416451" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="118" I2="87.02835153293476" ID="CMP-001.13.02" LOG_CI_END="0.15157618310679583" LOG_CI_START="-1.113966687382301" LOG_EFFECT_SIZE="-0.4811952521377527" NO="2" P_CHI2="4.487195851935466E-4" P_Z="0.13610131233692874" STUDIES="3" TAU2="1.3424115320255592" TOTAL_1="154" TOTAL_2="151" WEIGHT="100.0" Z="1.490467665243413">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4767667009009777" CI_START="0.010701336327987806" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.32169408489527707" LOG_CI_START="-1.9705619864611992" LOG_EFFECT_SIZE="-1.146128035678238" ORDER="98" O_E="0.0" SE="0.9685531674075709" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.9380952380952381" WEIGHT="24.23246316528105"/>
<DICH_DATA CI_END="0.8148735481416007" CI_START="0.11618312611684645" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.08890977973258558" LOG_CI_START="-0.9348569422251632" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="99" O_E="0.0" SE="0.49691355075412963" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.24692307692307694" WEIGHT="34.77071221753797"/>
<DICH_DATA CI_END="1.0029892242921044" CI_START="0.7489058807072021" EFFECT_SIZE="0.866685945633314" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="91" LOG_CI_END="0.0012962671623755592" LOG_CI_START="-0.12557275914689353" LOG_EFFECT_SIZE="-0.06213824599225903" ORDER="100" O_E="0.0" SE="0.07452349406587333" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.005553751167786258" WEIGHT="40.99682461718098"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1852075767243728" CI_START="0.323024902994722" DF="0" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" NO="3" P_CHI2="1.0" P_Z="0.14773361488268363" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.4475833341101076">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="1.1852075767243728" CI_START="0.323024902994722" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" ORDER="101" O_E="0.0" SE="0.3316244072361796" STUDY_ID="STD-Pointel-1986" TOTAL_1="30" TOTAL_2="33" VAR="0.10997474747474748" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.080658410516236" CI_END="1.049307085185408" CI_START="0.34591352497272493" DF="3" EFFECT_SIZE="0.6024695117724547" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="72" I2="75.16691642080953" ID="CMP-001.13.04" LOG_CI_END="0.02090260533803179" LOG_CI_START="-0.4610324570484032" LOG_EFFECT_SIZE="-0.22006492585518567" NO="4" P_CHI2="0.007111918514946303" P_Z="0.07346228572222131" STUDIES="4" TAU2="0.2223853665119306" TOTAL_1="125" TOTAL_2="116" WEIGHT="100.00000000000001" Z="1.7899479104128437">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0641010650963951" CI_START="0.7015273496905823" EFFECT_SIZE="0.864" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.026982877892531416" LOG_CI_START="-0.15395539293474494" LOG_EFFECT_SIZE="-0.06348625752110672" ORDER="102" O_E="0.0" SE="0.10628403594282773" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.011296296296296297" WEIGHT="34.29474811168166"/>
<DICH_DATA CI_END="1.2575147355900478" CI_START="0.19880482743026914" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.09951308283170253" LOG_CI_START="-0.701573074159665" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="103" O_E="0.0" SE="0.47056197405716016" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.22142857142857145" WEIGHT="18.057237682790937"/>
<DICH_DATA CI_END="0.7382545478648378" CI_START="0.2543537026908459" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" LOG_CI_END="-0.13179386897308396" LOG_CI_START="-0.5945619358525673" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="104" O_E="0.0" SE="0.27183225322388416" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.07389277389277388" WEIGHT="27.04908891820431"/>
<DICH_DATA CI_END="1.3355274698152124" CI_START="0.26955641732312" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.12565282524131058" LOG_CI_START="-0.5693503244740233" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="105" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Tsouderos-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.16666666666666669" WEIGHT="20.598925287323098"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.070548994624764" CI_START="0.760727623706627" DF="0" EFFECT_SIZE="0.9024390243902439" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-001.13.05" LOG_CI_END="0.029606547957654723" LOG_CI_START="-0.11877081326313567" LOG_EFFECT_SIZE="-0.04458213265274048" NO="5" P_CHI2="1.0" P_Z="0.23887665791095736" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.1777992765801402">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="1.070548994624764" CI_START="0.760727623706627" EFFECT_SIZE="0.9024390243902439" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.029606547957654723" LOG_CI_START="-0.11877081326313567" LOG_EFFECT_SIZE="-0.04458213265274048" ORDER="106" O_E="0.0" SE="0.08715759646087583" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.007596446620836875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.494391840954457" CI_END="0.7412393451412342" CI_START="0.47925726583728356" DF="8" EFFECT_SIZE="0.5960237762735698" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="353" I2="68.62054976675805" ID="CMP-001.13.06" LOG_CI_END="-0.1300415362983385" LOG_CI_START="-0.31943129422638644" LOG_EFFECT_SIZE="-0.22473641526236252" NO="6" P_CHI2="0.0012812211751466185" P_Z="3.294946697394671E-6" STUDIES="9" TAU2="0.06108553792443505" TOTAL_1="880" TOTAL_2="540" WEIGHT="100.00000000000001" Z="4.651521652994684">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.7903712751309083" CI_START="0.11978491525686698" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.1021688519209733" LOG_CI_START="-0.9215978700367755" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="107" O_E="0.0" SE="0.48133666148028004" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.2316849816849817" WEIGHT="4.227278282106197"/>
<DICH_DATA CI_END="0.8334668511039568" CI_START="0.5232340734719679" EFFECT_SIZE="0.660377358490566" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="53" LOG_CI_END="-0.07911166838416735" LOG_CI_START="-0.28130398211685953" LOG_EFFECT_SIZE="-0.18020782525051343" ORDER="108" O_E="0.0" SE="0.11876876595467818" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.014106019766397124" WEIGHT="16.45959330001661"/>
<DICH_DATA CI_END="1.115629165191512" CI_START="0.5909468666401837" EFFECT_SIZE="0.8119590873328089" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.04751985922987865" LOG_CI_START="-0.22845156575550984" LOG_EFFECT_SIZE="-0.0904658532628156" ORDER="109" O_E="0.0" SE="0.16210698111700278" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.026278673326868292" WEIGHT="14.166240860640409"/>
<DICH_DATA CI_END="0.8233214739870668" CI_START="0.018978006153943038" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.08443055711068892" LOG_CI_START="-1.7217494168731982" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="110" O_E="0.0" SE="0.9617692030835672" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.9249999999999999" WEIGHT="1.2550863100485654"/>
<DICH_DATA CI_END="1.318145566401421" CI_START="0.6846740018735968" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.11996337322768261" LOG_CI_START="-0.1645161626499871" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="111" O_E="0.0" SE="0.16710468757095692" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.02792397660818713" WEIGHT="13.904383881705618"/>
<DICH_DATA CI_END="0.6692806456188787" CI_START="0.4886292282983279" EFFECT_SIZE="0.5718654434250765" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="109" LOG_CI_END="-0.17439173382282044" LOG_CI_START="-0.31102055842475373" LOG_EFFECT_SIZE="-0.24270614612378708" ORDER="112" O_E="0.0" SE="0.08025644789476498" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.006441097428685126" WEIGHT="18.32791538796324"/>
<DICH_DATA CI_END="0.8202259906388952" CI_START="0.4710301512908947" EFFECT_SIZE="0.6215715344699778" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="71" LOG_CI_END="-0.08606647326821763" LOG_CI_START="-0.32695129219138175" LOG_EFFECT_SIZE="-0.20650888272979967" ORDER="113" O_E="0.0" SE="0.141496935034551" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.020021382624171944" WEIGHT="15.259147441606201"/>
<DICH_DATA CI_END="0.4674556575963953" CI_START="0.12597648307047615" EFFECT_SIZE="0.24266936299292213" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.330259579603341" LOG_CI_START="-0.899710520167806" LOG_EFFECT_SIZE="-0.6149850498855735" ORDER="114" O_E="0.0" SE="0.3344983013151838" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.1118891135827435" WEIGHT="7.154935410489737"/>
<DICH_DATA CI_END="0.8837520787736368" CI_START="0.3069496158781802" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" LOG_CI_END="-0.053669551640466745" LOG_CI_START="-0.5129329057666325" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="115" O_E="0.0" SE="0.2697735676039774" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.07277777777777777" WEIGHT="9.245419125423435"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="103.6429952834715" CI_END="-0.13849324541973013" CI_START="-0.4390569508350414" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2887750981273858" ESTIMABLE="YES" I2="91.31634513708879" I2_Q="89.43236472935675" ID="CMP-001.14" MODIFIED="2015-07-27 14:31:40 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="5.551115123125783E-16" P_Q="3.0100876282634914E-6" P_Z="1.6576305088544257E-4" Q="28.388564926478523" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4682958384433916" TOTALS="SUB" TOTAL_1="557" TOTAL_2="557" UNITS="" WEIGHT="400.0" Z="3.7661818893244425">
<NAME>Heaviness in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9460171195236821" CI_END="0.12997986828358046" CI_START="-0.22717728749717706" DF="1" EFFECT_SIZE="-0.0485987096067983" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2014-02-25 10:53:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3307353528103052" P_Z="0.5937648309268264" STUDIES="2" TAU2="0.0" TOTAL_1="238" TOTAL_2="245" WEIGHT="100.0" Z="0.5333882801044373">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.6592169063458659" CI_START="-0.3095350752070967" EFFECT_SIZE="0.17484091556938464" ESTIMABLE="YES" MEAN_1="36.22" MEAN_2="31.61" ORDER="116" SD_1="28.61" SD_2="22.82" SE="0.24713514870537281" STUDY_ID="STD-Marinello-2002" TOTAL_1="35" TOTAL_2="31" WEIGHT="13.592317291420903"/>
<CONT_DATA CI_END="0.10836465145350736" CI_START="-0.2758581875323997" EFFECT_SIZE="-0.08374676803944618" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="46.9" MODIFIED="2011-01-26 10:32:29 +0000" MODIFIED_BY="[Empty name]" ORDER="938" SD_1="28.4" SD_2="28.8" SE="0.09801783145420216" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="86.4076827085791"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3603295782741587" CI_START="-1.01978075735391" DF="0" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="1.0" P_Z="4.098687284737795E-5" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.1018450468118335">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.3603295782741586" CI_START="-1.01978075735391" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.3" ORDER="117" SD_1="0.87" SD_2="0.86" SE="0.16823043287565947" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7907404745599609" CI_START="-2.2107564729806075" DF="0" EFFECT_SIZE="-1.5007484737702843" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.03" NO="3" P_CHI2="1.0" P_Z="3.4310837200452554E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.142788478037817">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.7907404745599609" CI_START="-2.2107564729806075" EFFECT_SIZE="-1.5007484737702843" ESTIMABLE="YES" MEAN_1="0.94" MEAN_2="1.67" ORDER="118" SD_1="0.55" SD_2="0.39" SE="0.3622556357212561" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="64.75153515380913" CI_END="-0.35639715557078033" CI_START="-1.8731664296324493" DF="5" EFFECT_SIZE="-1.1147817926016148" ESTIMABLE="YES" I2="92.27817535426283" ID="CMP-001.14.04" NO="4" P_CHI2="1.2622125566963405E-12" P_Z="0.003963724826290071" STUDIES="6" TAU2="0.8083617280287005" TOTAL_1="223" TOTAL_2="218" WEIGHT="100.0" Z="2.881034316141257">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.27817683616857625" CI_START="-1.6773787193869785" EFFECT_SIZE="-0.9777777777777773" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.3" ORDER="119" SD_1="0.5" SD_2="0.5" SE="0.3569458148861734" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="16" TOTAL_2="20" WEIGHT="15.999735579921614"/>
<CONT_DATA CI_END="-0.9862975811839929" CI_START="-1.849785254898844" EFFECT_SIZE="-1.4180414180414185" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.2" ORDER="120" SD_1="0.7" SD_2="0.7" SE="0.22028151550894087" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="17.472698751138083"/>
<CONT_DATA CI_END="0.014698889849346086" CI_START="-0.866788140342994" EFFECT_SIZE="-0.42604462524682396" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" ORDER="121" SD_1="0.94" SD_2="0.92" SE="0.2248732724543403" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="40" TOTAL_2="41" WEIGHT="17.43111800278916"/>
<CONT_DATA CI_END="-2.02712182233849" CI_START="-3.8676183455235718" EFFECT_SIZE="-2.947370083931031" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="4.2" ORDER="122" SD_1="0.6" SD_2="0.9" SE="0.46952304677603346" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.552786786890236"/>
<CONT_DATA CI_END="-0.8576325843782733" CI_START="-1.9996033761561216" EFFECT_SIZE="-1.4286179802671974" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.77" ORDER="123" SD_1="0.45" SD_2="0.42" SE="0.29132443268998004" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.761727146183556"/>
<CONT_DATA CI_END="0.5397949297356679" CI_START="-0.1789787739176506" EFFECT_SIZE="0.18040807790900865" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.0" ORDER="124" SD_1="28.0" SD_2="27.0" SE="0.1833640080437482" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="17.78193373307734"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="41.845261966258924" CI_END="0.7950997126253455" CI_START="0.5000866434593818" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.630570175715858" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="325" I2="68.93316139236435" I2_Q="75.09063900639481" ID="CMP-001.15" LOG_CI_END="-0.09957840351025288" LOG_CI_START="-0.30095474463119765" LOG_EFFECT_SIZE="-0.20026657407072526" METHOD="MH" MODIFIED="2014-11-25 08:01:40 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="6.941705136709331E-5" P_Q="0.007235082543958327" P_Z="9.686012371894702E-5" Q="12.043665033278735" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10062919646646548" TOTALS="YES" TOTAL_1="544" TOTAL_2="528" WEIGHT="100.0" Z="3.898325595757086">
<NAME>Swelling in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.121508738565895" CI_END="0.4144421464212803" CI_START="0.08392244096274963" DF="1" EFFECT_SIZE="0.1864966395555564" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="29" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-0.38253608572552134" LOG_CI_START="-1.0761218927692697" LOG_EFFECT_SIZE="-0.7293289892473956" NO="1" P_CHI2="0.7274039280063906" P_Z="3.756997163840102E-5" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.468341656856384" Z="4.121937148335366">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5053433241361468" CI_START="0.05147899836737502" EFFECT_SIZE="0.16129032258064516" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.29641346719478834" LOG_CI_START="-1.2883699118017196" LOG_EFFECT_SIZE="-0.7923916894982539" ORDER="125" O_E="0.0" SE="0.5826801258257038" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.3395161290322581" WEIGHT="3.179040067598516"/>
<DICH_DATA CI_END="0.6547491999374693" CI_START="0.07013123093747059" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.1839250235830732" LOG_CI_START="-1.1540885383340782" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="126" O_E="0.0" SE="0.5698788509515902" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.3247619047619048" WEIGHT="3.289301589257868"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2380604448537903E-30" CI_END="0.9386337042179341" CI_START="0.5220353773768074" DF="1" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="-0.027503855308840846" LOG_CI_START="-0.2823000646626456" LOG_EFFECT_SIZE="-0.1549019599857432" NO="2" P_CHI2="0.9999999999999991" P_Z="0.017167588907441238" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="49" WEIGHT="14.16435239022676" Z="2.3830987397865524">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="0.9471991281342894" CI_START="0.5173146653599221" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.023558710374788606" LOG_CI_START="-0.2862452095966978" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="127" O_E="0.0" SE="0.15430334996209188" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.023809523809523805" WEIGHT="11.24440706416216"/>
<DICH_DATA CI_END="2.3379040026017486" CI_START="0.20958944398687923" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.36882667449208634" LOG_CI_START="-0.6786305944635728" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="128" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="2.9199453260645987"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.016197643368654" CI_START="0.637502633110976" DF="0" EFFECT_SIZE="0.8048780487804879" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.0069781834170477485" LOG_CI_START="-0.1955180171007437" LOG_EFFECT_SIZE="-0.09426991684184799" NO="3" P_CHI2="1.0" P_Z="0.06801912706784784" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.190871913859294" Z="1.824880085287075">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="1.016197643368654" CI_START="0.637502633110976" EFFECT_SIZE="0.8048780487804879" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.0069781834170477485" LOG_CI_START="-0.1955180171007437" LOG_EFFECT_SIZE="-0.09426991684184799" ORDER="129" O_E="0.0" SE="0.1189472705565093" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.014148453172843425" WEIGHT="12.190871913859294"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="24.381518904255408" CI_END="0.8786723363541962" CI_START="0.5036440248463995" DF="8" EFFECT_SIZE="0.6652353508365416" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="242" I2="67.18826242361904" ID="CMP-001.15.04" LOG_CI_END="-0.05617304647667647" LOG_CI_START="-0.29787631408407195" LOG_EFFECT_SIZE="-0.17702468028037424" NO="4" P_CHI2="0.0019773120791154453" P_Z="0.0040920811822790166" STUDIES="9" TAU2="0.09601046695394337" TOTAL_1="429" TOTAL_2="419" WEIGHT="67.17643403905757" Z="2.8709748209761914">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.3612065246002333" CI_START="0.022880159263634785" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="22" LOG_CI_END="-0.44224441347402005" LOG_CI_START="-1.64054095684243" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="130" O_E="0.0" SE="0.7038853212381584" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.49545454545454537" WEIGHT="2.3473876687481456"/>
<DICH_DATA CI_END="0.8319859354514977" CI_START="0.4923160146664264" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="50" LOG_CI_END="-0.07988401530474874" LOG_CI_START="-0.3077560367274769" LOG_EFFECT_SIZE="-0.1938200260161128" ORDER="131" O_E="0.0" SE="0.13385315336840845" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.017916666666666674" WEIGHT="11.803361065035446"/>
<DICH_DATA CI_END="1.3036070664342596" CI_START="0.5953619345651708" EFFECT_SIZE="0.8809756097560976" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.11514670597006874" LOG_CI_START="-0.22521893612660332" LOG_EFFECT_SIZE="-0.055036115078267306" ORDER="132" O_E="0.0" SE="0.19993246300468626" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.039972989763120234" WEIGHT="9.951762933770109"/>
<DICH_DATA CI_END="0.9269426096039015" CI_START="0.01685649126290228" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="133" O_E="0.0" SE="1.0222524150130436" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="1.045" WEIGHT="1.2213721766540115"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="134" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="2.4665077189153792"/>
<DICH_DATA CI_END="1.5429183637159785" CI_START="0.6946289966993215" EFFECT_SIZE="1.0352564102564104" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.18834294801674317" LOG_CI_START="-0.1582470913914229" LOG_EFFECT_SIZE="0.015047928312660138" ORDER="135" O_E="0.0" SE="0.2035887047967214" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.04144836072080657" WEIGHT="9.84842119351967"/>
<DICH_DATA CI_END="0.7465041278868161" CI_START="0.43092451697916057" EFFECT_SIZE="0.567174515235457" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="76" LOG_CI_END="-0.12696778644731532" LOG_CI_START="-0.36559879649908833" LOG_EFFECT_SIZE="-0.24628329147320185" ORDER="136" O_E="0.0" SE="0.14017303654696206" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.019648480174795962" WEIGHT="11.6334108240217"/>
<DICH_DATA CI_END="1.109055461819751" CI_START="0.6048172784324211" EFFECT_SIZE="0.8190091001011123" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.04495326495889572" LOG_CI_START="-0.21837581039595505" LOG_EFFECT_SIZE="-0.08671127271852963" ORDER="137" O_E="0.0" SE="0.1546808023633849" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.023926150619780547" WEIGHT="11.233878416779296"/>
<DICH_DATA CI_END="0.9951910458724644" CI_START="0.27257817706076365" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.0020935401549377042" LOG_CI_START="-0.5645089172521615" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="138" O_E="0.0" SE="0.3303655765079257" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.10914141414141412" WEIGHT="6.670332041613809"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="107.12981588376996" CI_END="-0.17947030475669962" CI_START="-0.5033827867647751" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3414265457607374" ESTIMABLE="YES" I2="95.33276524490182" I2_Q="91.47541799480663" ID="CMP-001.16" MODIFIED="2016-03-31 10:21:22 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="-6.661338147750939E-16" P_Q="1.1094380558684946E-7" P_Z="3.5980845195881976E-5" Q="35.19234137430239" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7813150735220376" TOTALS="SUB" TOTAL_1="436" TOTAL_2="435" UNITS="" WEIGHT="400.0" Z="4.131879876369065">
<NAME>Swelling in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1460235652886488" CI_START="-0.23808077606950617" DF="0" EFFECT_SIZE="-0.0460286053904287" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" MODIFIED="2011-01-26 10:34:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6385414492644592" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="214" WEIGHT="100.0" Z="0.46973907404877135">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.1460235652886488" CI_START="-0.23808077606950617" EFFECT_SIZE="-0.0460286053904287" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="37.5" MODIFIED="2011-01-26 10:33:54 +0000" MODIFIED_BY="[Empty name]" ORDER="939" SD_1="28.6" SD_2="27.8" SE="0.09798760191205577" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5830434537525135" CI_START="-1.2571036604182444" DF="0" EFFECT_SIZE="-0.920073557085379" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" MODIFIED="2014-03-22 11:19:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="8.766630872206274E-8" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="5.35059336594029">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.5830434537525135" CI_START="-1.2571036604182444" EFFECT_SIZE="-0.920073557085379" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.3" ORDER="1" SD_1="0.87" SD_2="0.86" SE="0.17195729410913463" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.5802602669773103E-31" CI_END="-0.9218080848802453" CI_START="-2.3764664634110773" DF="0" EFFECT_SIZE="-1.6491372741456614" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.16.03" MODIFIED="2014-03-22 11:19:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="8.830231225184385E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.4439982755986245">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.9218080848802453" CI_START="-2.3764664634110773" EFFECT_SIZE="-1.6491372741456614" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.39" ORDER="140" SD_1="0.53" SD_2="0.4" SE="0.37109313997731375" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="67.70260419666258" CI_END="0.04090040370302184" CI_START="-3.502601975760228" DF="2" EFFECT_SIZE="-1.730850786028603" ESTIMABLE="YES" I2="97.04590388548364" ID="CMP-001.16.04" MODIFIED="2014-08-29 16:11:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.9984014443252818E-15" P_Z="0.05552838252462859" STUDIES="3" TAU2="2.3218687052924833" TOTAL_1="137" TOTAL_2="127" WEIGHT="100.0" Z="1.9147187386637332">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-1.0862316464850301" CI_START="-1.9635915000065065" EFFECT_SIZE="-1.5249115732457683" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" ORDER="141" SD_1="0.6" SD_2="0.7" SE="0.22382040191605015" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="34.45094505491311"/>
<CONT_DATA CI_END="-2.9213570285933605" CI_START="-5.161022211028014" EFFECT_SIZE="-4.041189619810687" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="3.9" MODIFIED="2014-08-29 16:11:57 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="0.6" SD_2="1.0" SE="0.5713536575418852" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="30.856016330479573"/>
<CONT_DATA CI_END="0.47843011007575204" CI_START="-0.23950153595374585" EFFECT_SIZE="0.1194642870610031" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="20.0" ORDER="143" SD_1="24.0" SD_2="26.0" SE="0.18314919347815856" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="34.69303861460732"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="28.17286837486807" CI_END="0.8835812853930268" CI_START="0.5019056755678981" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6659387824450075" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="276" I2="71.6038853639181" I2_Q="11.814477736279596" ID="CMP-001.17" LOG_CI_END="-0.05375349123497602" LOG_CI_START="-0.29937789327215036" LOG_EFFECT_SIZE="-0.17656569225356314" METHOD="MH" MODIFIED="2014-11-25 08:02:29 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="4.42472162109242E-4" P_Q="0.3217527431308609" P_Z="0.004835124889373502" Q="2.2679459719237856" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10253774706214488" TOTALS="YES" TOTAL_1="896" TOTAL_2="560" WEIGHT="100.0" Z="2.817817731887986">
<NAME>Paraesthesia in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9764832950325375" CI_END="1.0803352038211682" CI_START="0.5101691787032272" DF="2" EFFECT_SIZE="0.7423972815532321" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="32.806610964764815" ID="CMP-001.17.01" LOG_CI_END="0.03355852824884056" LOG_CI_START="-0.29228578234606595" LOG_EFFECT_SIZE="-0.12936362704861265" NO="1" P_CHI2="0.22576935148037192" P_Z="0.11964800562252571" STUDIES="3" TAU2="0.03843542158405857" TOTAL_1="154" TOTAL_2="151" WEIGHT="34.43920153419198" Z="1.5562527359267988">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.890138731579122" CI_START="0.19503826196071922" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.05054230159788697" LOG_CI_START="-0.709880181825325" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="144" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.15000000000000002" WEIGHT="8.243125713697129"/>
<DICH_DATA CI_END="1.6730972932352277" CI_START="0.5022288788435925" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.22352119660291833" LOG_CI_START="-0.29909831838171796" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="145" O_E="0.0" SE="0.30698929011029724" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09424242424242424" WEIGHT="10.578811791281192"/>
<DICH_DATA CI_END="1.1594988882924713" CI_START="0.5830530667533707" EFFECT_SIZE="0.8222222222222222" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.0642703365801496" LOG_CI_START="-0.234291915996847" LOG_EFFECT_SIZE="-0.0850107897083487" ORDER="146" O_E="0.0" SE="0.1753769450707134" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.030757072862336025" WEIGHT="15.617264029213665"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009383939991687733" CI_END="1.0474309884172965" CI_START="0.6155073945102658" DF="1" EFFECT_SIZE="0.8029330723105399" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.020125418428893493" LOG_CI_START="-0.2107667252254116" LOG_EFFECT_SIZE="-0.09532065339825901" NO="2" P_CHI2="0.9228290473342848" P_Z="0.10560044302997537" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="22.989759985313825" Z="1.618288476052527">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="2.2172120454662894" CI_START="0.3182374917377869" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.3458072293220705" LOG_CI_START="-0.49724865719830724" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="147" O_E="0.0" SE="0.49521520093601257" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.24523809523809528" WEIGHT="5.985753302237551"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="148" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="17.004006683076273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.206217207975552" CI_END="0.8310870557321641" CI_START="0.3700003095945617" DF="3" EFFECT_SIZE="0.5545290505653725" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="162" I2="67.41332588371874" ID="CMP-001.17.03" LOG_CI_END="-0.0803534818189486" LOG_CI_START="-0.43179791254069816" LOG_EFFECT_SIZE="-0.2560756971798234" NO="3" P_CHI2="0.026671164264451264" P_Z="0.0042873457421081845" STUDIES="4" TAU2="0.08572002843875147" TOTAL_1="667" TOTAL_2="340" WEIGHT="42.571038480494195" Z="2.8562076955250397">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="149" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="0.8483725880518529"/>
<DICH_DATA CI_END="0.7891864271810392" CI_START="0.4438377403223627" EFFECT_SIZE="0.5918367346938775" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" LOG_CI_END="-0.10282039256716954" LOG_CI_START="-0.35277577169194557" LOG_EFFECT_SIZE="-0.22779808212955757" ORDER="150" O_E="0.0" SE="0.14682502699697503" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021557588552662443" WEIGHT="16.775009198965538"/>
<DICH_DATA CI_END="0.5029818868098265" CI_START="0.34516374379253173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="104" LOG_CI_END="-0.29844765430825204" LOG_CI_START="-0.4619748291149599" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="151" O_E="0.0" SE="0.09605667195403049" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009226884226884228" WEIGHT="18.62575282070876"/>
<DICH_DATA CI_END="3.405627712118229" CI_START="0.5266830012297969" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.532197171104675" LOG_CI_START="-0.2784506983336758" LOG_EFFECT_SIZE="0.1268732363854996" ORDER="152" O_E="0.0" SE="0.47617857127975816" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.22674603174603172" WEIGHT="6.321903872768047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.29150447441703403" CI_END="0.13248269992724704" CI_START="-0.4411360148059914" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.15432665743937218" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2014-11-25 08:02:46 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.5892581140458895" P_Q="0.5892581140458895" P_Z="0.2915994780158121" Q="0.291504474417034" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="91" UNITS="" WEIGHT="100.0" Z="1.054619323486633">
<NAME>Paraesthesia in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.20871518869762E-33" CI_END="0.20535162803696536" CI_START="-0.43537001730831004" DF="0" EFFECT_SIZE="-0.11500919463567236" ESTIMABLE="YES" I2="100.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.0" P_Z="0.48166635190796914" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="80.15079461834718" Z="0.7036249860277557">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="0.20535162803696538" CI_START="-0.43537001730831004" EFFECT_SIZE="-0.11500919463567234" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.5" ORDER="153" SD_1="0.87" SD_2="0.86" SE="0.16345240279903253" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="80.15079461834718"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.33066670307050433" CI_START="-0.9568466720899438" DF="0" EFFECT_SIZE="-0.31308998450971975" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.02" NO="2" P_CHI2="1.0" P_Z="0.34047599559087594" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="19.849205381652823" Z="0.9532251942357999">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="0.33066670307050433" CI_START="-0.9568466720899438" EFFECT_SIZE="-0.31308998450971975" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.82" ORDER="154" SD_1="0.75" SD_2="1.13" SE="0.3284533249886705" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="21" TOTAL_2="17" WEIGHT="19.849205381652823"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.240959375451794" CI_END="0.4735853711148099" CI_START="-2.5527239416044973" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0395692852448437" ESTIMABLE="YES" I2="75.73098095887222" I2_Q="84.8099244682641" ID="CMP-001.19" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.016236804978504438" P_Q="0.010294335622151762" P_Z="0.17812947562750167" Q="6.583245737723604" RANDOM="NO" SCALE="12.53" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="333" TOTAL_2="363" UNITS="" WEIGHT="200.0" Z="1.3465367534973591">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.9899999961253796" CI_START="-17.01000000387462" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005174671266969821" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="100.0" Z="2.7959543273277148">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="-2.9899999961253796" CI_START="-17.01000000387462" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-15.4" MEAN_2="-5.4" MODIFIED="2015-09-09 18:01:54 +0100" MODIFIED_BY="[Empty name]" ORDER="2475" SD_1="17.8" SD_2="13.1" SE="3.5765963350187073" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6577136377281905" CI_END="0.9480258996907798" CI_START="-2.151350977843382" DF="1" EFFECT_SIZE="-0.6016625390763011" ESTIMABLE="YES" I2="39.67595022199084" ID="CMP-001.19.02" MODIFIED="2015-09-09 18:00:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19791237709553755" P_Z="0.4466863643074521" STUDIES="2" TAU2="0.0" TOTAL_1="297" TOTAL_2="320" WEIGHT="100.0" Z="0.7609509614556228">
<NAME>Calcium dobesilate at 3 months of treatment</NAME>
<CONT_DATA CI_END="0.664100452096434" CI_START="-2.664100452096434" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="40.8" MODIFIED="2011-01-26 09:59:35 +0000" MODIFIED_BY="[Empty name]" ORDER="933" SD_1="11.0" SD_2="4.8" SE="0.849046444334001" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="197" TOTAL_2="216" WEIGHT="86.7220846358767"/>
<CONT_DATA CI_END="6.252843926845621" CI_START="-2.252843926845621" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="41.2" MEAN_2="39.2" MODIFIED="2013-12-29 07:26:56 +0000" MODIFIED_BY="[Empty name]" ORDER="943" SD_1="17.7" SD_2="12.8" SE="2.169858201676924" STUDY_ID="STD-Rabe-2011" TOTAL_1="100" TOTAL_2="104" WEIGHT="13.277915364123297"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="104.65488666613979" CI_END="0.7164953520913028" CI_START="0.41072504242523195" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5424781874740974" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="486" I2="85.66717668153271" I2_Q="37.66597515663694" ID="CMP-001.20" LOG_CI_END="-0.1447866225278325" LOG_CI_START="-0.3864488168553086" LOG_EFFECT_SIZE="-0.26561771969157044" METHOD="MH" MODIFIED="2016-03-31 10:21:44 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.4432899320127035E-15" P_Q="0.1860310112623148" P_Z="1.6436312686945133E-5" Q="4.812780832841442" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.28957349352714384" TOTALS="SUB" TOTAL_1="1265" TOTAL_2="939" WEIGHT="400.0" Z="4.3085031624406085">
<NAME>Global assessment by the participant (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.484677341094992" CI_END="1.456692130791106" CI_START="0.35504292357270323" DF="2" EFFECT_SIZE="0.719158002709714" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="97" I2="80.92454412344247" ID="CMP-001.20.01" LOG_CI_END="0.16336777412632272" LOG_CI_START="-0.4497191389339888" LOG_EFFECT_SIZE="-0.143175682403833" MODIFIED="2013-12-29 15:43:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00528788500310251" P_Z="0.3599657666253352" STUDIES="3" TAU2="0.27028746690497524" TOTAL_1="250" TOTAL_2="256" WEIGHT="100.0" Z="0.9154303411002753">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4451289704755189" CI_START="0.02103939567657449" EFFECT_SIZE="0.0967741935483871" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.351514139466709" LOG_CI_START="-1.6769667387625116" LOG_EFFECT_SIZE="-1.0142404391146103" MODIFIED="2013-12-29 11:51:13 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.778577417922537" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6061827956989247" WEIGHT="14.797287432583502"/>
<DICH_DATA CI_END="1.4074584102638539" CI_START="0.6033055026895294" EFFECT_SIZE="0.9214810924369747" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.14843557051466333" LOG_CI_START="-0.21946271350872457" LOG_EFFECT_SIZE="-0.03551357149703059" MODIFIED="2013-12-29 11:51:42 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.2161052731612147" STUDY_ID="STD-Labs-2004" TOTAL_1="112" TOTAL_2="121" VAR="0.04670148908808322" WEIGHT="40.91430365840841"/>
<DICH_DATA CI_END="1.5004603685863007" CI_START="0.8328573916734775" EFFECT_SIZE="1.1178861788617886" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="48" LOG_CI_END="0.17622452896341553" LOG_CI_START="-0.0794293555096484" LOG_EFFECT_SIZE="0.04839758672688353" MODIFIED="2013-12-29 15:43:18 +0000" MODIFIED_BY="[Empty name]" ORDER="979" O_E="0.0" SE="0.1501723572466157" STUDY_ID="STD-Rabe-2011" TOTAL_1="123" TOTAL_2="120" VAR="0.022551736881005174" WEIGHT="44.2884089090081"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.720065153479114" CI_END="1.0233034796181502" CI_START="0.4281742256927792" DF="3" EFFECT_SIZE="0.6619306421629294" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="142" I2="78.13421462332295" ID="CMP-001.20.02" LOG_CI_END="0.01000445089476458" LOG_CI_START="-0.36837947897595547" LOG_EFFECT_SIZE="-0.17918751404059546" MODIFIED="2013-12-29 12:12:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.003312057884133246" P_Z="0.06340777505934186" STUDIES="4" TAU2="0.13016620895522565" TOTAL_1="226" TOTAL_2="225" WEIGHT="99.99999999999997" Z="1.856321298416795">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="0.5141998646213117" CI_START="0.00992229124775049" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.28886804203431926" LOG_CI_START="-2.003388029322157" LOG_EFFECT_SIZE="-1.146128035678238" MODIFIED="2013-12-29 12:12:19 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="1.0071175275436897" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="1.0142857142857145" WEIGHT="4.31661203868594"/>
<DICH_DATA CI_END="1.1855043555846674" CI_START="0.6197310655924868" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.07390315393032808" LOG_CI_START="-0.20779673319155453" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="159" O_E="0.0" SE="0.16547190813232432" STUDY_ID="STD-Chassignolle-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.02738095238095238" WEIGHT="31.35667382173706"/>
<DICH_DATA CI_END="1.165515036767495" CI_START="0.6420464528341865" EFFECT_SIZE="0.8650519031141869" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.06651788089651227" LOG_CI_START="-0.19243354906553276" LOG_EFFECT_SIZE="-0.06295783408451022" ORDER="160" O_E="0.0" SE="0.15210935178995663" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.023137254901960783" WEIGHT="32.224679242481045"/>
<DICH_DATA CI_END="0.7171802726922488" CI_START="0.3921208023373117" EFFECT_SIZE="0.5303030303030303" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="66" LOG_CI_END="-0.14437166498092227" LOG_CI_START="-0.4065801174022639" LOG_EFFECT_SIZE="-0.27547589119159305" ORDER="161" O_E="0.0" SE="0.15402254290506864" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.023722943722943715" WEIGHT="32.10203489709594"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5720281032502694" CI_START="0.1370562032783537" DF="0" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="-0.24258263416729411" LOG_CI_START="-0.8631013031482674" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2013-12-29 15:44:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="4.786970579389238E-4" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="3.4924020883719655">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="0.5720281032502694" CI_START="0.1370562032783537" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.24258263416729411" LOG_CI_START="-0.8631013031482674" LOG_EFFECT_SIZE="-0.5528419686577808" ORDER="162" O_E="0.0" SE="0.36449573777637356" STUDY_ID="STD-Allegra-1981" TOTAL_1="40" TOTAL_2="40" VAR="0.13285714285714287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="43.99134660291989" CI_END="0.8377397725113125" CI_START="0.29544677625210475" DF="7" EFFECT_SIZE="0.49750127148243434" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="222" I2="84.08777966452297" ID="CMP-001.20.04" LOG_CI_END="-0.07689086551479052" LOG_CI_START="-0.529520744433884" LOG_EFFECT_SIZE="-0.3032058049743373" NO="4" P_CHI2="2.145365106676067E-7" P_Z="0.008642911206077325" STUDIES="8" TAU2="0.3918694679359761" TOTAL_1="749" TOTAL_2="418" WEIGHT="100.00000000000001" Z="2.6258649078683622">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.5088426833213036" CI_START="0.4045163682382569" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.17864396122882614" LOG_CI_START="-0.39306390052456286" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="163" O_E="0.0" SE="0.33582402799349803" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" VAR="0.11277777777777775" WEIGHT="14.00792265152227"/>
<DICH_DATA CI_END="0.2762811639284057" CI_START="0.02945641493441985" EFFECT_SIZE="0.0902122641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="32" LOG_CI_END="-0.5586487230487662" LOG_CI_START="-1.5308201111574262" LOG_EFFECT_SIZE="-1.0447344171030961" ORDER="164" O_E="0.0" SE="0.5710582857010101" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.32610756566777654" WEIGHT="9.845801820122551"/>
<DICH_DATA CI_END="0.9680143173409217" CI_START="0.37820149316348955" EFFECT_SIZE="0.6050656660412758" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.014118219245144973" LOG_CI_START="-0.42227676086542654" LOG_EFFECT_SIZE="-0.21819749005528571" ORDER="165" O_E="0.0" SE="0.23975434776511922" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.057482147272277725" WEIGHT="15.731688381682646"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.14671331190125317" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="166" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="10.022920762924354"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="167" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="2.3610595691110974"/>
<DICH_DATA CI_END="2.314669925833568" CI_START="0.8772849110521551" EFFECT_SIZE="1.425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.36448906895678185" LOG_CI_START="-0.05685934026772378" LOG_EFFECT_SIZE="0.153814864344529" ORDER="168" O_E="0.0" SE="0.24750214128673814" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06125730994152048" WEIGHT="15.600622009969024"/>
<DICH_DATA CI_END="0.43033352246510764" CI_START="0.2924255360642496" EFFECT_SIZE="0.3547400611620795" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="109" LOG_CI_END="-0.3661948215805824" LOG_CI_START="-0.5339847052861528" LOG_EFFECT_SIZE="-0.4500897634333676" ORDER="169" O_E="0.0" SE="0.09856060826197167" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009714193500969838" WEIGHT="17.602956153563422"/>
<DICH_DATA CI_END="1.2572325299104203" CI_START="0.4012167732897913" EFFECT_SIZE="0.7102272727272727" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.09941560952166471" LOG_CI_START="-0.3966209191338515" LOG_EFFECT_SIZE="-0.14860265480609341" ORDER="170" O_E="0.0" SE="0.2913743123526676" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.08489898989898989" WEIGHT="14.827028651104643"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="39.809710213968685" CI_END="-0.4554115330179291" CI_START="-0.7766265017533442" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6160190173856367" ESTIMABLE="YES" I2="84.92830023692389" I2_Q="51.31448239130935" ID="CMP-001.21" MODIFIED="2015-03-27 15:36:30 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="4.964677100538495E-7" P_Q="0.12822141148557809" P_Z="5.5811436567780647E-14" Q="4.107997815849426" RANDOM="YES" SCALE="9.37" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.21067110750142473" TOTALS="SUB" TOTAL_1="440" TOTAL_2="441" UNITS="" WEIGHT="300.0" Z="7.517551829050136">
<NAME>Global assessment by the participant (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4244542537870518" CI_END="-0.3349008493490506" CI_START="-0.7118962767537611" DF="1" EFFECT_SIZE="-0.5233985630514059" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.01" MODIFIED="2013-12-29 15:39:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5147228034306985" P_Z="5.2626422792112204E-8" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="226" WEIGHT="100.0" Z="5.442200401224041">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-0.19479102147677713" CI_START="-0.7270915890259755" EFFECT_SIZE="-0.46094130525137633" ESTIMABLE="YES" MEAN_1="15.19" MEAN_2="20.83" MODIFIED="2013-12-29 15:39:54 +0000" MODIFIED_BY="[Empty name]" ORDER="978" SD_1="12.49" SD_2="11.91" SE="0.1357934563461159" STUDY_ID="STD-Rabe-2011" TOTAL_1="108" TOTAL_2="115" WEIGHT="50.16008997784145"/>
<CONT_DATA CI_END="-0.319253244532848" CI_START="-0.8532608690053689" EFFECT_SIZE="-0.5862570567691084" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="7.39" MODIFIED="2013-12-29 11:46:04 +0000" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="4.4" SD_2="5.7" SE="0.13622893805312367" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" WEIGHT="49.83991002215854"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.47192747278546693" CI_START="-1.138201252113946" DF="0" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.02" MODIFIED="2013-12-29 11:14:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.1745916288072995E-6" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.736482823107488">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.47192747278546693" CI_START="-1.138201252113946" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.2" ORDER="171" SD_1="0.87" SD_2="0.86" SE="0.16997092410471867" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="26.15280644642006" CI_END="-0.38867804142120377" CI_START="-1.9635249459145996" DF="3" EFFECT_SIZE="-1.1761014936679017" ESTIMABLE="YES" I2="88.52895575032768" ID="CMP-001.21.03" MODIFIED="2013-12-29 11:14:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="8.860084947381885E-6" P_Z="0.003417905970690967" STUDIES="4" TAU2="0.5605714140977731" TOTAL_1="142" TOTAL_2="141" WEIGHT="100.00000000000001" Z="2.9274167072060515">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.8852781722347934" CI_START="-2.567878747649893" EFFECT_SIZE="-1.7265784599423433" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="6.0" MODIFIED="2013-12-27 22:36:02 +0000" MODIFIED_BY="[Empty name]" ORDER="942" SD_1="1.2" SD_2="2.0" SE="0.4292427281029749" STUDY_ID="STD-Cesarone-2002" TOTAL_1="16" TOTAL_2="15" WEIGHT="21.67049098671698"/>
<CONT_DATA CI_END="-1.3120424182781059" CI_START="-2.2237404554833864" EFFECT_SIZE="-1.7678914368807461" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="9.5" ORDER="172" SD_1="2.5" SD_2="3.3" SE="0.23258030361696397" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="26.259231758722454"/>
<CONT_DATA CI_END="0.3528616138779379" CI_START="-0.6086442995189438" EFFECT_SIZE="-0.12789134282050293" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.4" ORDER="173" SD_1="1.4" SD_2="1.7" SE="0.24528662796385997" STUDY_ID="STD-Ihme-1996" TOTAL_1="36" TOTAL_2="31" WEIGHT="26.002368884467792"/>
<CONT_DATA CI_END="-0.6934495545778849" CI_START="-1.6424031837429498" EFFECT_SIZE="-1.1679263691604174" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.0" ORDER="174" SD_1="1.1" SD_2="1.4" SE="0.24208445579875187" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="26.067908370092784"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="31.935314126285842" CI_END="1.4007152849789082" CI_START="1.046223699207864" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2105624837188829" ESTIMABLE="YES" EVENTS_1="329" EVENTS_2="249" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.14634986781358444" LOG_CI_START="0.01962455350314255" LOG_EFFECT_SIZE="0.08298721065836348" METHOD="MH" MODIFIED="2015-09-18 12:33:46 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5199754322166847" P_Q="0.49182941531889757" P_Z="0.010258259770599763" Q="4.411366315356458" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="34" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2080" TOTAL_2="1974" WEIGHT="100.00000000000001" Z="2.5670000497198027">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.320522299550465" CI_START="0.05643115644753237" DF="0" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6684881427861843" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="0.6985301418548517" Z="0.4282238668218129">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="6.320522299550465" CI_START="0.05643115644753237" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-09 21:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1241" O_E="0.0" SE="1.2037302057640382" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" VAR="1.448966408268734" WEIGHT="0.6985301418548517"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.582765279626607" CI_END="1.5269766046006017" CI_START="0.9905605728108574" DF="6" EFFECT_SIZE="1.2298629273711563" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="110" I2="43.30404349465361" ID="CMP-001.22.02" LOG_CI_END="0.18383238311359432" LOG_CI_START="-0.00411896219189289" LOG_EFFECT_SIZE="0.08985671046085071" MODIFIED="2015-09-09 21:48:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10215978593827368" P_Z="0.06092235051981754" STUDIES="7" TAU2="0.0" TOTAL_1="758" TOTAL_2="715" WEIGHT="44.42517212750575" Z="1.8740585866651869">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="0.39104224210978805"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.19161069863379615"/>
<DICH_DATA CI_END="2.6977689818668056" CI_START="0.42776421247572727" EFFECT_SIZE="1.074248120300752" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4310047569755741" LOG_CI_START="-0.3687955521030694" LOG_EFFECT_SIZE="0.031104602436252366" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4698066606281763" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.22071829837059842" WEIGHT="3.13651974379014"/>
<DICH_DATA CI_END="1.379115264279274" CI_START="0.5729205362707969" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" LOG_CI_END="0.13960056534080972" LOG_CI_START="-0.24190561023557236" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.22409861601959308" STUDY_ID="STD-Marinello-2002" TOTAL_1="82" TOTAL_2="41" VAR="0.05022018970189702" WEIGHT="9.197313534422214"/>
<DICH_DATA CI_END="1.5859185558605429" CI_START="0.7530972088851662" EFFECT_SIZE="1.0928635953026198" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" LOG_CI_END="0.20028088055500345" LOG_CI_START="-0.1231489619697851" LOG_EFFECT_SIZE="0.03856595929260917" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="940" O_E="0.0" SE="0.18998429050260193" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="246" TOTAL_2="263" VAR="0.03609403063777704" WEIGHT="16.669001444999004"/>
<DICH_DATA CI_END="5.9756959783431975" CI_START="1.5840886202364952" EFFECT_SIZE="3.0766917293233083" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.7763884940472019" LOG_CI_START="0.19977947409887165" LOG_EFFECT_SIZE="0.48808398407303677" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="0.33870299257833086" STUDY_ID="STD-Rabe-2011" TOTAL_1="133" TOTAL_2="124" VAR="0.11471971718151686" WEIGHT="3.966416018411656"/>
<DICH_DATA CI_END="1.6723232013260785" CI_START="0.6949016850698201" EFFECT_SIZE="1.0780075187969924" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.22332021508135724" LOG_CI_START="-0.1580766351968807" LOG_EFFECT_SIZE="0.03262178994223827" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2240343977982942" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.05019141139684433" WEIGHT="10.873268445139153"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2331012827270302" CI_START="0.5840929599486262" DF="0" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-001.22.03" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2015-09-09 21:48:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6977879098630941" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="33" WEIGHT="4.476352065955493" Z="0.38830828210084756">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="2.2331012827270302" CI_START="0.5840929599486262" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.34212017937049316" STUDY_ID="STD-Pointel-1986" TOTAL_1="61" TOTAL_2="33" VAR="0.11704621713249841" WEIGHT="4.476352065955493"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.300845449607167" CI_END="1.443609566962083" CI_START="0.7037978870133861" DF="7" EFFECT_SIZE="1.0079728978996525" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="49" I2="0.0" ID="CMP-001.22.04" LOG_CI_END="0.15944975151511834" LOG_CI_START="-0.15255204136528333" LOG_EFFECT_SIZE="0.003448855074917499" MODIFIED="2015-09-09 21:47:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7445468620510969" P_Z="0.9654379002716841" STUDIES="8" TAU2="0.0" TOTAL_1="424" TOTAL_2="413" WEIGHT="19.22858507718354" Z="0.04333072366239658">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.7926315021300137" CI_START="0.46873982565817657" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.25349102406348534" LOG_CI_START="-0.3290681458422849" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.3421981401170484" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.1170995670995671" WEIGHT="4.598656767211107"/>
<DICH_DATA CI_END="13.885529310369082" CI_START="0.6229880646092515" EFFECT_SIZE="2.9411764705882355" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1425624395195535" LOG_CI_START="-0.20552027360406375" LOG_EFFECT_SIZE="0.4685210829577449" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.7918704588058654" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.6270588235294117" WEIGHT="0.774031337055335"/>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="0.20135361551348072"/>
<DICH_DATA CI_END="49.07807360941349" CI_START="0.09356187798318824" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6908875076568242" LOG_CI_START="-1.0289010695739755" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="1.5976172734359604" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="2.552380952380952" WEIGHT="0.2235458150727622"/>
<DICH_DATA CI_END="2.9876119742706684" CI_START="0.5950497564904714" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4753241914111042" LOG_CI_START="-0.22544671819450432" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.41163630117428224" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.1694444444444444" WEIGHT="3.448992575408331"/>
<DICH_DATA CI_END="2.7613068900368742" CI_START="0.2231106212479665" EFFECT_SIZE="0.7849056603773585" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4411146765570192" LOG_CI_START="-0.6514797545051118" LOG_EFFECT_SIZE="-0.10518253897404628" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.6417953772355555" STUDY_ID="STD-Guilhou-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.4119013062409289" WEIGHT="1.9343556243030848"/>
<DICH_DATA CI_END="1.5460497575926389" CI_START="0.3100093890734195" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.18922346700803455" LOG_CI_START="-0.5086251527430584" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.4099197336481717" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.16803418803418801" WEIGHT="4.9818781644787"/>
<DICH_DATA CI_END="2.0190742752871254" CI_START="0.2785930200215189" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3051522955429512" LOG_CI_START="-0.5550297687595511" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.5052752025411797" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.25530303030303025" WEIGHT="3.0657711781407384"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7359925831763834" CI_START="0.18809447425601197" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-001.22.05" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-09-09 21:47:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3236085963801921" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="2.861386432931356" Z="0.9870694697483925">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.7359925831763834" CI_START="0.18809447425601197" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.3214285714285714" WEIGHT="2.861386432931356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.513240937769362" CI_END="1.8326820607776568" CI_START="1.0824039867728286" DF="15" EFFECT_SIZE="1.4084396930904706" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="71" I2="0.0" ID="CMP-001.22.06" LOG_CI_END="0.26308712877762613" LOG_CI_START="0.03438938321101093" LOG_EFFECT_SIZE="0.1487382559943185" MODIFIED="2015-09-18 12:33:46 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5627192639982304" P_Z="0.010790680610269669" STUDIES="16" TAU2="0.0" TOTAL_1="766" TOTAL_2="730" WEIGHT="28.309974154569026" Z="2.549405322294693">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="0.7664427945351846"/>
<DICH_DATA CI_END="8.03557043079218" CI_START="0.28000501263457733" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.905016711983248" LOG_CI_START="-0.5528341938718854" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Balmer-1980" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.7664427945351846"/>
<DICH_DATA CI_END="36.11328941979412" CI_START="0.06538021389049867" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5576670484324069" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.18655669273384623" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="40" TOTAL_2="20" VAR="2.59465737514518" WEIGHT="0.25342060141889167"/>
<DICH_DATA CI_END="6.518295566757786" CI_START="0.9719806783736777" EFFECT_SIZE="2.5170731707317073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8141340493021292" LOG_CI_START="-0.012342368159215193" LOG_EFFECT_SIZE="0.40089584057145705" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.48547633874104096" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.23568727547740592" WEIGHT="1.8704853914251531"/>
<DICH_DATA CI_END="7.355395653031318" CI_START="0.012976301617136022" EFFECT_SIZE="0.3089430894308943" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8666060387639877" LOG_CI_START="-1.8868490684091632" LOG_EFFECT_SIZE="-0.5101215148225877" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.6173931597761082" STUDY_ID="STD-Koscielnny-1996" TOTAL_1="40" TOTAL_2="37" VAR="2.6159606332905434" WEIGHT="0.5966611628343526"/>
<DICH_DATA CI_END="2.6300131119236196" CI_START="0.00775971920930058" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41995791366918006" LOG_CI_START="-2.110153993697694" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="981" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="1.341274890436573"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.19161069863379615"/>
<DICH_DATA CI_END="1.5391241333657362" CI_START="0.7027373403825276" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.18727364794175155" LOG_CI_START="-0.1532069693441908" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.2" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.04000000000000001" WEIGHT="9.580534931689808"/>
<DICH_DATA CI_END="7.267071756978603" CI_START="0.5504280312298803" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.25929945722445363" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="1.1496641918027768"/>
<DICH_DATA CI_END="2.496356013675377" CI_START="0.10014597222129622" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3973065216149974" LOG_CI_START="-0.9993665129429598" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Serralde-1990" TOTAL_1="26" TOTAL_2="26" VAR="0.6730769230769231" WEIGHT="1.5328855890703692"/>
<DICH_DATA CI_END="5.313494641645885" CI_START="0.28784520068821484" EFFECT_SIZE="1.2367149758454106" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7253802469539765" LOG_CI_START="-0.5408410072441131" LOG_EFFECT_SIZE="0.09226961985493179" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.7437846326122535" STUDY_ID="STD-Unkauf-1996" TOTAL_1="69" TOTAL_2="64" VAR="0.5532155797101449" WEIGHT="1.1928846501412271"/>
<DICH_DATA CI_END="3.343632810758682" CI_START="1.004540355835996" EFFECT_SIZE="1.8327067669172932" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5242185782714054" LOG_CI_START="0.00196738853557186" LOG_EFFECT_SIZE="0.26309298340348863" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.30677293403591116" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.09410963305700148" WEIGHT="5.295422944061276"/>
<DICH_DATA CI_END="5.502292199432192" CI_START="0.2934039860395668" EFFECT_SIZE="1.2705882352941176" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7405436498907105" LOG_CI_START="-0.5325339903453966" LOG_EFFECT_SIZE="0.10400482977265695" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1894" O_E="0.0" SE="0.7478121077106432" STUDY_ID="STD-Vanscheidt-2002b" TOTAL_1="85" TOTAL_2="81" VAR="0.5592229484386346" WEIGHT="1.1773669434124823"/>
<DICH_DATA CI_END="5.887545754238547" CI_START="0.18601750764417702" EFFECT_SIZE="1.0465116279069768" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7699342952089039" LOG_CI_START="-0.7304461788173894" LOG_EFFECT_SIZE="0.019744058195757187" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.8813309174461722" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.7767441860465115" WEIGHT="0.9029326072606285"/>
<DICH_DATA CI_END="7.273812287941877" CI_START="0.7551973910031008" EFFECT_SIZE="2.34375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8617620892176036" LOG_CI_START="-0.12193951907401532" LOG_EFFECT_SIZE="0.36991128507179405" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.5778311941119906" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.3338888888888889" WEIGHT="1.5016022097015862"/>
<DICH_DATA CI_END="198.0599697491454" CI_START="0.6273260464249563" EFFECT_SIZE="11.146666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2967967083816303" LOG_CI_START="-0.20250668028699764" LOG_EFFECT_SIZE="1.0471450140473164" MODIFIED="2013-12-29 23:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="1.468103182255255" STUDY_ID="STD-Zucarelli-1987" TOTAL_1="74" TOTAL_2="75" VAR="2.1553269537480064" WEIGHT="0.19034175360973127"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-03-31 10:31:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Sensitivity analysis excluding studies that allowed the use of elastic stockings</NAME>
<DICH_OUTCOME CHI2="14.937918719282074" CI_END="0.7618951803843856" CI_START="0.5999276343683605" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6760783780041038" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="300" I2="26.36189681631453" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.11810477368921027" LOG_CI_START="-0.22190113276620377" LOG_EFFECT_SIZE="-0.170002953227707" METHOD="MH" MODIFIED="2014-11-25 08:04:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1853567724907874" P_Q="0.7592725474417958" P_Z="1.3604421204686103E-10" Q="1.8720767261506899" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="570" TOTAL_2="561" WEIGHT="99.99999999999999" Z="6.420257291387147">
<NAME>Oedema in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9898150624110164" CI_START="0.2798586531655355" DF="0" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" NO="1" P_CHI2="1.0" P_Z="0.046400600556080585" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="6.2769578678126" Z="1.9917308171456887">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9898150624110164" CI_START="0.2798586531655355" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="244" O_E="0.0" SE="0.3222593538479378" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="41" TOTAL_2="41" VAR="0.10385109114249039" WEIGHT="6.2769578678126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.899456770961606" CI_END="1.0729272529886107" CI_START="0.47904989932324116" DF="1" EFFECT_SIZE="0.7169279549057601" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" I2="87.34090167217575" ID="CMP-002.01.02" LOG_CI_END="0.030570276768692478" LOG_CI_START="-0.31961924676907805" LOG_EFFECT_SIZE="-0.1445244850001928" NO="2" P_CHI2="0.004944983495852484" P_Z="0.10571250299104047" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="142" WEIGHT="14.426837982013007" Z="1.6177684736135471">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5227592596510281" CI_START="0.03903931472955589" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.28169826577049156" LOG_CI_START="-1.4084978142580222" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="245" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="4.625126849967179"/>
<DICH_DATA CI_END="1.5472751585524283" CI_START="0.6306423336104108" EFFECT_SIZE="0.9878143634949442" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.18956755301077963" LOG_CI_START="-0.20021687939162486" LOG_EFFECT_SIZE="-0.005324663190422592" ORDER="246" O_E="0.0" SE="0.22896130505723078" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.052423279213510296" WEIGHT="9.801711132045828"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.362592785530452" CI_END="0.855954061197527" CI_START="0.4577856440635609" DF="1" EFFECT_SIZE="0.625974025974026" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="43" I2="70.2610436713273" ID="CMP-002.01.03" LOG_CI_END="-0.06754954315437829" LOG_CI_START="-0.33933783071288626" LOG_EFFECT_SIZE="-0.2034436869336323" NO="3" P_CHI2="0.06669306889397486" P_Z="0.0033439515235160924" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="14.963645691070285" Z="2.9342125288318313">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0813372457404962" CI_START="0.6032963966376529" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.03396116215154717" LOG_CI_START="-0.21946926862534452" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="247" O_E="0.0" SE="0.14886628953921083" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.022161172161172152" WEIGHT="5.052659583997759"/>
<DICH_DATA CI_END="0.8601540175978909" CI_START="0.33069013063357905" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.06542377782153407" LOG_CI_START="-0.4805787663059413" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="248" O_E="0.0" SE="0.24386409528607725" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.05946969696969696" WEIGHT="9.910986107072526"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.058592434326117" CI_START="0.5831771688114353" DF="0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" NO="4" P_CHI2="1.0" P_Z="0.11283151328821682" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="9.866937279929981" Z="1.5855936691338377">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.058592434326117" CI_START="0.5831771688114353" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="249" O_E="0.0" SE="0.15209574906326898" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.023133116883116887" WEIGHT="9.866937279929981"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.717901020877989" CI_END="0.783716543214205" CI_START="0.5838159841592121" DF="5" EFFECT_SIZE="0.6764216473313497" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="163" I2="0.0" ID="CMP-002.01.05" LOG_CI_END="-0.1058409857562419" LOG_CI_START="-0.2337240187397252" LOG_EFFECT_SIZE="-0.16978250224798355" NO="5" P_CHI2="0.7433792953509584" P_Z="1.9478242499194695E-7" STUDIES="6" TAU2="0.0" TOTAL_1="271" TOTAL_2="269" WEIGHT="54.465621179174114" Z="5.204249255710367">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8442346751174894" CI_START="0.2961261925959252" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.07353681410660659" LOG_CI_START="-0.5285231772213558" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="250" O_E="0.0" SE="0.2672612419124244" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.07142857142857142" WEIGHT="5.946591664243515"/>
<DICH_DATA CI_END="1.032180072405786" CI_START="0.41586822229089504" EFFECT_SIZE="0.6551724137931034" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="29" LOG_CI_END="0.01375547018854748" LOG_CI_START="-0.3810442640808018" LOG_EFFECT_SIZE="-0.18364439694612714" ORDER="251" O_E="0.0" SE="0.23190731820001875" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.05378100423472475" WEIGHT="9.580619903503441"/>
<DICH_DATA CI_END="0.8916358832044371" CI_START="0.6245627925209027" EFFECT_SIZE="0.7462456680785522" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" LOG_CI_END="-0.0498124619907061" LOG_CI_START="-0.20442389183840623" LOG_EFFECT_SIZE="-0.12711817691455618" ORDER="252" O_E="0.0" SE="0.09081951923146003" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.008248185073433539" WEIGHT="16.49925058978676"/>
<DICH_DATA CI_END="0.9570860866973051" CI_START="0.5358355930265097" EFFECT_SIZE="0.7161290322580646" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="-0.019048997127923857" LOG_CI_START="-0.27096844163934425" LOG_EFFECT_SIZE="-0.14500871938363402" ORDER="253" O_E="0.0" SE="0.14797872872737033" STUDY_ID="STD-Ihme-1996" TOTAL_1="40" TOTAL_2="37" VAR="0.02189770415576866" WEIGHT="10.640366037030244"/>
<DICH_DATA CI_END="0.9272106717283771" CI_START="0.43674937102598566" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="-0.03282157850469006" LOG_CI_START="-0.3597677117832464" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="254" O_E="0.0" SE="0.19204977709728507" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="0.036883116883116886" WEIGHT="7.268056478519853"/>
<DICH_DATA CI_END="1.4497884349945172" CI_START="0.3093013748065556" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16130463105002965" LOG_CI_START="-0.5096181496069929" LOG_EFFECT_SIZE="-0.1741567592784816" ORDER="255" O_E="0.0" SE="0.39410336247926164" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.1553174603174603" WEIGHT="4.530736506090297"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.233030657778002" CI_END="-3.158834380278347" CI_START="-6.024677240315522" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.5917558102969345" ESTIMABLE="YES" I2="44.55748781766958" I2_Q="66.78365308586744" ID="CMP-002.02" MODIFIED="2015-12-19 22:26:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06217198192002149" P_Q="0.04926392445723293" P_Z="3.3716337703917613E-10" Q="6.021131719180896" RANDOM="NO" SCALE="23.53" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="606" TOTAL_2="606" UNITS="" WEIGHT="100.0" Z="6.280648628353464">
<NAME>Ankle perimeter circumference (mm)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.9915783188426" CI_END="3.3404650225274466" CI_START="-4.948462415713788" DF="2" EFFECT_SIZE="-0.8039986965931708" ESTIMABLE="YES" I2="49.89450687817342" ID="CMP-002.02.01" NO="1" P_CHI2="0.13590656257675715" P_Z="0.7037820266977312" STUDIES="3" TAU2="0.0" TOTAL_1="252" TOTAL_2="250" WEIGHT="11.953857415689068" Z="0.3802201191120863">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.7960630376235365" CI_START="-41.99606303762347" EFFECT_SIZE="-20.599999999999966" ESTIMABLE="YES" MEAN_1="335.6" MEAN_2="356.2" ORDER="256" SD_1="38.2" SD_2="38.2" SE="10.916559287003698" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.4485150475734731"/>
<CONT_DATA CI_END="6.4906763678853725" CI_START="-4.090676367885395" EFFECT_SIZE="1.1999999999999886" ESTIMABLE="YES" MEAN_1="229.5" MEAN_2="228.3" ORDER="257" SD_1="22.73" SD_2="19.59" SE="2.6993742791283735" STUDY_ID="STD-Labs-2004" TOTAL_1="124" TOTAL_2="123" WEIGHT="7.335375708350993"/>
<CONT_DATA CI_END="4.817074484380218" CI_START="-9.217074484380252" EFFECT_SIZE="-2.200000000000017" ESTIMABLE="YES" MEAN_1="230.1" MEAN_2="232.3" ORDER="258" SD_1="21.31" SD_2="29.43" SE="3.5802058301734228" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="4.1699666597646035"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.990809562527288E-4" CI_END="-4.0681158382476195" CI_START="-7.723001460520145" DF="1" EFFECT_SIZE="-5.895558649383882" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" MODIFIED="2014-08-27 13:53:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9747844722641873" P_Z="2.563863618259706E-10" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="61.483299514599366" Z="6.323088498923434">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-4.0519220810061265" CI_START="-7.748077918993872" EFFECT_SIZE="-5.8999999999999995" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.2" ORDER="259" SD_1="6.97" SD_2="4.3" SE="0.9429142237159843" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="60.11795506369879"/>
<CONT_DATA CI_END="6.5631280465892505" CI_START="-17.963128046589283" EFFECT_SIZE="-5.700000000000017" ESTIMABLE="YES" MEAN_1="229.1" MEAN_2="234.8" MODIFIED="2014-08-27 13:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="30.3" SD_2="31.0" SE="6.256812953359988" STUDY_ID="STD-Planchon-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="1.3653444509005799"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.219321538798251" CI_END="-0.49824259926213976" CI_START="-6.058758605293654" DF="4" EFFECT_SIZE="-3.278500602277897" ESTIMABLE="YES" I2="35.6843029412994" ID="CMP-002.02.03" NO="3" P_CHI2="0.1833571851975847" P_Z="0.02082159576716374" STUDIES="5" TAU2="0.0" TOTAL_1="230" TOTAL_2="234" WEIGHT="26.56284306971157" Z="2.31120388711678">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="3.891260641035477" CI_START="-11.891260641035476" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="221.0" MEAN_2="225.0" ORDER="261" SD_1="22.0" SD_2="19.0" SE="4.026227371156171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="3.297250780123491"/>
<CONT_DATA CI_END="8.004579588483077" CI_START="-10.004579588483077" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="236.0" MEAN_2="237.0" ORDER="262" SD_1="22.0" SD_2="20.0" SE="4.594257679993128" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" WEIGHT="2.5323158517301794"/>
<CONT_DATA CI_END="-9.197870941782313" CI_START="-58.80212905821769" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="243.0" ORDER="263" SD_1="50.0" SD_2="48.0" SE="12.654380005884656" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.3337850104395778"/>
<CONT_DATA CI_END="0.5214018041077106" CI_START="-6.321401804107712" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-0.8" ORDER="264" SD_1="7.2" SD_2="7.3" SE="1.7456452420020427" STUDY_ID="STD-Vin-1994" TOTAL_1="34" TOTAL_2="35" WEIGHT="17.54028297548586"/>
<CONT_DATA CI_END="5.274214804913063" CI_START="-11.67421480491304" EFFECT_SIZE="-3.1999999999999886" ESTIMABLE="YES" MEAN_1="232.5" MEAN_2="235.7" ORDER="265" SD_1="27.4" SD_2="24.9" SE="4.32365843033677" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" WEIGHT="2.859208451932464"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.071257199809411" CI_END="-0.20268371846996483" CI_START="-0.482708587938119" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3426961532040419" ESTIMABLE="YES" I2="13.272494895029572" I2_Q="16.333938258218545" ID="CMP-002.03" MODIFIED="2015-12-19 22:28:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3263526277363785" P_Q="0.302635076428032" P_Z="1.608733183247901E-6" Q="2.3904555304307253" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="392" TOTAL_2="410" UNITS="" WEIGHT="100.0" Z="4.797231897267102">
<NAME>Volume of the leg (mL)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27623133159938895" CI_START="-0.6109215354600945" DF="0" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45965052058283484" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="9.963141218324544" Z="0.7394224489400971">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="0.27623133159938895" CI_START="-0.6109215354600945" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" MEAN_1="3276.5" MEAN_2="3391.5" MODIFIED="2015-09-09 22:04:21 +0100" MODIFIED_BY="[Empty name]" ORDER="2474" SD_1="584.6" SD_2="751.1" SE="0.2263186655615185" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="9.963141218324544"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2547848708213776" CI_END="-0.24546387185897467" CI_START="-0.7658413875888216" DF="1" EFFECT_SIZE="-0.5056526297238981" ESTIMABLE="YES" I2="55.649870950406104" ID="CMP-002.03.02" MODIFIED="2015-09-09 22:04:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13320207163727849" P_Z="1.3952569833807803E-4" STUDIES="2" TAU2="0.0" TOTAL_1="118" TOTAL_2="118" WEIGHT="28.957172948714526" Z="3.8090075492858753">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-0.29058032887513097" CI_START="-1.8337557124459654" EFFECT_SIZE="-1.0621680206605482" ESTIMABLE="YES" MEAN_1="1097.0" MEAN_2="1205.0" ORDER="266" SD_1="92.95" SD_2="104.57" SE="0.39367442354635207" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.2927793772798926"/>
<CONT_DATA CI_END="-0.15787439319036783" CI_START="-0.7106273827218053" EFFECT_SIZE="-0.4342508879560865" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-1.15" ORDER="267" SD_1="6.08" SD_2="6.08" SE="0.14101100680713585" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="25.664393571434633"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.426016798557308" CI_END="-0.11489254978967217" CI_START="-0.47319370317196324" DF="4" EFFECT_SIZE="-0.2940431264808177" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.03" MODIFIED="2015-09-09 22:04:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4892167164671355" P_Z="0.0012957254426142761" STUDIES="5" TAU2="0.0" TOTAL_1="238" TOTAL_2="249" WEIGHT="61.07968583296094" Z="3.216924826301398">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.06339385236707562" CI_START="-1.21424466831304" EFFECT_SIZE="-0.6388192603400578" ESTIMABLE="YES" MEAN_1="1098.0" MEAN_2="1200.0" ORDER="268" SD_1="157.74" SD_2="156.5" SE="0.2935897866041745" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" WEIGHT="5.920455852063176"/>
<CONT_DATA CI_END="0.1902409432135067" CI_START="-0.5919359804828254" EFFECT_SIZE="-0.20084751863465933" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-4.4" ORDER="269" SD_1="43.4" SD_2="29.2" SE="0.19953859608289842" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="51" TOTAL_2="50" WEIGHT="12.816906289683734"/>
<CONT_DATA CI_END="0.4195584060852926" CI_START="-0.47459950667794526" EFFECT_SIZE="-0.02752055029632632" ESTIMABLE="YES" MEAN_1="2073.0" MEAN_2="2082.0" ORDER="270" SD_1="309.0" SD_2="339.0" SE="0.22810569985373236" STUDY_ID="STD-Ihme-1996" TOTAL_1="40" TOTAL_2="37" WEIGHT="9.807645474191403"/>
<CONT_DATA CI_END="0.18807153574891566" CI_START="-0.6898764827904679" EFFECT_SIZE="-0.2509024735207761" ESTIMABLE="YES" MEAN_1="1992.0" MEAN_2="2111.0" ORDER="271" SD_1="367.0" SD_2="541.0" SE="0.2239704467695645" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="10.17315358003041"/>
<CONT_DATA CI_END="-0.09661376983931858" CI_START="-0.6887830829154231" EFFECT_SIZE="-0.39269842637737085" ESTIMABLE="YES" MEAN_1="-95.7" MEAN_2="-44.6" MODIFIED="2014-08-27 14:00:19 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="127.9" SD_2="131.1" SE="0.15106637615462848" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="86" TOTAL_2="93" WEIGHT="22.361524636992215"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.25321558091335405" CI_END="3.099568648048876" CI_START="0.2699082350742646" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9146579159917638" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.4913012593805006" LOG_CI_START="-0.5687838646367003" LOG_EFFECT_SIZE="-0.03874130262809983" METHOD="MH" MODIFIED="2015-09-18 12:33:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6148199701758219" P_Q="0.6148286400152856" P_Z="0.886088331178764" Q="0.2532031693903565" RANDOM="YES" SCALE="63.625775799451304" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="62" WEIGHT="100.0" Z="0.1432555860750113">
<NAME>Ulcer cured</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1804728481415974" CI_START="0.17686049429055115" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 09:33:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6963273006688617" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="71.36583223539746" Z="0.3902829903211535">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="3.1804728481415974" CI_START="0.17686049429055115" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 09:33:35 +0100" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="0.7371114795831993" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.5433333333333332" WEIGHT="71.36583223539746"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.676521957113154" CI_START="0.15330607664232812" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="1.1666231486455823" LOG_CI_START="-0.8144406305342196" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-09-18 12:33:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7275161395952314" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="28.634167764602537" Z="0.3484315137843158">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="14.676521957113154" CI_START="0.15330607664232812" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1666231486455823" LOG_CI_START="-0.8144406305342196" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-09-16 09:33:35 +0100" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.1636866703140785" STUDY_ID="STD-Fermoso-1992" TOTAL_1="16" TOTAL_2="12" VAR="1.3541666666666667" WEIGHT="28.634167764602537"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1928059945201477" CI_END="0.940409734281273" CI_START="0.7949806011568484" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8646429875345537" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="232" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.026682884095415794" LOG_CI_START="-0.0996434687187811" LOG_EFFECT_SIZE="-0.06316317640709847" METHOD="MH" MODIFIED="2015-09-16 09:39:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8792816532086906" P_Q="0.690050171647429" P_Z="6.899396404906437E-4" Q="0.15903127362531436" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="303" TOTAL_2="298" WEIGHT="99.99999999999999" Z="3.3935460234077515">
<NAME>Trophic disorders (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.178481230360658E-31" CI_END="1.4431129148255155" CI_START="0.4061924985931362" DF="0" EFFECT_SIZE="0.7656249999999999" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="100.0" ID="CMP-002.05.01" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537358" NO="1" P_CHI2="0.0" P_Z="0.40892878096210405" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="6.809575966202472" Z="0.8257802261198307">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="1.4431129148255155" CI_START="0.4061924985931362" EFFECT_SIZE="0.765625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537351" ORDER="275" O_E="0.0" SE="0.3234066120763363" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10459183673469387" WEIGHT="6.809575966202472"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8533794788973021" CI_END="0.9431456591579286" CI_START="0.80599632187032" DF="3" EFFECT_SIZE="0.8718783930510314" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="216" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-0.025421229761688955" LOG_CI_START="-0.09366694007464701" LOG_EFFECT_SIZE="-0.05954408491816801" NO="2" P_CHI2="0.8366613631160584" P_Z="6.259350055939437E-4" STUDIES="4" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="93.19042403379751" Z="3.4201200748538434">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="3.045766512884973" CI_START="0.36197784542443584" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.4836966074529867" LOG_CI_START="-0.4413180093131106" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="276" O_E="0.0" SE="0.5433581647846061" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2952380952380952" WEIGHT="2.023679132112867"/>
<DICH_DATA CI_END="0.9720706154589744" CI_START="0.7758233945767989" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="76" LOG_CI_END="-0.012302184878028533" LOG_CI_START="-0.11023712859981677" LOG_EFFECT_SIZE="-0.06126965673892266" ORDER="277" O_E="0.0" SE="0.05752747072796835" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.003309409888357255" WEIGHT="32.6824179836228"/>
<DICH_DATA CI_END="0.978849596085834" CI_START="0.8198576822426757" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="-0.009284034047752895" LOG_CI_START="-0.08626152954424844" LOG_EFFECT_SIZE="-0.047772781796000675" ORDER="278" O_E="0.0" SE="0.04521696189938959" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.00204457364341085" WEIGHT="41.28305429510249"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="279" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="17.20127262295937"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.81697925077332" CI_END="0.8232856848713659" CI_START="0.5745111856303561" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6877403833772946" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="458" I2="66.53908245418651" I2_Q="47.592683298322" ID="CMP-002.06" LOG_CI_END="-0.08444943594937238" LOG_CI_START="-0.2407015112572467" LOG_EFFECT_SIZE="-0.1625754736033095" METHOD="MH" MODIFIED="2015-09-16 09:38:59 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="5.07479245303033E-5" P_Q="0.12581696287202204" P_Z="4.531465769059487E-5" Q="5.724391533108095" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0807091522639909" TOTALS="YES" TOTAL_1="739" TOTAL_2="728" WEIGHT="100.0" Z="4.078564363438839">
<NAME>Pain in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7915690026239909" CI_START="0.2285590502564194" DF="0" EFFECT_SIZE="0.42534722222222227" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586795" NO="1" P_CHI2="1.0" P_Z="0.006985329843852194" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="4.650782631717388" Z="2.69754282917697">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.7915690026239909" CI_START="0.2285590502564194" EFFECT_SIZE="0.4253472222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586796" ORDER="280" O_E="0.0" SE="0.31689930588126447" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10042517006802722" WEIGHT="4.650782631717388"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.014391818999428" CI_END="0.9320047135667524" CI_START="0.16373951790175087" DF="3" EFFECT_SIZE="0.39064818248851413" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="121" I2="86.96467834738365" ID="CMP-002.06.02" LOG_CI_END="-0.03058189121806354" LOG_CI_START="-0.7858464926377848" LOG_EFFECT_SIZE="-0.40821419192792424" NO="2" P_CHI2="4.0105347186680795E-5" P_Z="0.03411682294007755" STUDIES="4" TAU2="0.6444098217543911" TOTAL_1="179" TOTAL_2="175" WEIGHT="18.658836877427156" Z="2.118688238937399">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5949206861209944" CI_START="0.07718401531191658" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.22554092986137214" LOG_CI_START="-1.1124726320557794" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="281" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.27142857142857146" WEIGHT="2.3922922868812813"/>
<DICH_DATA CI_END="0.3646049822641113" CI_START="0.051750510994256024" EFFECT_SIZE="0.13736263736263737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.43817740108140707" LOG_CI_START="-1.2860853575446674" LOG_EFFECT_SIZE="-0.8621313793130372" ORDER="282" O_E="0.0" SE="0.49806533083859533" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="0.24806907378335943" WEIGHT="2.5622632326884225"/>
<DICH_DATA CI_END="1.107432316188807" CI_START="0.3250763001380784" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0443171925890425" LOG_CI_START="-0.4880146918217552" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="283" O_E="0.0" SE="0.3126943839882286" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09777777777777774" WEIGHT="4.719764971656527"/>
<DICH_DATA CI_END="1.1105908283879482" CI_START="0.70965574979841" EFFECT_SIZE="0.8877708978328174" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="68" LOG_CI_END="0.04555408260948905" LOG_CI_START="-0.14895227412508424" LOG_EFFECT_SIZE="-0.05169909575779759" ORDER="284" O_E="0.0" SE="0.1142539967678824" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01305397577743528" WEIGHT="8.984516386200923"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.905503795005838" CI_END="1.0760407124196056" CI_START="0.6308566465725802" DF="3" EFFECT_SIZE="0.8239098466535053" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="88" I2="49.19993104505263" ID="CMP-002.06.03" LOG_CI_END="0.03182870334216246" LOG_CI_START="-0.200069316945316" LOG_EFFECT_SIZE="-0.08412030680157676" NO="3" P_CHI2="0.11629951783100934" P_Z="0.15504307834592615" STUDIES="4" TAU2="0.034293085865943054" TOTAL_1="140" TOTAL_2="131" WEIGHT="26.42864648287108" Z="1.421942037238277">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.3845753025980523" CI_START="0.7811781691977737" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.14131658060414426" LOG_CI_START="-0.10724990200658352" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="285" O_E="0.0" SE="0.1460091823094744" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.021318681318681334" WEIGHT="8.256730842246556"/>
<DICH_DATA CI_END="1.1243680173221975" CI_START="0.659122633248303" EFFECT_SIZE="0.8608695652173913" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.05090848359314629" LOG_CI_START="-0.1810337751052698" LOG_EFFECT_SIZE="-0.06506264575606176" ORDER="286" O_E="0.0" SE="0.13624403089214698" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.018562435953740304" WEIGHT="8.485976455438458"/>
<DICH_DATA CI_END="1.7255701519985482" CI_START="0.2839641143725649" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.23693261996280243" LOG_CI_START="-0.5467365399342888" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="287" O_E="0.0" SE="0.46033114374845624" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2119047619047619" WEIGHT="2.8789347311208875"/>
<DICH_DATA CI_END="0.8834027356612968" CI_START="0.3916908418748" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="34" LOG_CI_END="-0.05384126018203567" LOG_CI_START="-0.40705658257451216" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="288" O_E="0.0" SE="0.20748042881738504" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.043048128342245986" WEIGHT="6.80700445406518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.490595323811048" CI_END="0.9140012845193414" CI_START="0.6088906525014981" DF="7" EFFECT_SIZE="0.7460072643870094" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="225" I2="48.11200075325865" ID="CMP-002.06.04" LOG_CI_END="-0.03905319391685802" LOG_CI_START="-0.21546069304710233" LOG_EFFECT_SIZE="-0.12725694348198013" NO="4" P_CHI2="0.06101990504648369" P_Z="0.0046874948597432865" STUDIES="8" TAU2="0.03822436970093123" TOTAL_1="372" TOTAL_2="373" WEIGHT="50.26173400798437" Z="2.827759899517429">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8383828698307714" CI_START="0.2283041041125227" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.07655760394571752" LOG_CI_START="-0.6414862813376184" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="289" O_E="0.0" SE="0.33184190154205606" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.11011904761904762" WEIGHT="4.41452762655613"/>
<DICH_DATA CI_END="1.134445340981303" CI_START="0.5558864888322862" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.05478357586479491" LOG_CI_START="-0.2550138816313306" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="290" O_E="0.0" SE="0.18197656005537105" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.03311546840958607" WEIGHT="7.401003010811752"/>
<DICH_DATA CI_END="1.2464351528371953" CI_START="0.6558182990958795" EFFECT_SIZE="0.904121110176619" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.09566968877837234" LOG_CI_START="-0.18321646951250722" LOG_EFFECT_SIZE="-0.04377339036706745" ORDER="291" O_E="0.0" SE="0.16381910988881074" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02683670076476225" WEIGHT="7.833090133976833"/>
<DICH_DATA CI_END="0.8225193613399201" CI_START="0.3383439819545119" EFFECT_SIZE="0.527536231884058" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.08485387036993415" LOG_CI_START="-0.47064154380646456" LOG_EFFECT_SIZE="-0.27774770708819935" ORDER="292" O_E="0.0" SE="0.2266135890564004" STUDY_ID="STD-Kl_x00fc_ken-1971" TOTAL_1="30" TOTAL_2="28" VAR="0.051353718745023105" WEIGHT="6.378903880199222"/>
<DICH_DATA CI_END="1.2716280494144636" CI_START="0.08737705271779238" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1043600989624348" LOG_CI_START="-1.05860260840176" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="293" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="1.5390090887744667"/>
<DICH_DATA CI_END="1.6076614930719757" CI_START="0.7473919476306546" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.20619460960700486" LOG_CI_START="-0.12645158553162028" LOG_EFFECT_SIZE="0.03987151203769228" ORDER="294" O_E="0.0" SE="0.1953980216496508" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.038180386864597404" WEIGHT="7.085706332821342"/>
<DICH_DATA CI_END="0.8655808361251482" CI_START="0.502901968655921" EFFECT_SIZE="0.6597744360902256" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="70" LOG_CI_END="-0.062692367368319" LOG_CI_START="-0.2985166642901292" LOG_EFFECT_SIZE="-0.1806045158292241" ORDER="295" O_E="0.0" SE="0.13852435936096785" STUDY_ID="STD-Vanscheidt-2002b" TOTAL_1="114" TOTAL_2="117" VAR="0.01918899813636656" WEIGHT="8.432752327580976"/>
<DICH_DATA CI_END="1.2931623653008395" CI_START="0.6104395151211877" EFFECT_SIZE="0.8884803921568627" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.11165305692002613" LOG_CI_START="-0.21435736128576102" LOG_EFFECT_SIZE="-0.051352152182867476" ORDER="296" O_E="0.0" SE="0.19150013343167616" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.036672301104349776" WEIGHT="7.1767416072636525"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.398860370113988" CI_END="-0.3657887512144089" CI_START="-0.8526472252045965" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6092179882095027" ESTIMABLE="YES" I2="76.1872455087278" I2_Q="83.30423811040417" ID="CMP-002.07" MODIFIED="2015-09-16 09:38:56 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.015004146326388912" P_Q="0.01439097325696781" P_Z="9.337864825272673E-7" Q="5.98954397297174" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.14160445709553499" TOTALS="SUB" TOTAL_1="159" TOTAL_2="155" UNITS="" WEIGHT="200.0" Z="4.905102321988703">
<NAME>Pain in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02250226945542" CI_START="-0.6675528983586143" DF="0" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.03601936842423832" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.0967087165869946">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.02250226945542" CI_START="-0.6675528983586143" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.9" ORDER="297" SD_1="0.87" SD_2="0.86" SE="0.16455675563206043" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2759999775367286" CI_END="-0.5878618140291868" CI_START="-1.3300230881220862" DF="1" EFFECT_SIZE="-0.9589424510756366" ESTIMABLE="YES" I2="21.630092664228446" ID="CMP-002.07.02" NO="2" P_CHI2="0.2586442027278312" P_Z="4.0857809475295177E-7" STUDIES="2" TAU2="0.01602861478896774" TOTAL_1="83" TOTAL_2="81" WEIGHT="100.0" Z="5.064917108891204">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.702291280518464" CI_START="-1.5311239528967693" EFFECT_SIZE="-1.1167076167076166" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.8" ORDER="298" SD_1="0.8" SD_2="0.8" SE="0.2114407914931171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="59.019494232487126"/>
<CONT_DATA CI_END="-0.2078591665203685" CI_START="-1.2556038045826323" EFFECT_SIZE="-0.7317314855515005" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.35" ORDER="299" SD_1="0.19" SD_2="0.56" SE="0.267286706880009" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="40.98050576751288"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="42.77216828434961" CI_END="0.9120092518535925" CI_START="0.5697790217753791" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7208631904676749" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="341" I2="74.28234190309936" I2_Q="20.056007470078043" ID="CMP-002.08" LOG_CI_END="-0.0400007559604192" LOG_CI_START="-0.24429354473310058" LOG_EFFECT_SIZE="-0.14214715034675987" METHOD="MH" MODIFIED="2015-09-16 09:38:53 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.189864543904573E-5" P_Q="0.2894449478191724" P_Z="0.006381814278025803" Q="3.752627189437831" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10587675286673734" TOTALS="YES" TOTAL_1="977" TOTAL_2="626" WEIGHT="99.99999999999999" Z="2.7274902541435693">
<NAME>Cramps in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9944179280734241" CI_START="0.3117869045301575" DF="0" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" NO="1" P_CHI2="1.0" P_Z="0.04782921624123524" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="7.445139846551127" Z="1.9788826843676004">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9944179280734241" CI_START="0.3117869045301575" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" ORDER="300" O_E="0.0" SE="0.29588237897725395" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.08754638218923934" WEIGHT="7.445139846551127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6229518707645461" CI_END="0.8392082235326647" CI_START="0.4978939577924044" DF="1" EFFECT_SIZE="0.6464028958989984" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="75" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="-0.07613026907407978" LOG_CI_START="-0.302863144086741" LOG_EFFECT_SIZE="-0.18949670658041035" NO="2" P_CHI2="0.42995267096033873" P_Z="0.0010522849380123908" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="18.551717222211423" Z="3.2761611660048735">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="301" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="7.289851990268813"/>
<DICH_DATA CI_END="0.8213434036775193" CI_START="0.4592535070488815" EFFECT_SIZE="0.6141700404858299" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="65" LOG_CI_END="-0.08547522638786782" LOG_CI_START="-0.3379475185580027" LOG_EFFECT_SIZE="-0.21171137247293528" ORDER="302" O_E="0.0" SE="0.14830347417873932" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.021993920453484" WEIGHT="11.26186523194261"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.238404536419256E-4" CI_END="1.0935544465115181" CI_START="0.6874143704146213" DF="1" EFFECT_SIZE="0.8670207848505276" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.0388404108129386" LOG_CI_START="-0.16278139316687879" LOG_EFFECT_SIZE="-0.061970491176970094" NO="3" P_CHI2="0.9856423894740494" P_Z="0.22826921950468881" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="49" WEIGHT="15.262564899862735" Z="1.204829323154721">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0987179385457573" CI_START="0.6836250549483773" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.04088621521191639" LOG_CI_START="-0.1651820287096053" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="303" O_E="0.0" SE="0.12104550653376048" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.014652014652014652" WEIGHT="11.947872028360745"/>
<DICH_DATA CI_END="2.6910797608830856" CI_START="0.28450475943855263" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4299265700038317" LOG_CI_START="-0.5459104639592052" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="304" O_E="0.0" SE="0.5732115042211109" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3285714285714286" WEIGHT="3.31469287150199"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="34.679048204945495" CI_END="1.0606631145089842" CI_START="0.49805280501323623" DF="6" EFFECT_SIZE="0.7268192618218611" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="210" I2="82.69848709647009" ID="CMP-002.08.04" LOG_CI_END="0.025577466142380267" LOG_CI_START="-0.30272460962961084" LOG_EFFECT_SIZE="-0.13857357174361526" NO="4" P_CHI2="4.972526323032689E-6" P_Z="0.09801196695195415" STUDIES="7" TAU2="0.18111511786279133" TOTAL_1="745" TOTAL_2="402" WEIGHT="58.7405780313747" Z="1.6545689465283278">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8613172651925229" CI_START="0.4316673002365558" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="41" LOG_CI_END="-0.06483684721934725" LOG_CI_START="-0.3648508488760486" LOG_EFFECT_SIZE="-0.2148438480476979" ORDER="305" O_E="0.0" SE="0.17622970966640583" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.031056910569105697" WEIGHT="10.516495753615754"/>
<DICH_DATA CI_END="1.3796221567587041" CI_START="0.7413452390106355" EFFECT_SIZE="1.0113240418118468" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.139760160529198" LOG_CI_START="-0.1299794971759597" LOG_EFFECT_SIZE="0.004890331676619154" ORDER="306" O_E="0.0" SE="0.15844641016884967" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02510526489539535" WEIGHT="10.99435109226435"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="307" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.6516788753391062"/>
<DICH_DATA CI_END="1.940929634757623" CI_START="0.7712361889198123" EFFECT_SIZE="1.2234848484848484" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.28800979103472396" LOG_CI_START="-0.11281260011218036" LOG_EFFECT_SIZE="0.0875985954612718" ORDER="308" O_E="0.0" SE="0.23544505666252696" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.05543437470682053" WEIGHT="8.927234665776073"/>
<DICH_DATA CI_END="0.5160706369098471" CI_START="0.3435291719387765" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="95" LOG_CI_END="-0.28729085046463954" LOG_CI_START="-0.4640363774571312" LOG_EFFECT_SIZE="-0.3756636139608854" ORDER="309" O_E="0.0" SE="0.10382119745985853" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.010778841041998936" WEIGHT="12.344562672036995"/>
<DICH_DATA CI_END="1.0256362635790959" CI_START="0.4745830580100198" EFFECT_SIZE="0.6976744186046512" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.010993367862993894" LOG_CI_START="-0.32368776958284207" LOG_EFFECT_SIZE="-0.15634720085992407" ORDER="310" O_E="0.0" SE="0.19659335683403326" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.03864894795127353" WEIGHT="9.964056786435807"/>
<DICH_DATA CI_END="2.092749239381821" CI_START="0.42850408931161393" EFFECT_SIZE="0.946969696969697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3207171927547774" LOG_CI_START="-0.3680450291503642" LOG_EFFECT_SIZE="-0.023663918197793433" ORDER="311" O_E="0.0" SE="0.4045823385750652" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.1636868686868687" WEIGHT="5.342198185906618"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.363785516581151" CI_END="-0.2379134546448497" CI_START="-1.1528303832589923" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.695371918951921" ESTIMABLE="YES" I2="72.84005630668399" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2015-09-16 09:38:50 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.025175354201860567" P_Q="0.3271931676937033" P_Z="0.0028891206423918656" Q="0.9599757892980662" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.11807552212586293" TOTALS="YES" TOTAL_1="159" TOTAL_2="155" UNITS="" WEIGHT="100.0" Z="2.979295440670685">
<NAME>Cramps in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1247995932872627E-31" CI_END="-0.13562938035194616" CI_START="-0.7844441767334328" DF="0" EFFECT_SIZE="-0.4600367785426895" ESTIMABLE="YES" I2="100.0" ID="CMP-002.09.01" NO="1" P_CHI2="0.0" P_Z="0.005446066160000927" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="37.448076630826804" Z="2.7793925864087403">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.1356293803519461" CI_START="-0.7844441767334327" EFFECT_SIZE="-0.46003677854268943" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.7" ORDER="312" SD_1="0.87" SD_2="0.86" SE="0.16551702008283187" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="37.448076630826804"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.076715053283268" CI_END="-0.1640351444890693" CI_START="-1.4972358265207695" DF="1" EFFECT_SIZE="-0.8306354855049194" ESTIMABLE="YES" I2="75.4704465009241" ID="CMP-002.09.02" NO="2" P_CHI2="0.04347820538559566" P_Z="0.014595370668457959" STUDIES="2" TAU2="0.17504944329393862" TOTAL_1="83" TOTAL_2="81" WEIGHT="62.551923369173196" Z="2.4422664311716487">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.737539762590484" CI_START="-1.5702757682450441" EFFECT_SIZE="-1.153907765417764" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.6" ORDER="313" SD_1="0.7" SD_2="1.0" SE="0.21243655807532064" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="33.379066772577524"/>
<CONT_DATA CI_END="0.04075842663632262" CI_START="-0.9863864258951338" EFFECT_SIZE="-0.47281399962940557" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.19" ORDER="314" SD_1="0.19" SD_2="0.4" SE="0.2620315629862191" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="29.172856596595675"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.306055387072275" CI_END="0.9124553805538703" CI_START="0.7196052357786104" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.810313315490329" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="204" I2="31.56361764178154" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.03978836353233983" LOG_CI_START="-0.14290568543003448" LOG_EFFECT_SIZE="-0.09134702448118714" METHOD="MH" MODIFIED="2015-09-16 09:38:48 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.19885550826978837" P_Q="0.39745173462342986" P_Z="5.156563268014984E-4" Q="1.8453638180505711" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="289" TOTAL_2="283" WEIGHT="100.0" Z="3.4724889045441385">
<NAME>Restless legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Plebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014524314160636997" CI_END="0.9067321847665462" CI_START="0.5885798978528514" DF="1" EFFECT_SIZE="0.7305370193835399" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="83" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="-0.04252096856648605" LOG_CI_START="-0.23019457472139648" LOG_EFFECT_SIZE="-0.13635777164394125" NO="1" P_CHI2="0.9040737254021073" P_Z="0.00439815110243004" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="40.87315871985595" Z="2.848097043690437">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.0471514391769654" CI_START="0.48723046404220255" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.02000949394521839" LOG_CI_START="-0.3122655653016944" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="315" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0380952380952381" WEIGHT="6.818687107697609"/>
<DICH_DATA CI_END="0.9398281433130286" CI_START="0.5729230757694193" EFFECT_SIZE="0.7337909992372235" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="69" LOG_CI_END="-0.026951554096481766" LOG_CI_START="-0.2419036852080609" LOG_EFFECT_SIZE="-0.13442761965227135" ORDER="316" O_E="0.0" SE="0.12626394584515102" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01594258402038723" WEIGHT="34.054471612158345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1470295339646062" CI_START="0.7007709655708828" DF="0" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.059574600353514244" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" NO="2" P_CHI2="1.0" P_Z="0.38500942450946507" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="14.124423294516475" Z="0.8687033375831925">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.1470295339646064" CI_START="0.7007709655708828" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.059574600353514334" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" ORDER="317" O_E="0.0" SE="0.12570377854054737" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.01580143993937098" WEIGHT="14.124423294516475"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.20610096140142" CI_END="1.0077783299331828" CI_START="0.7265759199342345" DF="2" EFFECT_SIZE="0.8557029082345046" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="92" I2="52.45002394489301" ID="CMP-002.10.03" LOG_CI_END="0.003365015568049202" LOG_CI_START="-0.13871899955475187" LOG_EFFECT_SIZE="-0.06767699199335131" NO="3" P_CHI2="0.12208350029186055" P_Z="0.06188382245596403" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="122" WEIGHT="45.002417985627574" Z="1.8671272313684488">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.9400697740764922" CI_START="0.5280292072025189" EFFECT_SIZE="0.7045454545454546" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="-0.026839910898372437" LOG_CI_START="-0.277342054405457" LOG_EFFECT_SIZE="-0.15209098265191473" ORDER="318" O_E="0.0" SE="0.1471461991016704" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021652003910068423" WEIGHT="21.43015948133534"/>
<DICH_DATA CI_END="1.1581867758840065" CI_START="0.8019457345949211" EFFECT_SIZE="0.963744232036915" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.06377860187399871" LOG_CI_START="-0.09585501820377643" LOG_EFFECT_SIZE="-0.016038208164888847" ORDER="319" O_E="0.0" SE="0.09376957863284864" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.008792733876981984" WEIGHT="17.591748881594"/>
<DICH_DATA CI_END="1.767505877093551" CI_START="0.6593575747233957" EFFECT_SIZE="1.0795454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.247360866534032" LOG_CI_START="-0.18087900025667367" LOG_EFFECT_SIZE="0.03324093313867916" ORDER="320" O_E="0.0" SE="0.25155021757438917" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06327751196172252" WEIGHT="5.980509622698236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.56668125263086" CI_END="1.0235109556345239" CI_START="0.41414655114365456" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6510633858033978" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="117" I2="91.79581001821388" I2_Q="31.958941470202245" ID="CMP-002.11" LOG_CI_END="0.010092495700190102" LOG_CI_START="-0.3828459509307137" LOG_EFFECT_SIZE="-0.18637672761526183" METHOD="MH" MODIFIED="2016-03-31 10:26:12 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="5.682738957180078E-8" P_Q="0.22999433786651313" P_Z="0.06298718912216998" Q="2.939401654258692" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4462879445377894" TOTALS="SUB" TOTAL_1="206" TOTAL_2="199" WEIGHT="300.0" Z="1.8592819145817603">
<NAME>Itching in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9101776359707308" CI_START="0.309592344001341" DF="0" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" NO="1" P_CHI2="1.0" P_Z="0.021330988620835198" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.3020741908173297">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9101776359707308" CI_START="0.309592344001341" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" ORDER="321" O_E="0.0" SE="0.2751028540826821" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.07568158032443749" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.248879154931936" CI_START="0.5082566580469068" DF="0" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" NO="2" P_CHI2="1.0" P_Z="0.4100989716659914" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.00000000000001" Z="0.8237194877511418">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="5.248879154931936" CI_START="0.5082566580469068" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" ORDER="322" O_E="0.0" SE="0.5956189257922424" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3547619047619047" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.645066156008205" CI_END="2.211282659580293" CI_START="0.20696351391226026" DF="1" EFFECT_SIZE="0.6765019064865861" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="89" I2="97.34360939663165" ID="CMP-002.11.03" LOG_CI_END="0.3446442602855613" LOG_CI_START="-0.6841062105973242" LOG_EFFECT_SIZE="-0.1697309751558815" NO="3" P_CHI2="8.486296110277181E-10" P_Z="0.5178007897206087" STUDIES="2" TAU2="0.711058010611193" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0" Z="0.6467391418657473">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.2460927890061566" CI_START="0.8423291969842424" EFFECT_SIZE="1.0245098039215685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.09555038281508714" LOG_CI_START="-0.07451814544477672" LOG_EFFECT_SIZE="0.010516118685155208" ORDER="323" O_E="0.0" SE="0.09989909535263612" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.009979829252275085" WEIGHT="50.645077619243956"/>
<DICH_DATA CI_END="0.6163595664241507" CI_START="0.3168008036596062" EFFECT_SIZE="0.4418859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="72" LOG_CI_END="-0.21016585901078652" LOG_CI_START="-0.4992137253638269" LOG_EFFECT_SIZE="-0.35468979218730673" ORDER="324" O_E="0.0" SE="0.1697881475057902" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.02882801503344797" WEIGHT="49.35492238075604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2016-03-31 10:31:32 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Itching in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.062421529897900396" CI_START="-1.0970469534983178" EFFECT_SIZE="-0.579734241698109" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.42" ORDER="325" SD_1="0.36" SD_2="0.57" SE="0.26393990699865166" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="70.05608840489226" CI_END="0.6589118562709212" CI_START="0.39077388654708434" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5074303370581441" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="398" I2="80.01601242837542" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.18117267781183388" LOG_CI_START="-0.40807446569897815" LOG_EFFECT_SIZE="-0.294623571755406" METHOD="MH" MODIFIED="2016-03-31 10:26:33 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.885472444840275E-9" P_Q="0.5259102647481978" P_Z="3.582876203337463E-7" Q="3.1939410172872806" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.146557324871367" TOTALS="SUB" TOTAL_1="609" TOTAL_2="588" WEIGHT="500.0" Z="5.089881353639745">
<NAME>Heaviness in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5967167771289194" CI_START="0.168201730597713" DF="0" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" NO="1" P_CHI2="1.0" P_Z="3.732965903623685E-4" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.5582762523938705">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.5967167771289194" CI_START="0.168201730597713" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" ORDER="326" O_E="0.0" SE="0.32303617929445816" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10435237313316133" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.418240827894476" CI_END="1.4176733751822246" CI_START="0.07691894388050581" DF="2" EFFECT_SIZE="0.33022104534164504" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="118" I2="87.02835153293476" ID="CMP-002.13.02" LOG_CI_END="0.15157618310679574" LOG_CI_START="-1.1139666873823013" LOG_EFFECT_SIZE="-0.4811952521377528" NO="2" P_CHI2="4.487195851935466E-4" P_Z="0.13610131233692863" STUDIES="3" TAU2="1.3424115320255592" TOTAL_1="154" TOTAL_2="151" WEIGHT="100.0" Z="1.4904676652434135">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4767667009009777" CI_START="0.010701336327987806" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.32169408489527707" LOG_CI_START="-1.9705619864611992" LOG_EFFECT_SIZE="-1.146128035678238" ORDER="327" O_E="0.0" SE="0.9685531674075709" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.9380952380952381" WEIGHT="24.232463165281054"/>
<DICH_DATA CI_END="0.8148735481416007" CI_START="0.11618312611684645" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.08890977973258558" LOG_CI_START="-0.9348569422251632" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="328" O_E="0.0" SE="0.49691355075412963" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.24692307692307694" WEIGHT="34.77071221753797"/>
<DICH_DATA CI_END="1.0029892242921044" CI_START="0.7489058807072021" EFFECT_SIZE="0.866685945633314" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="91" LOG_CI_END="0.0012962671623755592" LOG_CI_START="-0.12557275914689353" LOG_EFFECT_SIZE="-0.06213824599225903" ORDER="329" O_E="0.0" SE="0.07452349406587333" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.005553751167786258" WEIGHT="40.996824617180984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1852075767243728" CI_START="0.323024902994722" DF="0" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-002.13.03" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" NO="3" P_CHI2="1.0" P_Z="0.14773361488268363" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.4475833341101076">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="1.1852075767243728" CI_START="0.323024902994722" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" ORDER="330" O_E="0.0" SE="0.3316244072361796" STUDY_ID="STD-Pointel-1986" TOTAL_1="30" TOTAL_2="33" VAR="0.10997474747474748" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.89350064921898" CI_END="1.220486753995972" CI_START="0.2901780813703823" DF="2" EFFECT_SIZE="0.5951121781752722" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="62" I2="83.18409306908866" ID="CMP-002.13.04" LOG_CI_END="0.0865330703589645" LOG_CI_START="-0.5373353951353587" LOG_EFFECT_SIZE="-0.2254011623881971" NO="4" P_CHI2="0.0026143273846407356" P_Z="0.15670109857858716" STUDIES="3" TAU2="0.31779362341706247" TOTAL_1="105" TOTAL_2="96" WEIGHT="100.0" Z="1.4162541778875999">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0641010650963951" CI_START="0.7015273496905823" EFFECT_SIZE="0.864" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.026982877892531416" LOG_CI_START="-0.15395539293474494" LOG_EFFECT_SIZE="-0.06348625752110672" ORDER="331" O_E="0.0" SE="0.10628403594282773" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.011296296296296297" WEIGHT="40.808129843406114"/>
<DICH_DATA CI_END="1.2575147355900478" CI_START="0.19880482743026914" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.09951308283170253" LOG_CI_START="-0.701573074159665" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="332" O_E="0.0" SE="0.47056197405716016" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.22142857142857145" WEIGHT="24.905399485018208"/>
<DICH_DATA CI_END="0.7382545478648378" CI_START="0.2543537026908459" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" LOG_CI_END="-0.13179386897308396" LOG_CI_START="-0.5945619358525673" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="333" O_E="0.0" SE="0.27183225322388416" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.07389277389277388" WEIGHT="34.286470671575664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.747256301817313" CI_END="0.795151347828084" CI_START="0.38087065996285707" DF="6" EFFECT_SIZE="0.550317925037553" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="173" I2="76.69654611090928" ID="CMP-002.13.05" LOG_CI_END="-0.09955020056269719" LOG_CI_START="-0.41922248154490865" LOG_EFFECT_SIZE="-0.25938634105380287" NO="5" P_CHI2="2.481172073754978E-4" P_Z="0.0014692896882684027" STUDIES="8" TAU2="0.1563693527833239" TOTAL_1="272" TOTAL_2="259" WEIGHT="100.0" Z="3.1806816967991467">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.7903712751309083" CI_START="0.11978491525686698" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.1021688519209733" LOG_CI_START="-0.9215978700367755" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="334" O_E="0.0" SE="0.48133666148028004" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.2316849816849817" WEIGHT="9.086416188696004"/>
<DICH_DATA CI_END="0.8334668511039568" CI_START="0.5232340734719679" EFFECT_SIZE="0.660377358490566" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="53" LOG_CI_END="-0.07911166838416735" LOG_CI_START="-0.28130398211685953" LOG_EFFECT_SIZE="-0.18020782525051343" ORDER="335" O_E="0.0" SE="0.11876876595467818" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.014106019766397124" WEIGHT="20.683475472552864"/>
<DICH_DATA CI_END="1.115629165191512" CI_START="0.5909468666401837" EFFECT_SIZE="0.8119590873328089" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.04751985922987865" LOG_CI_START="-0.22845156575550984" LOG_EFFECT_SIZE="-0.0904658532628156" ORDER="336" O_E="0.0" SE="0.16210698111700278" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.026278673326868292" WEIGHT="19.30501665908617"/>
<DICH_DATA CI_END="0.8233214739870668" CI_START="0.018978006153943038" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.08443055711068892" LOG_CI_START="-1.7217494168731982" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="337" O_E="0.0" SE="0.9617692030835672" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.9249999999999999" WEIGHT="3.2607019772946924"/>
<DICH_DATA CI_END="1.318145566401421" CI_START="0.6846740018735968" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.11996337322768261" LOG_CI_START="-0.1645161626499871" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="338" O_E="0.0" SE="0.16710468757095692" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.02792397660818713" WEIGHT="19.132668547735744"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.4674556575963953" CI_START="0.12597648307047615" EFFECT_SIZE="0.24266936299292213" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.330259579603341" LOG_CI_START="-0.899710520167806" LOG_EFFECT_SIZE="-0.6149850498855735" ORDER="340" O_E="0.0" SE="0.3344983013151838" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.1118891135827435" WEIGHT="13.144126388894021"/>
<DICH_DATA CI_END="0.8837520787736368" CI_START="0.3069496158781802" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" LOG_CI_END="-0.053669551640466745" LOG_CI_START="-0.5129329057666325" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="341" O_E="0.0" SE="0.2697735676039774" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.07277777777777777" WEIGHT="15.387594765740515"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="62.679936843645415" CI_END="-0.4410321795754322" CI_START="-1.0641156379019465" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7525739087386893" ESTIMABLE="YES" I2="92.02296579769623" I2_Q="22.338000630873474" ID="CMP-002.14" MODIFIED="2016-03-31 10:26:45 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="3.390843161810153E-12" P_Q="0.2564850934257573" P_Z="2.195143302714401E-6" Q="1.2876310269157665" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.6821500982735521" TOTALS="SUB" TOTAL_1="259" TOTAL_2="251" UNITS="" WEIGHT="200.0" Z="4.734575239066647">
<NAME>Heaviness in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3603295782741587" CI_START="-1.01978075735391" DF="0" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.01" NO="1" P_CHI2="1.0" P_Z="4.098687284737795E-5" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.1018450468118335">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.3603295782741586" CI_START="-1.01978075735391" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.3" ORDER="342" SD_1="0.87" SD_2="0.86" SE="0.16823043287565947" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="62.22083327940478" CI_END="-0.3216747394380064" CI_START="-2.2242256087156154" DF="4" EFFECT_SIZE="-1.2729501740768108" ESTIMABLE="YES" I2="93.57128506775558" ID="CMP-002.14.02" NO="2" P_CHI2="9.902079156631771E-13" P_Z="0.008722894112349425" STUDIES="5" TAU2="1.0785245255258862" TOTAL_1="183" TOTAL_2="177" WEIGHT="100.0" Z="2.622727765751524">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.27817683616857625" CI_START="-1.6773787193869785" EFFECT_SIZE="-0.9777777777777773" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.3" ORDER="343" SD_1="0.5" SD_2="0.5" SE="0.3569458148861734" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="16" TOTAL_2="20" WEIGHT="19.534060984588443"/>
<CONT_DATA CI_END="-0.9862975811839929" CI_START="-1.849785254898844" EFFECT_SIZE="-1.4180414180414185" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.2" ORDER="344" SD_1="0.7" SD_2="0.7" SE="0.22028151550894087" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="20.901323507602484"/>
<CONT_DATA CI_END="-2.02712182233849" CI_START="-3.8676183455235718" EFFECT_SIZE="-2.947370083931031" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="4.2" ORDER="345" SD_1="0.6" SD_2="0.9" SE="0.46952304677603346" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="18.134897913273498"/>
<CONT_DATA CI_END="-0.8576325843782733" CI_START="-1.9996033761561216" EFFECT_SIZE="-1.4286179802671974" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.77" ORDER="346" SD_1="0.45" SD_2="0.42" SE="0.29132443268998004" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.248338559089568"/>
<CONT_DATA CI_END="0.5397949297356679" CI_START="-0.1789787739176506" EFFECT_SIZE="0.18040807790900865" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.0" ORDER="347" SD_1="28.0" SD_2="27.0" SE="0.1833640080437482" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="21.18137903544601"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="25.86600105430862" CI_END="0.8170757295882212" CI_START="0.5259960348093861" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6555750101265229" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="283" I2="57.47313248420487" I2_Q="80.69080029577943" ID="CMP-002.15" LOG_CI_END="-0.08773768958986113" LOG_CI_START="-0.27901752973769467" LOG_EFFECT_SIZE="-0.18337760966377786" METHOD="MH" MODIFIED="2015-09-16 09:38:35 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.006794482161548432" P_Q="0.00563435484309871" P_Z="1.7128624873780798E-4" Q="10.35775708282122" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0675325453441491" TOTALS="YES" TOTAL_1="484" TOTAL_2="468" WEIGHT="100.0" Z="3.7579863119319916">
<NAME>Swelling in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.121508738565895" CI_END="0.4144421464212803" CI_START="0.08392244096274963" DF="1" EFFECT_SIZE="0.1864966395555564" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="29" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="-0.38253608572552134" LOG_CI_START="-1.0761218927692697" LOG_EFFECT_SIZE="-0.7293289892473956" NO="1" P_CHI2="0.7274039280063906" P_Z="3.756997163840102E-5" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.319581794377166" Z="4.121937148335366">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5053433241361468" CI_START="0.05147899836737502" EFFECT_SIZE="0.16129032258064516" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.29641346719478834" LOG_CI_START="-1.2883699118017196" LOG_EFFECT_SIZE="-0.7923916894982539" ORDER="348" O_E="0.0" SE="0.5826801258257038" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.3395161290322581" WEIGHT="3.101467678890151"/>
<DICH_DATA CI_END="0.6547491999374693" CI_START="0.07013123093747059" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.1839250235830732" LOG_CI_START="-1.1540885383340782" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="349" O_E="0.0" SE="0.5698788509515902" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.3247619047619048" WEIGHT="3.2181141154870145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2380604448537903E-30" CI_END="0.9386337042179341" CI_START="0.5220353773768074" DF="1" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="-0.027503855308840846" LOG_CI_START="-0.2823000646626456" LOG_EFFECT_SIZE="-0.1549019599857432" NO="2" P_CHI2="0.9999999999999991" P_Z="0.017167588907441238" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="49" WEIGHT="16.651046620630538" Z="2.3830987397865524">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="0.9471991281342894" CI_START="0.5173146653599221" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.023558710374788606" LOG_CI_START="-0.2862452095966978" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="350" O_E="0.0" SE="0.15430334996209188" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.023809523809523805" WEIGHT="13.821104765971297"/>
<DICH_DATA CI_END="2.3379040026017486" CI_START="0.20958944398687923" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.36882667449208634" LOG_CI_START="-0.6786305944635728" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="351" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="2.8299418546592428"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.501538493692047" CI_END="0.8880043665451057" CI_START="0.5814397143836543" DF="7" EFFECT_SIZE="0.7185548032373202" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="220" I2="48.15405664124561" ID="CMP-002.15.03" LOG_CI_END="-0.05158489867885176" LOG_CI_START="-0.23549530770728494" LOG_EFFECT_SIZE="-0.1435401031930684" NO="3" P_CHI2="0.060791427496247" P_Z="0.0022173508692032223" STUDIES="8" TAU2="0.03864761788720671" TOTAL_1="389" TOTAL_2="379" WEIGHT="77.02937158499229" Z="3.0594617681708463">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8319859354514977" CI_START="0.4923160146664264" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="50" LOG_CI_END="-0.07988401530474874" LOG_CI_START="-0.3077560367274769" LOG_EFFECT_SIZE="-0.1938200260161128" ORDER="352" O_E="0.0" SE="0.13385315336840845" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.017916666666666674" WEIGHT="14.774253355943335"/>
<DICH_DATA CI_END="1.3036070664342596" CI_START="0.5953619345651708" EFFECT_SIZE="0.8809756097560976" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.11514670597006874" LOG_CI_START="-0.22521893612660332" LOG_EFFECT_SIZE="-0.055036115078267306" ORDER="353" O_E="0.0" SE="0.19993246300468626" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.039972989763120234" WEIGHT="11.743100539463702"/>
<DICH_DATA CI_END="0.9269426096039015" CI_START="0.01685649126290228" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="354" O_E="0.0" SE="1.0222524150130436" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="1.045" WEIGHT="1.1347517990343237"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="355" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="2.3632537804790847"/>
<DICH_DATA CI_END="1.5429183637159785" CI_START="0.6946289966993215" EFFECT_SIZE="1.0352564102564104" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.18834294801674317" LOG_CI_START="-0.1582470913914229" LOG_EFFECT_SIZE="0.015047928312660138" ORDER="356" O_E="0.0" SE="0.2035887047967214" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.04144836072080657" WEIGHT="11.584123796521329"/>
<DICH_DATA CI_END="0.7465041278868161" CI_START="0.43092451697916057" EFFECT_SIZE="0.567174515235457" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="76" LOG_CI_END="-0.12696778644731532" LOG_CI_START="-0.36559879649908833" LOG_EFFECT_SIZE="-0.24628329147320185" ORDER="357" O_E="0.0" SE="0.14017303654696206" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.019648480174795962" WEIGHT="14.480769178829737"/>
<DICH_DATA CI_END="1.109055461819751" CI_START="0.6048172784324211" EFFECT_SIZE="0.8190091001011123" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.04495326495889572" LOG_CI_START="-0.21837581039595505" LOG_EFFECT_SIZE="-0.08671127271852963" ORDER="358" O_E="0.0" SE="0.1546808023633849" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.023926150619780547" WEIGHT="13.803480292474376"/>
<DICH_DATA CI_END="0.9951910458724644" CI_START="0.27257817706076365" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.0020935401549377042" LOG_CI_START="-0.5645089172521615" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="359" O_E="0.0" SE="0.3303655765079257" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.10914141414141412" WEIGHT="7.145638842246406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="68.34915645456127" CI_END="-0.6172942301926859" CI_START="-1.2794802083228052" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9483872192577455" ESTIMABLE="YES" I2="95.61077245774875" I2_Q="0.0" ID="CMP-002.16" MODIFIED="2016-03-31 10:26:55 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="9.880984919163893E-15" P_Q="0.3782604554527822" P_Z="1.9753395417489598E-8" Q="0.7763479020331081" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.11717820265693" TOTALS="SUB" TOTAL_1="213" TOTAL_2="201" UNITS="" WEIGHT="200.0" Z="5.61414724724968">
<NAME>Swelling in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5830434537525135" CI_START="-1.2571036604182444" DF="0" EFFECT_SIZE="-0.920073557085379" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.01" MODIFIED="2013-12-29 23:05:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.766630872206274E-8" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="5.35059336594029">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.5830434537525135" CI_START="-1.2571036604182444" EFFECT_SIZE="-0.920073557085379" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.3" ORDER="1" SD_1="0.87" SD_2="0.86" SE="0.17195729410913463" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="67.70260419666258" CI_END="0.04090040370302184" CI_START="-3.502601975760228" DF="2" EFFECT_SIZE="-1.730850786028603" ESTIMABLE="YES" I2="97.04590388548364" ID="CMP-002.16.02" MODIFIED="2014-08-29 16:13:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.9984014443252818E-15" P_Z="0.05552838252462859" STUDIES="3" TAU2="2.3218687052924833" TOTAL_1="137" TOTAL_2="127" WEIGHT="100.0" Z="1.9147187386637332">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-1.0862316464850301" CI_START="-1.9635915000065065" EFFECT_SIZE="-1.5249115732457683" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" ORDER="361" SD_1="0.6" SD_2="0.7" SE="0.22382040191605015" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="34.45094505491311"/>
<CONT_DATA CI_END="-2.9213570285933605" CI_START="-5.161022211028014" EFFECT_SIZE="-4.041189619810687" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="3.9" ORDER="362" SD_1="0.6" SD_2="1.0" SE="0.5713536575418852" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="30.856016330479573"/>
<CONT_DATA CI_END="0.47843011007575204" CI_START="-0.23950153595374585" EFFECT_SIZE="0.1194642870610031" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="20.0" ORDER="363" SD_1="24.0" SD_2="26.0" SE="0.18314919347815856" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="34.69303861460732"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.358294910021818" CI_END="0.8831325174766795" CI_START="0.638063492377769" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7506627860321446" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="170" I2="18.459370365434165" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="-0.05397412395273713" LOG_CI_START="-0.19513610338334034" LOG_EFFECT_SIZE="-0.12455511366803872" METHOD="MH" MODIFIED="2015-09-16 09:38:30 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.28897903816064474" P_Q="0.7053269775869481" P_Z="5.426444503299417E-4" Q="0.6981878334946292" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="361" TOTAL_2="355" WEIGHT="100.0" Z="3.4587718005139254">
<NAME>Paraesthesias in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9764832950325375" CI_END="1.0132447467529284" CI_START="0.582997217394775" DF="2" EFFECT_SIZE="0.7685823754789273" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="32.806610964764815" ID="CMP-002.17.01" LOG_CI_END="0.005714360785672955" LOG_CI_START="-0.23433351809343622" LOG_EFFECT_SIZE="-0.11430957865388161" NO="1" P_CHI2="0.22576935148037192" P_Z="0.06195051447296882" STUDIES="3" TAU2="0.0" TOTAL_1="154" TOTAL_2="151" WEIGHT="40.62110704581793" Z="1.8666497558379755">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.890138731579122" CI_START="0.19503826196071922" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.05054230159788697" LOG_CI_START="-0.709880181825325" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="364" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.15000000000000002" WEIGHT="7.003639145830677"/>
<DICH_DATA CI_END="1.6730972932352277" CI_START="0.5022288788435925" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.22352119660291833" LOG_CI_START="-0.29909831838171796" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="365" O_E="0.0" SE="0.30698929011029724" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09424242424242424" WEIGHT="7.003639145830677"/>
<DICH_DATA CI_END="1.1594988882924713" CI_START="0.5830530667533707" EFFECT_SIZE="0.8222222222222222" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.0642703365801496" LOG_CI_START="-0.234291915996847" LOG_EFFECT_SIZE="-0.0850107897083487" ORDER="366" O_E="0.0" SE="0.1753769450707134" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.030757072862336025" WEIGHT="26.613828754156575"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009383939991687733" CI_END="1.0565320386401804" CI_START="0.6135463980129532" DF="1" EFFECT_SIZE="0.805128205128205" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="0.02388267128295247" LOG_CI_START="-0.21215258918952115" LOG_EFFECT_SIZE="-0.09413495895328432" NO="2" P_CHI2="0.9228290473342848" P_Z="0.11797374580078275" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="26.778620263470238" Z="1.5633353157937186">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="2.2172120454662894" CI_START="0.3182374917377869" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.3458072293220705" LOG_CI_START="-0.49724865719830724" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="367" O_E="0.0" SE="0.49521520093601257" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.24523809523809528" WEIGHT="3.433156444034646"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="368" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="23.34546381943559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9583970546632408" CI_END="0.908487547068777" CI_START="0.5143739920273456" DF="1" EFFECT_SIZE="0.6835951772013154" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="56" I2="66.19791118221514" ID="CMP-002.17.03" LOG_CI_END="-0.04168102132939735" LOG_CI_START="-0.28872099849082994" LOG_EFFECT_SIZE="-0.1652010099101137" MODIFIED="2013-12-29 23:05:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08543276736032523" P_Z="0.008758456690439106" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="135" WEIGHT="32.60027269071184" Z="2.6213411558233948">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.7891864271810392" CI_START="0.4438377403223627" EFFECT_SIZE="0.5918367346938775" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" LOG_CI_END="-0.10282039256716954" LOG_CI_START="-0.35277577169194557" LOG_EFFECT_SIZE="-0.22779808212955757" ORDER="369" O_E="0.0" SE="0.14682502699697503" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021557588552662443" WEIGHT="28.598193178808597"/>
<DICH_DATA CI_END="3.405627712118229" CI_START="0.5266830012297969" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.532197171104675" LOG_CI_START="-0.2784506983336758" LOG_EFFECT_SIZE="0.1268732363854996" ORDER="370" O_E="0.0" SE="0.47617857127975816" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.22674603174603172" WEIGHT="4.0020795119032435"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.18" MODIFIED="2016-03-31 10:31:19 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="76" TOTAL_2="74" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Paraesthesias in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.18.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="0.17686047151612821" CI_START="-0.37686047151612817" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.5" ORDER="371" SD_1="0.87" SD_2="0.86" SE="0.14125793825803343" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.19" MODIFIED="2016-03-31 10:31:11 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="22.52" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="-2.9899999961253796" CI_START="-17.01000000387462" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-15.4" MEAN_2="-5.4" MODIFIED="2015-09-09 22:05:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2475" SD_1="17.8" SD_2="13.1" SE="3.5765963350187073" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="40.58893623004574" CI_END="0.8987349614910354" CI_START="0.5289623275352797" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6894903458842829" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="320" I2="72.89901874329658" I2_Q="8.947047613527342" ID="CMP-002.20" LOG_CI_END="-0.046368363586642945" LOG_CI_START="-0.276575257125766" LOG_EFFECT_SIZE="-0.16147181035620445" METHOD="MH" MODIFIED="2015-09-16 09:38:22 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="2.835789641408848E-5" P_Q="0.33345036822660545" P_Z="0.005968308908712778" Q="2.196524052851175" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12112451992118155" TOTALS="YES" TOTAL_1="602" TOTAL_2="591" WEIGHT="100.0" Z="2.749517427138712">
<NAME>Global assessment by the participant (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.552029791417464" CI_END="1.1741416585372302" CI_START="0.4303771669361243" DF="2" EFFECT_SIZE="0.710861280829766" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="145" I2="76.61373909142442" ID="CMP-002.20.01" LOG_CI_END="0.06972049709016626" LOG_CI_START="-0.3661507776220775" LOG_EFFECT_SIZE="-0.1482151402659556" NO="1" P_CHI2="0.013897966474493484" P_Z="0.18254967477158146" STUDIES="3" TAU2="0.12505880106426343" TOTAL_1="262" TOTAL_2="253" WEIGHT="28.627607181060824" Z="1.332945544881833">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4451289704755189" CI_START="0.02103939567657449" EFFECT_SIZE="0.0967741935483871" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.351514139466709" LOG_CI_START="-1.6769667387625116" LOG_EFFECT_SIZE="-1.0142404391146103" ORDER="372" O_E="0.0" SE="0.778577417922537" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6061827956989247" WEIGHT="2.514165698783837"/>
<DICH_DATA CI_END="1.3012611117111792" CI_START="0.6355666651062011" EFFECT_SIZE="0.9094163981382026" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.11436445105595708" LOG_CI_START="-0.19683888921809106" LOG_EFFECT_SIZE="-0.04123721908106701" ORDER="373" O_E="0.0" SE="0.18280238255835482" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.03341671106901111" WEIGHT="11.832254044376446"/>
<DICH_DATA CI_END="0.9767533688245212" CI_START="0.7050314973967807" EFFECT_SIZE="0.8298444976076556" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="88" LOG_CI_END="-0.010215082217969828" LOG_CI_START="-0.1517914803985976" LOG_EFFECT_SIZE="-0.08100328130828371" ORDER="374" O_E="0.0" SE="0.08316267710577435" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.0069160308633992845" WEIGHT="14.281187437900538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06039100311643488" CI_END="1.0374812110167335" CI_START="0.684054749275346" DF="1" EFFECT_SIZE="0.842433350289466" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="62" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="0.015980240299174265" LOG_CI_START="-0.1649091375245905" LOG_EFFECT_SIZE="-0.0744644486127081" MODIFIED="2014-03-17 22:21:30 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8058790108053435" P_Z="0.10659960933125459" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="85" WEIGHT="25.447019644406517" Z="1.6136673050170367">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0989195384422978" CI_START="0.6140075541068498" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.0409658950715677" LOG_CI_START="-0.2118262857208204" LOG_EFFECT_SIZE="-0.08543019532462635" ORDER="375" O_E="0.0" SE="0.1484913783389251" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.02204968944099379" WEIGHT="12.77165149751967"/>
<DICH_DATA CI_END="1.165515036767495" CI_START="0.6420464528341865" EFFECT_SIZE="0.8650519031141869" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.06651788089651227" LOG_CI_START="-0.19243354906553276" LOG_EFFECT_SIZE="-0.06295783408451022" ORDER="376" O_E="0.0" SE="0.15210935178995663" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.023137254901960783" WEIGHT="12.675368146886846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="29.797911282836964" CI_END="0.9798855256231475" CI_START="0.27852464608927635" DF="6" EFFECT_SIZE="0.5224196294476229" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="113" I2="79.86436048134726" ID="CMP-002.20.03" LOG_CI_END="-0.008824657464715538" LOG_CI_START="-0.5551363689391339" LOG_EFFECT_SIZE="-0.2819805132019248" NO="3" P_CHI2="4.29427935417781E-5" P_Z="0.04304395934816399" STUDIES="7" TAU2="0.4979340915666993" TOTAL_1="254" TOTAL_2="253" WEIGHT="45.925373174532666" Z="2.0232831865394605">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.5088426833213036" CI_START="0.4045163682382569" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.17864396122882614" LOG_CI_START="-0.39306390052456286" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="378" O_E="0.0" SE="0.33582402799349803" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" VAR="0.11277777777777775" WEIGHT="7.817670554737594"/>
<DICH_DATA CI_END="0.2762811639284057" CI_START="0.02945641493441985" EFFECT_SIZE="0.0902122641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="32" LOG_CI_END="-0.5586487230487662" LOG_CI_START="-1.5308201111574262" LOG_EFFECT_SIZE="-1.0447344171030961" ORDER="379" O_E="0.0" SE="0.5710582857010101" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.32610756566777654" WEIGHT="4.08864024815792"/>
<DICH_DATA CI_END="0.9680143173409217" CI_START="0.37820149316348955" EFFECT_SIZE="0.6050656660412758" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.014118219245144973" LOG_CI_START="-0.42227676086542654" LOG_EFFECT_SIZE="-0.21819749005528571" ORDER="380" O_E="0.0" SE="0.23975434776511922" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.057482147272277725" WEIGHT="10.237977865775804"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.14671331190125317" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="381" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="4.208018709035647"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="382" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.6714603067117082"/>
<DICH_DATA CI_END="2.314669925833568" CI_START="0.8772849110521551" EFFECT_SIZE="1.425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.36448906895678185" LOG_CI_START="-0.05685934026772378" LOG_EFFECT_SIZE="0.153814864344529" ORDER="383" O_E="0.0" SE="0.24750214128673814" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06125730994152048" WEIGHT="10.02605965069645"/>
<DICH_DATA CI_END="1.2572325299104203" CI_START="0.4012167732897913" EFFECT_SIZE="0.7102272727272727" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.09941560952166471" LOG_CI_START="-0.3966209191338515" LOG_EFFECT_SIZE="-0.14860265480609341" ORDER="384" O_E="0.0" SE="0.2913743123526676" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.08489898989898989" WEIGHT="8.87554583941754"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.137048013387588" CI_END="-0.515568285385624" CI_START="-1.1434577068594614" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8295129961225427" ESTIMABLE="YES" I2="88.06542439509107" I2_Q="0.0" ID="CMP-002.21" MODIFIED="2016-03-31 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.4454621644954813E-5" P_Q="0.667201005318848" P_Z="2.234751224214224E-7" Q="0.1848936661274892" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.35417659633190196" TOTALS="SUB" TOTAL_1="202" TOTAL_2="200" UNITS="" WEIGHT="200.0" Z="5.178668541004689">
<NAME>Global assessment by the participant (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.47192747278546693" CI_START="-1.138201252113946" DF="0" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" I2="0.0" ID="CMP-002.21.01" NO="1" P_CHI2="1.0" P_Z="2.1745916288072995E-6" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.736482823107488">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.47192747278546693" CI_START="-1.138201252113946" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.2" ORDER="385" SD_1="0.87" SD_2="0.86" SE="0.16997092410471867" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="23.897017436540555" CI_END="-0.08504699212833944" CI_START="-1.9620467882631074" DF="2" EFFECT_SIZE="-1.0235468901957234" ESTIMABLE="YES" I2="91.630754736188" ID="CMP-002.21.02" NO="2" P_CHI2="6.468912400525717E-6" P_Z="0.03255115549047338" STUDIES="3" TAU2="0.6302379863422505" TOTAL_1="126" TOTAL_2="126" WEIGHT="100.0" Z="2.13757619516284">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-1.3120424182781059" CI_START="-2.2237404554833864" EFFECT_SIZE="-1.7678914368807461" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="9.5" ORDER="386" SD_1="2.5" SD_2="3.3" SE="0.23258030361696397" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="33.50469687100973"/>
<CONT_DATA CI_END="0.3528616138779379" CI_START="-0.6086442995189438" EFFECT_SIZE="-0.12789134282050293" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.4" ORDER="387" SD_1="1.4" SD_2="1.7" SE="0.24528662796385997" STUDY_ID="STD-Ihme-1996" TOTAL_1="36" TOTAL_2="31" WEIGHT="33.21003115172512"/>
<CONT_DATA CI_END="-0.6934495545778849" CI_START="-1.6424031837429498" EFFECT_SIZE="-1.1679263691604174" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.0" ORDER="388" SD_1="1.1" SD_2="1.4" SE="0.24208445579875187" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="33.285271977265154"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.214883607103435" CI_END="1.511418558100505" CI_START="1.0000368412431344" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="1.229420286411072" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="130" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.17938475044174276" LOG_CI_START="1.599965387797117E-5" LOG_EFFECT_SIZE="0.0897003750478104" METHOD="MH" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.8801640445410487" P_Q="0.5265737108192583" P_Z="0.04995914258053491" Q="4.160311792949905" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1280" TOTAL_2="1210" WEIGHT="99.99999999999999" Z="1.960313641269315">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.320522299550465" CI_START="0.05643115644753237" DF="0" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6684881427861843" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="1.3403100915978172" Z="0.4282238668218129">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="6.320522299550465" CI_START="0.05643115644753237" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-09 22:06:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1241" O_E="0.0" SE="1.2037302057640382" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" VAR="1.448966408268734" WEIGHT="1.3403100915978172"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4087782036796492" CI_END="1.6245694379188633" CI_START="0.7438305607577712" DF="3" EFFECT_SIZE="1.0992744861940194" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.2107382788453648" LOG_CI_START="-0.1285259823419196" LOG_EFFECT_SIZE="0.041106148251722596" MODIFIED="2015-09-09 22:06:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9384232278774707" P_Z="0.6348234972516102" STUDIES="4" TAU2="0.0" TOTAL_1="297" TOTAL_2="287" WEIGHT="27.99935884686801" Z="0.47494876020592786">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="0.750315314882565"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.36765450429245683"/>
<DICH_DATA CI_END="2.6977689818668056" CI_START="0.42776421247572727" EFFECT_SIZE="1.074248120300752" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4310047569755741" LOG_CI_START="-0.3687955521030694" LOG_EFFECT_SIZE="0.031104602436252366" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4698066606281763" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.22071829837059842" WEIGHT="6.0182214241103695"/>
<DICH_DATA CI_END="1.6723232013260785" CI_START="0.6949016850698201" EFFECT_SIZE="1.0780075187969924" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.22332021508135724" LOG_CI_START="-0.1580766351968807" LOG_EFFECT_SIZE="0.03262178994223827" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2240343977982942" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.05019141139684433" WEIGHT="20.863167603582617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2331012827270302" CI_START="0.5840929599486262" DF="0" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-002.22.03" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2015-09-09 22:06:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6977879098630941" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="33" WEIGHT="8.589035015172714" Z="0.38830828210084756">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="2.2331012827270302" CI_START="0.5840929599486262" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.34212017937049316" STUDY_ID="STD-Pointel-1986" TOTAL_1="61" TOTAL_2="33" VAR="0.11704621713249841" WEIGHT="8.589035015172714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1551053547928514" CI_END="1.794220055243353" CI_START="0.7639207267400173" DF="5" EFFECT_SIZE="1.170744160153283" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" I2="0.0" ID="CMP-002.22.04" LOG_CI_END="0.25387570677778504" LOG_CI_START="-0.11695170651021582" LOG_EFFECT_SIZE="0.06846200013378459" MODIFIED="2015-09-09 22:06:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6760872531502453" P_Z="0.46925273684445434" STUDIES="6" TAU2="0.0" TOTAL_1="271" TOTAL_2="261" WEIGHT="23.6244188966885" Z="0.7236954430204529">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.7926315021300137" CI_START="0.46873982565817657" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.25349102406348534" LOG_CI_START="-0.3290681458422849" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.3421981401170484" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.1170995670995671" WEIGHT="8.823708103018964"/>
<DICH_DATA CI_END="13.885529310369082" CI_START="0.6229880646092515" EFFECT_SIZE="2.9411764705882355" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1425624395195535" LOG_CI_START="-0.20552027360406375" LOG_EFFECT_SIZE="0.4685210829577449" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.7918704588058654" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.6270588235294117" WEIGHT="1.4851785915972513"/>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="0.3863488011208869"/>
<DICH_DATA CI_END="49.07807360941349" CI_START="0.09356187798318824" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6908875076568242" LOG_CI_START="-1.0289010695739755" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="1.5976172734359604" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="2.552380952380952" WEIGHT="0.4289302550078663"/>
<DICH_DATA CI_END="2.9876119742706684" CI_START="0.5950497564904714" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4753241914111042" LOG_CI_START="-0.22544671819450432" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.41163630117428224" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.1694444444444444" WEIGHT="6.6177810772642225"/>
<DICH_DATA CI_END="2.0190742752871254" CI_START="0.2785930200215189" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3051522955429512" LOG_CI_START="-0.5550297687595511" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.5052752025411797" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.25530303030303025" WEIGHT="5.882472068679309"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7359925831763834" CI_START="0.18809447425601197" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.22.05" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-09-09 22:06:15 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3236085963801921" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="5.4903072641006885" Z="0.9870694697483925">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.7359925831763834" CI_START="0.18809447425601197" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.3214285714285714" WEIGHT="5.4903072641006885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.886572673528073" CI_END="2.192391196448075" CI_START="1.081940045947781" DF="11" EFFECT_SIZE="1.5401414973373522" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="43" I2="0.0" ID="CMP-002.22.06" LOG_CI_END="0.3409180494931664" LOG_CI_START="0.034203195673089305" LOG_EFFECT_SIZE="0.1875606225831279" MODIFIED="2015-09-09 22:06:10 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7234271412196693" P_Z="0.016525713825318845" STUDIES="12" TAU2="0.0" TOTAL_1="580" TOTAL_2="546" WEIGHT="32.956569885572264" Z="2.397093330187958">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="1.4706180171698273"/>
<DICH_DATA CI_END="36.11328941979412" CI_START="0.06538021389049867" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5576670484324069" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.18655669273384623" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="40" TOTAL_2="20" VAR="2.59465737514518" WEIGHT="0.4862527314835719"/>
<DICH_DATA CI_END="6.518295566757786" CI_START="0.9719806783736777" EFFECT_SIZE="2.5170731707317073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8141340493021292" LOG_CI_START="-0.012342368159215193" LOG_EFFECT_SIZE="0.40089584057145705" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.48547633874104096" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.23568727547740592" WEIGHT="3.5890082561882695"/>
<DICH_DATA CI_END="2.6300131119236196" CI_START="0.00775971920930058" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41995791366918006" LOG_CI_START="-2.110153993697694" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="981" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="2.573581530047198"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Languillat-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.36765450429245683"/>
<DICH_DATA CI_END="7.267071756978603" CI_START="0.5504280312298803" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.25929945722445363" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="2.205927025754741"/>
<DICH_DATA CI_END="2.496356013675377" CI_START="0.10014597222129622" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3973065216149974" LOG_CI_START="-0.9993665129429598" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Serralde-1990" TOTAL_1="26" TOTAL_2="26" VAR="0.6730769230769231" WEIGHT="2.9412360343396546"/>
<DICH_DATA CI_END="5.313494641645885" CI_START="0.28784520068821484" EFFECT_SIZE="1.2367149758454106" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7253802469539765" LOG_CI_START="-0.5408410072441131" LOG_EFFECT_SIZE="0.09226961985493179" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.7437846326122535" STUDY_ID="STD-Unkauf-1996" TOTAL_1="69" TOTAL_2="64" VAR="0.5532155797101449" WEIGHT="2.2888566131891297"/>
<DICH_DATA CI_END="3.343632810758682" CI_START="1.004540355835996" EFFECT_SIZE="1.8327067669172932" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5242185782714054" LOG_CI_START="0.00196738853557186" LOG_EFFECT_SIZE="0.26309298340348863" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.30677293403591116" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.09410963305700148" WEIGHT="10.160633573173353"/>
<DICH_DATA CI_END="5.502292199432192" CI_START="0.2934039860395668" EFFECT_SIZE="1.2705882352941176" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7405436498907105" LOG_CI_START="-0.5325339903453966" LOG_EFFECT_SIZE="0.10400482977265695" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1894" O_E="0.0" SE="0.7478121077106432" STUDY_ID="STD-Vanscheidt-2002b" TOTAL_1="85" TOTAL_2="81" VAR="0.5592229484386346" WEIGHT="2.2590818938452166"/>
<DICH_DATA CI_END="5.887545754238547" CI_START="0.18601750764417702" EFFECT_SIZE="1.0465116279069768" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7699342952089039" LOG_CI_START="-0.7304461788173894" LOG_EFFECT_SIZE="0.019744058195757187" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.8813309174461722" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.7767441860465115" WEIGHT="1.7325088969397966"/>
<DICH_DATA CI_END="7.273812287941877" CI_START="0.7551973910031008" EFFECT_SIZE="2.34375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8617620892176036" LOG_CI_START="-0.12193951907401532" LOG_EFFECT_SIZE="0.36991128507179405" MODIFIED="2013-12-30 11:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.5778311941119906" STUDY_ID="STD-Welch-1985" TOTAL_1="72" TOTAL_2="75" VAR="0.3338888888888889" WEIGHT="2.8812108091490494"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-03-31 10:30:49 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Sensitivity analysis of published studies only</NAME>
<DICH_OUTCOME CHI2="14.886886629252974" CI_END="0.7787833953044897" CI_START="0.6301169478295768" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7005173916967514" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="336" I2="26.109466176864533" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.10858331678799824" LOG_CI_START="-0.20057883930269352" LOG_EFFECT_SIZE="-0.15458107804534588" METHOD="MH" MODIFIED="2014-11-25 08:09:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18773428158040584" P_Q="0.7429387128895497" P_Z="4.497167841770041E-11" Q="1.9609643976913478" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="550" TOTAL_2="538" WEIGHT="100.0" Z="6.586697643069668">
<NAME>Oedema in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9898150624110164" CI_START="0.2798586531655355" DF="0" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" NO="1" P_CHI2="1.0" P_Z="0.046400600556080585" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="5.605048544204343" Z="1.9917308171456887">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9898150624110164" CI_START="0.2798586531655355" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="567" O_E="0.0" SE="0.3222593538479378" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="41" TOTAL_2="41" VAR="0.10385109114249039" WEIGHT="5.605048544204343"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.899456770961606" CI_END="1.0729272529886107" CI_START="0.47904989932324116" DF="1" EFFECT_SIZE="0.7169279549057601" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" I2="87.34090167217575" ID="CMP-003.01.02" LOG_CI_END="0.030570276768692478" LOG_CI_START="-0.31961924676907805" LOG_EFFECT_SIZE="-0.1445244850001928" MODIFIED="2013-12-30 10:29:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004944983495852484" P_Z="0.10571250299104047" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="142" WEIGHT="12.88253464997897" Z="1.6177684736135471">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5227592596510281" CI_START="0.03903931472955589" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.28169826577049156" LOG_CI_START="-1.4084978142580222" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="568" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="4.130035769413727"/>
<DICH_DATA CI_END="1.5472751585524283" CI_START="0.6306423336104108" EFFECT_SIZE="0.9878143634949442" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.18956755301077963" LOG_CI_START="-0.20021687939162486" LOG_EFFECT_SIZE="-0.005324663190422592" MODIFIED="2013-12-30 10:29:54 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.22896130505723078" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.052423279213510296" WEIGHT="8.752498880565243"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.362592785530452" CI_END="0.855954061197527" CI_START="0.4577856440635609" DF="1" EFFECT_SIZE="0.625974025974026" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="43" I2="70.2610436713273" ID="CMP-003.01.03" LOG_CI_END="-0.06754954315437829" LOG_CI_START="-0.33933783071288626" LOG_EFFECT_SIZE="-0.2034436869336323" NO="3" P_CHI2="0.06669306889397486" P_Z="0.0033439515235160924" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="13.361880430456175" Z="2.9342125288318313">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0813372457404962" CI_START="0.6032963966376529" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.03396116215154717" LOG_CI_START="-0.21946926862534452" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="569" O_E="0.0" SE="0.14886628953921083" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.022161172161172152" WEIGHT="4.511803781712475"/>
<DICH_DATA CI_END="0.8601540175978909" CI_START="0.33069013063357905" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.06542377782153407" LOG_CI_START="-0.4805787663059413" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="570" O_E="0.0" SE="0.24386409528607725" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.05946969696969696" WEIGHT="8.8500766487437"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.058592434326117" CI_START="0.5831771688114353" DF="0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" NO="4" P_CHI2="1.0" P_Z="0.11283151328821682" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="8.810742974749283" Z="1.5855936691338377">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.058592434326117" CI_START="0.5831771688114353" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.024728785799061036" LOG_CI_START="-0.23419948683908698" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="571" O_E="0.0" SE="0.15209574906326898" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.023133116883116887" WEIGHT="8.810742974749283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.029525571466529" CI_END="0.8088948154550225" CI_START="0.6365107402027079" DF="5" EFFECT_SIZE="0.7175445893680819" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="199" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="-0.09210794814965934" LOG_CI_START="-0.19619426385413138" LOG_EFFECT_SIZE="-0.14415110600189537" NO="5" P_CHI2="0.6954337092005055" P_Z="5.67398313458802E-8" STUDIES="6" TAU2="0.0" TOTAL_1="251" TOTAL_2="246" WEIGHT="59.33979340061122" Z="5.428782336719633">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8442346751174894" CI_START="0.2961261925959252" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.07353681410660659" LOG_CI_START="-0.5285231772213558" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="572" O_E="0.0" SE="0.2672612419124244" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.07142857142857142" WEIGHT="5.31004598924622"/>
<DICH_DATA CI_END="0.9897781719413176" CI_START="0.5595323149391918" EFFECT_SIZE="0.7441860465116279" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="-0.004462128126364944" LOG_CI_START="-0.25217482639299615" LOG_EFFECT_SIZE="-0.12831847725968057" ORDER="573" O_E="0.0" SE="0.14550766515945146" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021172480620155042" WEIGHT="12.685109863199303"/>
<DICH_DATA CI_END="0.8916358832044371" CI_START="0.6245627925209027" EFFECT_SIZE="0.7462456680785522" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" LOG_CI_END="-0.0498124619907061" LOG_CI_START="-0.20442389183840623" LOG_EFFECT_SIZE="-0.12711817691455618" ORDER="574" O_E="0.0" SE="0.09081951923146003" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.008248185073433539" WEIGHT="14.733108369735506"/>
<DICH_DATA CI_END="0.9570860866973051" CI_START="0.5358355930265097" EFFECT_SIZE="0.7161290322580646" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="-0.019048997127923857" LOG_CI_START="-0.27096844163934425" LOG_EFFECT_SIZE="-0.14500871938363402" ORDER="575" O_E="0.0" SE="0.14797872872737033" STUDY_ID="STD-Ihme-1996" TOTAL_1="40" TOTAL_2="37" VAR="0.02189770415576866" WEIGHT="9.501380990859039"/>
<DICH_DATA CI_END="0.9272106717283771" CI_START="0.43674937102598566" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="-0.03282157850469006" LOG_CI_START="-0.3597677117832464" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="576" O_E="0.0" SE="0.19204977709728507" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="0.036883116883116886" WEIGHT="6.4900562090787135"/>
<DICH_DATA CI_END="1.089957868614159" CI_START="0.5953622353417175" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.03740971098464494" LOG_CI_START="-0.22521871672130728" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="577" O_E="0.0" SE="0.15426923846616009" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.023798997936928967" WEIGHT="10.62009197849244"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.823192360876043" CI_END="-0.45065793384417274" CI_START="-6.771331777712657" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.610994855778415" ESTIMABLE="YES" I2="53.530145179955184" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2015-12-19 22:26:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01136927362085871" P_Q="0.4115328033512752" P_Z="0.025126582350166595" Q="1.7757332734275464" RANDOM="YES" SCALE="37.22" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.778544853856582" TOTALS="YES" TOTAL_1="896" TOTAL_2="900" UNITS="" WEIGHT="100.00000000000001" Z="2.2394510587034056">
<NAME>Ankle perimeter circumference (mm)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.945952271176777" CI_END="2.018767959185113" CI_START="-8.36702575902629" DF="4" EFFECT_SIZE="-3.1741288999205883" ESTIMABLE="YES" I2="55.28704067774075" ID="CMP-003.02.01" MODIFIED="2013-12-30 10:58:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06246476719579874" P_Z="0.23091044986640807" STUDIES="5" TAU2="17.723840075124762" TOTAL_1="554" TOTAL_2="568" WEIGHT="42.7429094353299" Z="1.1980169248351835">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.7960630376235365" CI_START="-41.99606303762347" EFFECT_SIZE="-20.599999999999966" ESTIMABLE="YES" MEAN_1="335.6" MEAN_2="356.2" MODIFIED="2013-12-30 10:58:31 +0000" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="38.2" SD_2="38.2" SE="10.916559287003698" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" WEIGHT="1.9556127586355354"/>
<CONT_DATA CI_END="6.487842096264158" CI_START="-4.087842096264181" EFFECT_SIZE="1.1999999999999886" ESTIMABLE="YES" MEAN_1="229.5" MEAN_2="228.3" MODIFIED="2013-12-30 10:58:31 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="22.7" SD_2="19.6" SE="2.6979281956066505" STUDY_ID="STD-Labs-2004" TOTAL_1="124" TOTAL_2="123" WEIGHT="12.347147522328404"/>
<CONT_DATA CI_END="-2.301974796401309" CI_START="-21.4980252035987" EFFECT_SIZE="-11.900000000000006" ESTIMABLE="YES" MEAN_1="254.9" MEAN_2="266.8" MODIFIED="2013-12-30 10:58:31 +0000" MODIFIED_BY="[Empty name]" ORDER="934" SD_1="43.2" SD_2="53.9" SE="4.897041618778046" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="193" TOTAL_2="203" WEIGHT="6.885629428587943"/>
<CONT_DATA CI_END="5.844837594293494" CI_START="-5.4448375942934595" EFFECT_SIZE="0.20000000000001705" ESTIMABLE="YES" MEAN_1="240.9" MEAN_2="240.7" MODIFIED="2013-12-30 10:58:31 +0000" MODIFIED_BY="[Empty name]" ORDER="948" SD_1="21.3" SD_2="21.8" SE="2.8800721027627216" STUDY_ID="STD-Rabe-2011" TOTAL_1="109" TOTAL_2="115" WEIGHT="11.778829578003267"/>
<CONT_DATA CI_END="4.817074484380218" CI_START="-9.217074484380252" EFFECT_SIZE="-2.200000000000017" ESTIMABLE="YES" MEAN_1="230.1" MEAN_2="232.3" MODIFIED="2013-12-30 10:58:31 +0000" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="21.31" SD_2="29.43" SE="3.5802058301734228" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="9.775690147774755"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.30722696689729584" CI_END="-4.1792858820031835" CI_START="-7.783338744388352" DF="2" EFFECT_SIZE="-5.981312313195768" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2014-08-27 13:52:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8576034508816595" P_Z="7.74142989994743E-11" STUDIES="3" TAU2="0.0" TOTAL_1="144" TOTAL_2="142" WEIGHT="28.496777578605435" Z="6.5055409350412585">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-4.0519220810061265" CI_START="-7.748077918993872" EFFECT_SIZE="-5.8999999999999995" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.2" ORDER="579" SD_1="6.97" SD_2="4.3" SE="0.9429142237159843" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="17.725993270286416"/>
<CONT_DATA CI_END="6.5631280465892505" CI_START="-17.963128046589283" EFFECT_SIZE="-5.700000000000017" ESTIMABLE="YES" MEAN_1="229.1" MEAN_2="234.8" MODIFIED="2014-08-27 13:52:22 +0100" MODIFIED_BY="[Empty name]" ORDER="580" SD_1="30.3" SD_2="31.0" SE="6.256812953359988" STUDY_ID="STD-Planchon-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="4.91246464676351"/>
<CONT_DATA CI_END="1.8424279365966747" CI_START="-19.842427936596675" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="239.1" MEAN_2="248.1" MODIFIED="2014-08-27 13:52:27 +0100" MODIFIED_BY="[Empty name]" ORDER="581" SD_1="20.6" SD_2="13.7" SE="5.531952638987431" STUDY_ID="STD-Tsouderos-1989" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.858319661555509"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.185061851927266" CI_END="5.434172467045214" CI_START="-9.791206897145258" DF="4" EFFECT_SIZE="-2.1785172150500225" ESTIMABLE="YES" I2="56.4510281532759" ID="CMP-003.02.03" NO="3" P_CHI2="0.05663674221913839" P_Z="0.5748784617594271" STUDIES="5" TAU2="38.72610324220208" TOTAL_1="198" TOTAL_2="190" WEIGHT="28.760312986064672" Z="0.5608812994493906">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="3.891260641035477" CI_START="-11.891260641035476" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="221.0" MEAN_2="225.0" ORDER="582" SD_1="22.0" SD_2="19.0" SE="4.026227371156171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="8.669775566266585"/>
<CONT_DATA CI_END="10.395283346346224" CI_START="-5.99528334634619" EFFECT_SIZE="2.200000000000017" ESTIMABLE="YES" MEAN_1="226.8" MEAN_2="224.6" ORDER="583" SD_1="16.4" SD_2="14.0" SE="4.181343846616344" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="33" TOTAL_2="21" WEIGHT="8.316705282299411"/>
<CONT_DATA CI_END="8.004579588483077" CI_START="-10.004579588483077" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="236.0" MEAN_2="237.0" ORDER="584" SD_1="22.0" SD_2="20.0" SE="4.594257679993128" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" WEIGHT="7.452852782755372"/>
<CONT_DATA CI_END="26.334813927350318" CI_START="-8.334813927350318" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="258.0" MEAN_2="249.0" ORDER="585" SD_1="40.0" SD_2="42.0" SE="8.844455339019042" STUDY_ID="STD-MacLennan-1994" TOTAL_1="41" TOTAL_2="45" WEIGHT="2.8259788385170546"/>
<CONT_DATA CI_END="-9.197870941782313" CI_START="-58.80212905821769" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="243.0" ORDER="586" SD_1="50.0" SD_2="48.0" SE="12.654380005884656" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.4950005162262465"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.009638960316225" CI_END="-0.25277614208781335" CI_START="-0.49875601140049425" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3757660767441538" ESTIMABLE="YES" I2="11.206208869892258" I2_Q="39.74791589752199" ID="CMP-003.03" MODIFIED="2015-12-19 22:28:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34148354490553257" P_Q="0.19019744102660519" P_Z="2.121797678485783E-9" Q="3.319387254054744" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="512" TOTAL_2="529" UNITS="" WEIGHT="99.99999999999999" Z="5.988197156851546">
<NAME>Volume of the leg (mL)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27623133159938895" CI_START="-0.6109215354600945" DF="0" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45965052058283484" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="7.687802398694869" Z="0.7394224489400971">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="0.27623133159938895" CI_START="-0.6109215354600945" EFFECT_SIZE="-0.16734510193035282" ESTIMABLE="YES" MEAN_1="3276.5" MEAN_2="3391.5" MODIFIED="2015-09-09 22:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="2474" SD_1="584.6" SD_2="751.1" SE="0.2263186655615185" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="7.687802398694869"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2642349077041732" CI_END="-0.31350404210868443" CI_START="-0.67945142480911" DF="2" EFFECT_SIZE="-0.49647773345889723" ESTIMABLE="YES" I2="11.669942319372458" ID="CMP-003.03.02" MODIFIED="2015-09-09 22:08:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32235031420408045" P_Z="1.0483726732177644E-7" STUDIES="3" TAU2="0.0" TOTAL_1="238" TOTAL_2="237" WEIGHT="45.181624525163244" Z="5.318133276565082">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-0.29058032887513097" CI_START="-1.8337557124459654" EFFECT_SIZE="-1.0621680206605482" ESTIMABLE="YES" MEAN_1="1097.0" MEAN_2="1205.0" ORDER="587" SD_1="92.95" SD_2="104.57" SE="0.39367442354635207" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.540788757311455"/>
<CONT_DATA CI_END="-0.23013895092543318" CI_START="-0.7448632504722297" EFFECT_SIZE="-0.4875011006988314" ESTIMABLE="YES" MEAN_1="-64.72" MEAN_2="0.76" MODIFIED="2013-12-30 11:00:18 +0000" MODIFIED_BY="[Empty name]" ORDER="976" SD_1="111.9" SD_2="152.9" SE="0.13130963211744603" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="22.83756467734085"/>
<CONT_DATA CI_END="-0.15787439319036783" CI_START="-0.7106273827218053" EFFECT_SIZE="-0.4342508879560865" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-1.15" ORDER="588" SD_1="6.08" SD_2="6.08" SE="0.14101100680713585" STUDY_ID="STD-Widmer-1990" TOTAL_1="103" TOTAL_2="103" WEIGHT="19.803271090510936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.426016798557308" CI_END="-0.11489254978967214" CI_START="-0.4731937031719632" DF="4" EFFECT_SIZE="-0.29404312648081765" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" MODIFIED="2015-09-09 22:08:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4892167164671355" P_Z="0.0012957254426142785" STUDIES="5" TAU2="0.0" TOTAL_1="238" TOTAL_2="249" WEIGHT="47.13057307614187" Z="3.2169248263013976">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.06339385236707562" CI_START="-1.21424466831304" EFFECT_SIZE="-0.6388192603400578" ESTIMABLE="YES" MEAN_1="1098.0" MEAN_2="1200.0" ORDER="589" SD_1="157.74" SD_2="156.5" SE="0.2935897866041745" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" WEIGHT="4.568367917654835"/>
<CONT_DATA CI_END="0.1902409432135067" CI_START="-0.5919359804828254" EFFECT_SIZE="-0.20084751863465933" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-4.4" ORDER="590" SD_1="43.4" SD_2="29.2" SE="0.19953859608289842" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="51" TOTAL_2="50" WEIGHT="9.88983702614304"/>
<CONT_DATA CI_END="0.4195584060852926" CI_START="-0.47459950667794526" EFFECT_SIZE="-0.02752055029632632" ESTIMABLE="YES" MEAN_1="2073.0" MEAN_2="2082.0" ORDER="591" SD_1="309.0" SD_2="339.0" SE="0.22810569985373236" STUDY_ID="STD-Ihme-1996" TOTAL_1="40" TOTAL_2="37" WEIGHT="7.567818095698647"/>
<CONT_DATA CI_END="0.18807153574891566" CI_START="-0.6898764827904679" EFFECT_SIZE="-0.2509024735207761" ESTIMABLE="YES" MEAN_1="1992.0" MEAN_2="2111.0" ORDER="592" SD_1="367.0" SD_2="541.0" SE="0.2239704467695645" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="7.849853051465747"/>
<CONT_DATA CI_END="-0.09661376983931858" CI_START="-0.6887830829154231" EFFECT_SIZE="-0.39269842637737085" ESTIMABLE="YES" MEAN_1="-95.7" MEAN_2="-44.6" MODIFIED="2014-08-27 14:01:08 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="127.9" SD_2="131.1" SE="0.15106637615462848" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="86" TOTAL_2="93" WEIGHT="17.254696985179603"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.579138774406543" CI_END="1.1479177997973047" CI_START="0.7845810465786065" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9490176756790047" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="70" I2="12.647329616726877" I2_Q="32.18634298976649" ID="CMP-003.04" LOG_CI_END="0.0599107901764291" LOG_CI_START="-0.10536218749599054" LOG_EFFECT_SIZE="-0.02272569865978071" METHOD="MH" MODIFIED="2015-09-16 09:42:07 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.33326667970105894" P_Q="0.22886362674567962" P_Z="0.5898828204119053" Q="2.9492584358017844" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="198" TOTAL_2="194" WEIGHT="100.0" Z="0.539005849885082">
<NAME>Patients with ulcer (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1804728481415974" CI_START="0.17686049429055115" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 09:40:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6963273006688617" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="5.690706411282873" Z="0.3902829903211535">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="3.1804728481415974" CI_START="0.17686049429055115" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5024916923343051" LOG_CI_START="-0.7523691655509052" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-09-16 09:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="0.7371114795831993" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.5433333333333332" WEIGHT="5.690706411282873"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.279678661798027" CI_END="1.032025761727106" CI_START="0.6965888282557877" DF="1" EFFECT_SIZE="0.8478783026421136" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.013690538411622814" LOG_CI_START="-0.15702349494492393" LOG_EFFECT_SIZE="-0.07166647826665055" MODIFIED="2015-09-16 09:40:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5969119722376913" P_Z="0.09984563312647413" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="64" WEIGHT="67.6923076923077" Z="1.6456024562209306">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="14.676521957113154" CI_START="0.15330607664232812" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1666231486455823" LOG_CI_START="-0.8144406305342196" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-09-16 09:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.1636866703140785" STUDY_ID="STD-Fermoso-1992" TOTAL_1="16" TOTAL_2="12" VAR="1.3541666666666667" WEIGHT="1.6259161175093921"/>
<DICH_DATA CI_END="1.0047067054943812" CI_START="0.6886985965557255" EFFECT_SIZE="0.8318293683347006" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" LOG_CI_END="0.002039300785945326" LOG_CI_START="-0.16197080202807482" LOG_EFFECT_SIZE="-0.07996575062106476" MODIFIED="2015-09-16 09:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.0963403462560579" STUDY_ID="STD-Guilhou-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.00928146231673713" WEIGHT="66.0663915747983"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11365033071428013" CI_END="1.8663024447072112" CI_START="0.8355904751854998" DF="1" EFFECT_SIZE="1.248785228377065" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.2709820249538052" LOG_CI_START="-0.07800651914404438" LOG_EFFECT_SIZE="0.0964877529048804" MODIFIED="2015-09-16 09:40:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.73602599872443" P_Z="0.2784646120270309" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="80" WEIGHT="26.61698589640944" Z="1.0837749481526944">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="4.727779042593254" CI_START="0.21151580710326212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6746571711674341" LOG_CI_START="-0.6746571711674341" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-16 09:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.792593923901217" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.6282051282051281" WEIGHT="4.268029808462154"/>
<DICH_DATA CI_END="1.9160592312884113" CI_START="0.877000074085162" EFFECT_SIZE="1.2962962962962963" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.28240893032922065" LOG_CI_START="-0.05700036994664398" LOG_EFFECT_SIZE="0.11270428019128832" MODIFIED="2015-09-16 09:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.19937070308517563" STUDY_ID="STD-Schultz_x002d_Ehrenburg-1993" TOTAL_1="27" TOTAL_2="28" VAR="0.039748677248677255" WEIGHT="22.348956087947283"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2504169183636797" CI_END="0.9495827877473972" CI_START="0.8060448886183248" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8748750495834986" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="267" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.0224671660564919" LOG_CI_START="-0.09364077167332872" LOG_EFFECT_SIZE="-0.05805396886491032" METHOD="MH" MODIFIED="2014-11-25 08:10:11 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.939950086519207" P_Q="0.7978444679912317" P_Z="0.0013869349634246652" Q="0.4516835863982088" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="350" WEIGHT="100.0" Z="3.1973562993952687">
<NAME>Trophic disorders (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.178481230360658E-31" CI_END="1.4431129148255155" CI_START="0.4061924985931362" DF="0" EFFECT_SIZE="0.7656249999999999" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="100.0" ID="CMP-003.05.01" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537358" NO="1" P_CHI2="0.0" P_Z="0.40892878096210405" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="5.918739729132431" Z="0.8257802261198307">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="1.4431129148255155" CI_START="0.4061924985931362" EFFECT_SIZE="0.765625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.15930031332989222" LOG_CI_START="-0.39126810124063927" LOG_EFFECT_SIZE="-0.11598389395537351" ORDER="596" O_E="0.0" SE="0.3234066120763363" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10459183673469387" WEIGHT="5.918739729132431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8533794788973021" CI_END="0.9431456591579286" CI_START="0.80599632187032" DF="3" EFFECT_SIZE="0.8718783930510314" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="216" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="-0.025421229761688955" LOG_CI_START="-0.09366694007464701" LOG_EFFECT_SIZE="-0.05954408491816801" NO="2" P_CHI2="0.8366613631160584" P_Z="6.259350055939437E-4" STUDIES="4" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="80.99914999716665" Z="3.4201200748538434">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="3.045766512884973" CI_START="0.36197784542443584" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.4836966074529867" LOG_CI_START="-0.4413180093131106" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="597" O_E="0.0" SE="0.5433581647846061" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2952380952380952" WEIGHT="1.7589391964639884"/>
<DICH_DATA CI_END="0.9720706154589744" CI_START="0.7758233945767989" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="76" LOG_CI_END="-0.012302184878028533" LOG_CI_START="-0.11023712859981677" LOG_EFFECT_SIZE="-0.06126965673892266" ORDER="598" O_E="0.0" SE="0.05752747072796835" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.003309409888357255" WEIGHT="28.406868022893413"/>
<DICH_DATA CI_END="0.978849596085834" CI_START="0.8198576822426757" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="-0.009284034047752895" LOG_CI_START="-0.08626152954424844" LOG_EFFECT_SIZE="-0.047772781796000675" ORDER="599" O_E="0.0" SE="0.04521696189938959" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.00204457364341085" WEIGHT="35.88235960786536"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="600" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="14.950983169943902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2475566849424438" CI_START="0.71257651260772" DF="0" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.09606028768093586" LOG_CI_START="-0.1471684966257122" LOG_EFFECT_SIZE="-0.025554104472388168" NO="3" P_CHI2="1.0" P_Z="0.6804599978372128" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="13.082110273700913" Z="0.4118355034814503">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.2475566849424438" CI_START="0.71257651260772" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.09606028768093586" LOG_CI_START="-0.1471684966257122" LOG_EFFECT_SIZE="-0.025554104472388168" ORDER="601" O_E="0.0" SE="0.14287379190362523" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.020412920412920407" WEIGHT="13.082110273700913"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="85.28596536630431" CI_END="0.7868544317425805" CI_START="0.5683332889562909" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="0.668726825484139" ESTIMABLE="YES" EVENTS_1="442" EVENTS_2="560" I2="80.06706035748698" I2_Q="35.06881970133432" ID="CMP-003.06" LOG_CI_END="-0.10410560479263482" LOG_CI_START="-0.24539690530206454" LOG_EFFECT_SIZE="-0.17475125504734967" METHOD="MH" MODIFIED="2014-12-01 15:15:39 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="4.351030646887466E-11" P_Q="0.1874878605396577" P_Z="1.2456965736965706E-6" Q="6.1603685341943475" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13677637572261298" TOTALS="SUB" TOTAL_1="1212" TOTAL_2="868" WEIGHT="500.0" Z="4.848227242739834">
<NAME>Pain in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7915690026239909" CI_START="0.2285590502564194" DF="0" EFFECT_SIZE="0.42534722222222227" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586795" NO="1" P_CHI2="1.0" P_Z="0.006985329843852194" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.00000000000001" Z="2.69754282917697">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.7915690026239909" CI_START="0.2285590502564194" EFFECT_SIZE="0.4253472222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.10151122084883056" LOG_CI_START="-0.6410015772685286" LOG_EFFECT_SIZE="-0.3712563990586796" ORDER="602" O_E="0.0" SE="0.31689930588126447" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10042517006802722" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.014391818999428" CI_END="0.9320047135667524" CI_START="0.16373951790175087" DF="3" EFFECT_SIZE="0.39064818248851413" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="121" I2="86.96467834738365" ID="CMP-003.06.02" LOG_CI_END="-0.03058189121806354" LOG_CI_START="-0.7858464926377848" LOG_EFFECT_SIZE="-0.40821419192792424" MODIFIED="2013-12-30 11:02:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.0105347186680795E-5" P_Z="0.03411682294007755" STUDIES="4" TAU2="0.6444098217543911" TOTAL_1="179" TOTAL_2="175" WEIGHT="100.0" Z="2.118688238937399">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5949206861209944" CI_START="0.07718401531191658" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.22554092986137214" LOG_CI_START="-1.1124726320557794" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="603" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.27142857142857146" WEIGHT="21.490900755262874"/>
<DICH_DATA CI_END="0.3646049822641113" CI_START="0.051750510994256024" EFFECT_SIZE="0.13736263736263737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.43817740108140707" LOG_CI_START="-1.2860853575446674" LOG_EFFECT_SIZE="-0.8621313793130372" MODIFIED="2013-12-30 11:02:53 +0000" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="0.49806533083859533" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="0.24806907378335943" WEIGHT="22.05339769283311"/>
<DICH_DATA CI_END="1.107432316188807" CI_START="0.3250763001380784" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0443171925890425" LOG_CI_START="-0.4880146918217552" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="604" O_E="0.0" SE="0.3126943839882286" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09777777777777774" WEIGHT="26.519160422729993"/>
<DICH_DATA CI_END="1.1105908283879482" CI_START="0.70965574979841" EFFECT_SIZE="0.8877708978328174" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="68" LOG_CI_END="0.04555408260948905" LOG_CI_START="-0.14895227412508424" LOG_EFFECT_SIZE="-0.05169909575779759" ORDER="605" O_E="0.0" SE="0.1142539967678824" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01305397577743528" WEIGHT="29.936541129174035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.90550379500584" CI_END="1.0760407124196056" CI_START="0.6308566465725802" DF="3" EFFECT_SIZE="0.8239098466535053" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="88" I2="49.199931045052644" ID="CMP-003.06.03" LOG_CI_END="0.03182870334216246" LOG_CI_START="-0.200069316945316" LOG_EFFECT_SIZE="-0.08412030680157676" NO="3" P_CHI2="0.11629951783100911" P_Z="0.15504307834592618" STUDIES="4" TAU2="0.034293085865943054" TOTAL_1="140" TOTAL_2="131" WEIGHT="99.99999999999999" Z="1.4219420372382767">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.3845753025980523" CI_START="0.7811781691977737" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.14131658060414426" LOG_CI_START="-0.10724990200658352" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="606" O_E="0.0" SE="0.1460091823094744" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.021318681318681334" WEIGHT="33.36588051653022"/>
<DICH_DATA CI_END="1.1243680173221975" CI_START="0.659122633248303" EFFECT_SIZE="0.8608695652173913" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.05090848359314629" LOG_CI_START="-0.1810337751052698" LOG_EFFECT_SIZE="-0.06506264575606176" ORDER="607" O_E="0.0" SE="0.13624403089214698" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.018562435953740304" WEIGHT="35.1058038084542"/>
<DICH_DATA CI_END="1.7255701519985482" CI_START="0.2839641143725649" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.23693261996280243" LOG_CI_START="-0.5467365399342888" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="608" O_E="0.0" SE="0.46033114374845624" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.2119047619047619" WEIGHT="7.536766044045263"/>
<DICH_DATA CI_END="0.8834027356612968" CI_START="0.3916908418748" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="34" LOG_CI_END="-0.05384126018203567" LOG_CI_START="-0.40705658257451216" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="609" O_E="0.0" SE="0.20748042881738504" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.043048128342245986" WEIGHT="23.99154963097031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.912082885603881" CI_START="0.47547261450716666" DF="0" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" NO="4" P_CHI2="1.0" P_Z="0.011946501269335262" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.513720672049408">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="0.912082885603881" CI_START="0.47547261450716666" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" ORDER="610" O_E="0.0" SE="0.1661820286338354" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.027616466640856888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.84950678817635" CI_END="0.836200748048415" CI_START="0.4500410188492567" DF="7" EFFECT_SIZE="0.6134530435283693" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="307" I2="82.4339105695608" ID="CMP-003.06.05" LOG_CI_END="-0.07768944827429873" LOG_CI_START="-0.34674790078460316" LOG_EFFECT_SIZE="-0.21221867452945092" MODIFIED="2013-12-30 11:05:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.345087743187534E-6" P_Z="0.0019892941957519498" STUDIES="8" TAU2="0.1473608928809104" TOTAL_1="825" TOTAL_2="493" WEIGHT="99.99999999999999" Z="3.0918259957554897">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.5216372682006785" CI_START="0.05325113727704636" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2826313881432527" LOG_CI_START="-1.2736711126240345" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="611" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.3388888888888888" WEIGHT="5.13699407312146"/>
<DICH_DATA CI_END="0.8383828698307714" CI_START="0.2283041041125227" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.07655760394571752" LOG_CI_START="-0.6414862813376184" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="612" O_E="0.0" SE="0.33184190154205606" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.11011904761904762" WEIGHT="9.701191642960117"/>
<DICH_DATA CI_END="1.134445340981303" CI_START="0.5558864888322862" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.05478357586479491" LOG_CI_START="-0.2550138816313306" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="613" O_E="0.0" SE="0.18197656005537105" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.03311546840958607" WEIGHT="13.84038457528229"/>
<DICH_DATA CI_END="1.2464351528371953" CI_START="0.6558182990958795" EFFECT_SIZE="0.904121110176619" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.09566968877837234" LOG_CI_START="-0.18321646951250722" LOG_EFFECT_SIZE="-0.04377339036706745" ORDER="614" O_E="0.0" SE="0.16381910988881074" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02683670076476225" WEIGHT="14.339246568978723"/>
<DICH_DATA CI_END="0.8225193613399201" CI_START="0.3383439819545119" EFFECT_SIZE="0.527536231884058" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.08485387036993415" LOG_CI_START="-0.47064154380646456" LOG_EFFECT_SIZE="-0.27774770708819935" ORDER="615" O_E="0.0" SE="0.2266135890564004" STUDY_ID="STD-Kl_x00fc_ken-1971" TOTAL_1="30" TOTAL_2="28" VAR="0.051353718745023105" WEIGHT="12.570098527581422"/>
<DICH_DATA CI_END="1.6076614930719757" CI_START="0.7473919476306546" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.20619460960700486" LOG_CI_START="-0.12645158553162028" LOG_EFFECT_SIZE="0.03987151203769228" ORDER="617" O_E="0.0" SE="0.1953980216496508" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.038180386864597404" WEIGHT="13.462568817215123"/>
<DICH_DATA CI_END="0.5029818868098265" CI_START="0.34516374379253173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="104" LOG_CI_END="-0.29844765430825204" LOG_CI_START="-0.4619748291149599" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="618" O_E="0.0" SE="0.09605667195403049" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009226884226884228" WEIGHT="15.95183412871708"/>
<DICH_DATA CI_END="0.8655808361251482" CI_START="0.502901968655921" EFFECT_SIZE="0.6597744360902256" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="70" LOG_CI_END="-0.062692367368319" LOG_CI_START="-0.2985166642901292" LOG_EFFECT_SIZE="-0.1806045158292241" ORDER="619" O_E="0.0" SE="0.13852435936096785" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.01918899813636656" WEIGHT="14.997681666143789"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="39.75875454578835" CI_END="-0.181318561681694" CI_START="-0.5663265592811793" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.37382256048143664" ESTIMABLE="YES" I2="82.39381469573345" I2_Q="76.63762394962741" ID="CMP-003.07" MODIFIED="2014-12-01 15:16:36 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.3999361356820117E-6" P_Q="0.004993017581147008" P_Z="1.4120707801067574E-4" Q="12.841159621485316" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.15405031780331369" TOTALS="SUB" TOTAL_1="567" TOTAL_2="566" UNITS="" WEIGHT="400.0" Z="3.806044340483287">
<NAME>Pain in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.304841179465016" CI_END="0.18132827460139783" CI_START="-0.40506331116476796" DF="2" EFFECT_SIZE="-0.11186751828168508" ESTIMABLE="YES" I2="68.27834448052337" ID="CMP-003.07.01" MODIFIED="2014-08-27 15:05:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.042748568483158556" P_Z="0.4545715636030727" STUDIES="3" TAU2="0.04385465271992223" TOTAL_1="358" TOTAL_2="366" WEIGHT="100.0" Z="0.7478153240739415">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.6068659258536648" CI_START="-0.3608987227279502" EFFECT_SIZE="0.12298360156285733" ESTIMABLE="YES" MEAN_1="33.42" MEAN_2="29.9" MODIFIED="2013-12-30 11:06:30 +0000" MODIFIED_BY="[Empty name]" ORDER="450" SD_1="27.85" SD_2="28.77" SE="0.24688327342114932" STUDY_ID="STD-Marinello-2002" TOTAL_1="35" TOTAL_2="31" WEIGHT="21.35173281067052"/>
<CONT_DATA CI_END="0.1915932515611162" CI_START="-0.1915932515611162" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="37.8" MEAN_2="37.8" MODIFIED="2013-12-30 11:06:30 +0000" MODIFIED_BY="[Empty name]" ORDER="935" SD_1="25.8" SD_2="27.4" SE="0.09775345520243194" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="216" WEIGHT="41.898023053963506"/>
<CONT_DATA CI_END="-0.12002498033634995" CI_START="-0.6316796765336825" EFFECT_SIZE="-0.3758523284350162" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-0.92" MODIFIED="2014-08-27 15:05:28 +0100" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="26.2" SD_2="22.9" SE="0.13052655564928728" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="36.75024413536597"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02250226945542" CI_START="-0.6675528983586143" DF="0" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" MODIFIED="2013-12-30 11:06:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03601936842423832" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.0967087165869946">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.02250226945542" CI_START="-0.6675528983586143" EFFECT_SIZE="-0.34502758390701715" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.9" ORDER="620" SD_1="0.87" SD_2="0.86" SE="0.16455675563206043" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6923870569134023" CI_START="-2.088246271323353" DF="0" EFFECT_SIZE="-1.3903166641183777" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" MODIFIED="2013-12-30 11:06:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="9.447386050045113E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.9043630770883655">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.6923870569134023" CI_START="-2.088246271323353" EFFECT_SIZE="-1.3903166641183777" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="1.17" ORDER="621" SD_1="0.48" SD_2="0.34" SE="0.35609307758211634" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.824402309833114" CI_END="-0.18863540390384026" CI_START="-1.2303822263893753" DF="2" EFFECT_SIZE="-0.7095088151466078" ESTIMABLE="YES" I2="70.69340421038412" ID="CMP-003.07.04" MODIFIED="2013-12-30 11:06:35 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03296868299606015" P_Z="0.007590342973855324" STUDIES="3" TAU2="0.14941758619541598" TOTAL_1="113" TOTAL_2="106" WEIGHT="100.0" Z="2.66976907322479">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.702291280518464" CI_START="-1.5311239528967693" EFFECT_SIZE="-1.1167076167076166" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.8" ORDER="622" SD_1="0.8" SD_2="0.8" SE="0.2114407914931171" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="36.38205168934716"/>
<CONT_DATA CI_END="0.31363504842545054" CI_START="-0.7512746498872284" EFFECT_SIZE="-0.2188198007308889" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.04" ORDER="623" SD_1="1.03" SD_2="1.14" SE="0.27166562924435106" STUDY_ID="STD-Cornu_x002d_Thenard-1985" TOTAL_1="30" TOTAL_2="25" WEIGHT="31.63992754240296"/>
<CONT_DATA CI_END="-0.2078591665203685" CI_START="-1.2556038045826323" EFFECT_SIZE="-0.7317314855515005" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.35" ORDER="624" SD_1="0.19" SD_2="0.56" SE="0.267286706880009" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="31.978020768249884"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="47.05760864358881" CI_END="0.8567000235257458" CI_START="0.6606746500676351" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7523297071469442" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="379" I2="76.6243965278532" I2_Q="22.668578444603476" ID="CMP-003.08" LOG_CI_END="-0.06717122117303985" LOG_CI_START="-0.18001235665006382" LOG_EFFECT_SIZE="-0.12359178891155184" METHOD="MH" MODIFIED="2014-12-01 15:17:24 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="2.1004574368710394E-6" P_Q="0.2747840279380911" P_Z="1.7596616403219166E-5" Q="3.8794062486630274" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10066493952420874" TOTALS="SUB" TOTAL_1="990" TOTAL_2="636" WEIGHT="400.0" Z="4.293389179885397">
<NAME>Cramps in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9944179280734241" CI_START="0.3117869045301575" DF="0" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" NO="1" P_CHI2="1.0" P_Z="0.04782921624123524" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="99.99999999999999" Z="1.9788826843676004">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9944179280734241" CI_START="0.3117869045301575" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.0024310545261336126" LOG_CI_START="-0.5061421297171764" LOG_EFFECT_SIZE="-0.254286592121655" ORDER="625" O_E="0.0" SE="0.29588237897725395" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.08754638218923934" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6229518707645461" CI_END="0.8392082235326647" CI_START="0.4978939577924044" DF="1" EFFECT_SIZE="0.6464028958989984" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="75" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-0.07613026907407978" LOG_CI_START="-0.302863144086741" LOG_EFFECT_SIZE="-0.18949670658041035" NO="2" P_CHI2="0.42995267096033873" P_Z="0.0010522849380123908" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="100.00000000000001" Z="3.2761611660048735">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="626" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="19.350525112310233"/>
<DICH_DATA CI_END="0.8213434036775193" CI_START="0.4592535070488815" EFFECT_SIZE="0.6141700404858299" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="65" LOG_CI_END="-0.08547522638786782" LOG_CI_START="-0.3379475185580027" LOG_EFFECT_SIZE="-0.21171137247293528" ORDER="627" O_E="0.0" SE="0.14830347417873932" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.021993920453484" WEIGHT="80.64947488768978"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26013183709740584" CI_END="0.9824327455155154" CI_START="0.7039077444604738" DF="2" EFFECT_SIZE="0.8315900540410143" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="78" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="-0.007697170470325016" LOG_CI_START="-0.15248425662095003" LOG_EFFECT_SIZE="-0.08009071354563753" NO="3" P_CHI2="0.8780375560675879" P_Z="0.03013167313367989" STUDIES="3" TAU2="0.0" TOTAL_1="110" TOTAL_2="104" WEIGHT="100.0" Z="2.168355178890189">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0987179385457573" CI_START="0.6836250549483773" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.04088621521191639" LOG_CI_START="-0.1651820287096053" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="628" O_E="0.0" SE="0.12104550653376048" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.014652014652014652" WEIGHT="49.367088607594944"/>
<DICH_DATA CI_END="2.6910797608830856" CI_START="0.28450475943855263" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4299265700038317" LOG_CI_START="-0.5459104639592052" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="629" O_E="0.0" SE="0.5732115042211109" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3285714285714286" WEIGHT="2.201430930104568"/>
<DICH_DATA CI_END="1.0107411449882746" CI_START="0.6260237223167935" EFFECT_SIZE="0.7954545454545454" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="44" LOG_CI_END="0.004639945207715035" LOG_CI_START="-0.2034092094795386" LOG_EFFECT_SIZE="-0.09938463213591182" ORDER="630" O_E="0.0" SE="0.12220910332321787" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01493506493506494" WEIGHT="48.431480462300485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="35.97306966170521" CI_END="1.052825477005114" CI_START="0.45260820507864735" DF="5" EFFECT_SIZE="0.6903024332916373" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="204" I2="86.10071354204531" ID="CMP-003.08.04" LOG_CI_END="0.022356385757780938" LOG_CI_START="-0.34427757723042784" LOG_EFFECT_SIZE="-0.16096059573632343" MODIFIED="2013-12-30 11:07:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="9.616682509205887E-7" P_Z="0.08526226213560327" STUDIES="6" TAU2="0.2054418643858573" TOTAL_1="703" TOTAL_2="357" WEIGHT="100.0" Z="1.720936969407013">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.9860104274367028" CI_START="0.0035093012367547953" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.00611849220455492" LOG_CI_START="-2.454779350551993" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="631" O_E="0.0" SE="1.43835550926002" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="2.0688665710186513" WEIGHT="2.039347468998963"/>
<DICH_DATA CI_END="0.8613172651925229" CI_START="0.4316673002365558" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="41" LOG_CI_END="-0.06483684721934725" LOG_CI_START="-0.3648508488760486" LOG_EFFECT_SIZE="-0.2148438480476979" ORDER="632" O_E="0.0" SE="0.17622970966640583" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.031056910569105697" WEIGHT="19.611539858286456"/>
<DICH_DATA CI_END="1.3796221567587041" CI_START="0.7413452390106355" EFFECT_SIZE="1.0113240418118468" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.139760160529198" LOG_CI_START="-0.1299794971759597" LOG_EFFECT_SIZE="0.004890331676619154" ORDER="633" O_E="0.0" SE="0.15844641016884967" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.02510526489539535" WEIGHT="20.117817844554402"/>
<DICH_DATA CI_END="1.940929634757623" CI_START="0.7712361889198123" EFFECT_SIZE="1.2234848484848484" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.28800979103472396" LOG_CI_START="-0.11281260011218036" LOG_EFFECT_SIZE="0.0875985954612718" ORDER="635" O_E="0.0" SE="0.23544505666252696" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.05543437470682053" WEIGHT="17.778948238430644"/>
<DICH_DATA CI_END="0.5160706369098471" CI_START="0.3435291719387765" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="95" LOG_CI_END="-0.28729085046463954" LOG_CI_START="-0.4640363774571312" LOG_EFFECT_SIZE="-0.3756636139608854" ORDER="636" O_E="0.0" SE="0.10382119745985853" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.010778841041998936" WEIGHT="21.450790951251967"/>
<DICH_DATA CI_END="1.0256362635790959" CI_START="0.4745830580100198" EFFECT_SIZE="0.6976744186046512" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.010993367862993894" LOG_CI_START="-0.32368776958284207" LOG_EFFECT_SIZE="-0.15634720085992407" ORDER="637" O_E="0.0" SE="0.19659335683403326" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.03864894795127353" WEIGHT="19.001555638477562"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="21.422747641631275" CI_END="-0.0701757760988462" CI_START="-0.39159322645537453" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23088450127711038" ESTIMABLE="YES" I2="85.99619409150843" I2_Q="70.58211265967168" ID="CMP-003.09" MODIFIED="2015-03-27 15:40:29 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="8.60008215779473E-5" P_Q="0.033397018947131096" P_Z="0.00486543641060323" Q="6.798584741529842" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1761044506088334" TOTALS="SUB" TOTAL_1="363" TOTAL_2="366" UNITS="" WEIGHT="300.0" Z="2.8158104458215965">
<NAME>Cramps in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.09248432803789162" CI_START="-0.2926569625203677" DF="0" EFFECT_SIZE="-0.10008631724123805" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" MODIFIED="2013-12-30 11:07:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3083605666503222" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="211" WEIGHT="100.0" Z="1.0186681197112695">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.09248432803789162" CI_START="-0.2926569625203677" EFFECT_SIZE="-0.10008631724123805" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="26.9" MODIFIED="2013-12-30 11:07:53 +0000" MODIFIED_BY="[Empty name]" ORDER="936" SD_1="27.1" SD_2="28.7" SE="0.09825213463007604" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="211" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1247995932872627E-31" CI_END="-0.13562938035194616" CI_START="-0.7844441767334328" DF="0" EFFECT_SIZE="-0.4600367785426895" ESTIMABLE="YES" I2="100.0" ID="CMP-003.09.02" MODIFIED="2013-12-30 11:07:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.005446066160000927" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.7793925864087403">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.1356293803519461" CI_START="-0.7844441767334327" EFFECT_SIZE="-0.46003677854268943" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.7" ORDER="638" SD_1="0.87" SD_2="0.86" SE="0.16551702008283187" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.076715053283268" CI_END="-0.1640351444890693" CI_START="-1.4972358265207695" DF="1" EFFECT_SIZE="-0.8306354855049194" ESTIMABLE="YES" I2="75.4704465009241" ID="CMP-003.09.03" MODIFIED="2013-12-30 11:07:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04347820538559566" P_Z="0.014595370668457959" STUDIES="2" TAU2="0.17504944329393862" TOTAL_1="83" TOTAL_2="81" WEIGHT="100.0" Z="2.4422664311716487">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.737539762590484" CI_START="-1.5702757682450441" EFFECT_SIZE="-1.153907765417764" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.6" ORDER="639" SD_1="0.7" SD_2="1.0" SE="0.21243655807532064" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="52.53630320068183"/>
<CONT_DATA CI_END="0.04075842663632262" CI_START="-0.9863864258951338" EFFECT_SIZE="-0.47281399962940557" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.19" ORDER="640" SD_1="0.19" SD_2="0.4" SE="0.2620315629862191" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="47.46369679931818"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.292211963012542" CI_END="0.9133694029655157" CI_START="0.7195952423879156" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8107134369903314" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="215" I2="17.720438867752083" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-0.03935354095083404" LOG_CI_START="-0.14291171665987373" LOG_EFFECT_SIZE="-0.0911326288053539" METHOD="MH" MODIFIED="2014-11-25 08:11:08 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.29466699879844804" P_Q="0.40771718195594386" P_Z="5.614366751042217E-4" Q="1.794363255488174" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="329" TOTAL_2="323" WEIGHT="100.00000000000001" Z="3.449590900032811">
<NAME>Restless legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014524314160636997" CI_END="0.9067321847665462" CI_START="0.5885798978528514" DF="1" EFFECT_SIZE="0.7305370193835399" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="83" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="-0.04252096856648605" LOG_CI_START="-0.23019457472139648" LOG_EFFECT_SIZE="-0.13635777164394125" NO="1" P_CHI2="0.9040737254021073" P_Z="0.00439815110243004" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="126" WEIGHT="38.794716325152976" Z="2.848097043690437">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.0471514391769654" CI_START="0.48723046404220255" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.02000949394521839" LOG_CI_START="-0.3122655653016944" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="641" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0380952380952381" WEIGHT="6.471949815921612"/>
<DICH_DATA CI_END="0.9398281433130286" CI_START="0.5729230757694193" EFFECT_SIZE="0.7337909992372235" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="69" LOG_CI_END="-0.026951554096481766" LOG_CI_START="-0.2419036852080609" LOG_EFFECT_SIZE="-0.13442761965227135" ORDER="642" O_E="0.0" SE="0.12626394584515102" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.01594258402038723" WEIGHT="32.322766509231364"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1470295339646062" CI_START="0.7007709655708828" DF="0" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.059574600353514244" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" NO="2" P_CHI2="1.0" P_Z="0.38500942450946507" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="13.40618176155191" Z="0.8687033375831925">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.1470295339646064" CI_START="0.7007709655708828" EFFECT_SIZE="0.896551724137931" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.059574600353514334" LOG_CI_START="-0.1544239002097905" LOG_EFFECT_SIZE="-0.047424649928138114" ORDER="643" O_E="0.0" SE="0.12570377854054737" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.01580143993937098" WEIGHT="13.40618176155191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.29740418942822" CI_END="1.0062969951429677" CI_START="0.720872687890486" DF="3" EFFECT_SIZE="0.8517112302328944" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="103" I2="30.190415707693596" ID="CMP-003.10.03" LOG_CI_END="0.0027261758650494834" LOG_CI_START="-0.1421414285243635" LOG_EFFECT_SIZE="-0.06970762632965699" NO="3" P_CHI2="0.23108919394734628" P_Z="0.05926838167998257" STUDIES="4" TAU2="0.0" TOTAL_1="165" TOTAL_2="162" WEIGHT="47.79910191329513" Z="1.8861972299431267">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.756836446165568" CI_START="0.3810380238094276" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.24473133244919257" LOG_CI_START="-0.4190316838869928" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="644" O_E="0.0" SE="0.38989768147579695" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.15202020202020203" WEIGHT="5.085103426795552"/>
<DICH_DATA CI_END="0.9400697740764922" CI_START="0.5280292072025189" EFFECT_SIZE="0.7045454545454546" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="-0.026839910898372437" LOG_CI_START="-0.277342054405457" LOG_EFFECT_SIZE="-0.15209098265191473" ORDER="645" O_E="0.0" SE="0.1471461991016704" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021652003910068423" WEIGHT="20.340413707182208"/>
<DICH_DATA CI_END="1.1581867758840065" CI_START="0.8019457345949211" EFFECT_SIZE="0.963744232036915" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.06377860187399871" LOG_CI_START="-0.09585501820377643" LOG_EFFECT_SIZE="-0.016038208164888847" ORDER="646" O_E="0.0" SE="0.09376957863284864" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.008792733876981984" WEIGHT="16.697190256382797"/>
<DICH_DATA CI_END="1.767505877093551" CI_START="0.6593575747233957" EFFECT_SIZE="1.0795454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.247360866534032" LOG_CI_START="-0.18087900025667367" LOG_EFFECT_SIZE="0.03324093313867916" ORDER="647" O_E="0.0" SE="0.25155021757438917" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06327751196172252" WEIGHT="5.67639452293457"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.56668125263085" CI_END="1.0235109556345239" CI_START="0.41414655114365456" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6510633858033978" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="117" I2="91.79581001821388" I2_Q="31.958941470202245" ID="CMP-003.11" LOG_CI_END="0.010092495700190102" LOG_CI_START="-0.3828459509307137" LOG_EFFECT_SIZE="-0.18637672761526183" METHOD="MH" MODIFIED="2016-03-31 10:28:12 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="5.6827389349756174E-8" P_Q="0.22999433786651313" P_Z="0.06298718912216998" Q="2.939401654258692" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.44628794453778936" TOTALS="SUB" TOTAL_1="206" TOTAL_2="199" WEIGHT="300.0" Z="1.8592819145817603">
<NAME>Itching in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9101776359707308" CI_START="0.309592344001341" DF="0" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" NO="1" P_CHI2="1.0" P_Z="0.021330988620835198" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.3020741908173297">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.9101776359707308" CI_START="0.309592344001341" EFFECT_SIZE="0.5308333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.04087383977428408" LOG_CI_START="-0.5092097876502647" LOG_EFFECT_SIZE="-0.2750418137122744" ORDER="648" O_E="0.0" SE="0.2751028540826821" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.07568158032443749" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.248879154931936" CI_START="0.5082566580469068" DF="0" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" NO="2" P_CHI2="1.0" P_Z="0.4100989716659914" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.00000000000001" Z="0.8237194877511418">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="5.248879154931936" CI_START="0.5082566580469068" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.7200665741111827" LOG_CI_START="-0.2939169234934802" LOG_EFFECT_SIZE="0.21307482530885122" ORDER="649" O_E="0.0" SE="0.5956189257922424" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.3547619047619047" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.645066156008205" CI_END="2.211282659580293" CI_START="0.20696351391226026" DF="1" EFFECT_SIZE="0.6765019064865861" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="89" I2="97.34360939663165" ID="CMP-003.11.03" LOG_CI_END="0.3446442602855613" LOG_CI_START="-0.6841062105973242" LOG_EFFECT_SIZE="-0.1697309751558815" NO="3" P_CHI2="8.486296110277181E-10" P_Z="0.5178007897206087" STUDIES="2" TAU2="0.711058010611193" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0" Z="0.6467391418657473">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.2460927890061566" CI_START="0.8423291969842424" EFFECT_SIZE="1.0245098039215685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.09555038281508714" LOG_CI_START="-0.07451814544477672" LOG_EFFECT_SIZE="0.010516118685155208" ORDER="650" O_E="0.0" SE="0.09989909535263612" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.009979829252275085" WEIGHT="50.645077619243956"/>
<DICH_DATA CI_END="0.6163595664241507" CI_START="0.3168008036596062" EFFECT_SIZE="0.4418859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="72" LOG_CI_END="-0.21016585901078652" LOG_CI_START="-0.4992137253638269" LOG_EFFECT_SIZE="-0.35468979218730673" ORDER="651" O_E="0.0" SE="0.1697881475057902" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.02882801503344797" WEIGHT="49.35492238075604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.608100903390151" CI_END="0.18640087983738726" CI_START="-0.17412687749684894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.006137001170269159" ESTIMABLE="YES" I2="82.16865179092105" I2_Q="82.16865179092105" ID="CMP-003.12" MODIFIED="2016-03-31 10:28:20 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0178777505841774" P_Q="0.0178777505841774" P_Z="0.9467997749281273" Q="5.608100903390151" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1826937448578777" TOTALS="SUB" TOTAL_1="234" TOTAL_2="242" UNITS="" WEIGHT="200.0" Z="0.06672607599340309">
<NAME>Itching in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27942681068696745" CI_START="-0.10520880392223587" DF="0" EFFECT_SIZE="0.08710900338236578" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" MODIFIED="2013-12-30 11:09:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37467420179797384" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="212" WEIGHT="100.0" Z="0.8877519547017505">
<NAME>Calccium dobesilate</NAME>
<CONT_DATA CI_END="0.27942681068696745" CI_START="-0.10520880392223587" EFFECT_SIZE="0.08710900338236578" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="31.3" MODIFIED="2013-12-30 11:09:06 +0000" MODIFIED_BY="[Empty name]" ORDER="937" SD_1="68.6" SD_2="30.4" SE="0.09812313329305027" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="212" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06242152989790051" CI_START="-1.0970469534983178" DF="0" EFFECT_SIZE="-0.5797342416981092" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" MODIFIED="2013-12-30 11:09:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.028058820194008544" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.196463006638366">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.062421529897900396" CI_START="-1.0970469534983178" EFFECT_SIZE="-0.579734241698109" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.42" ORDER="652" SD_1="0.36" SD_2="0.57" SE="0.26393990699865166" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="82.87268912316554" CI_END="0.8361589851741617" CI_START="0.6491257324118175" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7367308285010882" ESTIMABLE="YES" EVENTS_1="489" EVENTS_2="570" I2="80.6932776415391" I2_Q="69.6336617959652" ID="CMP-003.13" LOG_CI_END="-0.07771113904510614" LOG_CI_START="-0.1876711743799701" LOG_EFFECT_SIZE="-0.1326911567125381" METHOD="MH" MODIFIED="2014-12-01 15:21:18 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="5.030675875872248E-11" P_Q="0.005633165761352865" P_Z="2.2423026578227865E-6" Q="16.465600713541566" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09590342384456993" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="824" WEIGHT="600.0" Z="4.730261998034792">
<NAME>Heaviness in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5967167771289194" CI_START="0.168201730597713" DF="0" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" NO="1" P_CHI2="1.0" P_Z="3.732965903623685E-4" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.5582762523938705">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="0.5967167771289194" CI_START="0.168201730597713" EFFECT_SIZE="0.3168103448275862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" LOG_CI_END="-0.2242317514770311" LOG_CI_START="-0.7741695401363786" LOG_EFFECT_SIZE="-0.4992006458067048" ORDER="653" O_E="0.0" SE="0.32303617929445816" STUDY_ID="STD-Lazzarini-1982" TOTAL_1="48" TOTAL_2="49" VAR="0.10435237313316133" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.418240827894476" CI_END="1.4176733751822246" CI_START="0.07691894388050581" DF="2" EFFECT_SIZE="0.33022104534164504" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="118" I2="87.02835153293476" ID="CMP-003.13.02" LOG_CI_END="0.15157618310679574" LOG_CI_START="-1.1139666873823013" LOG_EFFECT_SIZE="-0.4811952521377528" NO="2" P_CHI2="4.487195851935466E-4" P_Z="0.13610131233692863" STUDIES="3" TAU2="1.3424115320255592" TOTAL_1="154" TOTAL_2="151" WEIGHT="100.0" Z="1.4904676652434135">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4767667009009777" CI_START="0.010701336327987806" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.32169408489527707" LOG_CI_START="-1.9705619864611992" LOG_EFFECT_SIZE="-1.146128035678238" ORDER="654" O_E="0.0" SE="0.9685531674075709" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.9380952380952381" WEIGHT="24.232463165281054"/>
<DICH_DATA CI_END="0.8148735481416007" CI_START="0.11618312611684645" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.08890977973258558" LOG_CI_START="-0.9348569422251632" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="655" O_E="0.0" SE="0.49691355075412963" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.24692307692307694" WEIGHT="34.77071221753797"/>
<DICH_DATA CI_END="1.0029892242921044" CI_START="0.7489058807072021" EFFECT_SIZE="0.866685945633314" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="91" LOG_CI_END="0.0012962671623755592" LOG_CI_START="-0.12557275914689353" LOG_EFFECT_SIZE="-0.06213824599225903" ORDER="656" O_E="0.0" SE="0.07452349406587333" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.005553751167786258" WEIGHT="40.996824617180984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1852075767243728" CI_START="0.323024902994722" DF="0" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-003.13.03" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" NO="3" P_CHI2="1.0" P_Z="0.14773361488268363" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.4475833341101076">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="1.1852075767243728" CI_START="0.323024902994722" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07379441914877305" LOG_CI_START="-0.4907639952655227" LOG_EFFECT_SIZE="-0.20848478805837484" ORDER="657" O_E="0.0" SE="0.3316244072361796" STUDY_ID="STD-Pointel-1986" TOTAL_1="30" TOTAL_2="33" VAR="0.10997474747474748" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.080658410516236" CI_END="1.049307085185408" CI_START="0.34591352497272493" DF="3" EFFECT_SIZE="0.6024695117724547" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="72" I2="75.16691642080953" ID="CMP-003.13.04" LOG_CI_END="0.02090260533803179" LOG_CI_START="-0.4610324570484032" LOG_EFFECT_SIZE="-0.22006492585518567" NO="4" P_CHI2="0.007111918514946303" P_Z="0.07346228572222131" STUDIES="4" TAU2="0.2223853665119306" TOTAL_1="125" TOTAL_2="116" WEIGHT="100.00000000000001" Z="1.7899479104128437">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0641010650963951" CI_START="0.7015273496905823" EFFECT_SIZE="0.864" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.026982877892531416" LOG_CI_START="-0.15395539293474494" LOG_EFFECT_SIZE="-0.06348625752110672" ORDER="658" O_E="0.0" SE="0.10628403594282773" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="0.011296296296296297" WEIGHT="34.29474811168166"/>
<DICH_DATA CI_END="1.2575147355900478" CI_START="0.19880482743026914" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.09951308283170253" LOG_CI_START="-0.701573074159665" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="659" O_E="0.0" SE="0.47056197405716016" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.22142857142857145" WEIGHT="18.057237682790937"/>
<DICH_DATA CI_END="0.7382545478648378" CI_START="0.2543537026908459" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" LOG_CI_END="-0.13179386897308396" LOG_CI_START="-0.5945619358525673" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="660" O_E="0.0" SE="0.27183225322388416" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.07389277389277388" WEIGHT="27.04908891820431"/>
<DICH_DATA CI_END="1.3355274698152124" CI_START="0.26955641732312" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.12565282524131058" LOG_CI_START="-0.5693503244740233" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="661" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Tsouderos-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.16666666666666669" WEIGHT="20.598925287323098"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.070548994624764" CI_START="0.760727623706627" DF="0" EFFECT_SIZE="0.9024390243902439" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-003.13.05" LOG_CI_END="0.029606547957654723" LOG_CI_START="-0.11877081326313567" LOG_EFFECT_SIZE="-0.04458213265274048" NO="5" P_CHI2="1.0" P_Z="0.23887665791095736" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.1777992765801402">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="1.070548994624764" CI_START="0.760727623706627" EFFECT_SIZE="0.9024390243902439" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.029606547957654723" LOG_CI_START="-0.11877081326313567" LOG_EFFECT_SIZE="-0.04458213265274048" ORDER="662" O_E="0.0" SE="0.08715759646087583" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.007596446620836875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.551841950857014" CI_END="0.7761455011576944" CI_START="0.4937224030515342" DF="6" EFFECT_SIZE="0.6190318424356006" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="315" I2="72.16015218707834" ID="CMP-003.13.06" LOG_CI_END="-0.11005685551179197" LOG_CI_START="-0.30651716587159034" LOG_EFFECT_SIZE="-0.20828701069169114" MODIFIED="2013-12-30 11:09:53 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0014593467228627421" P_Z="3.240046594464419E-5" STUDIES="7" TAU2="0.057952788806789994" TOTAL_1="798" TOTAL_2="455" WEIGHT="99.99999999999999" Z="4.15590343571768">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.7903712751309083" CI_START="0.11978491525686698" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.1021688519209733" LOG_CI_START="-0.9215978700367755" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="663" O_E="0.0" SE="0.48133666148028004" STUDY_ID="STD-Cauwenberge-1972" TOTAL_1="21" TOTAL_2="21" VAR="0.2316849816849817" WEIGHT="4.598007335652916"/>
<DICH_DATA CI_END="0.8334668511039568" CI_START="0.5232340734719679" EFFECT_SIZE="0.660377358490566" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="53" LOG_CI_END="-0.07911166838416735" LOG_CI_START="-0.28130398211685953" LOG_EFFECT_SIZE="-0.18020782525051343" ORDER="664" O_E="0.0" SE="0.11876876595467818" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.014106019766397124" WEIGHT="18.481523907666507"/>
<DICH_DATA CI_END="1.115629165191512" CI_START="0.5909468666401837" EFFECT_SIZE="0.8119590873328089" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.04751985922987865" LOG_CI_START="-0.22845156575550984" LOG_EFFECT_SIZE="-0.0904658532628156" ORDER="665" O_E="0.0" SE="0.16210698111700278" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.026278673326868292" WEIGHT="15.810678808947824"/>
<DICH_DATA CI_END="1.318145566401421" CI_START="0.6846740018735968" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.11996337322768261" LOG_CI_START="-0.1645161626499871" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="667" O_E="0.0" SE="0.16710468757095692" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.02792397660818713" WEIGHT="15.507763793477253"/>
<DICH_DATA CI_END="0.6692806456188787" CI_START="0.4886292282983279" EFFECT_SIZE="0.5718654434250765" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="109" LOG_CI_END="-0.17439173382282044" LOG_CI_START="-0.31102055842475373" LOG_EFFECT_SIZE="-0.24270614612378708" ORDER="668" O_E="0.0" SE="0.08025644789476498" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.006441097428685126" WEIGHT="20.681413582236107"/>
<DICH_DATA CI_END="0.8202259906388952" CI_START="0.4710301512908947" EFFECT_SIZE="0.6215715344699778" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="71" LOG_CI_END="-0.08606647326821763" LOG_CI_START="-0.32695129219138175" LOG_EFFECT_SIZE="-0.20650888272979967" ORDER="669" O_E="0.0" SE="0.141496935034551" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.020021382624171944" WEIGHT="17.07945809443393"/>
<DICH_DATA CI_END="0.4674556575963953" CI_START="0.12597648307047615" EFFECT_SIZE="0.24266936299292213" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.330259579603341" LOG_CI_START="-0.899710520167806" LOG_EFFECT_SIZE="-0.6149850498855735" ORDER="670" O_E="0.0" SE="0.3344983013151838" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.1118891135827435" WEIGHT="7.841154477585452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="103.64165544381713" CI_END="-0.12941923755706353" CI_START="-0.43215685133802584" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2807880444475447" ESTIMABLE="YES" I2="92.28109589166424" I2_Q="89.25985360895176" ID="CMP-003.14" MODIFIED="2014-12-01 15:21:59 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="4.440892098500626E-16" P_Q="3.7523462266264573E-6" P_Z="2.772063258350208E-4" Q="27.932580160177892" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.5332754825407232" TOTALS="SUB" TOTAL_1="517" TOTAL_2="516" UNITS="" WEIGHT="400.0" Z="3.6357190474838013">
<NAME>Heaviness in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9460171195236821" CI_END="0.12997986828358046" CI_START="-0.22717728749717706" DF="1" EFFECT_SIZE="-0.0485987096067983" ESTIMABLE="YES" I2="0.0" ID="CMP-003.14.01" MODIFIED="2013-12-30 11:12:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3307353528103052" P_Z="0.5937648309268264" STUDIES="2" TAU2="0.0" TOTAL_1="238" TOTAL_2="245" WEIGHT="100.0" Z="0.5333882801044373">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.6592169063458659" CI_START="-0.3095350752070967" EFFECT_SIZE="0.17484091556938464" ESTIMABLE="YES" MEAN_1="36.22" MEAN_2="31.61" MODIFIED="2013-12-30 11:11:55 +0000" MODIFIED_BY="[Empty name]" ORDER="504" SD_1="28.61" SD_2="22.82" SE="0.24713514870537281" STUDY_ID="STD-Marinello-2002" TOTAL_1="35" TOTAL_2="31" WEIGHT="13.592317291420903"/>
<CONT_DATA CI_END="0.10836465145350736" CI_START="-0.2758581875323997" EFFECT_SIZE="-0.08374676803944618" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="46.9" MODIFIED="2013-12-30 11:11:55 +0000" MODIFIED_BY="[Empty name]" ORDER="938" SD_1="28.4" SD_2="28.8" SE="0.09801783145420216" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="86.4076827085791"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3603295782741587" CI_START="-1.01978075735391" DF="0" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" I2="0.0" ID="CMP-003.14.02" MODIFIED="2013-12-30 11:12:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.098687284737795E-5" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.1018450468118335">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.3603295782741586" CI_START="-1.01978075735391" EFFECT_SIZE="-0.6900551678140343" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.3" ORDER="671" SD_1="0.87" SD_2="0.86" SE="0.16823043287565947" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7907404745599609" CI_START="-2.2107564729806075" DF="0" EFFECT_SIZE="-1.5007484737702843" ESTIMABLE="YES" I2="0.0" ID="CMP-003.14.03" MODIFIED="2013-12-30 11:12:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="3.4310837200452554E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.142788478037817">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.7907404745599609" CI_START="-2.2107564729806075" EFFECT_SIZE="-1.5007484737702843" ESTIMABLE="YES" MEAN_1="0.94" MEAN_2="1.67" ORDER="672" SD_1="0.55" SD_2="0.39" SE="0.3622556357212561" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="62.220833279404786" CI_END="-0.3216747394380065" CI_START="-2.2242256087156154" DF="4" EFFECT_SIZE="-1.272950174076811" ESTIMABLE="YES" I2="93.57128506775558" ID="CMP-003.14.04" MODIFIED="2013-12-30 11:11:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="9.89763826453327E-13" P_Z="0.008722894112349413" STUDIES="5" TAU2="1.0785245255258866" TOTAL_1="183" TOTAL_2="177" WEIGHT="100.00000000000001" Z="2.6227277657515247">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.27817683616857625" CI_START="-1.6773787193869785" EFFECT_SIZE="-0.9777777777777773" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.3" ORDER="673" SD_1="0.5" SD_2="0.5" SE="0.3569458148861734" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="16" TOTAL_2="20" WEIGHT="19.534060984588447"/>
<CONT_DATA CI_END="-0.9862975811839929" CI_START="-1.849785254898844" EFFECT_SIZE="-1.4180414180414185" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.2" ORDER="674" SD_1="0.7" SD_2="0.7" SE="0.22028151550894087" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="20.901323507602488"/>
<CONT_DATA CI_END="-2.02712182233849" CI_START="-3.8676183455235718" EFFECT_SIZE="-2.947370083931031" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="4.2" ORDER="676" SD_1="0.6" SD_2="0.9" SE="0.46952304677603346" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="18.1348979132735"/>
<CONT_DATA CI_END="-0.8576325843782733" CI_START="-1.9996033761561216" EFFECT_SIZE="-1.4286179802671974" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.77" ORDER="677" SD_1="0.45" SD_2="0.42" SE="0.29132443268998004" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.248338559089568"/>
<CONT_DATA CI_END="0.5397949297356679" CI_START="-0.1789787739176506" EFFECT_SIZE="0.18040807790900865" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.0" ORDER="678" SD_1="28.0" SD_2="27.0" SE="0.1833640080437482" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="21.18137903544601"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="40.8676189336014" CI_END="0.8053197928804202" CI_START="0.48809830924144537" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6269571191904627" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="300" I2="73.08382458524935" I2_Q="75.0206173720689" ID="CMP-003.15" LOG_CI_END="-0.09403162683193335" LOG_CI_START="-0.3114926967245119" LOG_EFFECT_SIZE="-0.20276216177822265" METHOD="MH" MODIFIED="2014-11-25 08:12:29 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="2.539788727073944E-5" P_Q="0.007349321082667171" P_Z="2.5721490056927846E-4" Q="12.00990450678914" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10901320932406562" TOTALS="YES" TOTAL_1="462" TOTAL_2="443" WEIGHT="100.0" Z="3.6549671599529168">
<NAME>Swelling in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.121508738565895" CI_END="0.4144421464212803" CI_START="0.08392244096274963" DF="1" EFFECT_SIZE="0.1864966395555564" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="29" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="-0.38253608572552134" LOG_CI_START="-1.0761218927692697" LOG_EFFECT_SIZE="-0.7293289892473956" NO="1" P_CHI2="0.7274039280063906" P_Z="3.756997163840102E-5" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="7.399480455957991" Z="4.121937148335366">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.5053433241361468" CI_START="0.05147899836737502" EFFECT_SIZE="0.16129032258064516" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.29641346719478834" LOG_CI_START="-1.2883699118017196" LOG_EFFECT_SIZE="-0.7923916894982539" ORDER="679" O_E="0.0" SE="0.5826801258257038" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.3395161290322581" WEIGHT="3.637871791392793"/>
<DICH_DATA CI_END="0.6547491999374693" CI_START="0.07013123093747059" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.1839250235830732" LOG_CI_START="-1.1540885383340782" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="680" O_E="0.0" SE="0.5698788509515902" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.3247619047619048" WEIGHT="3.761608664565198"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2380604448537903E-30" CI_END="0.9386337042179341" CI_START="0.5220353773768074" DF="1" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="-0.027503855308840846" LOG_CI_START="-0.2823000646626456" LOG_EFFECT_SIZE="-0.1549019599857432" NO="2" P_CHI2="0.9999999999999991" P_Z="0.017167588907441238" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="49" WEIGHT="15.631216099130992" Z="2.3830987397865524">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="0.9471991281342894" CI_START="0.5173146653599221" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.023558710374788606" LOG_CI_START="-0.2862452095966978" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="681" O_E="0.0" SE="0.15430334996209188" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.023809523809523805" WEIGHT="12.28473612252379"/>
<DICH_DATA CI_END="2.3379040026017486" CI_START="0.20958944398687923" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.36882667449208634" LOG_CI_START="-0.6786305944635728" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="682" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="3.3464799766072"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.016197643368654" CI_START="0.637502633110976" DF="0" EFFECT_SIZE="0.8048780487804879" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-003.15.03" LOG_CI_END="0.0069781834170477485" LOG_CI_START="-0.1955180171007437" LOG_EFFECT_SIZE="-0.09426991684184799" NO="3" P_CHI2="1.0" P_Z="0.06801912706784784" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.248377738157712" Z="1.824880085287075">
<NAME>French maritime pine bark extract</NAME>
<DICH_DATA CI_END="1.016197643368654" CI_START="0.637502633110976" EFFECT_SIZE="0.8048780487804879" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.0069781834170477485" LOG_CI_START="-0.1955180171007437" LOG_EFFECT_SIZE="-0.09426991684184799" ORDER="683" O_E="0.0" SE="0.1189472705565093" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.014148453172843425" WEIGHT="13.248377738157712"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.307060149834037" CI_END="0.9131075587032065" CI_START="0.4866641689248516" DF="6" EFFECT_SIZE="0.6666158797953257" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="217" I2="74.25672752621817" ID="CMP-003.15.04" LOG_CI_END="-0.03947806211524455" LOG_CI_START="-0.3127706278905771" LOG_EFFECT_SIZE="-0.17612434500291085" MODIFIED="2013-12-30 11:12:27 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="6.998987670305823E-4" P_Z="0.011530013657542804" STUDIES="7" TAU2="0.1099344883982641" TOTAL_1="347" TOTAL_2="334" WEIGHT="63.72092570675331" Z="2.526211220031437">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.3612065246002333" CI_START="0.022880159263634785" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="22" LOG_CI_END="-0.44224441347402005" LOG_CI_START="-1.64054095684243" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="684" O_E="0.0" SE="0.7038853212381584" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.49545454545454537" WEIGHT="2.699386716196562"/>
<DICH_DATA CI_END="0.8319859354514977" CI_START="0.4923160146664264" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="50" LOG_CI_END="-0.07988401530474874" LOG_CI_START="-0.3077560367274769" LOG_EFFECT_SIZE="-0.1938200260161128" ORDER="685" O_E="0.0" SE="0.13385315336840845" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.017916666666666674" WEIGHT="12.855068319279539"/>
<DICH_DATA CI_END="1.3036070664342596" CI_START="0.5953619345651708" EFFECT_SIZE="0.8809756097560976" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.11514670597006874" LOG_CI_START="-0.22521893612660332" LOG_EFFECT_SIZE="-0.055036115078267306" ORDER="686" O_E="0.0" SE="0.19993246300468626" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.039972989763120234" WEIGHT="10.951968958303894"/>
<DICH_DATA CI_END="0.9269426096039015" CI_START="0.01685649126290228" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="687" O_E="0.0" SE="1.0222524150130436" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="1.045" WEIGHT="1.4139285533605517"/>
<DICH_DATA CI_END="1.5429183637159785" CI_START="0.6946289966993215" EFFECT_SIZE="1.0352564102564104" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.18834294801674317" LOG_CI_START="-0.1582470913914229" LOG_EFFECT_SIZE="0.015047928312660138" ORDER="689" O_E="0.0" SE="0.2035887047967214" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.04144836072080657" WEIGHT="10.844577968526604"/>
<DICH_DATA CI_END="0.7465041278868161" CI_START="0.43092451697916057" EFFECT_SIZE="0.567174515235457" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="76" LOG_CI_END="-0.12696778644731532" LOG_CI_START="-0.36559879649908833" LOG_EFFECT_SIZE="-0.24628329147320185" ORDER="690" O_E="0.0" SE="0.14017303654696206" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.019648480174795962" WEIGHT="12.682036385298524"/>
<DICH_DATA CI_END="1.109055461819751" CI_START="0.6048172784324211" EFFECT_SIZE="0.8190091001011123" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.04495326495889572" LOG_CI_START="-0.21837581039595505" LOG_EFFECT_SIZE="-0.08671127271852963" ORDER="691" O_E="0.0" SE="0.1546808023633849" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.023926150619780547" WEIGHT="12.27395880578764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="115.28070993193495" CI_END="-0.22237296340382587" CI_START="-0.5482572672344636" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3853151153191447" ESTIMABLE="YES" I2="95.66276092248899" I2_Q="93.26599665566107" ID="CMP-003.16" MODIFIED="2016-03-31 10:28:34 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="-2.220446049250313E-16" P_Q="1.153168449619102E-9" P_Z="3.572884332310896E-6" Q="44.55002242495185" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.8553200976231007" TOTALS="SUB" TOTAL_1="436" TOTAL_2="435" UNITS="" WEIGHT="400.0" Z="4.634796704519413">
<NAME>Swelling in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1460235652886488" CI_START="-0.23808077606950617" DF="0" EFFECT_SIZE="-0.0460286053904287" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.01" MODIFIED="2013-12-30 11:13:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6385414492644592" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="214" WEIGHT="100.0" Z="0.46973907404877135">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="0.1460235652886488" CI_START="-0.23808077606950617" EFFECT_SIZE="-0.0460286053904287" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="37.5" MODIFIED="2013-12-30 11:13:07 +0000" MODIFIED_BY="[Empty name]" ORDER="939" SD_1="28.6" SD_2="27.8" SE="0.09798760191205577" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8038967146357799" CI_START="-1.4962871780776674" DF="0" EFFECT_SIZE="-1.1500919463567236" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.02" MODIFIED="2013-12-30 11:13:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="7.456369759467952E-11" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="6.51117804992108">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.8038967146357799" CI_START="-1.4962871780776674" EFFECT_SIZE="-1.1500919463567236" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.5" ORDER="1" SD_1="0.87" SD_2="0.86" SE="0.17663346594717427" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.5802602669773103E-31" CI_END="-0.9218080848802453" CI_START="-2.3764664634110773" DF="0" EFFECT_SIZE="-1.6491372741456614" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.16.03" MODIFIED="2013-12-30 11:13:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="8.830231225184385E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.4439982755986245">
<NAME>French maritime pine bark extract</NAME>
<CONT_DATA CI_END="-0.9218080848802453" CI_START="-2.3764664634110773" EFFECT_SIZE="-1.6491372741456614" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.39" ORDER="693" SD_1="0.53" SD_2="0.4" SE="0.37109313997731375" STUDY_ID="STD-Arcangeli-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="67.70260419666258" CI_END="0.04090040370302184" CI_START="-3.502601975760228" DF="2" EFFECT_SIZE="-1.730850786028603" ESTIMABLE="YES" I2="97.04590388548364" ID="CMP-003.16.04" MODIFIED="2013-12-30 11:13:09 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.9984014443252818E-15" P_Z="0.05552838252462859" STUDIES="3" TAU2="2.3218687052924833" TOTAL_1="137" TOTAL_2="127" WEIGHT="100.0" Z="1.9147187386637332">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-1.0862316464850301" CI_START="-1.9635915000065065" EFFECT_SIZE="-1.5249115732457683" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" ORDER="694" SD_1="0.6" SD_2="0.7" SE="0.22382040191605015" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="34.45094505491311"/>
<CONT_DATA CI_END="-2.9213570285933605" CI_START="-5.161022211028014" EFFECT_SIZE="-4.041189619810687" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="3.9" ORDER="695" SD_1="0.6" SD_2="1.0" SE="0.5713536575418852" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="30.856016330479573"/>
<CONT_DATA CI_END="0.47843011007575204" CI_START="-0.23950153595374585" EFFECT_SIZE="0.1194642870610031" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="20.0" ORDER="696" SD_1="24.0" SD_2="26.0" SE="0.18314919347815856" STUDY_ID="STD-Unkauf-1996" TOTAL_1="64" TOTAL_2="56" WEIGHT="34.69303861460732"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.976545711899067" CI_END="0.8425727766002287" CI_START="0.4782470714757495" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6347896997543756" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="269" I2="71.9737065295417" I2_Q="69.01453703624334" ID="CMP-003.17" LOG_CI_END="-0.07439257697192501" LOG_CI_START="-0.32034768067508607" LOG_EFFECT_SIZE="-0.19737012882350552" METHOD="MH" MODIFIED="2014-11-25 08:12:56 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="7.661017760525191E-4" P_Q="0.039663721207939595" P_Z="0.0016574579798866416" Q="6.45463972037267" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09398954793085879" TOTALS="YES" TOTAL_1="824" TOTAL_2="485" WEIGHT="100.0" Z="3.145601276767732">
<NAME>Paraesthesias in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9764832950325375" CI_END="1.0803352038211682" CI_START="0.5101691787032272" DF="2" EFFECT_SIZE="0.7423972815532321" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="32.806610964764815" ID="CMP-003.17.01" LOG_CI_END="0.03355852824884056" LOG_CI_START="-0.29228578234606595" LOG_EFFECT_SIZE="-0.12936362704861265" NO="1" P_CHI2="0.22576935148037192" P_Z="0.11964800562252571" STUDIES="3" TAU2="0.03843542158405857" TOTAL_1="154" TOTAL_2="151" WEIGHT="36.37633681106758" Z="1.5562527359267988">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.890138731579122" CI_START="0.19503826196071922" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.05054230159788697" LOG_CI_START="-0.709880181825325" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="697" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.15000000000000002" WEIGHT="8.554914222373279"/>
<DICH_DATA CI_END="1.6730972932352277" CI_START="0.5022288788435925" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.22352119660291833" LOG_CI_START="-0.29909831838171796" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="698" O_E="0.0" SE="0.30698929011029724" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.09424242424242424" WEIGHT="11.089028232582033"/>
<DICH_DATA CI_END="1.1594988882924713" CI_START="0.5830530667533707" EFFECT_SIZE="0.8222222222222222" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.0642703365801496" LOG_CI_START="-0.234291915996847" LOG_EFFECT_SIZE="-0.0850107897083487" ORDER="699" O_E="0.0" SE="0.1753769450707134" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.030757072862336025" WEIGHT="16.732394356112273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009383939991687733" CI_END="1.0474309884172965" CI_START="0.6155073945102658" DF="1" EFFECT_SIZE="0.8029330723105399" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="0.020125418428893493" LOG_CI_START="-0.2107667252254116" LOG_EFFECT_SIZE="-0.09532065339825901" NO="2" P_CHI2="0.9228290473342848" P_Z="0.10560044302997537" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="24.48280928430079" Z="1.618288476052527">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="2.2172120454662894" CI_START="0.3182374917377869" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.3458072293220705" LOG_CI_START="-0.49724865719830724" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="700" O_E="0.0" SE="0.49521520093601257" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.24523809523809528" WEIGHT="6.153123708330974"/>
<DICH_DATA CI_END="1.0546918579385862" CI_START="0.6068123074837151" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.023125593335808884" LOG_CI_START="-0.21694561935192164" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="701" O_E="0.0" SE="0.14101901870444156" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.01988636363636364" WEIGHT="18.329685575969815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.329655480338114" CI_END="0.6558766349992895" CI_START="0.3537388838482797" DF="2" EFFECT_SIZE="0.48167319710236545" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="155" I2="53.806948172148445" ID="CMP-003.17.03" LOG_CI_END="-0.18317784016309685" LOG_CI_START="-0.4513171988434998" LOG_EFFECT_SIZE="-0.3172475195032983" NO="3" P_CHI2="0.11476977936386723" P_Z="3.520692724494593E-6" STUDIES="3" TAU2="0.03549244844696351" TOTAL_1="595" TOTAL_2="265" WEIGHT="39.14085390463163" Z="4.63783993122959">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="702" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Balmer-1980" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="0.8536323898605994"/>
<DICH_DATA CI_END="0.7891864271810392" CI_START="0.4438377403223627" EFFECT_SIZE="0.5918367346938775" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" LOG_CI_END="-0.10282039256716954" LOG_CI_START="-0.35277577169194557" LOG_EFFECT_SIZE="-0.22779808212955757" ORDER="703" O_E="0.0" SE="0.14682502699697503" STUDY_ID="STD-Cauwenberge-1978" TOTAL_1="60" TOTAL_2="60" VAR="0.021557588552662443" WEIGHT="18.06457275556814"/>
<DICH_DATA CI_END="0.5029818868098265" CI_START="0.34516374379253173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="104" LOG_CI_END="-0.29844765430825204" LOG_CI_START="-0.4619748291149599" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="704" O_E="0.0" SE="0.09605667195403049" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009226884226884228" WEIGHT="20.222648759202894"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.18" MODIFIED="2016-03-31 10:30:49 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="76" TOTAL_2="74" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Paraesthesias in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.18.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="0.20535162803696538" CI_START="-0.43537001730831004" EFFECT_SIZE="-0.11500919463567234" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.5" ORDER="705" SD_1="0.87" SD_2="0.86" SE="0.16345240279903253" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.240959375451796" CI_END="0.4735853711148099" CI_START="-2.5527239416044973" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0395692852448437" ESTIMABLE="YES" I2="75.73098095887224" I2_Q="84.8099244682641" ID="CMP-003.19" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.016236804978504327" P_Q="0.010294335622151762" P_Z="0.17812947562750167" Q="6.583245737723604" RANDOM="NO" SCALE="33.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="333" TOTAL_2="363" UNITS="" WEIGHT="100.0" Z="1.3465367534973591">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.9899999961253796" CI_START="-17.01000000387462" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.19.01" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005174671266969821" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="4.65940649598151" Z="2.7959543273277148">
<NAME>Aminaftone</NAME>
<CONT_DATA CI_END="-2.9899999961253796" CI_START="-17.01000000387462" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-15.4" MEAN_2="-5.4" MODIFIED="2015-09-09 22:07:42 +0100" MODIFIED_BY="[Empty name]" ORDER="2475" SD_1="17.8" SD_2="13.1" SE="3.5765963350187073" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" WEIGHT="4.65940649598151"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6577136377281905" CI_END="0.9480258996907798" CI_START="-2.151350977843382" DF="1" EFFECT_SIZE="-0.6016625390763011" ESTIMABLE="YES" I2="39.67595022199084" ID="CMP-003.19.02" MODIFIED="2015-09-09 22:07:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19791237709553755" P_Z="0.4466863643074521" STUDIES="2" TAU2="0.0" TOTAL_1="297" TOTAL_2="320" WEIGHT="95.34059350401849" Z="0.7609509614556228">
<NAME>Calcium dobesilate at 3 months of treatment</NAME>
<CONT_DATA CI_END="0.664100452096434" CI_START="-2.664100452096434" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="40.8" MODIFIED="2013-12-30 11:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="933" SD_1="11.0" SD_2="4.8" SE="0.849046444334001" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="197" TOTAL_2="216" WEIGHT="82.68135019090208"/>
<CONT_DATA CI_END="6.252843926845621" CI_START="-2.252843926845621" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="41.2" MEAN_2="39.2" MODIFIED="2013-12-30 11:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="943" SD_1="17.7" SD_2="12.8" SE="2.169858201676924" STUDY_ID="STD-Rabe-2011" TOTAL_1="100" TOTAL_2="104" WEIGHT="12.65924331311641"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="110.407078779019" CI_END="0.8508406598704409" CI_START="0.5929739358577758" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7103001723716548" ESTIMABLE="YES" EVENTS_1="451" EVENTS_2="564" I2="87.31965363559598" I2_Q="66.28680202783967" ID="CMP-003.20" LOG_CI_END="-0.07015176426127744" LOG_CI_START="-0.2269643956102976" LOG_EFFECT_SIZE="-0.1485580799357875" METHOD="MH" MODIFIED="2015-09-09 22:09:03 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.1102230246251565E-16" P_Q="0.030670014799700995" P_Z="2.043441124237588E-4" Q="8.898592184809457" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2064923716331263" TOTALS="SUB" TOTAL_1="1318" TOTAL_2="971" WEIGHT="400.0" Z="3.7135845981502347">
<NAME>Global assessment by the participant (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.193083593243646" CI_END="1.1902283485302416" CI_START="0.6074196461118951" DF="3" EFFECT_SIZE="0.8502752979221405" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="193" I2="73.19773434184968" ID="CMP-003.20.01" LOG_CI_END="0.07563028995804434" LOG_CI_START="-0.21651116556229655" LOG_EFFECT_SIZE="-0.07044043780212608" MODIFIED="2013-12-30 11:15:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010726344092059192" P_Z="0.34457541916244494" STUDIES="4" TAU2="0.0726934917207325" TOTAL_1="385" TOTAL_2="373" WEIGHT="100.0" Z="0.9451635058194483">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="0.4451289704755189" CI_START="0.02103939567657449" EFFECT_SIZE="0.0967741935483871" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.351514139466709" LOG_CI_START="-1.6769667387625116" LOG_EFFECT_SIZE="-1.0142404391146103" ORDER="707" O_E="0.0" SE="0.778577417922537" STUDY_ID="STD-Casley_x002d_Smith-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6061827956989247" WEIGHT="4.33781415931062"/>
<DICH_DATA CI_END="1.3012611117111792" CI_START="0.6355666651062011" EFFECT_SIZE="0.9094163981382026" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.11436445105595708" LOG_CI_START="-0.19683888921809106" LOG_EFFECT_SIZE="-0.04123721908106701" MODIFIED="2013-12-30 11:15:09 +0000" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.18280238255835482" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.03341671106901111" WEIGHT="27.75264861027913"/>
<DICH_DATA CI_END="1.5004603685863007" CI_START="0.8328573916734775" EFFECT_SIZE="1.1178861788617886" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="48" LOG_CI_END="0.17622452896341553" LOG_CI_START="-0.0794293555096484" LOG_EFFECT_SIZE="0.04839758672688353" MODIFIED="2013-12-30 11:15:09 +0000" MODIFIED_BY="[Empty name]" ORDER="979" O_E="0.0" SE="0.1501723572466157" STUDY_ID="STD-Rabe-2011" TOTAL_1="123" TOTAL_2="120" VAR="0.022551736881005174" WEIGHT="30.918495500734082"/>
<DICH_DATA CI_END="0.9767533688245212" CI_START="0.7050314973967807" EFFECT_SIZE="0.8298444976076556" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="88" LOG_CI_END="-0.010215082217969828" LOG_CI_START="-0.1517914803985976" LOG_EFFECT_SIZE="-0.08100328130828371" ORDER="708" O_E="0.0" SE="0.08316267710577435" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.0069160308633992845" WEIGHT="36.991041729676155"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5720281032502694" CI_START="0.1370562032783537" DF="0" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="-0.24258263416729411" LOG_CI_START="-0.8631013031482674" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2014-03-22 11:21:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.786970579389238E-4" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="3.4924020883719655">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="0.5720281032502694" CI_START="0.1370562032783537" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.24258263416729411" LOG_CI_START="-0.8631013031482674" LOG_EFFECT_SIZE="-0.5528419686577808" ORDER="713" O_E="0.0" SE="0.36449573777637356" STUDY_ID="STD-Allegra-1981" TOTAL_1="40" TOTAL_2="40" VAR="0.13285714285714287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.41893682719941" CI_END="0.9562041587901817" CI_START="0.5932755489532816" DF="3" EFFECT_SIZE="0.7531882548325192" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="156" I2="59.56293913972474" ID="CMP-003.20.03" LOG_CI_END="-0.01944937177210599" LOG_CI_START="-0.2267435501514834" LOG_EFFECT_SIZE="-0.12309646096179473" MODIFIED="2014-03-22 11:21:24 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05967834249815718" P_Z="0.01992532184910192" STUDIES="4" TAU2="0.03530044178577115" TOTAL_1="226" TOTAL_2="225" WEIGHT="100.00000000000003" Z="2.327751140872951">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.0989195384422978" CI_START="0.6140075541068498" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.0409658950715677" LOG_CI_START="-0.2118262857208204" LOG_EFFECT_SIZE="-0.08543019532462635" ORDER="709" O_E="0.0" SE="0.1484913783389251" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.02204968944099379" WEIGHT="25.853241275051385"/>
<DICH_DATA CI_END="1.1855043555846674" CI_START="0.6197310655924868" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.07390315393032808" LOG_CI_START="-0.20779673319155453" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="710" O_E="0.0" SE="0.16547190813232432" STUDY_ID="STD-Chassignolle-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.02738095238095238" WEIGHT="23.654336338111403"/>
<DICH_DATA CI_END="1.165515036767495" CI_START="0.6420464528341865" EFFECT_SIZE="0.8650519031141869" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.06651788089651227" LOG_CI_START="-0.19243354906553276" LOG_EFFECT_SIZE="-0.06295783408451022" ORDER="711" O_E="0.0" SE="0.15210935178995663" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.023137254901960783" WEIGHT="25.372094791557362"/>
<DICH_DATA CI_END="0.7171802726922488" CI_START="0.3921208023373117" EFFECT_SIZE="0.5303030303030303" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="66" LOG_CI_END="-0.14437166498092227" LOG_CI_START="-0.4065801174022639" LOG_EFFECT_SIZE="-0.27547589119159305" ORDER="712" O_E="0.0" SE="0.15402254290506864" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.023722943722943715" WEIGHT="25.12032759527988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="40.59755437002928" CI_END="0.9720514070816281" CI_START="0.26180526966005646" DF="5" EFFECT_SIZE="0.5044682158019899" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="190" I2="87.68398718201804" ID="CMP-003.20.04" LOG_CI_END="-0.012310766738828827" LOG_CI_START="-0.5820216161456474" LOG_EFFECT_SIZE="-0.29716619144223805" MODIFIED="2013-12-30 11:14:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.1313688963454638E-7" P_Z="0.04088751005815383" STUDIES="6" TAU2="0.48472406963259806" TOTAL_1="667" TOTAL_2="333" WEIGHT="100.0" Z="2.0446689167185474">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="1.5088426833213036" CI_START="0.4045163682382569" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.17864396122882614" LOG_CI_START="-0.39306390052456286" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="714" O_E="0.0" SE="0.33582402799349803" STUDY_ID="STD-Burnand-1989" TOTAL_1="24" TOTAL_2="25" VAR="0.11277777777777775" WEIGHT="18.743251464835033"/>
<DICH_DATA CI_END="0.2762811639284057" CI_START="0.02945641493441985" EFFECT_SIZE="0.0902122641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="32" LOG_CI_END="-0.5586487230487662" LOG_CI_START="-1.5308201111574262" LOG_EFFECT_SIZE="-1.0447344171030961" ORDER="715" O_E="0.0" SE="0.5710582857010101" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" VAR="0.32610756566777654" WEIGHT="13.81190235944287"/>
<DICH_DATA CI_END="0.9680143173409217" CI_START="0.37820149316348955" EFFECT_SIZE="0.6050656660412758" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.014118219245144973" LOG_CI_START="-0.42227676086542654" LOG_EFFECT_SIZE="-0.21819749005528571" ORDER="716" O_E="0.0" SE="0.23975434776511922" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.057482147272277725" WEIGHT="20.654738045323686"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="718" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="3.6279826042663323"/>
<DICH_DATA CI_END="2.314669925833568" CI_START="0.8772849110521551" EFFECT_SIZE="1.425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.36448906895678185" LOG_CI_START="-0.05685934026772378" LOG_EFFECT_SIZE="0.153814864344529" ORDER="719" O_E="0.0" SE="0.24750214128673814" STUDY_ID="STD-Pedersen-1992" TOTAL_1="24" TOTAL_2="19" VAR="0.06125730994152048" WEIGHT="20.511921826806276"/>
<DICH_DATA CI_END="0.43033352246510764" CI_START="0.2924255360642496" EFFECT_SIZE="0.3547400611620795" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="109" LOG_CI_END="-0.3661948215805824" LOG_CI_START="-0.5339847052861528" LOG_EFFECT_SIZE="-0.4500897634333676" ORDER="720" O_E="0.0" SE="0.09856060826197167" STUDY_ID="STD-Pulvertaft-1983" TOTAL_1="495" TOTAL_2="165" VAR="0.009714193500969838" WEIGHT="22.650203699325804"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="39.809710213968685" CI_END="-0.4554115330179292" CI_START="-0.7766265017533445" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6160190173856368" ESTIMABLE="YES" I2="84.92830023692389" I2_Q="51.31448239130932" ID="CMP-003.21" MODIFIED="2015-09-09 22:09:06 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="4.964677100538495E-7" P_Q="0.1282214114855783" P_Z="5.5811436567780034E-14" Q="4.107997815849425" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.21067110750142473" TOTALS="SUB" TOTAL_1="440" TOTAL_2="441" UNITS="" WEIGHT="300.0" Z="7.517551829050138">
<NAME>Global assessment by the participant (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4244542537870518" CI_END="-0.3349008493490506" CI_START="-0.7118962767537611" DF="1" EFFECT_SIZE="-0.5233985630514059" ESTIMABLE="YES" I2="0.0" ID="CMP-003.21.01" MODIFIED="2013-12-30 11:16:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5147228034306985" P_Z="5.2626422792112204E-8" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="226" WEIGHT="100.0" Z="5.442200401224041">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-0.19479102147677713" CI_START="-0.7270915890259755" EFFECT_SIZE="-0.46094130525137633" ESTIMABLE="YES" MEAN_1="15.19" MEAN_2="20.83" MODIFIED="2013-12-30 11:16:04 +0000" MODIFIED_BY="[Empty name]" ORDER="978" SD_1="12.49" SD_2="11.91" SE="0.1357934563461159" STUDY_ID="STD-Rabe-2011" TOTAL_1="108" TOTAL_2="115" WEIGHT="50.16008997784145"/>
<CONT_DATA CI_END="-0.319253244532848" CI_START="-0.8532608690053689" EFFECT_SIZE="-0.5862570567691084" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="7.39" MODIFIED="2013-12-30 11:16:04 +0000" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="4.4" SD_2="5.7" SE="0.13622893805312367" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" WEIGHT="49.83991002215854"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.47192747278546693" CI_START="-1.138201252113946" DF="0" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" I2="0.0" ID="CMP-003.21.02" MODIFIED="2013-12-30 11:16:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.1745916288072995E-6" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="4.736482823107488">
<NAME>Diosmine, Hidrosmine</NAME>
<CONT_DATA CI_END="-0.47192747278546693" CI_START="-1.138201252113946" EFFECT_SIZE="-0.8050643624497065" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.2" ORDER="721" SD_1="0.87" SD_2="0.86" SE="0.16997092410471867" STUDY_ID="STD-Gilly-1994" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="26.15280644642006" CI_END="-0.38867804142120355" CI_START="-1.9635249459145996" DF="3" EFFECT_SIZE="-1.1761014936679015" ESTIMABLE="YES" I2="88.52895575032768" ID="CMP-003.21.03" MODIFIED="2013-12-30 11:16:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="8.860084947381885E-6" P_Z="0.003417905970690976" STUDIES="4" TAU2="0.5605714140977732" TOTAL_1="142" TOTAL_2="141" WEIGHT="100.00000000000001" Z="2.9274167072060506">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-0.8852781722347934" CI_START="-2.567878747649893" EFFECT_SIZE="-1.7265784599423433" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="6.0" MODIFIED="2013-12-30 11:16:35 +0000" MODIFIED_BY="[Empty name]" ORDER="942" SD_1="1.2" SD_2="2.0" SE="0.4292427281029749" STUDY_ID="STD-Cesarone-2002" TOTAL_1="16" TOTAL_2="15" WEIGHT="21.67049098671698"/>
<CONT_DATA CI_END="-1.3120424182781059" CI_START="-2.2237404554833864" EFFECT_SIZE="-1.7678914368807461" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="9.5" ORDER="722" SD_1="2.5" SD_2="3.3" SE="0.23258030361696397" STUDY_ID="STD-Cloarec-1996" TOTAL_1="53" TOTAL_2="51" WEIGHT="26.25923175872245"/>
<CONT_DATA CI_END="0.3528616138779379" CI_START="-0.6086442995189438" EFFECT_SIZE="-0.12789134282050293" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.4" ORDER="723" SD_1="1.4" SD_2="1.7" SE="0.24528662796385997" STUDY_ID="STD-Ihme-1996" TOTAL_1="36" TOTAL_2="31" WEIGHT="26.002368884467796"/>
<CONT_DATA CI_END="-0.6934495545778849" CI_START="-1.6424031837429498" EFFECT_SIZE="-1.1679263691604174" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.0" ORDER="724" SD_1="1.1" SD_2="1.4" SE="0.24208445579875187" STUDY_ID="STD-Kiesewetter-1997" TOTAL_1="37" TOTAL_2="44" WEIGHT="26.06790837009278"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="29.999112178584202" CI_END="1.3787354630109154" CI_START="1.026696043656241" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="1.189765626130568" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="245" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.1394809463966236" LOG_CI_START="0.011441888483968503" LOG_EFFECT_SIZE="0.07546141744029608" METHOD="MH" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5173425094223781" P_Q="0.594540692850634" P_Z="0.020873847485421506" Q="3.692097128418329" RANDOM="NO" SCALE="227.9963925930342" SORT_BY="STUDY" STUDIES="32" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1998" TOTAL_2="1889" WEIGHT="99.99999999999997" Z="2.310258491689585">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.320522299550465" CI_START="0.05643115644753237" DF="0" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.22.01" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-18 12:18:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6684881427861843" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="43" WEIGHT="0.7105614602209694" Z="0.4282238668218129">
<NAME>Aminaftone</NAME>
<DICH_DATA CI_END="6.320522299550465" CI_START="0.05643115644753237" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8007529679090034" LOG_CI_START="-1.2484810496123675" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2015-09-09 22:07:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1241" O_E="0.0" SE="1.2037302057640382" STUDY_ID="STD-Belczak-2014" TOTAL_1="36" TOTAL_2="43" VAR="1.448966408268734" WEIGHT="0.7105614602209694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.582765279626608" CI_END="1.526976604600602" CI_START="0.9905605728108575" DF="6" EFFECT_SIZE="1.2298629273711565" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="110" I2="43.30404349465362" ID="CMP-003.22.02" LOG_CI_END="0.18383238311359437" LOG_CI_START="-0.004118962191892841" LOG_EFFECT_SIZE="0.0898567104608508" MODIFIED="2015-09-09 22:07:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10215978593827335" P_Z="0.060922350519817335" STUDIES="7" TAU2="0.0" TOTAL_1="758" TOTAL_2="715" WEIGHT="45.19034081144589" Z="1.8740585866651884">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Flota_x002d_Cervera-2008" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="0.3977774614332241"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Hachen-1982" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.19491095610227982"/>
<DICH_DATA CI_END="2.6977689818668056" CI_START="0.42776421247572727" EFFECT_SIZE="1.074248120300752" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4310047569755741" LOG_CI_START="-0.3687955521030694" LOG_EFFECT_SIZE="0.031104602436252366" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4698066606281763" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.22071829837059842" WEIGHT="3.1905424198896264"/>
<DICH_DATA CI_END="1.379115264279274" CI_START="0.5729205362707969" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" LOG_CI_END="0.13960056534080972" LOG_CI_START="-0.24190561023557236" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.22409861601959308" STUDY_ID="STD-Marinello-2002" TOTAL_1="82" TOTAL_2="41" VAR="0.05022018970189702" WEIGHT="9.355725892909431"/>
<DICH_DATA CI_END="1.5859185558605429" CI_START="0.7530972088851662" EFFECT_SIZE="1.0928635953026198" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" LOG_CI_END="0.20028088055500345" LOG_CI_START="-0.1231489619697851" LOG_EFFECT_SIZE="0.03856595929260917" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="940" O_E="0.0" SE="0.18998429050260193" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="246" TOTAL_2="263" VAR="0.03609403063777704" WEIGHT="16.95610439333782"/>
<DICH_DATA CI_END="5.9756959783431975" CI_START="1.5840886202364952" EFFECT_SIZE="3.0766917293233083" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.7763884940472019" LOG_CI_START="0.19977947409887165" LOG_EFFECT_SIZE="0.48808398407303677" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="0.33870299257833086" STUDY_ID="STD-Rabe-2011" TOTAL_1="133" TOTAL_2="124" VAR="0.11471971718151686" WEIGHT="4.0347326321561425"/>
<DICH_DATA CI_END="1.6723232013260785" CI_START="0.6949016850698201" EFFECT_SIZE="1.0780075187969924" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.22332021508135724" LOG_CI_START="-0.1580766351968807" LOG_EFFECT_SIZE="0.03262178994223827" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2240343977982942" STUDY_ID="STD-Widmer-1990" TOTAL_1="114" TOTAL_2="111" VAR="0.05019141139684433" WEIGHT="11.060547055617374"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2331012827270302" CI_START="0.5840929599486262" DF="0" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-003.22.03" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2015-09-09 22:07:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6977879098630941" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="33" WEIGHT="4.553451697878792" Z="0.38830828210084756">
<NAME>Centella asiatica</NAME>
<DICH_DATA CI_END="2.2331012827270302" CI_START="0.5840929599486262" EFFECT_SIZE="1.1420765027322404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.34890842102573155" LOG_CI_START="-0.23351802826448254" LOG_EFFECT_SIZE="0.05769519638062451" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.34212017937049316" STUDY_ID="STD-Pointel-1986" TOTAL_1="61" TOTAL_2="33" VAR="0.11704621713249841" WEIGHT="4.553451697878792"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.300845449607167" CI_END="1.443609566962083" CI_START="0.7037978870133861" DF="7" EFFECT_SIZE="1.0079728978996525" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="49" I2="0.0" ID="CMP-003.22.04" LOG_CI_END="0.15944975151511834" LOG_CI_START="-0.15255204136528333" LOG_EFFECT_SIZE="0.003448855074917499" MODIFIED="2015-09-09 22:07:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7445468620510969" P_Z="0.9654379002716841" STUDIES="8" TAU2="0.0" TOTAL_1="424" TOTAL_2="413" WEIGHT="19.559773690146276" Z="0.04333072366239658">
<NAME>Diosmine, Hidrosmine</NAME>
<DICH_DATA CI_END="1.7926315021300137" CI_START="0.46873982565817657" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.25349102406348534" LOG_CI_START="-0.3290681458422849" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.3421981401170484" STUDY_ID="STD-Biland-1982" TOTAL_1="35" TOTAL_2="35" VAR="0.1170995670995671" WEIGHT="4.677862946454716"/>
<DICH_DATA CI_END="13.885529310369082" CI_START="0.6229880646092515" EFFECT_SIZE="2.9411764705882355" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1425624395195535" LOG_CI_START="-0.20552027360406375" LOG_EFFECT_SIZE="0.4685210829577449" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.7918704588058654" STUDY_ID="STD-Danielsson-2002" TOTAL_1="51" TOTAL_2="50" VAR="0.6270588235294117" WEIGHT="0.7873630701953482"/>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Dominguez-1992" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="0.2048216826837517"/>
<DICH_DATA CI_END="49.07807360941349" CI_START="0.09356187798318824" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6908875076568242" LOG_CI_START="-1.0289010695739755" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="1.5976172734359604" STUDY_ID="STD-Fermoso-1992" TOTAL_1="20" TOTAL_2="14" VAR="2.552380952380952" WEIGHT="0.2273961154526598"/>
<DICH_DATA CI_END="2.9876119742706684" CI_START="0.5950497564904714" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4753241914111042" LOG_CI_START="-0.22544671819450432" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.41163630117428224" STUDY_ID="STD-Gilly-1994" TOTAL_1="80" TOTAL_2="80" VAR="0.1694444444444444" WEIGHT="3.5083972098410365"/>
<DICH_DATA CI_END="2.7613068900368742" CI_START="0.2231106212479665" EFFECT_SIZE="0.7849056603773585" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4411146765570192" LOG_CI_START="-0.6514797545051118" LOG_EFFECT_SIZE="-0.10518253897404628" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.6417953772355555" STUDY_ID="STD-Guilhou-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.4119013062409289" WEIGHT="1.9676725092230152"/>
<DICH_DATA CI_END="1.5460497575926389" CI_START="0.3100093890734195" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.18922346700803455" LOG_CI_START="-0.5086251527430584" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.4099197336481717" STUDY_ID="STD-Laurent-1988" TOTAL_1="100" TOTAL_2="100" VAR="0.16803418803418801" WEIGHT="5.067684858659275"/>
<DICH_DATA CI_END="2.0190742752871254" CI_START="0.2785930200215189" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3051522955429512" LOG_CI_START="-0.5550297687595511" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.5052752025411797" STUDY_ID="STD-Planchon-1990" TOTAL_1="55" TOTAL_2="55" VAR="0.25530303030303025" WEIGHT="3.118575297636477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7359925831763834" CI_START="0.18809447425601197" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-003.22.05" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-09-09 22:07:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3236085963801921" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="2.910670277794045" Z="0.9870694697483925">
<NAME>Grape seed extract</NAME>
<DICH_DATA CI_END="1.7359925831763834" CI_START="0.18809447425601197" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2395478653724715" LOG_CI_START="-0.7256239627450604" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Thebaut-1985" TOTAL_1="35" TOTAL_2="40" VAR="0.3214285714285714" WEIGHT="2.910670277794045"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.142641461086571" CI_END="1.7642967157058835" CI_START="1.0241570543234586" DF="13" EFFECT_SIZE="1.3442161014174359" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="67" I2="0.0" ID="CMP-003.22.06" LOG_CI_END="0.24657162566954377" LOG_CI_START="0.01036656073740967" LOG_EFFECT_SIZE="0.12846909320347674" MODIFIED="2015-09-09 22:07:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5159834616607006" P_Z="0.03300670971955511" STUDIES="14" TAU2="0.0" TOTAL_1="684" TOTAL_2="645" WEIGHT="27.075202062514013" Z="2.1320016645509186">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Alterkamper-1987" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="0.7796438244091193"/>
<DICH_DATA CI_END="8.03557043079218" CI_START="0.28000501263457733" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.905016711983248" LOG_CI_START="-0.5528341938718854" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Balmer-1980" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.7796438244091193"/>
<DICH_DATA CI_END="36.11328941979412" CI_START="0.06538021389049867" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5576670484324069" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.18655669273384623" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Diebschlag-1994" TOTAL_1="40" TOTAL_2="20" VAR="2.59465737514518" WEIGHT="0.25778545807075715"/>
<DICH_DATA CI_END="6.518295566757786" CI_START="0.9719806783736777" EFFECT_SIZE="2.5170731707317073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8141340493021292" LOG_CI_START="-0.012342368159215193" LOG_EFFECT_SIZE="0.40089584057145705" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.48547633874104096" STUDY_ID="STD-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.23568727547740592" WEIGHT="1.9027021905222556"/>
<DICH_DATA CI_END="7.355395653031318" CI_START="0.012976301617136022" EFFECT_SIZE="0.3089430894308943" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8666060387639877" LOG_CI_START="-1.8868490684091632" LOG_EFFECT_SIZE="-0.5101215148225877" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.6173931597761082" STUDY_ID="STD-Koscielnny-1996" TOTAL_1="40" TOTAL_2="37" VAR="2.6159606332905434" WEIGHT="0.6069379139387447"/>
<DICH_DATA CI_END="2.6300131119236196" CI_START="0.00775971920930058" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41995791366918006" LOG_CI_START="-2.110153993697694" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="981" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Kriner-1985" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="1.3643766927159588"/>
<DICH_DATA CI_END="1.5391241333657362" CI_START="0.7027373403825276" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.18727364794175155" LOG_CI_START="-0.1532069693441908" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.2" STUDY_ID="STD-MacLennan-1994" TOTAL_1="52" TOTAL_2="52" VAR="0.04000000000000001" WEIGHT="9.745547805113992"/>
<DICH_DATA CI_END="7.267071756978603" CI_START="0.5504280312298803" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.25929945722445363" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Parrado-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="1.169465736613679"/>
<DICH_DATA CI_END="2.496356013675377" CI_START="0.10014597222129622" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3973065216149974" LOG_CI_START="-0.9993665129429598" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Serralde-1990" TOTAL_1="26" TOTAL_2="26" VAR="0.6730769230769231" WEIGHT="1.5592876488182386"/>
<DICH_DATA CI_END="5.313494641645885" CI_START="0.28784520068821484" EFFECT_SIZE="1.2367149758454106" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7253802469539765" LOG_CI_START="-0.5408410072441131" LOG_EFFECT_SIZE="0.09226961985493179" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.7437846326122535" STUDY_ID="STD-Unkauf-1996" TOTAL_1="69" TOTAL_2="64" VAR="0.5532155797101449" WEIGHT="1.2134306139299826"/>
<DICH_DATA CI_END="3.343632810758682" CI_START="1.004540355835996" EFFECT_SIZE="1.8327067669172932" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5242185782714054" LOG_CI_START="0.00196738853557186" LOG_EFFECT_SIZE="0.26309298340348863" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.30677293403591116" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.09410963305700148" WEIGHT="5.386630059553915"/>
<DICH_DATA CI_END="5.502292199432192" CI_START="0.2934039860395668" EFFECT_SIZE="1.2705882352941176" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7405436498907105" LOG_CI_START="-0.5325339903453966" LOG_EFFECT_SIZE="0.10400482977265695" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="1894" O_E="0.0" SE="0.7478121077106432" STUDY_ID="STD-Vanscheidt-2002b" TOTAL_1="85" TOTAL_2="81" VAR="0.5592229484386346" WEIGHT="1.1976456338814785"/>
<DICH_DATA CI_END="5.887545754238547" CI_START="0.18601750764417702" EFFECT_SIZE="1.0465116279069768" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7699342952089039" LOG_CI_START="-0.7304461788173894" LOG_EFFECT_SIZE="0.019744058195757187" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.8813309174461722" STUDY_ID="STD-Vin-1994" TOTAL_1="43" TOTAL_2="30" VAR="0.7767441860465115" WEIGHT="0.9184845054682775"/>
<DICH_DATA CI_END="198.0599697491454" CI_START="0.6273260464249563" EFFECT_SIZE="11.146666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2967967083816303" LOG_CI_START="-0.20250668028699764" LOG_EFFECT_SIZE="1.0471450140473164" MODIFIED="2013-12-30 11:17:59 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="1.468103182255255" STUDY_ID="STD-Zucarelli-1987" TOTAL_1="74" TOTAL_2="75" VAR="2.1553269537480064" WEIGHT="0.19362015506848987"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-03-31 10:30:35 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Sensitivity analysis based on low risk of bias</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-03-31 10:30:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="133" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Oedema in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="29" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-23 21:55:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.5472751585524283" CI_START="0.6306423336104108" EFFECT_SIZE="0.9878143634949442" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.18956755301077963" LOG_CI_START="-0.20021687939162486" LOG_EFFECT_SIZE="-0.005324663190422592" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.22896130505723078" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.052423279213510296" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.792687796777786" CI_END="4.109564028384986" CI_START="-8.791904716358296" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3411703439866547" ESTIMABLE="YES" I2="65.4737132370139" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2015-12-19 22:27:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.055224836588953385" P_Q="1.0" P_Z="0.4768789373835598" Q="0.0" RANDOM="YES" SCALE="48.4993433058706" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="20.799702944445794" TOTALS="YES" TOTAL_1="426" TOTAL_2="441" UNITS="" WEIGHT="100.0" Z="0.7113313447752571">
<NAME>Ankle perimeter circumference (mm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.792687796777786" CI_END="4.109564028384986" CI_START="-8.791904716358296" DF="2" EFFECT_SIZE="-2.3411703439866547" ESTIMABLE="YES" I2="65.4737132370139" ID="CMP-004.02.01" MODIFIED="2014-03-20 22:48:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.055224836588953385" P_Z="0.4768789373835598" STUDIES="3" TAU2="20.799702944445794" TOTAL_1="426" TOTAL_2="441" WEIGHT="100.0" Z="0.7113313447752571">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="6.487842096264158" CI_START="-4.087842096264181" EFFECT_SIZE="1.1999999999999886" ESTIMABLE="YES" MEAN_1="229.5" MEAN_2="228.3" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="22.7" SD_2="19.6" SE="2.6979281956066505" STUDY_ID="STD-Labs-2004" TOTAL_1="124" TOTAL_2="123" WEIGHT="38.57873037956919"/>
<CONT_DATA CI_END="-2.301974796401309" CI_START="-21.4980252035987" EFFECT_SIZE="-11.900000000000006" ESTIMABLE="YES" MEAN_1="254.9" MEAN_2="266.8" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="934" SD_1="43.2" SD_2="53.9" SE="4.897041618778046" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="193" TOTAL_2="203" WEIGHT="24.18973262630039"/>
<CONT_DATA CI_END="5.844837594293494" CI_START="-5.4448375942934595" EFFECT_SIZE="0.20000000000001705" ESTIMABLE="YES" MEAN_1="240.9" MEAN_2="240.7" MODIFIED="2014-03-20 22:48:36 +0000" MODIFIED_BY="[Empty name]" ORDER="948" SD_1="21.3" SD_2="21.8" SE="2.8800721027627216" STUDY_ID="STD-Rabe-2011" TOTAL_1="109" TOTAL_2="115" WEIGHT="37.23153699413043"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.30597249674043725" CI_END="-33.7574252596924" CI_START="-84.40177587539557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-59.079600567543984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2016-02-28 13:21:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5801623027301253" P_Q="0.5801623027301253" P_Z="4.811908378383982E-6" Q="0.30597249674043725" RANDOM="NO" SCALE="159.8233139775472" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="212" UNITS="" WEIGHT="99.99999999999999" Z="4.572825514618976">
<NAME>Volume of the leg (mL)</NAME>
<GROUP_LABEL_1>Favours phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-31.48696997431874" CI_START="-99.47303002568127" DF="0" EFFECT_SIZE="-65.48" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2016-02-28 13:21:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.5972930691736568E-4" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="119" WEIGHT="55.49096361296234" Z="3.775434011346586">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-31.48696997431874" CI_START="-99.47303002568127" EFFECT_SIZE="-65.48" ESTIMABLE="YES" MEAN_1="-64.72" MEAN_2="0.76" MODIFIED="2014-03-20 22:49:20 +0000" MODIFIED_BY="[Empty name]" ORDER="976" SD_1="111.9" SD_2="152.9" SE="17.343701360746394" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="55.49096361296234"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-13.144307883274081" CI_START="-89.05569211672592" DF="0" EFFECT_SIZE="-51.1" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" MODIFIED="2014-08-27 14:03:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.008322152239026636" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="93" WEIGHT="44.509036387037646" Z="2.6387125098915503">
<NAME>Rutosides</NAME>
<CONT_DATA CI_END="-13.144307883274081" CI_START="-89.05569211672592" EFFECT_SIZE="-51.1" ESTIMABLE="YES" MEAN_1="-95.7" MEAN_2="-44.6" MODIFIED="2014-08-27 14:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="127.9" SD_2="131.1" SE="19.365504884842565" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="86" TOTAL_2="93" WEIGHT="44.509036387037646"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-03-31 10:30:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Pain in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="70" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-23 21:55:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8655808361251482" CI_START="0.502901968655921" EFFECT_SIZE="0.6597744360902256" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="70" LOG_CI_END="-0.062692367368319" LOG_CI_START="-0.2985166642901292" LOG_EFFECT_SIZE="-0.1806045158292241" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.13852435936096785" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.01918899813636656" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2016-03-31 10:29:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="44.92" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="323" TOTAL_2="335" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.01" MODIFIED="2014-08-27 15:06:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="323" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="5.093929246696296" CI_START="-5.093929246696296" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="37.8" MEAN_2="37.8" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="935" SD_1="25.8" SD_2="27.4" SE="2.5989912502865153" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="216" WEIGHT="0.0"/>
<CONT_DATA CI_END="-3.0427737337329113" CI_START="-15.517226266267087" EFFECT_SIZE="-9.28" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-0.92" MODIFIED="2014-08-27 15:05:58 +0100" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="26.2" SD_2="22.9" SE="3.182316774933383" STUDY_ID="STD-Rabe-2011" TOTAL_1="120" TOTAL_2="119" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2016-03-31 10:30:15 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="52.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="204" TOTAL_2="211" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cramps in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.06.01" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="211" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="2.5689395764090186" CI_START="-8.168939576409013" EFFECT_SIZE="-2.799999999999997" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="26.9" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="936" SD_1="27.1" SD_2="28.7" SE="2.739305221299231" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="211" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-03-31 10:30:08 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Itching in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="72" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-23 21:54:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.6163595664241507" CI_START="0.3168008036596062" EFFECT_SIZE="0.4418859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="72" LOG_CI_END="-0.21016585901078652" LOG_CI_START="-0.4992137253638269" LOG_EFFECT_SIZE="-0.35468979218730673" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.1697881475057902" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.02882801503344797" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2014-11-25 09:04:56 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="36.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="204" TOTAL_2="212" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Itching in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.08.01" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="204" TOTAL_2="212" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="14.864613505616155" CI_START="-5.66461350561616" EFFECT_SIZE="4.599999999999998" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="31.3" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="937" SD_1="68.6" SD_2="30.4" SE="5.23714394069591" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="204" TOTAL_2="212" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-11-25 09:05:04 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Heaviness in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="71" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-23 21:54:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.8202259906388952" CI_START="0.4710301512908947" EFFECT_SIZE="0.6215715344699778" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="71" LOG_CI_END="-0.08606647326821763" LOG_CI_START="-0.32695129219138175" LOG_EFFECT_SIZE="-0.20650888272979967" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.141496935034551" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.020021382624171944" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.10" MODIFIED="2014-11-25 09:05:13 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.45" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="203" TOTAL_2="214" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Heaviness in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.10.01" MODIFIED="2013-12-30 11:34:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="214" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="3.0910796139700683" CI_START="-7.891079613970065" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="46.9" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="938" SD_1="28.4" SD_2="28.8" SE="2.8016227120921617" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-11-25 09:05:21 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Swelling in the lower legs (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="76" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-23 21:55:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="0.7465041278868161" CI_START="0.43092451697916057" EFFECT_SIZE="0.567174515235457" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="76" LOG_CI_END="-0.12696778644731532" LOG_CI_START="-0.36559879649908833" LOG_EFFECT_SIZE="-0.24628329147320185" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.14017303654696206" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.019648480174795962" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.12" MODIFIED="2014-11-25 09:05:31 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="33.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="203" TOTAL_2="214" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Swelling in the lower legs (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.12.01" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="214" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="4.117718206517237" CI_START="-6.717718206517231" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="37.5" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="939" SD_1="28.6" SD_2="27.8" SE="2.764192734790794" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="203" TOTAL_2="214" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6577136377281905" CI_END="0.9480258996907798" CI_START="-2.151350977843382" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6016625390763011" ESTIMABLE="YES" I2="39.67595022199084" I2_Q="0.0" ID="CMP-004.13" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.19791237709553755" P_Q="1.0" P_Z="0.4466863643074521" Q="0.0" RANDOM="NO" SCALE="33.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="297" TOTAL_2="320" UNITS="" WEIGHT="100.0" Z="0.7609509614556228">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6577136377281905" CI_END="0.9480258996907798" CI_START="-2.151350977843382" DF="1" EFFECT_SIZE="-0.6016625390763011" ESTIMABLE="YES" I2="39.67595022199084" ID="CMP-004.13.01" MODIFIED="2014-03-20 22:51:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19791237709553755" P_Z="0.4466863643074521" STUDIES="2" TAU2="0.0" TOTAL_1="297" TOTAL_2="320" WEIGHT="100.0" Z="0.7609509614556228">
<NAME>Calcium dobesilate at 3 months of treatment</NAME>
<CONT_DATA CI_END="0.664100452096434" CI_START="-2.664100452096434" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="40.8" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="933" SD_1="11.0" SD_2="4.8" SE="0.849046444334001" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="197" TOTAL_2="216" WEIGHT="86.7220846358767"/>
<CONT_DATA CI_END="6.252843926845621" CI_START="-2.252843926845621" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="41.2" MEAN_2="39.2" MODIFIED="2014-03-20 22:51:16 +0000" MODIFIED_BY="[Empty name]" ORDER="943" SD_1="17.7" SD_2="12.8" SE="2.169858201676924" STUDY_ID="STD-Rabe-2011" TOTAL_1="100" TOTAL_2="104" WEIGHT="13.277915364123297"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5461065886456469" CI_END="1.3246811009507642" CI_START="0.8147741736426202" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0389013183970628" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.12211134033579996" LOG_CI_START="-0.08896274553129871" LOG_EFFECT_SIZE="0.016574297402250634" METHOD="MH" MODIFIED="2015-08-17 11:40:31 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4599130096338033" P_Q="1.0" P_Z="0.7582293005001631" Q="0.0" RANDOM="NO" SCALE="2.8509138372515768" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="241" WEIGHT="99.99999999999999" Z="0.3078068616904588">
<NAME>Global assessment by the participant (dichotomous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5461065886456469" CI_END="1.3246811009507642" CI_START="0.8147741736426202" DF="1" EFFECT_SIZE="1.0389013183970628" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="82" I2="0.0" ID="CMP-004.14.01" LOG_CI_END="0.12211134033579996" LOG_CI_START="-0.08896274553129871" LOG_EFFECT_SIZE="0.016574297402250634" MODIFIED="2014-03-20 22:51:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4599130096338033" P_Z="0.7582293005001631" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="241" WEIGHT="99.99999999999999" Z="0.3078068616904588">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="1.4074584102638539" CI_START="0.6033055026895294" EFFECT_SIZE="0.9214810924369747" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.14843557051466333" LOG_CI_START="-0.21946271350872457" LOG_EFFECT_SIZE="-0.03551357149703059" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.2161052731612147" STUDY_ID="STD-Labs-2004" TOTAL_1="112" TOTAL_2="121" VAR="0.04670148908808322" WEIGHT="40.215282558357835"/>
<DICH_DATA CI_END="1.5004603685863007" CI_START="0.8328573916734775" EFFECT_SIZE="1.1178861788617886" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="48" LOG_CI_END="0.17622452896341553" LOG_CI_START="-0.0794293555096484" LOG_EFFECT_SIZE="0.04839758672688353" MODIFIED="2014-03-20 22:51:56 +0000" MODIFIED_BY="[Empty name]" ORDER="979" O_E="0.0" SE="0.1501723572466157" STUDY_ID="STD-Rabe-2011" TOTAL_1="123" TOTAL_2="120" VAR="0.022551736881005174" WEIGHT="59.78471744164215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.15" MODIFIED="2014-11-25 09:05:40 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="32.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="108" TOTAL_2="115" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Global assessment by the participant (continuous variable)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.15.01" MODIFIED="2014-03-20 22:53:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="0.0" Z="0.0">
<NAME>Calcium dobesilate</NAME>
<CONT_DATA CI_END="-2.4326537625645424" CI_START="-8.847346237435456" EFFECT_SIZE="-5.639999999999999" ESTIMABLE="YES" MEAN_1="15.19" MEAN_2="20.83" MODIFIED="2014-03-20 22:52:48 +0000" MODIFIED_BY="[Empty name]" ORDER="978" SD_1="12.49" SD_2="11.91" SE="1.636431211356226" STUDY_ID="STD-Rabe-2011" TOTAL_1="108" TOTAL_2="115" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.199277622512788" CI_END="2.6256220901672904" CI_START="0.9652388731385686" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.591964983157861" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="77" I2="63.411410881333154" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="0.41923221757761997" LOG_CI_START="-0.015365196036338026" LOG_EFFECT_SIZE="0.20193351077064098" METHOD="MH" MODIFIED="2014-11-25 08:57:19 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.04206789548164758" P_Q="0.7014586783344379" P_Z="0.06854988932992284" Q="0.14695901657885893" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.15930720296116135" TOTALS="YES" TOTAL_1="626" TOTAL_2="631" WEIGHT="100.0" Z="1.8213748908029677">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.467326933427658" CI_END="3.0870723704509486" CI_START="0.7578434002655914" DF="2" EFFECT_SIZE="1.5295481104197102" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="63" I2="73.21665412763763" ID="CMP-004.16.01" LOG_CI_END="0.4895468107969927" LOG_CI_START="-0.12042052712101477" LOG_EFFECT_SIZE="0.18456314183798894" MODIFIED="2014-03-20 22:54:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.023905191811315896" P_Z="0.23558803504886894" STUDIES="3" TAU2="0.2753886134094496" TOTAL_1="512" TOTAL_2="514" WEIGHT="74.28337248344552" Z="1.1860868226509569">
<NAME>Calcium dobesilate</NAME>
<DICH_DATA CI_END="2.6977689818668056" CI_START="0.42776421247572727" EFFECT_SIZE="1.074248120300752" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4310047569755741" LOG_CI_START="-0.3687955521030694" LOG_EFFECT_SIZE="0.031104602436252366" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4698066606281763" STUDY_ID="STD-Labs-2004" TOTAL_1="133" TOTAL_2="127" VAR="0.22071829837059842" WEIGHT="17.148918573792074"/>
<DICH_DATA CI_END="1.5859185558605429" CI_START="0.7530972088851662" EFFECT_SIZE="1.0928635953026198" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" LOG_CI_END="0.20028088055500345" LOG_CI_START="-0.1231489619697851" LOG_EFFECT_SIZE="0.03856595929260917" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="940" O_E="0.0" SE="0.18998429050260193" STUDY_ID="STD-Martinez_x002d_Zapata-2008" TOTAL_1="246" TOTAL_2="263" VAR="0.03609403063777704" WEIGHT="33.352022698480376"/>
<DICH_DATA CI_END="5.9756959783431975" CI_START="1.5840886202364952" EFFECT_SIZE="3.0766917293233083" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.7763884940472019" LOG_CI_START="0.19977947409887165" LOG_EFFECT_SIZE="0.48808398407303677" MODIFIED="2014-03-20 22:54:46 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="0.33870299257833086" STUDY_ID="STD-Rabe-2011" TOTAL_1="133" TOTAL_2="124" VAR="0.11471971718151686" WEIGHT="23.782431211173066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3097438852633263E-31" CI_END="3.343632810758682" CI_START="1.004540355835996" DF="0" EFFECT_SIZE="1.8327067669172932" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" I2="100.0" ID="CMP-004.16.02" LOG_CI_END="0.5242185782714054" LOG_CI_START="0.00196738853557186" LOG_EFFECT_SIZE="0.26309298340348863" MODIFIED="2014-03-23 21:55:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.04829869822780426" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="117" WEIGHT="25.716627516554475" Z="1.9747308658764788">
<NAME>Rutosides</NAME>
<DICH_DATA CI_END="3.343632810758682" CI_START="1.004540355835996" EFFECT_SIZE="1.8327067669172932" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5242185782714054" LOG_CI_START="0.00196738853557186" LOG_EFFECT_SIZE="0.26309298340348863" MODIFIED="2013-12-30 11:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.30677293403591116" STUDY_ID="STD-Vanscheidt-2002a" TOTAL_1="114" TOTAL_2="117" VAR="0.09410963305700148" WEIGHT="25.716627516554475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-03-31 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-02-24 17:10:44 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAAPTCAYAAAAq/BacAACAAElEQVR42uy9D2Qdy////yGqIipK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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-03-31 10:13:26 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiIAAAEACAMAAAC55u24AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-03-31 10:13:26 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAW8AAAjVCAIAAAAkl6iDAACAAElEQVR42uydv24iyfqwW0JCBBM4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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-03-30 15:48:24 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAG8CAMAAAA1hSvnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-03-31 10:13:26 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxMAAAMgCAMAAABvas9hAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-03-31 10:13:26 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.22" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.22 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyMAAATQCAMAAADXrGrOAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-03-30 15:52:59 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-03-30 15:52:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-21 10:07:14 +0100" MODIFIED_BY="Karen Welch">CRS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-30 15:52:59 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="28">
<TR>
<TD COLSPAN="2">
<P>Search run on Fri Aug 21 2015</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Venous Insufficiency EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>333</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>(insuffic* or insufic* or CVI or isch* or incompet* ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>29524</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>(saphenous or vein* or veno*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>21111</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>#1 OR #2 OR #3</P>
</TD>
<TD ALIGN="RIGHT">
<P>48620</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Flavonoids EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>1732</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Saponins EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>149</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Calcium Dobesilate</P>
</TD>
<TD ALIGN="RIGHT">
<P>37</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>*rutin*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>516</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>*rutoside*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>183</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>(*escin* or *aescin* or *essaven*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>196</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>(*rosskastani* or *aesculus*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>(horse near3 (chestnut or chest-nut)):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>42</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>(calcium near2 dobesilate):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>81</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>(naftazone* or aminaftone* or aminaphtone* or chromocarbe* ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>18</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(bark* near3 extract):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>80</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>(*french* near3 maritime*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>(*grape* near3 *seed*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(disodium* near2 flavodate*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(*dioxium* or hidrosmin* or *diosmin*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>102</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(*venostasin* or *venorutin* or pycnogenol* ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>86</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>(*flavono* or *flaven* or centella or aminaftone ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>1007</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>*phlebotonic*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(*quercetin or hesperidin or saponosides or saponin* ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>465</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>daflon:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>70</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24</P>
</TD>
<TD ALIGN="RIGHT">
<P>3207</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>#4 AND #25</P>
</TD>
<TD ALIGN="RIGHT">
<P>513</P>
</TD>
</TR>
</TABLE>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2011-01-07 15:18:05 +0000" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;53 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="196">
<FLOWCHARTBOX TEXT="&lt;p&gt;66 studies (95 reports) included in qualitative synthesis&lt;/p&gt;" WIDTH="197">
<FLOWCHARTBOX TEXT="&lt;p&gt;59 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;6 NEW studies (7 reports) included&lt;/p&gt;&lt;p&gt;1 study (1 report) previously classed as excluded now reclassified as included&lt;/p&gt;&lt;p&gt;6&lt;span&gt; &lt;/span&gt;additional&lt;span&gt; reports added to previously included studies&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;129 reports related to the topic and assessed for elegibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;292 reports after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="194">
<FLOWCHARTBOX TEXT="&lt;p&gt;513 reports of studies identified from the CRS search&lt;/p&gt;&lt;p&gt;&lt;span&gt;8 studies identified from the WHO search&lt;/span&gt; update&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;221 reports from Specialised Register&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;163 reports not related to the topic&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;115 additional studies excluded (118 reports) excluded with reasons&lt;/p&gt;&lt;p&gt;1 additional report added to previously excluded study&lt;/p&gt;&lt;p&gt;3 ongoing studies (3 reports)&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>